Annual Report
2010–2011
Copies of this Annual Report are available on QIMR’s website at www.qimr.edu.au/annualreport and at no cost by contacting QIMR on (07) 3362 0222, freecall 1800 993 000 or by emailing enquiries@qimr.edu.au.
Queensland Institute of Medical Research 300 Herston Road, Herston, Queensland Australia 4006 T: +61 7 3362 0222 F: +61 7 3362 0102 W: www.qimr.edu.au QIMR is committed to providing accessible services to people from culturally and linguistically diverse backgrounds. If you have difficulty in understanding the annual report, you can contact us on (07) 3362 0222 and we will arrange an interpreter to communicate the report to you. ISSN 1839 – 1877 © 2011 Queensland Institute of Medical Research
AnnuAl RepoRt
2010–2011
Contents Letter of compliance
2
Our governance
22
Student awards
125
Research highlights
3
Our management
27
Patents
127
Awards and achievements
6
Our performance
32
Grants and funding
129
QIMR at a glance
8
Our research
48
QIMR Fellows
131
Message from our Patron
10
Supporting our research
70
Overseas travel
132
Chairman’s report
11
Financial statements
72
Scientific publications
133
Director’s report
12
Awards
111
Compliance checklist
154
Our organisation
14
Invited lectures
112
Acronyms
156
Our people
19
Graduated students
124 Page 1
Letter of compLiance
31 August 2011
The Hon Geoff Wilson MP Minister for Health Parliament House BRISBANE QLD 4000
Dear Minister I am pleased to present the Annual Report 2010–2011 for the Council of the Queensland Institute of Medical Research. I certify that this Annual Report complies with:
• the prescribed requirements of the Financial Accountability Act 2009 and the Financial and Performance Management Standard 2009; and • the detailed requirements set out in the Annual Report Requirements for Queensland Government Agencies. A checklist outlining annual reporting requirements can be found on the final pages of this Annual Report or accessed at our website: http://www.qimr.edu.au/annualreport
Yours sincerely
PROFESSOR JOHN HAY AC Chair QIMR Council
300 Herston Road, Herston Q 4006 Australia | QIMR Locked Bag 2000, Royal Brisbane Hospital Q 4029 T (617) 3362 0222 F (617) 3362 0111 W www.qimr.edu.au
Page 2
QIMR Annual Report 2010–2011
2010-11 CANCER ReSeARCH HIGHlIGHtS Identified small changes in a section of DNA associated with an increased breast cancer risk in women who carry the mutated BRCA1 gene. Discovered that 75% of oesophageal cancers in Australia can be attributed to obesity, acid reflux and smoking. Identified several new genes that increase the risks of melanoma, cancers of the breast, ovary, prostate and endometrium. Identified a potential new cancer treatment that reduces the size of cancerous tumours by blocking the function of microRNA. Discovered that although Indigenous Queenslanders are 21% less likely to be diagnosed with cancer than the total Queensland population, they are 36% more likely to die from cancer.
Found that using sunscreen every day can halve the risk of developing melanoma. Found that for ovarian cancer patients, decreasing the time between symptom onset and diagnosis will not improve survival rates. Began Phase I clinical trials using a monoclonal antibody as a potential cancer treatment for acute leukaemias, melanomas, brain tumours and lung cancers. Influenced a major change in clinical practice with the acceptance nationally and internationally that it is important to remove proximal serrated polyps from the colon.
Image source: National Cancer Institute , Dr Cecil Fox
Page 3
2010-11 INFECTIOUS DISEASES ReSeARCH HIGHlIGHtS
Developed a computer system for tracking mosquito-borne disease such as Ross River fever and Barmah Forest virus disease. Discovered new regions of the Epstein-Barr virus that are targeted by the immune response. Established a system to test antimalarial drugs in human volunteers infected with malaria parasites. Undertook a pilot study, releasing Wolbachia infected mosquitoes in Cairns to test the effectiveness against the spread of dengue fever.
Page 4
QIMR Annual Report 2010–2011
Found that applying clove oil is as effective at killing scabies mites as other existing treatments. Demonstrated the efficacy of novel proteins for the treatment of schistosomiasis. Identified new antimalarial compounds from plants and fungi. Completed preclinical testing of a vaccine for cytomegalovirus, which aims to prevent clinical complications in transplant patients and newborn babies. Obtained data to support a causal link between scabies and streptococcal infections.
2010-11 MENTAL HEALTH / COMPLEX DISORDERS ReSeARCH HIGHlIGHtS Published the world’s largest genome-wide association study for major depression which showed the disease is underpinned by many small genetic variants, and implicated a protein called galanin. Developed a new diagnostic and monitoring test for major depression based on a combination of video and imaging technology. Developed a brain stress test for dementia using brain imaging and showed that it could predict the functioning of patients for up to two years. Discovered that eating or drinking full-fat dairy may reduce the risk of cardiovascularrelated death. Found 59 new DNA regions that influence levels of LDL and HDL cholesterol and triglycerides in the blood – key indicators of heart disease risk.
Discovered new genes for myopia (long or short sightedness), optic nerve hypoplasia (one of the leading causes of blindness in children) and glaucoma risk. Discovered 30 new genes that control the age of sexual maturation in women and identified several genetic links between early puberty and body fat. Located new genetic regions that increase endometriosis risk and demonstrated a stronger genetic contribution to more severe cases of the disease. Demonstrated that liver fibrosis identified via liver biopsy, predicts the future development of clinically significant liver disease (portal hypertension) in children with cystic fibrosis (CF) and should be adopted clinically.
Page 5
AWARDS AND
ACHIevementS QIMR was inducted into the Queensland Business Leaders Hall of Fame. Professor Geoff Hill (Immunology Department Coordinator and Head of the Bone Marrow Transplantation Laboratory) was awarded a prestigious National Health and Medical Research Council (NHMRC) Australia Fellowship. He also received a Senior Clinical Research Fellowship from the Queensland Government. Professor Emma Whitelaw (Cell and Molecular Biology Department Coordinator and Head of the Epigenetics Laboratory) was elected as an Australian Academy of Science Fellow, and received both the Australia and New Zealand Society for Cell and Developmental Biology President’s Medal and the International Union of Biochemistry and Molecular Biology Jubilee Medal. Professors Kum Kum Khanna (Head of the Signal Transduction Laboratory) and Georgia Chenevix-Trench (Cancer Program Coordinator and Head of the Cancer Genetics Laboratory) were awarded a medical research program grant from the NHMRC. The grant worth $5.6 million over five years will be used to support research into the susceptibility and progression of breast cancer. Professor James McCarthy (Infectious Diseases Program Coordinator and Head of the Clinical Tropical Medicine Laboratory ) and Professor Michael Breakspear (Mental Health/Complex Disorders Program Coordinator and Head of the Systems Neuroscience Group) were awarded Health Research Fellowships from the Queensland Government for their work in malaria and mental health respectively.
Page 6
QIMR Annual Report 2010–2011
Professor Don McManus (Head of the Molecular Parasitology Laboratory) received an honorary membership of the American Society of Tropical Medicine and Hygiene, in recognition of outstanding accomplishment by an individual not an American citizen who has made eminent contributions to some phase of tropical medicine and hygiene. Dr Patricia Valery (Indigenous Health Program) was awarded a NHMRC Excellence Award, the highest ranking Career Development Award in the category of population health. Dr Sarah Medland (Genetic Epidemiology Laboratory) was awarded a 2010 Queensland Young Tall Poppy Science Award. Professor Michael Breakspear and Dr Susan Woods (Oncogenomics Laboratory) won 2011 Australian Society for Medical Research (ASMR) Queensland Awards.
Page 7
QImR At A GlAnCe Business development agreements
Patent portfolio 2010-2011
research agreements
patent portfolio
Patent portfolio 2010-2011
Research service agreements
Intellectual property agreements
Clinical trial agreements
License agreements
Commercialisation agreements
Others
Research service agreements
Intellectual property agreements
Clinical trial agreements
License agreements
New Tre
Commercialisation agreements
Others
Drug Tar
Vaccine Patents
Diagnostic Patents
New Treatment Patents
Delivery Platform Patents
Drug Target Patents
nHmrc grants awarded ($ millions) 20
15
10
5
0
2007 Grants
Page 8
QIMR Annual Report 2010–2011
2008 Fellowships
2009
2010
2011
Vaccine
Fundraising
fundraising undraising revenue ($ millions) 10
8
6
4
2
0
2006-07
2007-08
2008/09
2009/10
Donations & Gifts
Event Revenue
Sponsorships
Bequests / Gifts in Kind
2010/11
Scientific publications 600 500 400 300 200 100 0
2007
2008
Articles
2009
2010
2011
High Impacts (publications in journals with impact factors of 10 or more)
Staff numbers 600 500 400 300 200 100 0
2007 Staff
2008
2009
2010
2011
Students
Page 9
meSSage from our patron
QIMR Annual Report 2010-11 Patron’s Message 2010-11 was a challenging year for QIMR, in some ways, but one which nevertheless delivered many gains and advances, for the Institute itself and for the individual researchers and research teams working across its diverse research program, consolidating its reputation as one of Australia’s most highly regarded and most successful medical research institutes. The decision by Professor Michael Good AO to relinquish his position as Director and CEO, after ten years of committed and energetic leadership, to concentrate on his own research, posed a significant challenge for the Council, needing to find a worthy successor and assure a smooth transition during a period of significant expansion and ongoing growth. The appointment of distinguished molecular biologist, Professor Frank Gannon of Ireland - after an extensive national and international search - however, met this challenge admirably, assisted by the contribution of Professor Adèle Green, who stepped into the Director role for several months. I congratulate Professor Gannon on his appointment and welcome him most warmly to Queensland, as I thank Professor Green, equally warmly, for her steady leadership at a demanding time for the Institute and its 600 scientists, staff and students. Many of those demands, of course, related to the major expansion of QIMR’s research facilities ongoing through the year and now approaching completion. Professor Gannon has joined the Institute at a significant point in its development. Following a decade of impressive achievements under Professor Good, QIMR is now approaching what is arguably the most exciting period in its history, with the imminent completion of the state-of-the-art Smart State Medical Research Centre at Herston in 2012. The capacity and capability that this Centre will add is immense, creating new opportunities for many more hundreds of scientists to pursue the Institute’s mission of preventing and curing disease through research, and it is they who will further cement the reputation of QIMR – and of Queensland – as a centre of excellence in this field. It is no exaggeration to say that their explorations could affect the health and hopes of millions, as they work to unravel the secrets of the diseases and conditions that confront contemporary society, to find answers to those still unsolved medical riddles and puzzles and to realise the scientific break-throughs we all want to see in our lifetime. I congratulate and thank the Council, staff and supporters of the Institute for all they have done throughout the year to build and strengthen QIMR. I was particularly delighted to see the Institute inducted into the Queensland Business Leaders Hall of Fame in September, 2010 and to have the honour, as Governor, of presenting this highly prestigious award to Council Chairman, Professor John Hay AC, accepting it on behalf of all QIMR scientists and staff. It was just recognition of QIMR’s significant contribution to Queensland - a contribution I have every confidence will be sustained and enhanced during the year ahead.
Penelope Wensley AC Governor of Queensland
Page 10
QIMR Annual Report 2010–2011
cHairman’S report In January 2011, we welcomed Professor Frank Gannon as QIMR’s seventh Director and CEO. Professor Gannon, an internationally renowned expert in the field of molecular biology has significant experience in managing science, widespread ties with the international scientific community and a passion for scientific excellence. I would like to pay tribute to Professor Adèle Green, who stepped into the Director role until Professor Gannon commenced. Professor Gannon’s appointment comes at a particularly important juncture in QIMR’s history. The Institute is poised for a period of exponential growth and research achievements when our new 15 floor research facility is completed in early 2012. The capital expansion was made possible by a most generous gift from The Atlantic Philanthropies, and funding from the State and Federal Governments. A highlight of the new building will be a piece of art commissioned by acclaimed Indigenous artist Ms Judy Watson. This three-storey piece will be featured in the foyer of the new facility, greeting visitors and encapsulating the history of both QIMR and the local Herston area. QIMR continues to be recognised as one of Australia’s largest and most successful medical research institutes. This year I had the honour of representing QIMR when we were inducted into the Queensland Business Leaders Hall of Fame.
We have also embarked on our largest signature fundraising event – the Rio Tinto Ride to Conquer Cancer. The event promises to both raise the profile of QIMR as well as raise much needed funds for our Cancer Program. Thank you to Rio Tinto and Sunsuper for sponsoring this event. I would also like to acknowledge the ongoing support of Suncorp, who continue to support our skin cancer research. A change to the Queensland Institute of Medical Research Act 1945 saw the abolition of the QIMR Trust. The role of Trust has been absorbed by the QIMR Council and I would like to take the opportunity of thanking the members of Trust for their commitment and guidance over the past 31 years. I would like to acknowledge the significant contribution of Mr Clive Berghofer, who has been a major supporter of QIMR for the past 10 years, Mr Chuck Feeney whose vision and support was instrumental for the construction of our new facility and former Director, Professor Michael Good, whose leadership enabled QIMR to achieve its vision of better health through medical research.
QIMR Council Chairman Professor John Hay AC
“QIMR continues to be recognised as one of Australia’s largest and most successful medical research institutes.”
Her Excellency, the Governor of Queensland Ms Penelope Wensley AC presents the Queensland Business Leaders Hall of Fame award to Professor John Hay AC, Chairman of QIMR Council.
Page 11
Director’S report It is with great pleasure that I write my first annual report as Director and CEO of the Queensland Institute of Medical Research. Taking over from Michael Good is both a challenge, because of what has been achieved in the past ten years, and a benefit because much of what is needed for QIMR is already in place. Since its inception in 1945, QIMR has become a world recognised centre of excellence for medical research. Our research continues to make an enormous impact on the health of society and it has been another productive year for the Institute. In response to a review of the current strengths of QIMR and the opportunities and future needs, I have prepared a roadmap. This will allow us to concentrate our research effort on areas that are of high importance to Queensland including regionally relevant diseases and those that are major causes of mortality and morbidity to the community. Our research will focus on cancer; infectious diseases; and mental health/ complex disorders. These scientific activities will be supported by cross program departments in Immunology, Genetics, Population Health, Computational Biology, Biology, Cell and Molecular Biology to increase collaboration across the Institute. I am excited about the new direction for the Institute as we move into a period of growth. We will be recruiting to further strengthen QIMR in priority areas such as computational biology, imaging, mental and infectious diseases, as well as increasing the number of students supported at the Institute. We will also be working to further support our current researchers by providing world-class facilities, the best equipment and training, as well as providing clear career paths and financial security. In order to make a real benefit to society, I believe our research has to go beyond the laboratory and be effectively translated into the clinical setting. This has been achieved in many disease areas (highlighted elsewhere) including the development of an online based system to help track mosquito-borne diseases such as Ross River fever; clinical trials that have began for a new antibody that has been effective as a treatment against acute leukaemia; and we have embarked on the largest ever purpose built study of skin cancer in order to develop an effective predictive tool for general practitioners. QIMR continues to employ and support excellent researchers. Special congratulations must go to Professor Geoff Hill who was awarded a NHMRC Australia Fellowship, which will be used to continue to improve the outcome for bone marrow transplant patients; Professor Emma Whitelaw who has been recognised as one of the world’s leading epigeneticists having been elected as an Australian Academy of Science Fellow and receiving the International Union of Biochemistry and Molecular Biology Jubilee Medal; and Dr Susan Woods
Page 12
QIMR Annual Report 2010–2011
“i am excited about the new direction for the institute as we move into a period of growth.”
who not only won ASMR’s Senior Researcher Award but was also awarded a joint Cancer Australian and Cure Cancer Foundation Research Grant for her work on the regulation of melanoma growth. QIMR continues to provide excellent research facilities for over 400 researchers. On 29 March 2011, we celebrated the topping out of our new 15 floor research facility made possible by generous support from the Commonwealth and Queensland Governments and The Atlantic Philanthropies. The building, due for completion in early 2012, will include 20 purpose built laboratories and increase QIMR’s current research capacity in areas such as tropical diseases, vaccine development, cancer and genetics. It will allow the expansion of our mental health research, as well as QIMR’s highly successful Education Program. Located in the heart of the Herston medical campus, QIMR is well placed to bridge the gap between scientists and clinicians. As it expands, QIMR will place a particular emphasis on increasing the frequency of these interactions and incorporating researchers with a clinical background into our laboratories. To achieve this we will expand our bioseurity capability, and maintain our good manufacturing practice (GMP) facilities. In addition to the Herston based activities, we will work to strengthen current collaborations and continue to build our relationships with universities and other medical research institutes. I want to thank our team of dedicated researchers for their hard work and determination. Thanks also to all the corporate staff for providing the services and support needed to make our Institute what it is today. I look forward to working with Council and staff to continue to build on our world-class reputation and take QIMR into the future.
Professor Frank Gannon Director and CEO
Page 13
Page 14
QIMR Annual Report 2010–2011
ouR oRGAnISAtIon
Page 15
our organiSation role and main function QIMR was established under the Queensland Institute of Medical Research Act 1945 for the purpose of research into any branch or branches of medical science. QIMR is a world leading medical research institute. Our research focuses on three areas: cancer; infectious diseases; and mental health and a range of complex disorders.
our vision to be a world renowned medical research institution
our mission Better health through medical research
our philosophy Qimr supports scientists who perform world-class medical research aimed at improving the health and well-being of all people
Page 16
QIMR Annual Report 2010–2011
Working in close collaboration with clinicians and other research institutes, our aim is to improve health by developing prevention strategies, new diagnostics and better treatments.
government objectives for the community QIMR conducts medical research that supports the Queensland Government’s Smart State Strategy 2005–2015 and Towards Q2: Tomorrow’s Queensland ambitions of Healthy – Making Queenslanders Australia’s healthiest people and Strong – Creating a diverse economy powered by bright ideas. This is evidenced by research undertaken by QIMR across the three research programs that focuses on areas of high importance to Queensland including those that are major causes of ill health and death. In particular, QIMR supports the Queensland Government’s commitment to making Queenslanders Australia’s healthiest people and, through the Toward Q2 strategy, targets to reduce tobacco smoking, overweight and obesity, risky alcohol consumption, and unsafe sun exposure by one-third by 2020. In 2010, QIMR embarked on the largest skin cancer research study every conducted in Australia. More than 200,000 men and women will be invited to participate in the QSkin study, which aims to help us better understand the factors that underlie skin cancer risk. QIMR researchers found that using sunscreen every day can halve the risk of melanoma and discovered that 75% of oesophageal cancers in Australia can be attributed to obesity, acid reflux and smoking.
machinery of government changes The Queensland Institute of Medical Research Act 1945 was amended by legislation, entitled the Water and Other Legislation Amendment Act 2010. This was enacted and assented to by the Queensland Parliament on 25 November 2010. As per section 137 of the Amendment Act, the Trust was abolished on 1 February 2011. Responsibilities of the Trust have been transferred to the QIMR Council. The QIMR Final Trust Annual Report can be found at www.qimr.edu.au/trustreport or a copy can be obtained by calling (07) 3362 0222 or freecall 1800 993 000.
operating environment rapid growth QIMR is preparing for a period of accelerated growth with the construction of a 15 floor research facility scheduled for completion in early 2012. QIMR will be actively recruiting researchers in specific areas in order to increase its capacity by 50% to approximately 1,000 staff and students.
competition for funding QIMR operates in a competitive environment with much of its research funded by competitive grants obtained by our researchers. For the 2010–2011 year, QIMR researchers secured more than $21 million in funding from NHMRC. Funds were provided from 1 January 2011 for a total of 17 new research projects ranging from the genetics of brain structure and function, to understanding the causes and risks of breast and ovarian cancers, to improving the health of Indigenous populations.
economic climate The global financial crisis has impacted philanthropic giving for both individuals and the corporate sector. In this environment, with a large number of charities competing for the fundraising dollar and especially after the devastating Queensland floods, securing funding to support our operating costs has been even more challenging. However, QIMR continues to secure ongoing funding support from the community and valued donors.
Decline of students completing science degrees Over the next few years, QIMR will recruit up to an additional 500 scientists. Regrettably, the number of students completing science degrees is declining, with less than 10% of undergraduates enrolling in science related degrees. As a society that relies on medical research to improve our health, we must ensure a continual supply of researchers into the future. QIMR is committed to inspiring the scientists of tomorrow through its Education Program which saw over 1,000 senior school students tour QIMR and hear first-hand from researchers about medical research and potential career options.
Page 17
objectives
progress
QIMR is committed to better health through medical research by achieving the following objectives:
Changes have already been implemented in line with the new direction for QIMR. QIMR’s activities are now organised into three programs with disease related themes: Cancer, Infectious Diseases and Mental Health/Complex Disorders. These will be underpinned by the following departments: Immunology, Genetics, Population Health, Computational Biology, Biology and Cell and Molecular Biology. Each research group will align itself with at least one program and one department.
1.
To transfer outstanding fundamental knowledge and understanding from the laboratory to the clinic in the form of improved diagnostics, prevention and treatment strategies;
2.
To perform excellent world class research;
3.
To seek and utliise commercial opportunities and to diversify income sources;
4.
To perform research with consequence and have a positive impact on society; and
5.
To continue to build QIMR’s world leading reputation.
Our performance against the outputs translation, scientific quality, commercial consequence, societal impact and international reputation is detailed in our performance section on page 32.
future outlook Excellence in research and researchers will continue to characterise QIMR under the leadership of Professor Frank Gannon and the QIMR Council. The future goals for the Institute are to: 1.
Become a world leader in medically relevant research and the transfer of this knowledge and understanding to the clinic;
2.
Focus on areas that are of high importance to Queensland including regionally relevant diseases and those that are major causes of mortality and morbidity to the community; and
3.
Undertake outstanding fundamental research of direct relevance to the research that is closer to translation.
Our vision to be a world renowned medical research institution will be achieved by focusing QIMR’s research on cancer, infectious diseases and mental health/complex disorders. Research activities, particularly in systems biology and computational biology, will be strengthened to further support excellent translational research. QIMR will build on existing inter-institutional collaborations and continue to strengthen collaborations on the Herston campus, including the RBWH, in order to increase the health outcomes of our research. Opportunities to diversify sources of income for QIMR will be sought with a particular emphasis on identifying and leveraging commercial opportunities that arise naturally from excellent research. QIMR will support and develop staff and provide funding stability for outstanding early stage and senior research scientists.
Page 18
QIMR Annual Report 2010–2011
The individual laboratories remain the core entities of QIMR and the programs and departments are established to provide functioning support for the laboratories. Coordinators of each program and department will collectively provide a strong input from all scientists into the decision making processes of QIMR through the Management Advisory Group (MAG). This has replaced the previous Interim Management Executive Committee (IMEC).
our peopLe QIMR has 567 employees. Due to the reliance on short-term grant funding, 83.72% of employees are employed on fixed-term contracts. In 2010–2011, 91.52% of permanent FTE staff who were employed with QIMR as at 1 July 2010 were retained (i.e. still employed as at 30 June 2011) by the organisation. Taking into account the number of permanent FTE employees as at 1 July 2010, a slight increase in recruitment for new permanent positions over the reporting period, and the number of employees who voluntarily ceased (e.g. resigned) from the organisation, QIMR experienced a separation rate (or turnover) of 13.26% over the reporting period. These figures continue to reflect a stable and permanent workforce consistent with previous years. 63.81% of QIMR’s workforce and 60.58% of the current student population are women. Women hold 33% of QIMR’s scientific leadership positions. This compares to 15% in 2003.
ethics and code of conduct QIMR has in place a Code of Conduct which sets out the expected standards of the official conduct, relationships and behaviour for staff.
carers act 2008 QIMR’s Human Resource policies were reviewed to ensure that they comply with obligations set out for public authorities under the Carers Act 2008. QIMR provides access to flexible working arrangements, flexible leave options, a child care assistance policy, and definitions of a carer compliant with the Act. Employees have access to information regarding benefits and policy on the QIMR intranet.
Workforce planning, attraction and retention Workforce planning initiatives at QIMR include an Education and Higher Degrees program to attract students to medical research and a career at QIMR, the ongoing support for a culture of work and life balance to attract and retain employees, and maximising salary benefits for employees. Resource planning is limited by short term funding cycles for research employees; however within the Corporate Division QIMR has planned resourcing requirements to ensure growth is supported when the new building is completed in 2012. The strategic plan for QIMR has identified priority recruitment in the areas of bioinformatics, systems biology, basic immunology, and imaging in cell biology and scientific recruitment will be focussed on these areas over the next 12 months. Initial attraction efforts have focused on increasing exposure, and strengthening QIMR’s reputation both nationally and internationally. A key attraction strategy at QIMR is the promotion of work/life balance. Initiatives include access to variable working hours, flexible working arrangements, flexible leave options (including taking leave at half pay), and the implementation of a child care policy to support parents returning to work after the birth of a child. QIMR is covered by the QIMR Enterprise Agreement 2010, which expires on 31 August 2011 and is to be replaced by a new agreement. QIMR has in place a range of workforce policies that support the operation of the agreement and the achievement of strategic objectives, addressing workplace conduct and performance, professional and career development, leave provisions and remuneration.
Page 19
organiSationaL Structure
QIMR Council
Director
Administrative Support
Corporate Division
Cancer Program
Administrative Support
Human Resources
Antigen Presentation & Immunoregulation
Gynaecological Cancer Group
Building Services
Information Services
Bone Marrow Transplantation
Indigenous Health
Business Development
Procurement
Cancer & Population Studies
Leukaemia Foundation of Queensland
External Relations
Regulatory Affairs
Cancer Control Group
Membrane Transport
Finance
Safety
CCQ Transgenics
Molecular Cancer Epidemiology
Grants
Scientific Services
Cancer Genetics
Oncogenomics
Cancer Immunotherapy
Radiation Biology & Oncology
Clinical Immunohaematology
RBWH Foundation Conjoint Gastroenterology
Dendritic Cells & Cancer
Signal Transduction
Drug Discovery Group
Skin Cancer Carcinogenesis
Epigenetics
Tumour Immunology
Familial Cancer
Page 20
QIMR Annual Report 2010–2011
Deputy Director
Management Advisory Group
Mental Health/Complex Disorders Program
Infectious Diseases Program
Bacterial Pathogenesis
Malaria Drug Resistance & Chemotherapy
Cancer Genetics
Membrane Transport
Bioinformatics
Molecular Parasitology
CCQ Transgenics
Molecular Epidemiology
Cellular Immunology
Molecular Vaccinology
Epigenetics
Neurogenetics
Clinical Tropical Medicine
Mosquito Control
Genetic Epidemiology
Psychiatric Genetics
EBV Biology
Parasite Cell Biology
Hepatic Fibrosis
Qld Statistical Genetics
HIV Molecular Virology
Protein Discovery Centre
Indigenous Health
Radiation Biology & Oncology
Immunity & Vaccinology
Scabies
Inflammatory Bowel Disease
Systems Neuroscience
Immunology & Infection
Tropical Parisitology
Iron Metabolism
Immunovirology
Tumour Immunology
Malaria Biology
Key Laboratory is also represented in another program
Page 21
our goVernance council purpose and membership In accordance with Part 2, Section 4A of the Queensland Institute of Medical Research Act 1945, QIMR is controlled and governed by The Council of the Queensland Institute of Medical Research (“The Council”). Under the Statutory Bodies Financial Arrangements Act 1982, the QIMR Council is a statutory body.
functions of the council
membership of the council
The functions of the QIMR Council are to:
The Council consists of the following members appointed by the Governor in Council:
(a) control and manage the Institute;
1.
The Chief Health Officer (an official member) – Dr Jeannette Young
2.
The chairperson of the Trust (Trust abolished 01/02/11)
3.
Two nominees of the National Health and Medical Research Council, at least one of whom has expertise in health research – Professor Judith Clements + one vacancy
4.
number of meetings
One nominee of the senate of The University of Queensland – Vacant
5.
Attendance by Members of Council who held office during the 2010–2011 financial year are as follows:
One person with expertise in health research – Professor Lyn Griffiths
6.
One medical practitioner with expertise in health research – Associate Professor Paula Marlton
7.
One person with expertise in health research ethics – Professor Bryan Campbell
(b) raise and accept moneys for the purposes of the Institute; (c) invest moneys raised or accepted by the Council for the purposes of the Institute; and (d) invest moneys derived from any property or other invested moneys of the Council for the purposes of the Institute.
Appointed Members
Meetings Attended
John Hay
7
Bryan Campbell
7
8.
One lawyer – Mr Christopher Coyne
Judith Clements
5
9.
Chris Coyne
4
Two persons with expertise in financial management, business or public administration – Mr Paul Fennelly/ Professor John Hay (Chair)
Paul Fennelly
2
Lyn Griffiths
4
Paula Marlton
5
Jeannette Young
7
Secretary: Donna Hancock
6
remuneration of council The aggregate remuneration for the QIMR Council for the 2010–2011 financial year was $51,837.
Page 22
QIMR Annual Report 2010–2011
All members of the QIMR Council are appointed for a three year term. If at the expiration of the term of office the member’s successor has not been duly appointed, the member shall hold office as a member of the Council until the member’s successor takes up office.
members of council professor John Hay ac BA (Hons) (Western Australia and Cambridge), MA (Cambridge), PhD (Western Australia), Hon LittD (Deakin), Hon DLitt. (UWA); Hon DU (QUT), Hon LLD (Queensland), FAHA, FACE, FAIM, FQA
Professor Hay is Chair of QIMR Council. Professor Hay was ViceChancellor of The University of Queensland from 1996–2007. In that time, he led the development of many major new research institutes including the Institute for Molecular Bioscience and the Queensland Brain Institute. He was also instrumental in securing funding for the Translational Research Institute to be built at the Princess Alexandra Hospital. Under his leadership, both Deakin University and The University of Queensland were named Australian Universities of the Year by the Good Universities Guide. Professor Hay was appointed as Chair of QIMR by the Queensland Government in September 2009.
professor Bryan campbell
professor Judith clements BAppSc MAppSc PhD
Professor Clements has over 20 years’ experience as a basic researcher in biomedical research, primarily in the general field of molecular endocrinology. Her current research seeks understanding of the molecular basis of hormone dependent cancers such as prostate and ovarian cancer. She is currently Scientific Director of the Australian Prostate Cancer Research Centre-Queensland and Program Leader of the Cancer Program within the Institute of Health and Biomedical Innovation at the Queensland University of Technology. She coordinates the Australian Prostate Cancer BioResource, a national tissue bank for prostate cancer research. She is also an NHMRC Principal Research Fellow and an NHMRC Academy member since 2009. In 2007 Professor Clements was awarded the prestigious international Frey-Werle Foundation Gold Medal for her significant contributions to the kallikrein protease field. Professor Clements is Chair of the QIMR Appointment and Promotions Committee.
AM MD BS FRACP FRACMA
Professor Campbell was formerly Chief Health Officer of Queensland and Head of The University of Queensland Medical School. He has been a Councillor of the Royal Australasian College of Physicians, the Royal Australian College of Medical Administrators and a member of the National Health and Medical Research Council (NHMRC). He was Deputy Chair of the Australian Health Ethics Committee and a member of the NHMRC Embryo Research Licensing Committee until June 2006. Professor Campbell is the Chair of the QIMR Finance and Audit Committee.
mr christopher coyne Christopher Coyne is a solicitor of the Supreme Court of Queensland, an accredited specialist in the field of Commercial Litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law firm Clayton Utz from 1984 to 2004. Mr Coyne now practices on his own account. He was appointed an Adjunct Professor of The University of Queensland School of Law in 2002. Chris is Board Chairman of Lexon Insurance Pte Ltd (Queensland Law Society, Singapore Captive Insurer), a Director of the Incorporated Council of Law Reporting for the State of Queensland, past president Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee. Christopher is a sessional member of the Queensland Civil and Administrative Tribunal and also a member of the QIMR Personnel Administration Committee.
Page 23
members of council | continued mr paul fennelly BA LLB
Paul Fennelly has wide experience in financial management, business and public administration. He is an executive with Hastings Funds Management, which is a member of the Westpac Group. His focus is on major equity investments, primarily in social and economic infrastructure. From 2002–2006, Mr Fennelly was Director-General of the then Department of State Development; concurrently he served as Queensland’s Coordinator-General. Prior to joining the Queensland Government he was Victorian Director of the Australian Industry Group, which is the nation’s largest industry association. Mr Fennelly chaired the QIMR Finance and Audit Committee.
professor Lyn griffiths BSc (Hons) PhD
Professor Griffiths is Director of the Griffith Health Institute and the Genomics Research Centre at Griffith University. She has expertise in human molecular genetics, undertaking research to map and identify genes involved in common complex human disorders, including studies on migraine, cardiovascular disease risk, multiple sclerosis and certain types of cancer. Her research has been well funded by national competitive grants and industry and she has authored more than 200 peer-reviewed publications to date in molecular genetics international journals as well as supervising 28 PhD students to completion. She is a current Queensland President Human Genetics Society Australasia, past ASMR Director, current Member and past Chair of the Scientific Program Committee for the International Congress of Human Genetics and has been awarded the Centenary Medal for Distinguished Service to Education and Medical Research. Professor Griffiths is a member of the QIMR Appointments and Promotions Committee.
associate professor paula marlton MB BS (Hons I) FRACP FRCPA
Paula Marlton is the Head of Leukaemia and Lymphoma Services at the Princess Alexandra Hospital where she is also Deputy Director of Haematology. Her previous appointments include three years at the MD Anderson Cancer Centre in Houston, Texas. She has extensive experience in clinical research including the role of principal investigator for national multi-centre trials and supervisor of molecular translational research associated with trials. She was the founding Chair of the Australasian Leukaemia and Lymphoma Group (ALLG) Laboratory Science Committee and has established and continues to direct the ALLG Tissue Bank. Her other professional roles include Medical Advisor and Board member of the Leukaemia Foundation, member of several Drug Advisory Boards and Government and College Advisory Committees as well as a wide range of academic and clinical service roles.
Dr Jeannette Young MB BS FRACMA AFACHSE
Dr Jeannette Young is the Chief Health Officer for Queensland, a role she has filled since August 2005. Prior to this, she held the position of Executive Director of Medical Services at the Princess Alexandra Hospital in Brisbane and has previously worked in a range of positions in Queensland and Sydney. She has specialist qualifications as a Fellow of the Royal Australasian College of Medical Administrators and as a Fellow by Distinction of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom. She is an Adjunct Professor at Queensland University of Technology and at Griffith University. Today she is responsible for such matters as health disaster planning and response, aero-medical retrieval services, licensing of private pospitals, organ and tissue donation services, provision of health services to prisoners, cancer screening services, communicable diseases, environmental health and other population health services and mental health, alcohol and other drugs policy and legislation. Along with sitting on the QIMR Council, Dr Young is a member of numerous State and National committees and Boards, some of which include the Queensland Board of the Medical Board of Australia, NHMRC, the Australian Health Protection Committee, the Clinical Technical Ethical Principal Committee of Australian Health Ministers’ Advisory Council, the Australian Population Health Development Principal Committee and the newly created Australian National Preventive Health Agency Advisory Council.
Page 24
QIMR Annual Report 2010–2011
committees to council
• Mr John Stead
finance and audit committee
• Dr Tom Sculley
The primary objective of the Finance and Audit Committee is to assist QIMR Council in fulfilling its responsibilities relating to financial planning, policy and performance of QIMR. The Finance and Audit Committee has observed the terms of its charter and has due regard to Queensland Treasury’s Audit Committee Guidelines. • Mr Paul Fennelly (Chair to 23/02/11) • Professor Bryan Campbell (Chair from 23/02/11) • Mr Rodney Wylie • Professor John Hay
appointments and promotions committee The Appointments and Promotions Committee (APC) assists Council with the maintenance of academic standards at QIMR by reviewing all proposals for the appointment and promotion of Faculty staff.
• Associate Professor Katharine Trenholme • Ms Donna Hancock • Dr Agnieszka Mitchell (ex officio) • Ms Nicola Yu – Secretary (From 01/07/10)
animal ethics committee The QIMR Animal Ethics Committee (AEC) on behalf of Council ensures the maintenance of ethical standards in research and compliance with regulatory guidelines.
the Smart State medical research Steering committee (to 22/09/10) The Smart State Medical Research Steering Committee (SSMRSC) on behalf of Council oversees the development of the Smart State Medical Research Centre Project. • Professor John Hay (Chair) • Mr Rodney Wylie
• Professor Judith Clements (Chair)
• Mr John Parnell
• Professor Graham Brown
• Mr Alan Stockman
• Professor Julie Campbell (Chair for the Senior Research Officer APC, a subset of the APC)
• Ms Rosemary Hood
• Professor Lyn Griffiths
• Ms Karen Thompson
• Professor James McCluskey
• Ms Donna Hancock
• Dr Jurgen Michaelis
• Ms Beatrix Wanrooy – Secretary
• Dr Rick Andrew
• Professor Joe Trapani • Professor Adèle Green (ex officio) (From 01/07/10 to 04/01/11) • Professor Frank Gannon (ex officio) (From 04/01/11)
investment committee The Investment Committee is responsible for overseeing the investment of QIMR Council funds.
the Smart State medical research committee (from february 2011) • Professor Frank Gannon (Chair) • Professor Adèle Green • Mr Alan Stockman • Mr John Parnell • Ms Donna Hancock
• Mr Rodney Wylie (Chair)
• Dr Joseph Pereira
• Mr Bruce Phillips
• Ms Beatrix Wanrooy – Secretary
• Mr Michael Sargent (From 08/08/10)
Human research ethics committee The Human Research Ethics Committee (HREC) on behalf of Council ensures the maintenance of ethical standards in research and compliance with regulatory guidelines. • Dr Ian Wilkey (Chair) • Dr Roger Allison • Ms Madeline Brennan • Mrs Gwen Eardley • Mr Angus Edmonds • Mr Colin Forrest (To 01/02/11) • Mrs Mary Mackenzie • Mr David Russell
risk management The review and management of risk at QIMR is undertaken by QIMR Council through the Finance and Audit Committee. Through the Finance and Audit Committee, QIMR management have developed a register of potential risks applicable to functions of the Institute. A schedule of quarterly reviews incorporates the actions required to improve any identified gaps in controls. The review process will record all incidents reported to Committees, Management or Council and allocate those incidents to risk categories. If a risk has not previously been described in the register, it will be added in the appropriate category and controls developed.
• Dr Christopher Schmidt (To 14/06/11) Page 25
audit committee The primary objective of the Finance and Audit Committee is to assist QIMR Council in fulfilling its responsibilities relating to financial planning, policy and performance of QIMR with the following prime objectives: • Sound financial planning and management processes; • Low level financial and business risk; • Establish guidelines for the financial budgeting process; • Processes to manage variations to budget; • Measure financial performance against budget, including the establishment of provisions and write-offs; • Internal controls to establish exposure to business risk and fraud; • Effective and adequate accounting, administrative, operating and delegation policies; • Responsive management actions to accounting reports produced by external and internal auditors; • Policies to avoid conflicts of interest for past, present and future transactions between QIMR and staff; • Policies and procedures to ensure QIMR complies with Federal, State and local government legislation; • Ethical approaches to QIMR’s policies and practices. The Committee meets quarterly to review business and financial risk, financial operating performance and audit performance. The Committee reviews all issues and recommendations arising from internal audit and Queensland Audit Office, along with agreed management action implemented to address any issues found. The Finance and Audit Committee has observed the terms of its charter and has due regard to Queensland Treasury’s Audit Committee Guidelines. The Finance and Audit Committee comprises: • Mr Paul Fennelly (Chair until 23/02/11) • Professor Bryan Campbell (Chair from 23/02/11) • Mr Rodney Wylie • Professor John Hay Committee members are paid $167 (Chair) or $141 (member) per meeting, up to four hours per meeting.
internal audit The role of Internal Audit is to provide the Finance and Audit Committee and QIMR Council with independent, objective assurance and advice designed to add value and assist QIMR in accomplishing its objectives by bringing a systematic, disciplined approach to evaluating and improving the appropriateness and effectiveness of risk management and internal control. Internal audit is a fundamental part of corporate governance that ensures that the organisation operates effectively, efficiently and economically. The Finance and Audit Committee acts as a forum to oversee the planning, performance and reporting of the Internal Auditor. The internal audit contractor (KPMG) met with the Finance and Audit Committee on the following occasions during
Page 26
QIMR Annual Report 2010–2011
the period 1 July 2010 – 30 June 2011: 27 August 2010, 26 November 2010, 25 February 2011 and 10 June 2011. The approach taken to identifying areas of significant risk combines a focus on both cyclical reviews of core business processes as well as reviews of key risk areas. KPMG’s integrated Governance, Risk and Controls (GRC) Framework builds on a traditional internal audit model to take a holistic view of QIMR’s key objectives, risks, controls and supporting structure across the organisation. In formulating an internal audit plan for presentation to the Finance and Audit Committee for approval, consideration is given to past internal audit findings, recent and forthcoming changes in systems and processes, key business risks and the period since the last internal audit of each core business process. Annual internal audit plans are prepared and presented to the Finance and Audit Committee prior to the commencement of each financial year. The internal audit function has observed the terms of its charter and has due regard to Queensland Treasury’s Audit Committee Guidelines.
external Scrutiny QIMR was not subject to any reports of any parliamentary committees, the Crime and Misconduct committee or the Queensland Ombudsman.
Whistleblowers protection act 1994 No public interest disclosures were received during the 2010–2011 reporting year.
information systems and recordkeeping QIMR maintains full and accurate records of its activities in accordance with the Public Records Act 2002, Information Standard 40 and Information Standard 31. The QIMR Recordkeeping Policy 2008 was established and adopted to provide an organisation-wide policy on the management of documents and records, both hardcopy and electronic. QIMR has implemented a single, official records and electronic document management system called Total Records and Information Management (TRIM) Context. The implementation of TRIM Context has enabled QIMR to maximise the value of records with consistent and timely capture. It also improves accessibility, reduces duplication and promotes informationsharing across the organisation. Records are not disposed of, or archived, unless their disposal is authorised under the Public Records Act 2002 or by reference to the Retention and Disposal Schedule approved by the Queensland Studies Authority (QSA). All QIMR records are registered into TRIM Context before transfer to the off-site storage provider or QSA. All QIMR hardcopy records stored off-site are managed under legislatively appropriate risk management standards and guidelines.
our management executive management Director and CEO, Professor Frank Gannon Professor Frank Gannon is QIMR’s seventh Director and CEO. In that role he is responsible for the research work undertaken by the Institute and management of our employees, under the overall control of the Council. Professor Frank Gannon joined QIMR as Director and CEO in January 2011. Previously, Professor Gannon was the Director General at Science Foundation Ireland (SFI) from 2007. From 1994–2007, Professor Gannon was the Executive Director of the European Molecular Biology Organisation (EMBO) and Senior Scientist at the European Molecular Biology Laboratory (EMBL), based in Germany; and Director of the National Diagnostic Centre and Associate Professor in the Department of Microbiology at University College Galway, Ireland (1981–1994). He obtained a Bachelor of Science from the National University of Ireland, Galway in 1970, a PhD from the University of Leicester, England in 1973, was a post-doctoral fellow at the University of Madison Wisconsin, USA from 1973 to 1975, and Chargé de Recherche in INSERM at the University of Strasbourg, France from 1975 to 1981, when he returned to Galway. His major research interest is the expression and functional regulation of the oestrogen receptor, which plays a major role in breast cancer and osteoporosis. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers. Professor Gannon has authored over 200 research articles published in international journals. In addition, from 2000–2008, he contributed to a monthly editorial to EMBO Reports of which he was founding Senior Editor and also writes extensively on diverse topics related to science policy. Professor Gannon has seven patent applications, four of which are active and was the founder of both Bimini Ltd (1990) and Elara Pharmaceuticals (2006). He was a member of the interim Board of Science Foundation Ireland from 2002 to 2004 and was elected as a Member of the Royal Irish Academy in May 2008. He has been awarded honorary Doctorates by the University of Jozsef Attila Szeged (Hungary), The University of Queensland and Queens University Belfast (Northern Ireland). He has served on a range of high-level scientific advisory boards at institutes throughout the world and was co-founder of the European Life Sciences Forum (ELSF) and the Initiative for Science Europe (ISE) that played significant roles in the establishment of the European Research Council (ERC). He was Vice President of the European Heads of Research Council and an advisor to the European Union Commissioner for Research and Innovation prior to his move to Brisbane.
Page 27
management advisory group (mag) membership Program/Department Director:
Professor Frank Gannon
Deputy Director:
Professor Adèle Green
Chief Operating Officer:
Ms Donna Hancock
Program Coordinators:
Professor Georgia Chenevix-Trench
Cancer
Professor James McCarthy
Infectious Diseases
Professor Michael Breakspear
Mental Health/Complex Disorders
Professor Geoff Hill
Immunology
Professor Emma Whitelaw
Cell and Molecular Biology
Professor Grant Montgomery
Genetics Computational Biology
Professor David Whiteman
Population Health
Professor Denise Doolan
Biology
Department Coordinators:
Secretary:
Ms Nerida Fox
Standing left to right: Professor Emma Whitelaw, Professor Geoff Hill, Professor Grant Montgomery, Professor James McCarthy, Professor Michael Breakspear, Professor Denise Doolan, and Professor David Whiteman Sitting left to right: Professor Adèle Green, Professor Frank Gannon, Ms Donna Hancock Absent: Professor Georgia Chenevix-Trench
Page 28
QIMR Annual Report 2010–2011
Adèle Green
Grant Montgomery
AC MBBS MSc PhD
BAgSc (Hons) PhD
Deputy Director, QIMR Head, Cancer and Population Studies Group, QIMR
Coordinator, Genetics Department, QIMR Coordinator, Computational Biology Department, QIMR Head, Molecular Epidemiology Laboratory, QIMR
Adèle Green is the Deputy Director of QIMR and Head of QIMR’s Cancer and Population Studies Group. She has served on national and international health and research committees including the NHMRC, and the Scientific Council of the International Agency for Research on Cancer. She is currently a member of the International Commission on Non-Ionising Radiation Protection and its Epidemiology Standing Committee. In 2004, Professor Green was awarded a Companion of the Order of Australia (AC) for “Service to medical research to public health including improved Indigenous health, and for leadership in the wider scientific community”. Georgia Chenevix-Trench BA (Hons) BSc PhD
NHMRC Senior Principal Research Fellow Coordinator, Cancer Program, QIMR Head, Cancer Genetics Laboratory, QIMR Georgia Chenevix-Trench is a NHMRC Senior Principal Research Fellow and Head of the Cancer Genetics Laboratory at QIMR. She is also the conjoint Professor in the Division of Health Sciences at The University of Queensland. She holds a BA (Hons) from the Department of Genetics at Trinity College in Ireland, and was awarded a PhD in 1985 from the Department of Human Genetics at the Medical College of Virginia, USA. Her current research focuses mainly on the study of genes that predispose stomach, breast and ovarian cancers, and genes involved in response to chemotherapy in ovarian cancer patients. She has played a leading role in national efforts to establish resources for this kind of research, and is involved in many international consortia aimed at coordinating these gene finding efforts. She possesses an impressive national and international profile, with invitations to speak at many high profile conferences. She was the Sutherland Lecturer at the International Congress of Human Genetics in 2006. She has received funding from many national and international grant funding bodies, and published more than 200 papers in peer reviewed journals.
Professor Montgomery graduated with a PhD from Massey University, Palmerston North in 1977 and spent the first 20 years of his career working in animal reproduction and genetics in New Zealand. He trained in endocrinology, including two years as a postdoctoral fellow at the Institute National de la Researches Agronomique, Tours, France. After returning to New Zealand, he set up a genomics laboratory located in the Biochemistry Department at the University of Otago and helped build the first sheep genetic map and mapped and cloned genes affecting twinning frequency. He moved to QIMR in 1999 and is currently an NHMRC Principal Research Fellow, Head of the Molecular Epidemiology Laboratory, Coordinator of the Genetics Division at QIMR, and a co-leader of the International ENDOGENE Consortium. The goal of Professor Montgomery’s research is to determine critical genes and pathways increasing risk for common diseases, with specific interests in the genetics of endometriosis, melanoma and inflammatory bowel disease. Emma Whitelaw BSc (Hons) PhD
NHMRC Australia Fellow Coordinator, Cell and Molecular Biology Department, QIMR Head, Epigenetics Laboratory, QIMR Emma Whitelaw is an NHMRC Australia Fellow at QIMR. After completing her undergraduate degree at the Australian National University, she obtained a Doctor of Philosophy at the University of Oxford and remained working in London and Oxford for the next 15 years, moving back to Australia in 1991. She was offered a Senior Lectureship at the University of Sydney and carried out both teaching and research. She has focused her research on eukaryotic transcription using the mouse as a model organism. Her most notable research achievements are in the area of epigenetics. In particular, her studies on the transgenerational inheritance of epigenetic marks have stimulated a great deal of interest from the wider scientific community. In 2008, she was awarded an Australia Fellowship, the most prestigious fellowship in medical research in Australia. In 2011 Professor Whitelaw, was elected as an Australian Academy of Science Fellow, and received both the Australia and New Zealand Society for Cell and Developmental Biology President’s Medal and the International Union of Biochemistry and Molecular Biology Jubilee Medal.
Page 29
management advisory group (mag) membership | continued James McCarthy
Michael Breakspear
MBBS MD FRACP DHTM
BSc (Med Hons) BA (Hons) MBBS PhD FRANZCP
Coordinator, Infectious Diseases Program, QIMR Head, Clinical Tropical Medicine Laboratory QIMR Senior Consultant Infectious Diseases Physician, RBWH Professor of Medicine, The University of Queensland After graduating in Medicine from the University of Melbourne in 1984, James McCarthy undertook postgraduate training in Internal Medicine and Infectious Diseases in Australia, the UK and the USA. He then undertook research training in molecular parasitology at the Laboratory of Parasitic Diseases, NIH (1991–1996), graduating as a Doctor of Medicine in 1997. He returned to Australia in 1996 to take a post in the Department of Medicine at the University of Western Australia, before moving to QIMR in 2002. At QIMR his research focuses on translational aspects of vaccines, drugs and diagnostics in tropical diseases. James is an NHMRC Practitioner Fellow and Queensland Health Research Fellow. He serves on the Editorial Board of the American Journal of Tropical Medicine, the International Journal of Parasitology and as Associate Editor of PLoS Neglected Tropical Diseases. His laboratory includes a multidisciplinary team of scientists undertaking bench research, a regulatory affairs specialist in clinical trial management, and staff and students undertaking epidemiologic studies and clinical research. Sources of research funding include competitive grants from NHMRC, Medicines for Malaria, and Queensland Health, and the World Health Organization. Geoff Hill MBChB MD BHB FRCPA FRACP
NHMRC Australia Fellow Coordinator, Immunology Department, QIMR Head, Bone Marrow Transplantation Laboratory, QIMR Geoff Hill is a medical graduate of the University of Auckland and haematologist, training in New Zealand, The Dana Farber Cancer Institute, and Harvard Medical School in Boston. He is a NHMRC Australia Fellow and his immunology laboratory focuses on the interactions between cytokines, antigen presenting cells and regulatory cells during transplantation. Professor Hill was 2005 Queenslander of the Year and recipient of the Transplantation Society of Australia and New Zealand 2009 Ian McKenzie Award for excellence within basic and clinical research in the transplant field. He was also awarded a Queensland Health Senior Clinical Research Fellowship in 2010 to translate new therapies into clinic practice; and in 2011 received a prestigious NHMRC Australia Fellowship worth $800,000 annually for five years.
Page 30
QIMR Annual Report 2010–2011
Coordinator, Mental Health/Complex Disorders Program, QIMR Head, Systems Neuroscience Laboratory, QIMR Michael Breakspear undertook undergraduate studies at the University of Sydney, graduating in 1994 with Honours in Arts, Science and Medicine. Following three years of basic medical residency, he commenced training in clinical psychiatry at St Vincent’s Hospital, Sydney, and a concurrent PhD at the University of Sydney. After completing post-doctoral fellowships in Physics at the University of Sydney and the Black Dog Institute, he became an Associate Professor in Psychiatry at the University of New South Wales in 2006. He accepted the position of Head of a new Division of Mental Health Research at QIMR in 2008. This division aims to add the latest advances in neuroscience to the Institute’s internationally renowned expertise in genetics, cell biology and population health. He has also completed his clinical training and is a Fellow of the Royal Australian and New Zealand College of Psychiatrists. Michael’s expertise lies in both computational and experimental neurosciences. He has made theoretical, methodological and empirical contributions in a “system’s neuroscience” framework that sees the brain as a complex, dynamical network. His interests are in the application of this framework to underpin a novel generation of diagnostic brain imaging tests in clinical psychiatry. He is a chief investigator on a number of major national and international grants totalling approximately $8 million and leads an independently funded research team of 10 young students and scientists. He is a Section Editor at NeuroImage, a major international brain imaging journal. Donna Hancock BCom MBA MAICD
Secretary and Chief Operating Officer, QIMR Donna Hancock is the Chief Operating Officer, Secretary to QIMR Council and heads the Corporate Division. She holds a Bachelor of Commerce from Newcastle University and a Masters in Business Administration from the University of Melbourne. She has an extensive background in finance, business planning, business development, systems development and commercial management. Prior to joining QIMR, Donna worked for over 20 years as a senior executive with BHP Billiton. Donna is a director of Q-Pharm Pty Ltd, a member of the Medical Board of Australia (Qld Registrations Committee) and a former member of the Pharmacists Board of Queensland.
David Whiteman
Denise Doolan
BMedSc MBBS (Hons) PhD FAFPHM
BSc (Hons) MPh PhD
Australian Research Council Future Fellow Coordinator, Population Health Department, QIMR Head, Cancer Control Laboratory, QIMR
Pfizer Australia Research Fellow, 2007–2011 Coordinator, Biology Department, QIMR Head, Molecular Vaccinology Laboratory, QIMR
David Whiteman is a medical epidemiologist with a special interest in the causes, diagnosis, prevention and treatment of cancer. He received his medical degree from The University of Queensland in 1991. With a PhD in cancer epidemiology at QIMR (1997) and specialist training in Public Health Medicine, David was invited to the University of Oxford as a Nuffield Medical Research Fellow to work in several areas of cancer research. He returned to Queensland in 2000, where he is currently studying the causes of melanoma and diseases of the oesophagus, ovary and skin. In addition to his research activities, he is currently a member of the Academy of the NHMRC, the National Research Advisory Committee for Cancer Australia, the Research Committees of Cure Cancer Australia Foundation and Wesley Research Institute, and the Fellowships Committee of the International Agency for Research on Cancer. He has previously served as a Member of Council of NHMRC, and served on the NHMRC National Asbestos Research Working Group and the NHMRC Strategic Research Development Committee. In 2006, he was awarded a Fulbright Scholarship to visit cancer researchers in the USA.
Denise Doolan graduated from The University of Queensland with a Bachelor of Science (Honours) (Biochemistry major) in 1985. She began her research career at the CSIRO and was subsequently awarded an MPhil in 1991. In 1993, she completed her PhD in the laboratory of Professor Michael Good at QIMR and went on to complete a postdoctoral fellowship at the Naval Medical Research Institute in the USA where she worked with Dr Stephen Hoffman to develop malaria vaccines. She was later appointed as Head of Basic Research, and later Head of Preclinical Research and Development, and finally as Scientific Director of the Naval Medical Research Center Malaria Program, a major biomedical research facility of the United States Department of Defence. Professor Doolan returned to Australia in 2006 and was awarded a Pfizer Australia Senior Research Fellowship, establishing the Molecular Vaccinology Laboratory at QIMR in 2007. Subsequently, she was appointed as Professor, Griffith Medical Research College, Griffith University, and as Professor, School of Medicine, The University of Queensland. Her laboratory investigates the molecular basis of immunity to disease and vaccine development, with a focus on malaria.
Page 31
Page 32
QIMR Annual Report 2010–2011
ouR peRFoRmAnCe
Translation Scientific quality Commercial consequence Societal impacts International reputation
Page 33
Translation In order to improve the health of all, scientific discoveries need to be translated from the laboratory into the clinic. QIMR was the prototype of what is, today, referred to as a translational medical research institute. It is one of Australia’s only fully integrated biomedical research and development centres. Translational research undertaken at QIMR has lead to the development of a T cell therapy for EBV-associated nasopharyngeal carcinoma; influenced a major change in clinical practice with the acceptance that it is important to remove proximal serrated polyps; and human clinical trials are underway using a monoclonal antibody developed at QIMR for the teatment of acute leukaemias, melanomas, brain tumours and lung cancers.
Page 34
translation facilities
Q-gen
QIMR is one of Australia’s only fully integrated biomedical research and development centres. Within the Institute, there is the capability to translate fundamental basic research from the discovery phase through development, scale-up and manufacture, to Phase I and II clinical trials.
Q-Gen is licensed by the Therapeutic Goods Administration (TGA) for the maintenance and storage of working cell banks, the storage on site of cellular products. The TGA license makes Q-Gen one of a very small number of organisations in Australia able to store human samples under GMP conditions.
QIMR also has facilities for the manufacture of cell-based and molecular therapies. Co-located within the Institute is an associated commercial Phase I/II clinical trials facility, Q-Pharm Pty Ltd, providing QIMR scientists and external clients the capability to take research findings from bench to the bedside.
Q-Gen is one of the largest facilities of its type in Australia, with 13 ISO Class 7 clean rooms. Each clean room is fully equipped for the manufacture of clinical therapies.
QIMR Annual Report 2010–2011
Q-Gen provides QIMR with a unique facility to conduct its translational research and processes for clinical therapies and is currently utilised in the manufacture of a number of QIMR sponsored developmental immunotherapies. Under a joint funding agreement with Therapeutic Innovation Australia (formerly Research Infrastructure Support Services) and the Australian Red Cross Blood Service, Q-Gen is able to manufacture clinical trial products for eligible external researchers.
Q-pharm Q-Pharm is a specialist contract research organisation that conducts early phase clinical trials of pharmaceutical and biotechnology products spanning the areas of therapeutic, diagnostic and disease prevention agents. In order to facilitate the translation of QIMR’s research into clinical practice, QIMR holds a 24.5% share in Q-Pharm. The company offers the best appointed early phase clinical trials facilities in Australasia, which include recruitment and outpatient clinics, a specialised 18-bed clinic for the conduct of the most medically demanding trials and an open plan 24 bed facility for larger healthy volunteer trials.
clinical collaborations Because of its close proximity to major teaching hospitals and The University of Queensland Medical School, QIMR is ideally placed for clinical research collaborations. It has a proud history of working closely with hospitals, in particular the RBWH. Clinicians have research groups in QIMR and medical researchers in QIMR have clinical sessions at the RBWH. QIMR’s researchers also have significant relationships with clinicians nationally and internationally. Last year, 64% of QIMR researchers collaborated with clinicians in over 100 projects, in hospitals worldwide. Some of QIMR’s current clinical collaborations include: • Collection of samples from cystic fibrosis, glioma, ataxiatelangiectasia, melanoma and oesophageal cancer patients for genetic, tissue and cell culture studies (Prince Charles Hospital, BrizBrain and Spine, Wesley Hospital, RBWH, Greenslopes Hospital, St Vincent’s Hospital, Murdoch Children’s Research Institute, Royal Brisbane Children’s Hospital, Princess Alexandra Hospital); • Recruitment of patients into national tissue and data bank (Flinders University, University of New South Wales); • Looking at the effect of advanced paternal age on risk of autism or schizophrenia (Queensland Centre for Schizophrenia Research, Wolston Park Hospital, Brain Research Institute);
In 2010–2011, QIMR’s clinical collaborations have produced a range of significant outcomes: • Helped better identify patients at high risk of developing primary melanoma; • Identified a novel oncogene in asbestos-related lung cancers; • Identified a microRNA that appears to suppress lung cancer development; • Discovered that major depression consists of multiple partly overlapping subtypes and bipolar depression, in comparison to unipolar depression, has a distinct clinical profile; • Discovered that working memory-related cortical activity predicts functional decline in people with mild cognitive impairment; and • Showing that patients with haemochromatosis are at increased risk of colon and breast cancer.
Drug discovery The discovery of small molecules or related agents, reveal new insights and new biological pathways, which may ultimately lead to the development of therapeutics for a range of human diseases. Examples of drug discovery projects currently underway at QIMR include screening for: • Small molecules that might inhibit or enhance membrane iron transport, or that interfere with the action of iron regulatory molecules such as hepcidin (implications for disorders of iron metabolism); • Drugs that convert hepatic stellate cells to myofibroblasts or reverse the conversion (implications for therapeutic intervention in chronic liver disease); • Modifiers of p53 regulation, in cell lines where novel proteins involved in the regulation of p53 have been deleted (implications for cancer treatment); • Antimalarial (antigametocyte) drugs;
• Assessing disease risk in patients with haemochromatosis (Royal Children’s Hospital Melbourne, University of Western Australia, RBWH);
• Novel compounds to improve the efficacy of malaria vaccines, especially compounds that stimulate a robust cell mediated immune responses to malaria in vivo;
• Investigating the role of Epstein-Barr virus in multiple sclerosis (RBWH);
• Compounds that affect the immune system (immunomodulators);
• Ongoing collection of samples of diffuse large B cell lymphoma (Westmead Hospital, Princess Alexandra Hospital);
• Protease inhibitors in malaria;
• Developing a model for scabies to study the interaction between scabies mite and bacterial infection (RBWH, Royal Darwin Hospital); and • Identifying serum and tissue biomarkers to predict outcome in biliary atresia and cystic fibrosis liver disease (St Louis Children’s Hospital, St Louis and Washington University).
• Antibacterials, especially against group A streptococcus; • Activators or inhibitors of ATM kinase to target DNA damage pathways in cancer; • Synergistic modulators of pathways in breast cancer cells; • Inhibitors of MIC-1 transcription in reporter cancer cells; and • Inhibitors of HIV-1 Tat medicated transactivation using a dual luciferase cell based assay in order to develop a treatment for HIV.
Page 35
Vaccine development The Australian Centre for Vaccine Development (ACVD) at QIMR is one of the largest vaccine research centres in Australia. It provides opportunities for its members to develop collaborative links with national and international academic institutions and the biotechnology industry and also provides a platform for young Australian and international scientists to develop new techniques in the field of vaccine research. ACVD is collaborating with internationally renowned Emory Vaccine Centre (EVC) Atlanta, USA under the Queensland Government funded National and International Smart State Research Program (Queensland-US Vaccine Technology Alliance) to explore new technologies that can be used to develop and improve vaccines. Both organisations have strong links with the biotechnology industry and health institutions that are being leveraged to translate the outcomes of research from bench to bedside, which will have significant implications for improving health outcomes for Australians. This collaborative program is also aiming to bring new technologies to Queensland and create training and employment opportunities for Queenslanders. ACVD has unique expertise and resources in antigen discovery with a strong focus on immunomics, bioinformatics and high throughput re-sequencing. This approach allows rapid whole genome scanning of infectious pathogens and cancer antigens to map novel vaccine determinants. The major achievements for the ACVD include: • Completion of in vitro screen of natural products library as immune adjuvants capable of activating innate immunity; • Completion of Phase I of clinical testing of novel immunotherapy for nasopharyngeal carcinoma patients; • In vivo immune analysis of natural products identified through in vitro screen with primary objective to identify the most promising candidates for further research;
• Establishment of collaborative links with international biotechnology companies on the development and testing of a vaccine to prevent birth defects in newborn babies; • Initiation of project aiming to conduct gene signature analysis of potential immune adjuvants identified using natural product library; • Development of strategies to revert the dysfunctional cellular and humoral anti-viral response (e.g. targeting of PD-1); and • Establishment of collaborative studies with RBWH and BrizBrain and Spine (Wesley Hospital) to test novel killer T cell therapy for stem cell transplant and brain cancer patients respectively;
current clinical trials Fundamental research at QIMR in 2010–2011 underpinned a number of clinical trials that may ultimately lead to improved treatment options for patients. Some highlights include: • Began Phase I clinical trials using a monoclonal antibody as a potential cancer treatment for acute leukaemias, melanomas, brain tumours and lung cancers; • Completed a human malaria infection study to develop a sensitive protocol for testing new antimalarial drugs; • Completed an EBV immunotherapy trial; • Developed a killer T cell therapy for EBV-associated nasopharyngeal carcinoma; • Completed the preclinical testing of a prophylactic vaccine for cytomegalovirus. A Phase I clinical trial is planned for this vaccine, which aims to prevent clinical complications in transplant patients and newborn babies; • Continued trialling a novel immunotherapy for brain cancer; and • Started a clinical trial of a novel immune-based diagnostic tool for cytomegalovirus.
QIMR’s fundamental research has led to the development of a potential cancer therapy QIMR’s fundamental research has lead to the development of a potential cancer therapy.
neck cancers and other solid tumours where injection can be guided by imaging.
EBC-46 is a novel and highly potent compound in development for local treatment of solid tumours. Research by QIMR’s Professor Peter Parsons from the Drug Discovery Laboratory has assisted in this compound being further developed by QBiotics.
Although only in late pre-clinical development for humans, QIMR and QBiotics have conducted studies in laboratory cell culture and in mice. They have also successfully treated dogs, cats and horses with advanced spontaneous tumours that were considered untreatable with current standards of care.
EBC-46 has potential applications for skin cancers including melanomas, squamous cell carcinomas (SCC) and basal cell carcinomas (BCC); head and
Page 36
QIMR Annual Report 2010–2011
QIMR researchers continue to uncover the mode of action of this compound to develop analogues and other potential anti-cancer therapies.
Scientific quality QIMR’s philosophy is to support scientists who perform world-class medical research aimed at improving the health and well being of all people. QIMR has demonstrated scientific quality in a number of ways in 2010-2011 including producing 567 peer reviewed publications, securing more than $21 million of competitive NHMRC funding, as well as producing a range of world-class research outcomes across its 50 laboratories. QIMR will continue to strive for the highest standard of scientific quality by attracting outstanding researchers; producing and contributing to publications and high-impact publications; and gaining ongoing support from funding bodies to continue our medical research.
publications Publications and citations are a key indicator of achievement and excellence in academic research and are a core output of QIMR. Confirming our ongoing pursuit of excellence in science, researchers at QIMR contributed to 567 scientific publications; a significant increase on 390 publications in 2009–2010 and 419 in the 2008–2009 financial year. Not only have the number of publications increased but at the same time the quality of the research has improved. Of these 567 publications, 61 were published in very high impact journals (those with an impact factor over 10); compared to 55 in 2009–2010, and 42 in 2008–2009. For a full list of publications, see page 133.
Scientific publications 600 500 400 300 200 100 0
2007
Articles
2008
2009
2010
2011
High Impacts (publications in journals with impact factors of 10 or more)
Page 37
This year, QIMR researchers been published in a range of high impact scientific journals such as Science, Nature and Nature Genetics. These include articles on: • the genetics of breast and ovarian cancer, migraine, myopia (short or long sightedness), open angle glaucoma, endometriosis, ulcerative colitis, height, and personality traits (Nature Genetics); • DNA damage and repair mechanisms in Science; • the genetics of human height and new genes associated with blood lipids, a key indicator of heart disease (Nature); • training T cells to fight malaria (Nature Medicine); • diagnosing and treating schistosomiasis, a parasitic disease that affects 207 million people worldwide (British Medical Journal (BMJ) and Lancet Infectious Diseases); and • papillomaviruses and the number of cases of non-melanoma skin cancer (BMJ).
• Associate Professor Don Gardiner presenting at the Medicines for Malaria Venture ESCA Meeting in Geneva in October 2010; • Professor Denise Doolan presenting at the International Congress of Parasitology in Melbourne in August 2010; • Professor Grant Montgomery discussed the genetics of endometriosis at the Society for Gynaecological Investigation in Miami in March 2011; and • Professor Jeff Gorman spoke at the Australian Proteomics Society in Lorne in February 2011. For a full list of invited lectures, see page 112.
Institute staff members also received over 90 local and international awards in the last financial year, including:
QIMR was recognised and gained support for our innovative work, with researchers securing more than $21 million in funding from the National Health and Medical Research Council (NHMRC). Funds were provided from 1 January 2011 for a total of 17 new research projects ranging from the genetics of brain structure and function, to understanding the causes of breast and ovarian cancer and risks, to improving the health of Indigenous populations.
nHmrc grants awarded ($ millions) 20
15
• Professor Emma Whitelaw, Head of the Epigenetics Laboratory, was elected as an Australian Academy of Science Fellow, and received both the Australia and New Zealand Society for Cell and Developmental Biology President’s Medal and The International Union of Biochemistry and Molecular Biology Jubilee Medal; • Professor Geoff Hill receiving an Australian Fellowship. Australian Fellowships are the most prestigious of the NHMRC fellowships and awards, with only six awarded this year. They are designed to support the most outstanding and creative health and medical researchers across the range of disciplines in biomedical, clinical, health services and public health research and are highly competitive among leading researchers both in Australia and around the world. • Professor Don McManus, Professor Rajiv Khanna and Dr David Duffy received Senior Principal Research Fellowships from the NHMRC;
10
• Dr Darren Gray was awarded Publication of the Year by Griffith University;
5
2007
2008
Grants
2009
2010
2011
Fellowships
employment Ensuring the ongoing quality of research, QIMR employed 17 NHMRC Fellows in 2010–2011.
Page 38
QIMR researchers are well respected throughout Australia and the world and were invited to speak about their work at over 340 lectures in 2010–2011, including:
awards
funding
0
invited lectures
QIMR Annual Report 2010–2011
• Dr Susan Woods received the Queensland Senior Researcher Award from the Australian Society for Medical Research; • Dr Patricia Valery, from the Indigenous Health Program, was awarded a NHMRC Excellence Award, the highest ranking Career Development Award in the category of population health; and • Dr Sarah Medland from the Genetic Epidemiology Laboratory was awarded a 2010 Queensland Young Tall Poppy Science Award. For a full list of awards, see page 111.
postgraduate students Today’s students are the scientists of the future, so in order to ensure the continuation of the Institute’s scientific quality, postgraduate students are an important part of the research effort at QIMR. The excellent research facilities, support services, extensive network of international and national research collaborations, and the internationally-ranked quality of QIMR scientists, combine to provide an outstanding environment for advanced training in health and biomedical research. Mentoring of the students remains a high priority. 2010–2011 was again a productive year for students at QIMR with a total of nine PhD students, five Research Masters and 10 Honours students successfully graduating from their degree programs. During the year, the Institute admitted 17 new PhD, two Research Masters, two coursework Masters and 20 Honours students. Janine Whitney joined the Institute under the Australian Government’s Indigenous Cadetship Program. QIMR also hosted 43 visiting students during the year, many from overseas.
QIMR’s postgraduate students have continued to make an impressive impact on the wider scientific community this year with many receiving external awards during their candidature. Highlights include: • Renee Robb, a third year PhD student, was awarded a Young Investigator Award and the President’s Prize from the Transplantation Society of Australia and New Zealand; • Karin Verweij received a Research Excellence Award from the School of Psychology at The University of Queensland; and • Vijayendra Dasari was awarded a Training Fellowship from the ACVD-Emory Vaccine Centre. In total, more than 20 travel awards were received from organisations including the Australian Twin Registry, the Cancer Council Queensland and the Australian Society for Parasitology. These awards allow students to attend and present at conferences within Australia and overseas. PhD students Franziska Bieri, Yi Lu and Maggy Sikulu were also awarded prizes for their conference presentations.
Top recognition for QIMR researchers australia fellowship The Australia Fellowships, awarded by the NHMRC, recognise outstanding health and medical researchers across all disciplines. The recipients have international status in their fields and are now conducting research programs of major impact and benefit to Australia. Only 39 Australia Fellowships were ever awarded and two of QIMR researchers, Professors Emma Whitelaw and Geoff Hill are among them.
australian academy of Science fellows Election to the Australian Academy of Science (AAS) Fellowship recognises a research career that has significantly advanced the world’s store of scientific knowledge. QIMR currently has five AAS Fellows: • Professor Brian Kay; • Professor David Kemp; • Professor Nick Martin; • Professor Peter Visscher; and • Professor Emma Whitelaw.
Queensland government fellowships Professor James McCarthy and Professor Michael Breakspear were awarded Health Research Fellowships from the Office of Health and Medical Research for their work in malaria and mental health respectively. Professor Geoff Hill also received a Senior Clinical Research Fellowship for his work in bone marrow transplantation for leukaemia.
Page 39
Commercial consequence QIMR has achieved significant health outcomes and secondary economic benefits through its connections with industry. These include the development of cancer therapeutics, diagnostic targets, cancer vaccines and infectious disease vaccines. Its reputation for excellence is further enhanced through its collaborative projects with companies and its involvement in projects of commercial significance. QIMR undertakes industry sponsored collaborative research with a large number of local, national and international companies. Currently, QIMR has contracts with over 20 national and international biotechnology and pharmaceutical companies. In 2010-2011, 15 new projects were established with companies attracting approximately $2 million in external revenue. QIMR is a strong research partner of Queensland companies CBio and Ecobiotics. Contract research carried out in QIMR has resulted in the discovery and development of cancer therapeutic agents and other commercial products.
related commercial entities QIMR has assisted in the economic development of the State through its involvement in the establishment of start-up companies based in Queensland. QIMR has also been a key research provider to Queensland based company Ecobiotics Ltd since 2004.
Vactx QIMR is a shareholder in VacTx Pty Ltd, a Melbourne based company established to develop vaccine technology arising out of the CRC for Vaccine Technology.
trust for cooperative research centre (crc) for Vaccine technology (crcVt trust i) QIMR is the Trustee of the CRC for Vaccine Technology Trust, a trust managing shares in VacTx Ltd on behalf of the participants of the CRC.
Page 40
QIMR Annual Report 2010–2011
trust for the cooperative research centre (crc) for Vaccine technology (crcVt trust ii) QIMR is the Trustee of the CRC for Vaccine Technology (CRC –VT) Trust (CRCT Trust II), a trust responsible for managing patent families and licensing agreements on behalf of those participating in the CRC for Vaccine Technology, which was abolished in June 2006.
Vaccine Solutions QIMR is a shareholder in Vaccines Solutions Pty Ltd, a company established to commercialise intellectual property resulting from the CRC for Vaccine Technology. The company has key licence agreements with Pfizer Inc.
Q-pharm Q-Pharm Pty Limited is a specialised contract research organisation that undertakes a broad range of early phase (Phase I and Phase II) clinical trials for clients in the global pharmaceutical and biotechnology industries. QIMR holds a 24.5% share and Q-Pharm pays a licence fee per annum to QIMR to lease office, laboratory and clinical trial ward facilities in the Clive Berghofer Cancer Research Centre, and for information technology services and stores services. For details, see page 99.
Business development Through commercial grant proposals and the negotiation of commercial agreements with industry partners, QIMR is working to build and strengthen the Institute’s reputation. The majority of agreements this financial year have been providing research services to Queensland-based Business development agreements
research agreements
industries, and also include collaborative research with large international companies. QIMR’s patent portfolio supports a strong presence in tropical and infectious diseases, with a significant proportion in vaccine technologies. For a full list of patents, see page 127.
Patent portfolio 2010-2011
patent portfolio
Patent portfolio 2010-2011
Research service agreements
Intellectual property agreements
Clinical trial agreements
License agreements
Commercialisation agreements
Others
Research service agreements
Intellectual property agreements
Clinical trial agreements
License agreements
New Treatment Patents
Commercialisation agreements
Others
Drug Target Patents
Vaccine Patents
Diagnostic Patents
New Treatment Patents
Delivery Platform Patents
Vaccine Patents
Drug Target Patents
Life work culminates in testing of cancer therapy in humans Phase I clinical trials have commenced using the monoclonal antibody KB004 to determine if it might be efficacious in humans. It is the culmination of 25 years of research for QIMR researcher Professor Andrew Boyd, Head of the Leukaemia Foundation Laboratory. KB004 has been shown to kill certain types of cancerous tumours in a laboratory using human samples. It is targeted towards EphA3 expressing haematologic malignancies, which are believed to account for about 50% of acute leukaemias as well as a number of other human cancers including a significant proportion of malignant melanomas, brain tumours and lung cancers. KaloBios Pharmaceuticals, a San Francisco biotechnology company took the original mouse antibody and through a process known as Humaneering™ technology, developed an antibody that could be used in humans as it would be more likely to be tolerated by the human immune system.
The initiation of a Phase I clinical trial in patients with acute leukaemia by KaloBios is an important landmark and will hopefully lead to further testing and the ultimate use of this antibody as a treatment. The development of this antibody as an anti-cancer therapeutic was the result of a collaboration between QIMR’s Professor Andrew Boyd, Professor Andrew Scott from the Ludwig Institute and Associate Professor Martin Lackmann from Monash University, who initiated and lead the translational aspects of this venture. It would not have been possible without ongoing financial support for Professor Boyd from the Leukaemia Foundation. KB004 is a first-in-class engineered IgG1κ antibody targeting the EphA3 receptor tyrosine kinase. Developed using KaloBios’ proprietary antibody Humaneering™ technology, KB004 has variable regions that are very similar to human germ-line sequences, providing the potential for low immunogenicity in patients. In addition, KB004 is engineered to enhance antibody-dependent cytotoxic (ADCC) activity.
Page 41
Societal impacts QIMR’s mission is better health through medical research. Gaining support from funding bodies, the government and the community, QIMR is committed to performing research which addresses the health needs of our society. The Institute’s research provides valuable information to assist policy makers enhance the health of the wider community and help individuals make well informed decisions about their own health. QIMR researchers also rely on members of the community to support their research by sitting on advisory groups and volunteering to participate in a range of research projects. QIMR ensures the public is informed about our research and is committed to inspiring the students of tomorrow through its education program.
addressing society’s health needs cancer 1 in 2 Australian’s will be affected by cancer before the age of 85. For that reason cancer research continues to be a major focus for QIMR. In 2010-2011, QIMR made a number of important cancer discoveries that can help the community in making informed decisions about their health and lifestyle, including: • Showing that people with many moles, or with a family history of melanoma are significantly more like than others to develop a second melanoma. This result will help identify people who are at higher at risk and require more regular surveillance; • Showing scientifically that the regular use of sunscreen prevents melanoma. The effectiveness of sunscreen to prevent melanomas has been a point of conjecture among researchers and clinicians for many years. This evidence supports the importance of regular sunscreen application, which provides valuable strength to the long running slip slop slap health campaigns; • Finding evidence that long chain fatty acids found in oily fish such as salmon, anchovies and sardines, may be able to precent skin tumour formation, reinforcing the importance of oily fish in a well balanced diet; Page 42
QIMR Annual Report 2010–2011
• Finding that in combination smoking, obesity (BMI ≥30 kg/m2) and acid reflux together accounted for 76% of oesophageal adenocarcinoma cases. When considered separately, smoking, obesity and frequent reflux (≥weekly) accounted for 29%, 23% and 36% of these cancers respectively. This study suggests that these cancers may be largely prevented by maintaining healthy BMI, avoiding smoking and controlling symptomatic gastroesophageal reflux in the population; • Discovering that high intakes of folates from food sources are associated with lower risks of oesophageal cancers; • Demonstrating that regular walking for women undergoing chemotherapy for ovarian cancer is safe, feasible and acceptable to women; • Finding that diets with a high glycaemic load may increase the risk of ovarian cancer, particularly among overweight/obese women, and a high intake of fibre may provide modest protection; and • Discovering an increased risk of both pancreatic and colorectal cancer in the relatives of patients with serrated polyposis, which help identify people at higher risk and require regular checkups.
infectious Diseases Infectious disease is the cornerstone of QIMR, having been established in 1945 to combat tropical diseases affecting Queensland. Researchers at the Institute are world leaders in a range of infectious diseases that affect communities thoughout the world including malaria, HIV, schistosomiasis and scabies. Many of the diseases under study are simultaneously the cause of very significant morbidity and mortality, but are also often understudied by other research groups elsewhere in the world. The infectious agent may be parasitic (e.g. malaria), viral (e.g. HIV/AIDS), or bacterial (e.g. streptococcus A). In 2010–2011, QIMR carried out a number of studies to reduce the spread of infectious diseases through the community, including: • Developing a new system for public health officials to monitor for outbreaks of Ross River virus disease and Barmah Forest virus disease. The VEDS (vector-borne disease early detection and surveillance) system is a joint venture between QIMR and Queensland Health to provide timely data about the prevalence of mosquito-borne diseases within Local Government Areas in Queensland; • Conducting surveys on domestic mosquito breeding in and around Brisbane, using GPS and portable tablets to integrate this data into VEDS. Information collected will help advise local council and residents on strategies to remove potential breeding grounds for mosquitoes and reduce the overall incidence of mospquito-borne diseases; • Commencing a field trial in Cairns to test how well Wolbachia can spread into mosquito populations in the wild and prevent the spread of Dengue Fever; and • Contributing to the World Health Organization Malaria Rapid Diagnostic Tests Product Testing Program (Round 3) to provide invaluable guidance for governments and non-profit organisations that purchase these products.
mental Health/complex Disorders Disorders such as cardiovascular disease, endometriosis, asthma and mental illness are complex to treat and are often poorly understood, despite affecting large numbers of people in Australia and throughout the world. Complex conditions can impact greatly on an individual’s lifestyle and make daily life difficult. QIMR has a dedicated Mental Health/ Complex Disorders Program to investigate these disorders. In 2010–2011, the Program made several discoveries that may offer solutions to individuals to improve their behaviours, and in turn their health, including: • Discovering that eating or drinking full fat dairy may reduce the risk of cardiovascular related death; • Finding 30 new genes that control the age of sexual maturation in women and identified several genetic links between early puberty and body fat; • Developing a Supportive Care Needs Survey for Indigenous People (SCNS-IP) with cancer. The SCNS-IP tool provides a standardised assessment of the supportive care needs of Indigenous adults with cancer in a culturally appropriate manner; and
• Identifying two genetic variants that increase the risk of developing endometriosis, giving hope to patients, by validating he condition which has often been dismissed by clinicians. Endometriosis is a painful, gynaecological disease that is estimated to affect six to ten per cent of all women in their reproductive years.
partnership with the community Much of QIMR’s research could not be completed without contribution from the community. QIMR has teamed up with individuals, patient groups and community groups to conduct a range of research projects including: • QIMR researchers have embarked on the world’s largest skin cancer survey. 200,000 people will be invited to participate. The survey was developed in close consultation with Melanoma Patients Australia. Data collected will support the development of a scientifically based risk assessment tool to be used by all general practicians. This will enable doctors to accurately identify those at greater risk of developing skin cancers and melanomas and to work with the patient to implement risk minimising strategies; • QIMR is heading the largest Australian study of asthma genetics. Over 5,000 people have participated, enabling researchers to search for genes that increase the risk of developing asthma; • Researchers in the Clinical Medicine Laboratory are conducting a human clinical trial on healthy volunteers to develop a sensitive scientific protocol that will enable the testing of potential new antimalarial drugs in a controlled clinical setting; • Depression is the leading cause of disability worldwide (WHO, 1990). In response to this growing health crisis, QIMR’s Mental Health Division, which officially opened on 11 February 2010, continues to be an area of much growth within the Institute. The aim is to work with the community to reduce the stigma of mental illness and improve treatment and access so it is on parity with physical illnesses. An area of focus is the development of a diagnostic tool for depression and other major psychiatric diseases. The techniques will also be applied to identifying depression or early dementia in our ageing population and will rely on volunteers from the healthy population as well as patients suffering from mental illness; and • Over 6,000 identical and non-identical twins have volunteered to assist researchers from the Genetic Epidemiology and Molecular Epidemiology Laboratories disentangle the impact of genes versus environmental on the risk of developing a range of diseases. By studying twin data, QIMR researchers have found genes responsible for: schizophrenia, bipolar disorder, glaucoma, dyslexia, endometriosis, addiction, migraine, and melanoma.
Page 43
community engagement
education program
QIMR strongly values the support of the community and is committed to keeping the public informed about its research outcomes.
To address the decline in the number of students completing science based degrees and to ensure a supply of quality researchers into the future, QIMR’s Education Program aims to inspire the scientists of tomorrow. Over 1,000 senior school students and their teachers from all around Australia have toured QIMR this year and heard first hand from researchers about science and potential career options. This included 600 students and 55 teachers attending the High School Lecture Series and more than 40 students placed in QIMR laboratories as part of the school work experience program.
The External Relations Department’s Community Engagement Program aims to increase community awareness, support and involvement in QIMR’s research. During the past year 4,000 people from 116 different community groups toured QIMR or booked a speaking engagement. QIMR also kept the community informed through a series of research roadshows located at Kedron; Toowoomba; Gold Coast and Nambour. QIMR’s public seminar program continues to provide opportunities for members of the public, community groups, and health specialists to hear from our researchers. This year, a Mental Health Forum was held on 26 October 2010 and a Women’s Health Forum on 16 March 2011.
Other outreach educational activities included a Science and DNA day at Albany Creek primary school; Professor Emma Whitelaw participating in the Scientist-in-Schools program; and QIMR joining Operation Archimedes to support Milpera State High School badly affected by the Queensland floods.
As part of the National Science Week activities, QIMR participated in the annual Exhibition (Ekka) at the Brisbane Showgrounds from 5 – 14 August 2010. Children and adults participated in hands-on science activities including pipetting, diluting, running a DNA gel, as well as examining a range of cells and parasites under microscopes.
QIMR improving health in China PhD student Franziska Bieri from the Molecular Parasitology Laboratory travelled to the remote Chinese province of Hunan to teach local children how to avoid contracting intestinal worms, such as whipworm, hookworm and roundworm. Infection with these worms in children leads to malnutrition, stunted growth and development.
Page 44
QIMR Annual Report 2010–2011
The aim of the project was to improve personal hygiene habits and reduce reinfection. An entertaining cartoon DVD was developed to educate the schoolchildren about the importance of wearing shoes, washing their hands, boiling water for drinking and using lavatories instead of the local river. Over 2,000 children between 9 and 11 years old participated in the study.
International reputation QIMR is an internationally recognised centre for medical research, attracting outstanding researchers, funding and collaborators from around the world. Its research community consists of researchers and students from all corners of the globe. QIMR researchers are highly regarded on the world stage and are regularly invited to participate in international conferences, meetings, committees and lectures. Making their mark on a world-wide scale, QIMR researchers have also won numerous international awards and contribute to various collaborations.
international lectures
international awards
Researchers from QIMR attended and presented at over 145 lectures throughout the world, reflecting its strong international reputation. Specific examples for 2010–2011 include:
QIMR researchers were also recognised internationally with a number of awards:
• Professor Adèle Green was the Plenary Speaker for the British Society for Investigative Dermatology Annual Conference in Manchester; • Associate Professor Grant Ramm was a session chair at the World Congress on Iron Metabolism in Vancouver; • Professor David Whiteman presented at the 1st International Conference on UV and Skin Cancer Prevention in Copenhagen; and • Professor Frank Gannon was invited to deliver the Redfern Lecture at the 50th Anniversary of the Department of Biochemistry at the University of Leicester. For a full list of international lectures please see our invited lectures table on page 112.
• Professor Emma Whitelaw received the International Union of Biochemists and Molecular Biologists Jubilee Medal for her contribution to the understanding of transcription and epigenetic inheritance; • Professor Don Mc Manus received an honorary membership of the American Society of Tropical Medicine and Hygiene, in recognition of outstanding accomplishment by an individual not an American citizen who has made eminent contributions to some phase of tropical medicine and hygiene; • Dr Sarah Medland received the Fulker Awards by the Behavior Genetics Association for the best paper published in Behavior Genetics in 2010; and • QIMR students Karin Verweij and Miriam Mosing received Early Career Investigator Program Travel Awards from the World Congress on Psychiatric Genetics.
Page 45
international conferences/meetings
overseas travel
In 2010–2011, QIMR supported a number of international conferences and meetings including:
Travel by researchers and corporate staff is critical to facilitate collaborations and ensure the Institute keeps pace with new technologies and techniques.
• 7th Indo-Australian Biotechnology Conference in Brisbane, October 2010; • Boden Research Conference in Canberra, November– December 2010 covering Metals in biological systems: structure, catalysis and metabolism; and • International Skin Cancer Research Workshop in Brisbane showcasing the ongoing research into skin cancer in Queensland and Arizona, March 2011.
Attendance of these meetings often give rise to new international contacts that are reflected in the many consortia that QIMR is involved in (see table page 47), in addition to individual international collaborations. For a full list of overseas travel refer to page 132.
international panels/committees Internationally, QIMR researchers are recognised for their expertise and are sought after to hold positions on international boards, societies and publication editorial groups, including: • Professor Frank Gannon Chair of the Selection Panel for the European Research and Innovation Area Board; • Professor Greg Anderson was awarded President Elect of the Society for the International BioIron Society; • Professor David Whiteman is a member of the Fellowships committee for the International Agency for Research on Cancer; and • Professor Don McManus was invited to become an editorial board member on the international Veterinarni Medicina journal.
Nasopharyngeal carcinoma (NPC) trials In Hong Kong, nasopharyngeal carcinoma (NPC) is one of the major cancers of males. This cancer is associated with a virus known as Epstein-Barr virus (EBV). In NPC patients, tumour cells contain EBV proteins while normal cells do not. Researchers at QIMR have used this point of differentiation to develop a new experimental treatment for NPC. Unlike many other cancers, the presence of the EBV virus gives the body’s immune system a definite target. By enhancing the patient’s own immune cells to more effectively target the EBV infected cells, while leaving the non-tumour cells alone, the treatment is noninvasive and nontoxic.
Page 46
QIMR Annual Report 2010–2011
QIMR researchers have used similar immunotherapy techniques to successfully treat heart and lung transplant patients who had developed EBVassociated lymphomas after transplantation. The first stage of the funded trial is to determine if the treatment is safe. NPC patients are recruited in Hong Kong where blood is taken. The blood is flown to QIMR where the white blood cells (lymphocytes) are grown and trained to selectively kill EBV infected cells. The cells are then returned to Hong Kong where they are infused into the patient. The Princess Alexandra Hospital in Brisbane has joined the study, allowing NPC patients in Queensland to participate.
major international collaborations Collaborations are important for sharing resource and expertise, facilitating joint research and publications and building networks and relationships, all of which are essential for scientific excellence. QIMR has a diverse research program as demonstrated by our extensive range of international collaborations including the following: Program
Project
Research
Collaborator locations
Cancer
Ovarian Cancer Association Consortium
Studying genetic and environmental risk factors to inform preventive efforts, screening, future drug development and treatment
Germany, Belgium, USA, Finland, Japan, Denmark, Netherlands, Canada, Poland, UK
Breast Cancer Association Consortium
Analysing genetic and epidemiological data from breast cancer studies from around the world
Ireland, France, Denmark, Spain, Finland Japan, Russia, Sweden, Belgium, Cyprus, Italy, Australia, Mexico, Malaysia, Norway, Nigeria, Finland, Canada, Netherlands, Singapore, Sweden, Korea, Germany, Poland, Thailand, Taiwan, USA, UK
International Melanoma Genetics Consortium
Identifying new melanoma risk genes and assessing genetic and environmental interactions
UK, France, Germany, Israel, Italy, Latvia, Netherlands, Poland, Scotland, Slovenia, Spain, Sweden, USA, Argentina, Brazil, Chile, Colombia, Mexico, Uruguay
kConfab
Understanding the genetics of familial breast cancer
UK, New Zealand
Colon Cancer Family Registry
Increasing our understanding of multiple factors affecting familial colorectal cancer
New Zealand, Canada and USA
Nasopharyngeal Cancer
Developing novels treatments for nasopharyngeal cancer (cancer of the nose and throat)
Hong Kong
Transplant Research
Understanding the causes of graft-versushost disease
North Carolina, USA
Nanotechnology
Developing novel nanoparticle-based iron supplements and metal-based nanoparticles in order to develop novel diagnostic and therapeutic agents
Beijing, China
Eliminate Dengue Project
Developing a biological control to eliminate dengue fever
Vietnam and UK, USA
International Research Alliance for Schistosomiasis Elimination
Developing strategies for eliminating schistosomiasis from developing countries worldwide
US, Switzerland, Mexico, UK and China
Malaria
Assessing the quality of commercially available rapid diagnostic tests and antimalarial drug development
UK, Switzerland and USA
International Schizophrenia Consortium
Identifying the genetic causes of schizophrenia
UK and USA
Psychiatric Genome Wide Association Studies Consortium
Analysing the genetic causes of ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia
USA and Sweden
Indigenous Health
Comparative study: Patterns of care, comorbidities and quality of life of Indigenous and non-Indigenous people with lung, head and neck, breast or gynaecological cancers
New Zealand
Alcohol and Nicotine Dependency
Generation of a large biobank of adult twin families to identify novel genes for nicotine and alcohol dependence
St Louis, USA
Infectious Diseases
Mental Health/ Complex Disorders
Page 47
Page 48
QIMR Annual Report 2010–2011
ouR ReSeARCH
Page 49
Cancer Program professor georgia chenevix-trench, coordinator The Cancer Program consists of 23 laboratories located in QIMR’s Bancroft Centre and the Clive Berghofer Cancer Research Centre. Research carried out in the Cancer Program covers a variety of topics, including: • Identification of the genetic, epigenetic and environmental risk factors that underlie an individual’s risk of cancer;
• Recruitment of 22,000 people to QSkin, which upon completion will be the world’s largest study of melanoma and skin cancer; • Development of a unique mouse model that spontaneously develops melanoma; • Finding that deregulation of the HER3 receptor and its downstream pathway is involved in brain metastases;
• Studying the molecular changes that occur in precursor lesions that can subsequently give rise to cancer and those that occur during the formation of a tumour and its subsequent metastasis; and
• Delineation of the interleukin-17 pathway in chronic graft-versus-host disease following bone marrow transplantation for treatment of leukaemia, and of interleukin-6 in acute graft-versus-host disease;
• Development and testing of novel therapies for cancer in the laboratory and in clinical trials.
• Development of a new compound from the rain forest that has anti-cancer activity;
The Program has a strong focus on skin cancers, including melanoma; hormone-related cancers, such as those of the breast, prostate, ovary and endometrium; leukaemia and lymphoma, including exploring the complications that can arise after stem cell transplantation, which is used for the treatment of leukaemia; brain tumours; and tumours of the gastrointestinal tract. Members of the Cancer Program have productive local and national collaborations with clinical oncologists, pathologists and biobanks, and many are also leading, or are involved in, large international consortia that have made great advances into our understanding of the genes that predispose individuals to many types of cancer.
Page 50
The highlights for the Cancer Research Program in the last year have included:
QIMR Annual Report 2010–2011
• Completion of the first stage of a clinical study in Hong Kong to test a killer T cell-based therapy in patients with advanced nasopharyngeal cancer; and • Acceptance in clinical practise both nationally and internationally that it is important to remove proximal serrated polyps from the colon.
antigen presentation and immunoregulation Laboratory Head: Dr Kelli MacDonald The Antigen Presentation and Immunoregulation Laboratory investigates how donor and host antigen presenting cells contribute to immune responses after haematopoietic stem cell transplantation. This laboratory conducts research on antigen presenting cell (APC) development, mechanisms of antigen presentation and APC induced T cell responses and their regulation.
Bone marrow transplantation Laboratory Head: Professor Geoff Hill The Bone Marrow Transplantation Laboratory works towards understanding the mechanisms by which transplant recipients eradicate leukaemia but also develop life-threatening complications, particularly graft-versus-host disease.
Highlights: • Used a novel CSF-1R blocking antibody (M279) to demonstrate that macrophages protect against the early stages of graft-versus-host disease (GVHD). • Published a study that explains why stem cell transplant recipients of mobilised stem cell grafts develop more chronic GVHD than recipients of bone marrow grafts, and identified the IL-17 pathway and macrophages as therapeutic targets for the prevention and treatment of chronic GVHD. • Identified SOCS3 as a molecule involved in dampening T cell activity during GVHD.
Highlights: • Delineated the IL-17 pathway as controlling factor in chronic graft-versus-host disease, the major late complication of bone marrow transplantation. • Identified IL-6 as a critical pathogenic molecule in acute graft-versus-host disease. • Demonstrated that the SOCS3 molecule regulates immune responses and poor outcome after bone marrow transplantation. • Demonstrated that natural killer cells limit the ability of the immune system to generate killer T cells to control infection.
cancer and population Studies Laboratory Head: Professor Adèle Green The Cancer and Population Studies Group aims to understand the causes of cancer and how to better prevent and manage cancer. The group investigates the roles of environmental and personal factors in the causation of cancer and its precursors, and in cancer prognosis. The group collaborates with clinicians, statisticians and behavioural scientists and also with laboratory scientists to better understand the underlying mechanisms of carcinogenesis. Particular focuses are cancers of the skin and of the pancreas.
cancer control group Laboratory Head: Professor David Whiteman The Cancer Control Group performs research into a number of different cancers, with a view to gaining practical knowledge for preventing these diseases, or limiting their adverse impacts. The need for such research is clear, given that almost one in three deaths in Australia is due to cancer.
Highlights: • Provided the first evidence from a randomised controlled trial that regular use of sunscreen prevents melanoma. • Conducted a 16-year longitudinal population-based study, and showed no association between tobacco smoking and cutaneous squamous cell carcinoma (SCC), suggesting that cutaneous SCC should be taken off the list of tobacco–related cancers. • Found evidence that that long-chain fatty acids found in oily fish such as salmon, anchovies and sardines, may be able to modify and prevent skin tumour formation.
Highlights: • Recruited more than 22,000 people in the world’s largest study of melanoma and skin cancer, QSkin. • Showed that people with many moles, or with a family history of melanoma, are significantly more likely than others to develop a second melanoma. • Showed that obesity, acid reflux and smoking together account for more than 75% of all cases of oesophageal adenocarcinomas in Australia. • Found that high intakes of folates from food sources are associated with lower risks of oesophageal cancers.
Page 51
cancer program | continued cancer council Queensland (ccQ) transgenics Laboratory Head: Associate Professor Graham Kay The CCQ Transgenics Laboratory studies the epigenetic mechanisms that modulate gene expression and the role of tumour suppressor genes in preventing cancer during normal development.
cancer genetics Laboratory Head: Professor Georgia Chenevix-Trench The Cancer Genetics Laboratory investigates why some people get cancer, and how these cancers, particularly those of the breast, ovary and stomach, develop from a normal cell. The laboratory also looks at why these cancers are often found together in the same families and share many similar characteristics.
cancer immunotherapy
Highlights: • Used genome-wide analysis of epigenetic modifications to identify autosomal genes whose expression is modulated by Smchd1. • Developed a unique mouse model that spontaneously develops melanoma.
Highlights: • Identified many genetic variants that increase the risk of breast and/or ovarian cancer, in the general population and in women who are already at high risk because they inherit a mutation in the BRCA1 or BRCA2 genes. • Discovered that genetic variants in the gene that encodes telomerase can also alter a woman’s risk of ovarian cancer. • Found that deregulation of the HER3 receptor and its downstream pathway is involved in the colonisation of brain metastasis, which suggests that anti-HER inhibitors may provide effective therapies.
Highlights:
Laboratory Head: Dr Chris Schmidt
• Optimised a novel technology for examining antigenspecific immune responses.
The focus of the Cancer Immunotherapy Laboratory is on understanding how the immune system succeeds in its fight against malignancies which is central to the future development of cancer immunotherapies.
• Finalised a bank of matched normal and cancer cell lines from melanoma patients. This resource is generally available to researchers through an Enabling Grant from the NHMRC to the Australasian Biospecimen Network. • Developed lentivirus vectors encoding cancer antigens, and found they could stimulate both helper and killer T lymphocytes efficiently.
Page 52
QIMR Annual Report 2010–2011
clinical immunohaemotology
Highlights:
Laboratory Head: Associate Professor Maher Gandhi
• Entered the second year of Phase I clinical trial of adoptive immunotherapy in EBV-positive lymphomas.
The major research area in the Clinical Immunohaemotology Laboratory is the immunobiology of lymphoma. Interests include biomarkers, immuno-evasion, microRNA expression and cellular immunotherapies for virus associated lymphomas.
• Performed an in-depth profile of viral microRNAs in a range of primary samples from histologically diverse EBV-positive lymphomas.
The research aims to understand the basis of lymphoma to devise new treatments that are less toxic and more effective; to establish new biomarkers that will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas.
• Completed the second year of a multi-centre Phase II lymphoma trial, in which the laboratory will perform a correlative study in collaboration with Griffith University. • Established the genetic susceptibility to immune thrombocytopenic purpura. • Characterised the clinical and immunobiological characteristics of a new and highly aggressive EBV-positive lymphoma. • Characterised a subtype of monocyte that has profound immunosuppressive properties in aggressive lymphoma.
Dendritic cells and cancer Laboratory Head: Associate Professor Alejandro Lopez The Dendritic Cells and Cancer Laboratory explores the function of dendritic cells in patients with breast cancer and investigates the role of breast cancer stem cells in the generation of tumours. Resulting findings will yield novel dendritic cell-based immunotherapies.
Highlights: • Generated data supporting a mathematical model for the initiation of cancer. • Identified two molecules that are highly expressed in breast cancer stem cells that could be targets for immunotherapy. • Identified characteristics of the breast cancer cells cultured in vivo that resemble primary tumours. • Characterised a dendritic cell-like line to be used in an animal model of cancer immunotherapy.
Drug Discovery group Laboratory Head: Professor Peter Parsons The Drug Discovery Group combines expertise in cancer biology with genomics and drug discovery. Cell communication networks in serious cancers reveal responses that provide opportunities for prevention and treatment.
Highlights: • Developed a new compound from the rainforest with anti-cancer activity. Studies of the mechanism of action have so far revealed the primary target of the compound, and given important clues about the cell signalling pathways that might be relevant to its action. • Identified key regulators of melanoma invasiveness (in conjunction with the Oncogenomics Laboratory). • Profiled cutaneous squamous cell carcinoma of the head and neck tumours with perineural invasion. • Identified other plants from the rainforest that possess a range of potentially useful bioactivities including antiinflammatory properties.
Page 53
cancer program | continued familial cancer Laboratory Head: Dr Joanne Young The Familial Cancer Laboratory examines the genetic changes that make some families more susceptible to colorectal and other cancers. This work is augmented by tumour pathology studies in families, and epidemiology studies in a multi-ethnic population.
Highlights: • Discovered an increased risk of both pancreatic and colorectal cancer in the relatives of patients with serrated polyposis. • Demonstrated that cryptic mutations in non-coding areas of genes can cause Lynch syndrome. • Confirmed that Lynch syndrome can arise when neither parent is affected, but this is very rare. • Described a model for serrated polyposis involving hypermaturity of the normal bowel wall producing a variety of polyp types. • Found further evidence that genetic background can influence the expression of polyposis through studies of PTEN germline mutation.
gynaecological cancers group Laboratory Head: Associate Professor Penny Webb The Gynaecological Cancers Group investigates all aspects of gynaecological cancer from aetiology to diagnosis, patterns of care, quality of life and survival. A particular focus is on the role of environmental (non-genetic) factors and the interaction between genetic and environmental factors in the causation and prognosis of gynaecological cancer.
Highlights: • Showed that once a woman with ovarian cancer experiences symptoms, shortening the time taken to diagnose her cancer is unlikely to lead to better survival. • Found that approximately half of caregivers of women with ovarian cancer do not meet Australian guidelines for diet and physical activity and more than half report negative behaviour changes after becoming a caregiver. • Showed that a walking intervention for women undergoing chemotherapy for ovarian cancer is safe, feasible and acceptable to women. • Found that diets with a high glycaemic load may increase the risk of ovarian cancer, particularly among overweight/ obese women, and a high intake of fibre may provide modest protection. • Contributed to international studies that identified new genes for ovarian cancer. • Found that women with polycystic ovarian syndrome are at increased risk of endometrial cancer.
Leukaemia foundation of Queensland Laboratory Laboratory Head: Professor Andrew Boyd The Leukaemia Foundation of Queensland Laboratory is exploring the biology of leukaemia and other cancers through studies of leukaemia-associated proteins. A major project is to understand the function of Eph and ephrin membrane proteins in cancer. Members of these protein families are highly expressed in many human cancers where, by actively promoting de-adhesion of cells, they contribute to tumour spread and invasion. The laboratory explores how these proteins function in a number of cancers through work in animal models and through in vitro studies.
Page 54
QIMR Annual Report 2010–2011
Highlights: • Started a clinical trial of anti-EphA3 antibody against leukaemias. • Identified genes that may prove to be key therapy targets in glioma.
molecular cancer epidemiology Laboratory Head: Associate Professor Amanda Spurdle The Molecular Cancer Epidemiology Laboratory studies breast and ovarian cancer, endometrial cancer, colon cancer and prostate cancer, with a focus on identifying molecular signatures of normal and tumour tissue that can point to the genetic and environmental causes of these cancers. The laboratory covers a range of projects with the themes of cancer epidemiology and molecular pathology.
Highlights: • Identified a genetic link between prostate and endometrial cancer. • Confirmed that a prostate cancer locus identified in Japanese patients is also associated with disease in Caucasian individuals. • Developed a qualitative scheme and a quantitative statistical model to interpret the significance of variants in mismatch repair genes, which predispose to familial endometrial and colorectal cancer. • Continued work to assess the role of splicing aberrations as the underlying mechanism for mutation of breast and ovarian cancer predisposition genes BRCA1 and BRCA2, by leading a quality control project within the ENIGMA consortium Splicing Working Group.
oncogenomics Laboratory Head: Professor Nick Hayward The Oncogenomics Laboratory identifies novel cancer genes and studies the way in which defects in these genes are associated with cancer predisposition or development. In particular, the laboratory focuses on melanoma, oesophageal cancer, and endocrine tumours. The laboratory is interested in investigating the process of cancer development at the level of individual cancer predisposition genes, and by looking at the whole genome scale. This work will lead to a better understanding of the genetic events that cause cancer and hopefully better ways of diagnosing or treating cancers in the future.
Highlights: • Completed a genome-wide association study for melanoma and identified two new genes (PARP1 and SETDB1) that confer risk of melanoma in the general population. • Carried out sequencing of selected cases from large melanoma-prone families and identified a variant in the MITF gene that is associated will melanoma susceptibility in some families, as well as the population at large. • Shown that gene expression changes associated with the ability to combat the adverse effects of acid reflux may influence oesophageal cancer risk. • Proven that individuals with Barrett’s oesophagus, a pre-cancerous tissue associated with oesophageal adenocarcinoma, often have chromosomal changes similar to those seen in oesophageal cancer. • Found that expression of GATA4, a general transcription factor, is dysregulated in pancreatic tumours and may contribute to the development of multiple endocrine neoplasia.
radiation Biology and oncology Laboratory Head: Professor Martin Lavin The focus of the Radiation Biology and Oncology Laboratory is DNA damage response and its role in maintaining the integrity of DNA to minimise the risk of cancer and neurodegeneration.
Highlights: • Revealed a new mechanism for activation of the protein defective in ataxia-telangiectasia (A-T) by oxidative stress. • Identified additional sites of autophosphorylation for ATM activation. • Used ATM mouse models to investigate DNA damage signalling and DNA repair. • Developed a new mouse model for the autosomal recessive ataxia with oculomotor apraxia type 2(AOA2). • Contributed to the establishment of a clinic for A-T patients on the Herston campus at UQCCR.
Page 55
cancer program | continued rBWH foundation conjoint gastroenterology Laboratory Head: Professor Barbara Leggett The RBWH Foundation Conjoint Gastroenterology Laboratory identifies genetic changes which define distinct subtypes of colon cancers and premalignant polyps with the aim of predicting the clinical behaviour of these tumours. In this laboratory, scientists collaborate with gastroenterologists, pathologists, surgeons and oncologists on research that is only possible due to the large tissue bank comprised of samples kindly donated by patients.
Highlights: • Influenced a major change in clinical practice with the acceptance nationally and internationally that it is important to remove proximal serrated polyps. • Completed expression and methylation arrays on representative series of serrated polyps and cancers. • Developed a mouse model of mutant BRAF expression in the adult intestine that leads to hyperplasia, which likely equates to early serrated polyp development. • Found that villous change in polyps is associated with increased malignant potential even if it makes up less than 25% of the polyp. • Demonstrated that the bacteria in the bowel are different in the proximal bowel of female subjects where serrated polyps are most likely to occur.
Signal transduction Laboratory Head: Professor Kum Kum Khanna The Signal Transduction Laboratory researches signal transduction pathways involved in the detection, signalling or repair of DNA damage and seeks other genes in these pathways, which might have similar involvement in cancer susceptibility by preventing the generation of mutations in DNA.
Skin carcinogenesis
Highlights: • Discovered that the loss of a new DNA damage repair gene SSB1 is linked with susceptibility to lymphoma. • Identified a new regulator of cell division (FBX031) that is lost in breast cancer. • Developed a novel combination treatment to prevent recurrence and relapse of breast cancer. • Identified a specific target necessary to improve treatment outcomes for patients with triple negative breast cancers.
Highlights:
Laboratory Head: Dr Graeme Walker
• Found that melanoma localisation in the skin is controlled by stem cell factor released by other skin cells.
The Skin Carcinogenesis Laboratory studies the mechanisms by which sun exposure modulates melanoma development.
• Discovered that the Cdk4 gene drives the development of naevi (moles). • Revealed that p53 gene loss in melanocytes resulted in the complete bypass of the precursor stage of melanoma progression. • Completed studying 40 animal model strains, and found one carrying genes that greatly exacerbate melanoma development, and another with genes that dramatically slow it. • Found that stem cells only divide in response to ultraviolet light in the presence of surrounding normal melanocytes. • Constructing a model for the regulation of the activation of follicular melanocyte precursors, leading to better understanding of vitiligo, a condition characterised by white areas of skin due to a complete loss of melanocytes.
Page 56
QIMR Annual Report 2010–2011
Infectious Diseases Program professor James mccarthy, coordinator The 19 laboratories that contribute to QIMR’s Infectious Diseases Program study how a range of important pathogenic organisms cause illness, search for better ways to diagnose and treat them, as well as developing vaccines to prevent infections. A major emphasis of work is on infections that disproportionately affect people living in the developing world and the tropics. Pathogens studied include viruses such as HIV, cytomegalovirus, Epstein Barr virus and mosquito-borne viruses; bacteria such as streptococci; and parasites such as malaria, intestinal protozoa, worms and scabies. One laboratory in the program focuses on the application of proteomic technology to biomedical science. QIMR’s ability to analyse large quantities of data has been enhanced with the establishment of the Bioinformatics Laboratory. This facilitates researchers’ ability to utilise advances in computational science and information technologies to understand biological systems and ultimately provide valuable insights into the causes of diseases. A focus continues to be strong collaborations with clinicians, researchers from within QIMR and other institutes, as well as working with pharmaceutical companies to develop patented therapeutic technologies that improve the health of many. QIMR is a founding member of the Queensland Tropical Health Alliance (QTHA), which is designed to enhance collaborations and networking in tropical health issues. QIMR’s Professor Brian Kay is currently Deputy Director.
Highlights for the Infectious Diseases Program in the last year have included: • Development of molecular methods for rapid and accurate identification of the three human pathogenic streptococci species; • Demonstration that the current diagnostic methods for assessing intravascular catheter related infection are inadequate for the care of critically ill patients; • Successful establishment of the Bioinformatics Laboratory; • Discovery of new regions of Epstein-Barr virus that are targeted by the immune response; • Identification of a series of aminopeptidase inhibitors with potential as new antimalarial drugs, which are currently in the medicinal chemistry phase of development; • The world’s first high throughput screening against malaria parasite gametocytes to identify compounds that are potential antimalarial therapies; • The first gene atlas of multiple schistosome tissues. This dataset is a major resource to the research community in enhancing functional knowledge of key parasite proteins, particularly those used by the helminths in their feeding biology; • Substantial data supporting a causal link between the biology of scabies and associated streptococcal infections; and • Establishment of a system to test antimalarial drugs in human volunteers experimentally infected with malaria parasites.
Page 57
infectiouS DiSeaSeS program | continued Bacterial pathogenesis Laboratory Head: Professor Kadaba Sriprakash The Bacterial Pathogenesis Laboratory undertakes research into Streptococcus and Staphylococcus and other medically important bacteria that cause a wide range of potentially fatal diseases in humans.
Highlights: • Optimised and improved one of the current group A streptococcus (GAS) vaccine candidate molecules so that it remains immunogenic. • Developed molecular methods for rapid and accurate identification of the three human pathogenic streptococci species. • Demonstrated that the current diagnostic methods for assessing intravascular catheter related infection are inadequate for the care of critically ill patients. • Established a multi-locus sequence typing scheme for group G streptococcus (GGS) with collaborators in Portugal and the USA. • Collaborated on a project that will sequence 108 GGS genomes at the Wellcome Trust Sanger Centre, Cambridge, UK.
Bioinformatics Laboratory Head: Dr Lutz Krause The Bioinformatics Laboratory develops and applies computational science and information technologies to biological systems. It specialises in data-mining, machine learning, phylogenetics, computational ecology, efficient algorithms for next-generation sequencing, epigenetics, biomarker-discovery, whole-genome-association studies, and genetics of complex disorders.
cellular immunology Laboratory Head: Associate Professor Scott Burrows The Cellular Immunology Laboratory researches Epstein-Barr virus (EBV) as a way to observe the human immune system. The main focus is the cytotoxic T lymphocyte and factors controlling its primary function in recognising and killing virus-infected cells, which affects vaccine development. By investigating the interaction of the immune system with EBV (a virus that remains in the body for life) it provides insights into how to combat glandular fever and EBVrelated cancers such as nasopharyngeal carcinoma and Hodgkin’s lymphoma.
Page 58
QIMR Annual Report 2010–2011
Highlights: • Developed a computing infrastructure for mining, visualising and interpreting complex molecular biological datasets, which has already been applied in various medical research projects. • Found that epigenetics – modifications of DNA that regulate the activity of genes – could play a role in mental disorders. The research findings could lead to the development of novel biomarkers or treatments. • Demonstrated that used blood catheters are colonised by various different bacteria. These findings are important for preventing and maintaining blood infections, particular in intensive care units.
Highlights: • Discovered new regions of EBV that are targeted by the immune response. • Discovered that inherited deletions in the genes that encode T cell receptors influence the immune response to viral infection.
clinical tropical medicine
Highlights:
Laboratory Head: Professor James McCarthy
• Discovered that the main ingredient of clove oil is as effective against scabies mites as existing therapies.
The Clinical Tropical Medicine Laboratory undertakes translational research in tropical infectious diseases. A particular focus is the identification and testing of new drugs, study of drug resistance, and the development of novel diagnostic techniques.
• Developed and tested a system for experimental malaria infection of human volunteers to test the activity of antimalarial drugs in collaboration with the Malaria Biology Laboratory. • Used its recently developed porcine scabies model to: - demonstrate that Th17 associated cytokines contribute to the severe immune pathology of crusted scabies, a life-threatening and poorly understood complication of scabies; - profile the humoral immune response to Sarcoptes scabiei over the course of infection, thereby informing the development of serodiagnostic tests for scabies; and - completed an exploratory clinical trial to define activity of a licensed veterinary tick treatment against S. scabiei infection. • Completed a study investigating whether hookworm infection improves gluten tolerance in celiac disease and showed no obvious benefit for symptoms. • Developed a motility-based assay to test the efficacy of antihelmintic drugs. • Began a project to investigate the benefits of communitybased de-worming programs in a remote northern Australian Indigenous community.
epstein-Barr Virus Biology Laboratory Head: Professor Denis Moss The Epstein-Barr Virus Biology Laboratory is committed to understanding the biology and immunology of two clinically important human pathogens, namely Epstein-Barr virus (EBV) and vaccinia virus. The EBV Laboratory findings are captured for use in human clinical trials.
Highlights: • Completed an immunotherapy trial in collaboration with the Head and Neck Department, Princess Alexandra Hospital, Brisbane. • Screened 1,000 extracts from EcoBiotics’ plant extract library and identified 240 extracts which may have adjuvant or immunosuppresive activity and will be further studied.
EBV causes glandular fever and is associated with a number of cancers, including lymphomas in transplant patients and a relatively common form of cancer in the back of the nose called nasopharyngeal carcinoma. The EBV Biology Laboratory has a broad interest in all aspects of the biology of the virus and is closely linked with other EBV laboratories within the Immunology Department.
Page 59
infectiouS DiSeaSeS program | continued HiV molecular Virology Laboratory Head: Dr David Harrich The HIV Molecular Virology Laboratory analyses human immunodeficiency virus (HIV) replication. This includes the process by which HIV is able to convert its genetic material composed of RNA into a form compatible with human DNA. The laboratory’s focus is the discovery of key viral or cellular molecules required for HIV to grow, and then to target their action so that HIV growth can be effectively blocked.
Highlights: • Revealed a non-canonical role for translation factors in early steps of HIV replication. • Disrupted HIV-1 Rev trafficking by mutating a HIV Tat protein. • Defined critical parameters of Tat and PRMT6 interaction. • Created a potent HIV-1 inhibitor called Nullbasic that can target the virus replication complex, acting even before a cell becomes infected. Further research will define precisely how the inhibitor functions with a goal to advance this as a new HIV therapy. • Found that human cells treated in the laboratory with gene therapy vectors are strongly resistant to HIV-1 infection.
immunity and Vaccinology Laboratory Head: Associate Professor Colleen Olive The Immunity and Vaccinology Laboratory investigates the immunological mechanisms of pathogen recognition and intracellular signalling pathways that culminate in host immunity, with the objective of developing new vaccines for infectious diseases.
Highlights: • Designed a multifunctional vaccine delivery platform that can be tailored to generate specific types of immune responses against various pathogens through the combination of different Toll-like receptor (TLR) agonists, peptides, and targeting moieties. • Designed a novel group A streptococcal vaccine based on polyfunctional liposomes that is designed to optimally activate key immune cells called dendritic cells (DCs) and provide protection against mucosal bacterial colonisation. • Demonstrated functionality of the vaccine in terms of ability to bind to DCs, stimulate TLRs and induce the production of cytokines required for an effective immune response. • Identified TLR signalling pathways in DCs that may be altered for modulation of immune responses.
immunology and infection Laboratory Head: Dr Christian Engwerda The Immunology and Infection Laboratory studies the host immune response during malaria and leishmaniasis, and aims to distinguish anti-parasitic host immune responses that control disease from those that cause disease.
Highlights: • Identified the lymphotoxin beta receptor found on immune cells as an important therapeutic target to treat visceral leishmaniasis. • Discovered that type I interferons potently suppress antiparasitic T cell responses directed against blood stage malaria parasites. • Showed an interdependent relationship between parasite burden in tissues and the activation status of immune cells in these sites during malaria. This has implications for understanding how disease develops and can be treated.
Page 60
QIMR Annual Report 2010–2011
immunovirology Laboratory Head: Professor Andreas Suhrbier The Immunovirology Laboratory is developing and exploiting knowledge about interactions between viruses and the immune system to develop new anti-cancer, antiviral and antiinflammation strategies. The search for the role of SerpinB2 in inflammatory disease has been a major theme of the laboratory for several years.
Highlights: • Tested chikungunya virus vaccines. • Investigated the activity of ingenol mebutate, a new topical treatment for actinic keratoses and non-melanoma skin cancer. • Investigating further the mechanism of action of chaperonin 10, a new drug being trialled in rheumatoid arthritis and psoriasis patients.
Work on mosquito-borne viruses has been a long standing research field for the laboratory with work on Ross River fever and chikungunya virus, illustrating the importance of immune cells, called macrophages, in the development of arthritis. The research aims to understand how the disease is caused and develop new strategies for treatment.
malaria Biology Laboratory Head: Associate Professor Don Gardiner The Malaria Biology Laboratory researches the molecular and cellular processes involved in critical phases of the malaria parasite life cycle in order to identify novel drug targets and to translate fundamental biological research into new interventions for the control of malaria. The laboratory has a fully integrated research program that uses established research methods in conjunction with recent advances in malaria transgenics, molecular modelling and in vivo and in vitro testing.
Highlights: • Completed two US National Institutes of Health (NIH) funded high throughput screens and identified a series of novel aminopeptidase inhibitors with the potential to undergo development as antimalarial drugs. • Completed a human malaria infection study for testing new antimalarial drugs in collaboration with the Clinical Tropical Medicine Laboratory. • Identified an aminopeptidase inhibitor with potent in vivo antimalarial activity. • Developed a high throughput screening assay for drugs that inhibit the growth and development of malaria parasite gametocytes. • Performing the first high throughput screen against Plasmodium falciparum gametocytes to identify compounds with anti-gametocyte activity.
Page 61
infectiouS DiSeaSeS program | continued malaria Drug resistance and chemotherapy Laboratory Head: Dr Michelle Gatton This Malaria Drug Resistance and Chemotherapy Laboratory studies malaria and selected other mosquito-borne diseases using theoretical and laboratory techniques for the purpose of improving surveillance, diagnosis, treatment and control of those diseases.
Highlights: • Demonstrated a variety of phenotypic changes in vitro that occur when Plasmodium falciparum parasites become resistant to artemisinin. • Established that the amount of HRP2 antigen produced by a parasite varies between different parasite lines and this affects the sensitivity of malaria rapid diagnostic tests. • Identified that pre-existing antibodies against HRP2 in patient blood can block the detection of malaria parasites by some malaria rapid diagnostic tests. • Contributed to the World Health Organization Malaria Rapid Diagnostic Tests Product Testing Program (Round 3) to provide invaluable guidance for governments and non-profit organisations that purchase these products. • Developed statistical methodology to increase the utility of data and results produced by the Schizont Maturation Test when used on Plasmodium vivax parasites. • Estimated the duration of each asexual life stage in Plasmodium vivax, a parasite that can not readily be cultured in the laboratory. • Developed an interactive web-interface for scientists to estimate the age of a mosquito population. • Produced the Vector-borne disease early detection and surveillance (VEDS) system. The VEDS system currently monitors Ross River virus and Barmah Forest virus in real-time in Queensland.
molecular parasitology Laboratory Head: Professor Don McManus The Molecular Parasitology Laboratory researches the biology and epidemiology of parasitic worms of humans and works on developing new interventions and diagnostic procedures that will lead to their elimination. The laboratory researches parasitic worms of humans, particularly schistosome blood flukes, which are responsible for the potentially debilitating disease schistosomiasis (Bilharzia), and dog tapeworms (Echinococcus), which are the cause of hydatid disease.
Highlights: • Determined that the dominant antigen in hydatid cyst fluid, Antigen B (EgAgB), is encoded by a gene family comprising 10 unique genes and that these are expressed at different life cycle stages of Echinococcus granulosus. • Showed that inconsistent protective efficacy and marked polymorphism limits the value of Schistosoma japonicum tetraspanin-2 as a vaccine target. • Determined aspartate aminotransferase, hyaluronic acid and matrix metalloproteinase were reliable and sensitive markers for the diagnosis of fibrosis and cirrhosis in advanced schistosomiasis patients. • Identified cellular and transcriptional features that correlate to the outcome of hepatic pathology using contrasting mouse models.
Page 62
QIMR Annual Report 2010–2011
molecular Vaccinology Laboratory Head: Professor Denise Doolan Research in the Molecular Vaccinology Laboratory investigates the molecular basis of immunity to disease, with a focus on malaria and model systems that can inform the basic immunology, mechanisms and antigenic targets of immunity, and evaluation of candidate vaccines. This laboratory works with humans using samples from areas such as Africa and Papua New Guinea.
Highlights: • Established that T cell responses and antibody responses to the Plasmodium parasite are broadly distributed throughout the genome, suggesting that vaccine efforts restricted to only one or a few parasite proteins are not likely to be highly effective. • Established that antigens that are highly reactive for T cells are not highly reactive for antibody responses. Different approaches are required to identify the most effective targets of T cell responses and antibody responses. • Identified a putative signature of sterile protective immunity against malaria comprising 19 proteins, 17 of which are novel. These proteins are excellent candidates for the development of a malaria vaccine or a diagnostic tool. • Identified novel proteins targeted by T cell responses of individuals with immunity to malaria that are much better targets than current vaccine candidates. These proteins are excellent candidates for a vaccine designed to prevent both the clinical symptoms and transmission of malaria. • Developed an assay for the rapid and reliable analysis of multiple parameters of parasite infection and host response from very small quantities of blood. This assay allows the progression of infection and immune responses to be closely monitored in the laboratory or field.
mosquito control Laboratory Head: Professor Brian Kay Research in the Mosquito Control Laboratory focuses on the biology and control of mosquito-borne viruses such as dengue, Ross River virus and Barmah Forest virus. This laboratory is designated by the World Health Organization (WHO) as an official global Collaborating Centre for Environmental Management for Vector Control. The laboratory specialises in designing new mosquito surveillance and control strategies and has strong collaborative linkages with dengue prevention research groups in Vietnam and Australia and work directly with local government in Queensland regarding mosquito control and all mosquito-transmitted arboviruses. The Mosquito Control Laboratory has the largest quarantine approved insectary in Australia.
Highlights: • Evaluated the safety of infecting mosquito with strains of the endosymbiont bacteria, Wolbachia. • Commenced a field trial in Cairns to now test how well Wolbachia can spread into mosquito populations in the wild. • In collaboration with the Malaria Drug Resistance and Chemotherapy Laboratory, created a decision support tool called VEDS (vector-borne diseases early detection system) to include Barmah Forest, and Ross River virus data and supporting entomological surveillance data. This system is designed to take raw incidence data and transform it into a risk analysis framework to prompt early response. • Conducted surveys on domestic mosquito breeding in and around Brisbane, using GPS and portable tablets to integrate this data into VEDS. • Developed a proteomic assay to determine the age of Aedes aegypti mosquitoes. These assays will be essential to evaluating mosquito control strategies that are designed to modify or shorten life expectancy. • Identified proteins in Anopheles mosquitoes that will be used to evaluate their age.
Page 63
infectiouS DiSeaSeS program | continued parasite cell Biology Laboratory Head: Associate Professor Malcolm Jones The Parasite Cell Biology Laboratory researches three specific parasites: schistosomes (human blood flukes), the hydatid tapeworm Echinococcus granulosus and the malaria parasite Plasmodium. A range of molecular, protein and advanced microstructural characterisation technologies are employed to study the cell biology of these parasites, particularly in relation to their host interactions – an aspect which can be exploited in control strategies.
protein Discovery centre Laboratory Head: Professor Jeff Gorman The Protein Discovery Centre is a state-of-the-art facility in the mass spectrometry and proteomics field. It is one of the most advanced and best equipped of its kind in Australia. The centre collaborates broadly on both national and international projects. The centre aims to discover the identities of proteins involved in and/or affected by physiological and disease processes and the ways in which these proteins function and interact and to develop techniques to observe stimulated cells and the reaction within cell proteins.
Highlights: • Completed a gene atlas of human schistosomes, providing essential functional data on many schistosome molecules for future vaccine development. • Described the native structure of two helminth SAPLIPs+C11 molecules proposed to have major roles in red blood cell lysis. • Demonstrated efficacy of novel peptide as antihelminthics for treatment of schistosomiasis.
Highlights: • Uncovered a mechanism by which respiratory syncytial virus dampens the oxidative stress response of infected cells. • Discovered that proteins of viruses from the same family as respiratory syncytial virus are modified extensively by phosphorylation and by ubiquitination. • Uncovered evidence for association between proteins of the infected cell and viruses from the same family as respiratory syncytial virus that modulate budding of new viruses from the infected cell. • Identified a cohort of novel cartilage proteins and biological processes associated with cartilage development. • Characterised protein expression differences that appear to correlate with a breast cancer stem cell phenotype. • Invested in two new state-of-the-art LTQ-VelosOrbitrap mass spectrometers to complement other high performance MALDI-TOF/TOF mass spectrometers.
Scabies Laboratory Head: Dr Katja Fischer Work in the Scabies Laboratory concentrates on the control of diseases caused by the scabies mites, Sarcoptes scabiei that burrow under the skin to cause the condition commonly known as scabies.
Highlights: • Biochemically characterised two scabies mite Serpins and provided a detailed analysis of their anti-complement activities. • Identified and characterised a novel scabies mite’s peritrophin. • Provided substantial data supporting a causal link between the biology of scabies and associated streptococcal infections. • Constructed a library of expressed Sarcoptes scabiei sequences from mites obtained from skin shed into the bedding of patients with the severe form of the disease, crusted scabies. A multi-gene family was identified during this sequencing in which the amino acids necessary for catalysis are mutated and therefore cannot function as active proteases. • Established material and preliminary data to commence a S. scabiei genome project.
Page 64
QIMR Annual Report 2010–2011
tropical parasitology Laboratory Head: Dr Kathy Andrews The Tropical Parasitology Laboratory is using different approaches to investigate new antimalarial compounds and potential new drug targets. In a piggy back approach, anti-cancer and anti-HIV drugs (and related compounds) are being investigated for their ability to kill malaria parasites. To complement this work, the laboratory is using molecular, biochemical and synthetic chemistry approaches to identify and validate the targets of antimalarial compounds and to better understand essential processes, such as transcriptional regulation, in malaria parasites.
tumour immunology
Highlights: • Conducted genome wide microarray analysis that provided new insights into how histone deacetylase inhibitors (a promising new antimalarial drug class) kill malaria parasites. • Identified new antimalarial compounds from plants and fungi in collaboration with Griffith University researchers.
Highlights:
Laboratory Head: Professor Rajiv Khanna
• Developed a killer T cell therapy for EBV-associated nasopharyngeal carcinoma.
The main goal of the Tumour Immunology Laboratory is to obtain a deeper understanding of the mechanisms by which an immune response to tumours may be generated, augmented and applied to the inhibition of tumour growth.
• Completed the preclinical testing of a prophylactic vaccine for cytomegalovirus. A Phase I clinical trial is planned for this vaccine, which aims to prevent clinical complications in transplant patients and newborn babies.
The members of this laboratory share the expectation that such insight will be applicable to the treatment and prevention of cancer.
• Continued trialling a novel immunotherapy for brain cancer. • Started a clinical trial of a novel immune-based diagnostic tool for cytomegalovirus.
Page 65
Mental Health/Complex Disorders Program associate professor michael Breakspear, coordinator Recent structural change at QIMR brought teams from a variety of disciplines together into the new Mental Health/ Complex Disorders Program. The new structure recognises that QIMR must continue on the road to building a major research capacity in mental health whilst fostering outstanding biomedical research of major clinical relevance. Whilst the disease focus is broad and multi-system, the program is united by a number of common conceptual and methodological themes. The diseases studied within the program, ranging from schizophrenia and depression to haemochromatosis and migraine, all arise from an interaction of genetic and multi-factorial environmental influences. The last twelve months have been a watershed year for Mental Health with a series of high profile national developments, new funding opportunities and, most importantly, growing awareness in the community. QIMR scientists continue to make important breakthroughs in mental health research from genetics and epidemiology to brain imaging and computational modelling. Research capabilities, technology opportunities and public awareness into mental health continue to grow - creating a unique opportunity for research at QIMR to improve recovery and outcome for those in the community with mental health disorders. Important discoveries have also occurred in the Complex Disorders of other key systems that we study, including diseases of iron metabolism, those involving fibrosis of the liver, those arising from abnormal membrane transport and a constellation of disorders with a strong genetic underpinning. Advances in basic clinical science include the development of new laboratory techniques to study foetal alcohol syndrome, insights into the role of inflammation in haemochromatosis and the nature of genetic factors in endometriosis and inflammatory bowel disease. Insights into the genetic determinants of a range of healthy variants of human intelligence, emotion and appearance have also been achieved. Here it again becomes
Page 66
QIMR Annual Report 2010–2011
clear that the two arms of the program (Mental Health/ Complex Disorders) overlap. Technology plays a crucial role in the study of these disorders. QIMR is home to a growing number of imaging technologies that enable unprecedented insight into the biology of cells, animals and humans. Cutting edge animal imaging facilities were recently installed and plans for a major new human imaging facility on the Herston campus are well advanced. The growth of sequencing technologies that underpin genetic research also continue. The enormous volume of biological data generated by these technologies demands a new approach to data analysis. Scientists across the program are actively engaged in QIMR’s expansion in Information Technologies and Bioinformatics. Highlights for the Mental Health/Complex Disorders Program in the last year include: • Development of a new brain stress test to predict outcome in older Australians at risk of dementia, a major national public health priority. • Advancing our understanding of healthy brain activity, including the nature of brain rhythms and the disturbance of these rhythms in schizophrenia. • Through participation in large international consortia, QIMR researchers also made important discoveries in the genetic basis of major mental illnesses, including depression, schizophrenia and migraine. • Providing new insights into the genetic contributions to a myriad of healthy human behaviours including visual perception and personality style. • The use of a liver biopsy to provide vital clinical information to predict the future development liver disease in children with cystic fibrosis, • Improving our understanding of the role of malabsorption of iron in anaemia. • Confirming a genetic contribution to endometriosis risk, with stronger genetic effects for more severe disease.
epigenetics Laboratory Head: Professor Emma Whitelaw The Epigenetics Laboratory aims to understand the basic mechanisms of disease at a molecular level. The laboratory focuses on chemical changes to DNA and chromatin, the proteins that package DNA.
Highlights: • Developed a mouse model of fetal alcohol syndrome to increase understanding of the condition in humans. • Investigated the effects of epigenetic reprogramming on telomere length. • Developed a new model to study tissue regeneration in mammals. • Discovered that the Dnmt3L gene is involved in regulating expression of a large number of genes within cells, including gametes. • Found that a particular missense mutation Foxo3a gene may be involved in ovarian cancer.
genetic epidemiology Laboratory Head: Professor Nick Martin The Genetic Epidemiology Laboratory investigates the pattern of disease in families to assess the relative importance of genes and environment in a variety of important health problems and to locate the genes responsible using genomewide association analysis.
Highlights: • Identified two new loci predisposing for asthma risk. • Discovered a new gene, ITGA4, identified as a major regulator of peripheral blood monocyte counts. • Demonstrated that many genes contribute to variation in alcohol use and alcohol dependence. • Discovered gene variants that affect the carbohydrate component of transferrin, the main iron transport protein in plasma. • Combined personality data with 10 other samples from around the world, leading to the identification of a gene influencing conscientiousness and region associated with a person’s openness to experience. • Showed that genetic factors influencing the personality trait of neuroticism, a measure of emotional stability, also contribute to symptoms of anxiety and depression and to perceived somatic symptoms.
Hepatic fibrosis Laboratory Head: Associate Professor Grant Ramm The Hepatic Fibrosis Laboratory investigates the cellular and molecular mechanisms of scar tissue formation in the liver, such as the iron overload disease haemochromatosis, that leads to fibrosis and cirrhosis in adults, and cystic fibrosis (CF) and biliary atresia in children.
indigenous Health Laboratory Head: Associate Professor Gail Garvey The Indigenous Health Program aims to promote improved health and wellbeing for Aboriginal and Torres Strait Islander peoples through medical research and education; develop culturally appropriate research projects in partnership with Aboriginal and Torres Strait Islander peoples; cooperate with and assist the work of other agencies to improve the health and wellbeing of Aboriginal and Torres Strait Islander peoples and act as a health advocate.
Highlights: • Demonstrated that liver fibrosis identified via liver biopsy, predicts the future development of clinically significant liver disease (portal hypertension), in children with CF. • Proved the poor performance of non-biopsy tests currently employed to detect or predict the development of clinically significant CF liver disease. • Proposed biopsy as the “gold standard” to detect liver scarring and thus this approach should be adopted clinically to better manage patient care and assist in developing more targeted medical interventions in children with CF.
Highlights: • Developed a Supportive Care Needs Survey for Indigenous People (SCNS-IP) with cancer. The SCNSIP tool provides a standardised assessment of the supportive care needs of Indigenous adults with cancer in a culturally appropriate manner. • Sponsored the National Roundtable on Priorities for Aboriginal and Torres Strait Islander Cancer Research conference in partnership with the Lowitja Institute.
Page 67
mentaL HeaLtH/compLeX DiSorDerS program | continued iron metabolism Laboratory Head: Professor Greg Anderson The Iron Metabolism Laboratory focuses on understanding the homeostasis of iron in the body and the natural history of disorders of iron metabolism such as the iron loading disease haemochromatosis.
Highlights: • Examined mechanisms of intestinal iron absorption during suckling. • Defined disease progression and penetrance in hereditary haemochromatosis. • Showed a critical role for hephaestin and related oxidases in iron absorption. • Identified factors responsible for regulating iron homeostasis in thalassaemia and other haemolytic anaemias. • Examined links between iron and gut and lung microbiota is cystic fibrosis.
membrane transport Laboratory Head: Associate Professor Nathan Subramaniam The Membrane Transport Laboratory studies how iron metabolism is regulated by the liver and has an interest in both basic and applied studies of membrane biology. Identification of the molecules involved in iron metabolism and defining the way they work, has major implications for the treatment of iron-related disorders such as hereditary haemochromatosis and anaemia. The majority of projects in the laboratory focus on defining how the liver and a number of liver-expressed molecules regulate the absorption, recycling and distribution of iron in the body.
molecular epidemiology Laboratory Head: Professor Grant Montgomery The Molecular Epidemiology Laboratory seeks to identify genes and gene pathways contributing to risk for common human diseases. The laboratory is a world leader in the genetics of endometriosis and works on melanoma, inflammatory bowel disease and a range of other diseases including asthma, migraine, depression, alcohol, nicotine and drug dependence. This laboratory holds a large biobank supporting projects for QIMR’s Genetic Epidemiology, Queensland Statistical Genetics and Neurogenetics Laboratories.
Page 68
QIMR Annual Report 2010–2011
Highlights: • Showed that in the absence of HFE and TfR2 (genes mutated in hereditary haemochromatosis) the response to inflammation is reduced. • Demonstrated increased liver iron levels in a mouse model of the cancer-related disorder ataxia-telangiectasia. • Demonstrated that iron loading leads to increased oxidative stress in livers of ataxia-telangiectasia null mice. • Identified the first case of ferroportin disease in Australia in an Australian family of Vietnamese origin. • Demonstrated that the trafficking protein Syntaxin 5 plays an important role in regulating copper levels suggesting that it may be involved in copper-related disorders.
Highlights: • Published the world’s largest genome-wide association study for endometriosis identifying new risk loci and applied novel methods to confirm a genetic contribution to endometriosis risk and identified a stronger genetic effect in the more severe cases of the disease. • Identified some of the first genetic variants (on chromosomes 1 and 7) that increase endometriosis risk. Follow up from these discoveries will lead to greater understanding of mechanisms increasing disease risk and help improve treatments. • Discovered new genes for a range of diseases including Crohn’s disease, ulcerative colitis, endometrial cancer, and glaucoma. Completed a genome-wide search for new genes contributing to melanoma risk, identifying several new leads to follow up.
neurogenetics Laboratory Head: Dr Dale Nyholt The Neurogenetics Laboratory studies the role of genetics in the development and mechanism of the nervous system with the specific goal of identifying genes responsible for neurological disorders, with a primary focus on migraine. The work includes monitoring the inheritability of relevant genes, establishing DNA markers to find inheritability in family blood samples and identifying common genetic links with other disorders.
psychiatric genetics Laboratory Head: Dr Naomi Wray The Psychiatric Genetics Laboratory specialises in the development and application of statistical methods and theory to psychiatric disorders and related quantitative traits. The underlying aim is to further our understanding of the causes of these common, complex genetic disorders and in particular, to understand the genetic basis of differences in risk of disease between individuals.
Queensland Statistical genetics Laboratory Laboratory Head: Professor Peter Visscher The Queensland Statistical Genetics Laboratory (QSTAG) specialises in quantitative and statistical genetics, population genetics, human genetics and bioinformatics, with the ultimate aim of trying to understand the genetic basis of differences in risk to disease and other phenotypes between individuals.
Systems neuroscience group Laboratory Head: Professor Michael Breakspear The Systems Neuroscience Group studies brain sciences by utilising principles across three broad domains – empirical, computational and clinical neuroscience. The overarching aim of this work is to contribute towards unifying mathematical models of brain architecture, dynamics and cognitive function and dysfunction. These models then inform the design of brain imaging experiments to improve our understanding of major mental illnesses.
Highlights: • Completed the first Australian genome-wide association study (GWAS) of the more common forms of migraine (migraine with and migraine without aura). This has produced some exciting results that are currently undergoing replication and meta-analysis by international collaborators. • Published the first GWAS for endometriosis in Caucasian patients that identified two novel susceptibility loci. • Published the second GWAS for migraine.
Highlights: • Published the largest genome-wide association study for major depression showing the disease is underpinned by many variants of small effect size, and implicating the neuropeptide galanin. • Furthered understanding of the genetic architecture of schizophrenia and major depression, shedding light on future research strategies. • Challenged the role of synthetic associations in complex genetic disease.
Highlights: • Shone light on the ‘missing heritability’ problem in complex trait genetics. • Demonstrated that complex traits, including common diseases and traits such as height and body-massindex, are caused by the cumulative effect of hundreds of genes. • Discovered, in conjunction with Australian ophthalmologists, two new genes linked to open angle glaucoma. This discovery will help to identify patients at the highest risk of severe glaucoma.
Highlights: • Developed a new diagnostic and monitoring test for major depression based on a combination of video and imaging technology. • Developed a brain stress test for dementia using brain imaging and showed that it could predict the functioning of patients for up to two years. • Discovered changes in brain activity in healthy young people who were related to patients with bipolar disorder.
Page 69
SuppoRtInG ouR ReSeARCH corporate Division Dedicated corporate staff are committed to providing the high level of support required to keep QIMR researchers at the forefront of medical research. Consisting of Scientific Services, Finance, Procurement, Grant Management, Human Resources, Regulatory Affairs, Safety, Information Services, Building Services, External Relations and Business Development, the Corporate Division ensures researchers have the services and equipment to undertake world class research. A focus for the Corporate Division this year has been preparing for the new research facility, which continues to meet budget and timing estimates. In preparation for the opening in 2010, the Bancroft Centre building management system has been upgraded to ensure compatibility with the new facility’s system. Following the comprehensive IT review in early 2010, the entire network infrastructure has been replaced and
modernised and work continues on implementing a large scale, research data storage solution. A new ethics approval and occupational health and safety system is under development, as is a new grants management system, scheduled for completion late 2011. QIMR strived to provide the best equipment and scientific and laboratory services for its researchers including media preparation, glassware services, peptide synthesis, DNA sequencing, flow cytometry, histology, microscopy, as well as regulatory and safety services. QIMR committed more than 9% of its 2010–2011 budget to purchasing new and improved equipment, making certain that our researchers are using the most up-to-date tools to ensure efficient and quality outcomes. These included a new PET/CT scanner, Nanodispenser, iScan, Flow Cytometer (Fortessa), BioTek Synergy H4 and ViiA 7 quantitative PCR machine. In December 2010, QIMR received NHMRC certification for the review process of multi-centre human research thus reducing the administrative burden borne by researchers collaborating with other institutes.
fundraising Much of QIMR’s research would not be possible without the support of community groups, individuals and corporate sponsors. QIMR would also like to recognise the contributions from our monthly donors; planned givers who kindly made provision for the Institute in their Wills; and long-term supporters Mrs Marno Parsons AM and Mr Royce Blackburne.
2010–2011 marked the tenth year that Mr Clive Berghofer AM provided substantial support to QIMR. Above: Chair of QIMR Council Professor John Hay (left) and QIMR Director and CEO Professor Frank Gannon (right) present a commemorative plaque to Mr Clive Berghofer (centre) in recognition of his ten years of outstanding support of the Clive Berghofer Cancer Research Centre at QIMR.
QIMR also welcomed many new supporters through the inaugural Rio Tinto Ride to Conquer Cancer event, which is raising vital funds for cancer research at QIMR. In particular, the Institute would like to thank the event’s major sponsors: Rio Tinto, Sunsuper and the Ausenco Foundation. Above: Rio Tinto’s Jason Gallagher, John Becker, Tim Lane and Neil Cox with QIMR’s Professor David Whiteman celebrate the announcement of Rio Tinto’s major sponsorship of the inaugural Rio Tinto Ride to Conquer Cancer.
Page 70
QIMR Annual Report 2010–2011
a special thank you to the following major donors: • Mr Clive Berghofer AM – Jeteld Pty Ltd
• The Estate of Cathryn Janet Christensen
• John Thomas Wilson Foundation (managed by Perpetual)
• Riverside Centre Charity Golf Day (organised by Riverside Centre Management)
• The Estate of Kevin Joseph Hill
• Mrs Ailsa Zinns
• Mrs Lorraine Duckwitz
• Walking on Sunshine event (organised by Mrs Anne Stanton)
• Clipsal Australia Pty Ltd
• Mrs Helen Gow
• Selwyn Thomas Fassifern Ozanne and Doreen Elaine Ozanne Trust
• Henderson Foundation
• Miss Valmai Pidgeon AM
• William and Hilde Chenhall Research Trust
• Mrs Marno Parsons AM • Data #3 Limited
• The Estate of Heather Maldwyn Stoney
• Rio Tinto Coal Australia Pty Ltd
• The Estate of Evelyn Monica Dutton
• J J Richards and Sons Pty Ltd
• Brisbane Girls Grammar School
• Mr Barry and Mrs Maureen Stevenson
• Campbell Brothers Ltd
• The Estate of Elsie Rutter
• Mrs L B Burgess
• Rotary Club of Blackwater
• Mr Gerry and Mrs Geeske Gerrard (in memory of Peggy Stephens)
• Reuben Pelerman Benevolent Foundation
• The Estate of Melvin James Anderson • Sunsuper Pty Ltd • Suncorp Metway • The Estate of Brian Musgrove O’Connor
• The Pamela Joan Dinning Perpetual Charitable Trust • The Estate of Esme Joy Shipham
• Mr Ron Statham
• Shop Distributive and Allied Employees Association
• The Estate of Lila Marian Kenny
• Sherrin Investments Pty Ltd
• Mr Robert Gerrard (in memory of Peggy Stephens)
• BT Investment Management Pty Ltd
• Queensland Community Foundation
• Kenneth Trice Peters Discretionary Will Trust
• Mr Douglas and Mrs Helen Cowlishaw
• The Estate of John Francis Pickering
• Fitton Insurance Brokers • Witchery
• Barbara Rhoda Phyllis Dalton Perpetual Charitable Trust Qld
• Mr Kevin and Mrs Elsie Hayes
• The Estate of Thelma Josephine Bingham
• Tattersall’s Club
• Mr Peter R Rowland
• The Henry Cyril Robjohns and Stella May Robjohns Memorial Trust
• The Estate of Camrin Anthony Reeve • Mr Ronald E Hancock
• Ms Barbara McKay
• In Vitro Technologies Life Science
• Sidney Richard and Beryl Lillian Early Perpetual Trust
• The Estate of Ronald Graeme Douglas
• Moran Cup Charity Golf Day (organised by Scott Moran)
• Endometriosis Association (Qld) Inc.
• Mr Tim and Mrs Kym Reid
• Mrs Jacqueline Pascual
• Mr Ivan and Mrs Sandra Mitchell • Mr Royce Blackburne – Roycorp Pty Ltd • Dr E Glen Truscott
• Biniris Pty Ltd
• Mr Leo Weninger
• Happy Face Cent Auctions (organised by Mrs Sunny Drescher)
• E M Squires Charitable Trust (managed by Perpetual)
Another important source of support was generated by individuals and businesses that allocate resources and organise fundraising events benefiting QIMR. Suncorp has supported QIMR’s research for many years and continues to work closely with the Institute on a number of skin cancer related projects.
Each year QIMR also acknowledges community members for their outstanding support of medical research. In 2010, recipients of the QIMR Ambassador Awards included: Ms Denise Schellbach, Mr Mark Newman, Ms Carol Ramsay (Suncorp), and Mrs Lorraine Duckwitz.
• Mr Lindsay Evans
• Mr Dan Holzapfel • Mrs Margaret J Gibson • Mrs Heather Jordan
QIMR’s mental health research received vital funding from Trusts managed by Perpetual. Above: Mr Andrew Thomas, General Manager of Perpetual Philanthropy (far left) discusses mental health research with Professor Michael Breakspear and Professor Emma Whitelaw. The establishment of this research area was funded by the John Thomas Wilson Endowment and the EM Squires Charitable Trust.
Page 71
FInAnCIAl StAtementS
Page 72
QIMR Annual Report 2010–2011
operating result The operating result for the 2010–2011 financial year was a surplus of $137,867k (2009–2010: $19,978k) after providing for depreciation of $5,412k. This surplus includes recognition of capital grants from Commonwealth Government, Queensland State Government, and The Atlantic Philanthropies towards the construction of the Smart State Medical Research Centre ($71,840k), and a gain on the transfer of net assets of the former QIMR Trust that was abolished 1 February 2011 ($54,985k). QIMR’s financial structure is based on the management of core and grant funds. Funding for competitive research grants for the 2010-11 financial year was $40,218k (2009-10: $44,209k), representing 53% of total comprehensive income, excluding capital grants and gain from abolition of QIMR Trust (2009-10: 60%). A majority of the Institute’s core funding is provided through a grant from Queensland Health $13,969k (2009-10: $6,169k). QIMR’s total funding resources, including amounts under management at 30 June 2011 totalled $172,269k (2009-10: $94,633k), of which $66,550k was represented by capital grants (2009-10: $57,511k). The increase in funds held during the year is mainly due to transfer of cash and investments from the abolished QIMR Trust, and capital grants received in relation to the Smart State Medical Research Centre.
consultancies Category
Summary
$
Business Services
Global Philanthropic engaged to provide fundraising services to assist QIMR in managing donor relations with supporters of its Hong Kong research program.
$16,800
financial documentation The financial reports should include the following documentation: • Final Financial Statements as audited by QAO, in line with Treasury’s Financial Reporting Requirements for Govt Agencies; • Certification of Final Financial Statements, in line with the Financial Accountability Act (s62) and FPMS 2009 (s42,43 + 50); • Independent Auditors Report, in line with the Financial Accountability Act (s62) and FPMS 2009 (s50); and • Remuneration Disclosures, in line with Financial Reporting Requirements for Qld Government Agencies.
Construction of the Smart State Medical Research Centre is fully funded with total contributions from Commonwealth Government ($110M), Queensland State Government ($35M), and The Atlantic Philanthropies ($27.5M). Occupation of the new building is scheduled for early 2012.
abolition of Qimr trust The Queensland Institute of Medical Research Act 1945 was amended by legislation, entitled the Water and Other Legislation Amendment Act 2010, enacted and assented to by the Queensland Parliament on 25 November 2010. As per section 137 of the Amendment Act, the Trust was abolished with effect on 1 February 2011, with the responsibilities of the Trust transferred to the Council of the Queensland Institute of Medical Research as of the abolition date. To support this transfer, total assets valued at $55.116 million and total liabilities valued at $0.131 million were transferred to the Council at 31 January 2011.
Page 73
tHe counciL of tHe QueenSLanD inStitute of meDicaL reSearcH
financiaL StatementS 2010-11 contents • Statement of Comprehensive Income • Statement of Financial Position • Statement of Changes in Equity • Statement of Cash Flows
general information These financial statements cover the Queensland Institute of Medical Research and its jointly controlled entities. The Queensland Institute of Medical Research is a Queensland statutory body established under the Queensland Institute of Medical Research Act 1945. The statutory body is controlled by the State of Queensland which is the ultimate parent.
• Notes To and Forming Part of the Financial Statements
The head office and principal place of business of the statutory body is:
• Management Certificate
300 Herston Rd, Herston QLD 4006 A description of the nature of the Council’s operations and its principal activities is included in the notes to the financial statements. For information in relation to the statutory body’s financial statements please call +61 7 3362 0222, email enquiries@qimr.edu.au or visit the statutory bodies’s website www.qimr.edu.au Amounts shown in these financial statements may not add to the exact sub-totals or totals due to rounding.
Page 74
QIMR Annual Report 2010–2011
The Council of The Queensland Institute of Medical Research of medical research
the council of the Queensland Statement of Comprehensive Income institute
Statement of comprehensive income for the year ended 30 June 2011 Notes
2011
2010
$'000
$'000
Income from Continuing Operations Grants and other contributions
2
137,835
75,623
User charges
3
4,386
5,204
Other revenue
4
9,950
10,776
152,171
91,603
Total Revenue Gains Total Income from Continuing Operations
5
53,932
990
206,103
92,593
Expenses from Continuing Operations Employee expenses
6
39,892
39,920
Supplies and services
7
18,106
23,359
Depreciation and amortisation
8
5,412
5,272
Other expenses
9
4,496
3,879
141
56
Finance Costs Share of loss of equity accounted investees
24
Total Expenses from Continuing Operations Operating Result from Continuing Operations
189
130
68,236
72,616
137,867
19,977
(1,480)
(5,290)
(1,480)
(5,290)
136,387
14,687
Other Comprehensive Income Increase (decrease) in asset revaluation surplus Total Other Comprehensive Income Total Comprehensive Income
19
The accompanying notes form part of these statements.
Page 75
The Council of The Queensland Institute of Medical Research the council of the Queensland institute of medical research Statement of Financial Position
Statement of financial position as at 30 June 2011 Notes
2011
2010
$'000
$'000
Current Assets Cash and cash equivalents
10
112,453
80,648
Receivables
11
10,488
8,346
Inventories
12
277
269
398
752
123,616
90,015
Prepayments Total Current Assets Non Current Assets Other financial assets
13
59,863
14,031
Intangible assets
14
722
786
Property, plant and equipment
15
206,287
132,822
Investments accounted for using the equity method
24
301
490
Total Non Current Assets
267,173
148,129
Total Assets
390,789
238,144
10,804
7,381
Current Liabilities Payables
16
Accrued employee benefits
17
3,104
3,213
Unearned revenue
18
87,243
74,406
101,151
85,000
870
763
870
763
Total Liabilities
102,021
85,763
Net Assets
288,768
152,381
249,641
111,774
39,127
40,607
288,768
152,381
Total Current Liabilities Non Current Liabilities Accrued employee benefits
17
Total Non Current Liabilities
Equity Accumulated surplus Asset revaluation surplus Total Equity The accompanying notes form part of these statements.
Page 76
QIMR Annual Report 2010–2011
19
The Council of The Queensland Institute of Medical Research the council of the Queensland institute of medical research Statement of Changes in Equity
Statement of changes in equity for the year ended 30 June 2011 Accumulated Surplus
Asset Revaluation Surplus (Note 19)
TOTAL
$'000
$'000
$'000
Balance as at 1 July 2009
91,797
45,897
137,694
Operating Result from Continuing Operations
19,977
-
19,977
Total Other Comprehensive Income Increase/(decrease) in Asset Revaluation Surplus
-
(5,290)
(5,290)
Balance as at 30 June 2010
111,774
40,607
Balance as at 1 July 2010
111,774
40,607
152,381
Operating result from Continuing Operations
137,867
-
137,867
152,381
Total Other Comprehensive Income Increase/(decrease) in Asset Revaluation Surplus Balance as at 30 June 2011
249,641
(1,480) 39,127
(1,480) 288,768
The accompanying notes form part of these statements.
Page 77
The Council of The Queensland Institute of Medical Research the council of the Queensland institute of medical research Statement of Cash Flows
Statement of cash flows for the year ended 30 June 2011 Notes
2011
2010
$'000
$'000
Cash flows from operating activities Inflows: 150,889
66,462
User charges
Grants and other contributions
4,152
6,392
Other income
6,328
10,229
GST collected
(640)
(178)
Employee expenses
(39,644)
(39,592)
Supplies and services
(18,489)
(23,801)
Outflows:
Finance costs GST paid Other Net cash provided by (used in) operating activities
0
2
(141)
(56)
(71)
(223)
(4,438)
(3,879)
97,946
15,354
Cash flows from investing activities Inflows: Sales of property, plant and equipment
1,049
4
Proceeds from sales of other financial assets
9,671
18,919
Payments for property, plant and equipment
(77,512)
(19,236)
Net cash provided by (used in) in investing activities
(66,792)
(313)
Net increase (decrease) in cash and cash equivalents
31,154
15,041
Cash and cash equivalents at beginning of financial year
80,648
65,607
Outflows:
Cash and cash equivalent transferred from QIMR Trust Cash and cash equivalents at end of financial year
The accompanying notes form part of these statements.
Page 78
QIMR Annual Report 2010–2011
651 0
1
112,453
80,648
the council institute of medical research The Councilofofthe TheQueensland Queensland Institute of Medical Research
notes to and forming part of the financial statements 2010–11
Notes to and forming part of the financial statements 2010-11
Objectives and Principal Activities of the Council Note 1:
Summary of Significant Accounting Policies
Note 2:
Grants and other contributions
Note 3:
User charges
Note 4:
Other revenue
Note 5:
Gains
Note 6:
Employee expenses
Note 7:
Supplies and services
Note 8:
Depreciation and amortisation
Note 9:
Other expenses
Note 10:
Cash and cash equivalents
Note 11:
Receivables
Note 12:
Inventories
Note 13:
Other financial assets
Note 14:
Intangible assets
Note 15
Property, plant and equipment
Note 16:
Payables
Note 17:
Accrued employee benefits
Note 18:
Unearned revenue
Note 19:
Asset revaluation surplus by class
Note 20:
Reconciliation of operating surplus to net cash from operating activities
Note 21:
Non-cash financing and investing activities
Note 22:
Commitments for expenditure
Note 23:
Contingencies
Note 24:
Jointly controlled entities
Note 25:
Trust transactions and balances
Note 26:
Key executive management personnel and remuneration
Note 27:
Transfer of the assets and liabilities of the abolished QIMR Trust to the Council of the Queensland Institute of Medical Research
Note 28:
Financial instruments
Note 29:
Events Occurring After Balance Date
Note 30:
Changes in Accounting Estimates and Correction of Errors
`
Page 79
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 Objective and Principal Activities of the Council The objective of the Council is to control and manage the Queensland Institute of Medical Research (the Institute). The Institute has been established to conduct research into all branches of medical science. The Institute operates predominantly in one geographical area, being Queensland, Australia, although it has research collaborations in Australia and overseas. The Smart State Medical Research Centre project has been funded with total contributions from Federal Government $110m, Queensland State Government $35m and Atlantic Philanthropies $27.5m. The Council receives an operational grant from Queensland Health on an annual basis. The majority of the Institute's funding is generated from competitive, peer reviewed research grants, commercial and other earned revenue. Funds are also received from donation, fundraising and investment activities performed by the Institute under the guidance of the Council. 1.
Summary of Significant Accounting Policies
(a)
Statement of Compliance
The Council has prepared this financial report in compliance with section 43 of the Financial and Performance Management Standard 2009 . These financial statements are general purpose financial statements, and have been prepared on an accrual basis in accordance with Australian Accounting Standards and Interpretations. In addition, the financial statements have regard to Treasury's Minimum Reporting Requirements for the year ending 30 June 2011, and other authoritative pronouncements. With respect to compliance with Australian Accounting Standards and Interpretations, the Council has applied those requirements applicable to not-for-profit entities, as the Council is a not-for-profit statutory body. Except where stated, the historical cost convention is used. (b)
The Reporting Entity
The financial statements include the value of all revenues, expenses, assets, liabilities and equity of the Council. The Council has no material controlled entities as at 30 June 2011. (c)
Investment in Joint Ventures
Jointly controlled entities are those where the Council has joint control, established by contractual agreement. As at 30 June 2011, the Council has entered into two material joint ventures — Vaccine Solutions Pty Ltd and Q-Pharm Pty Ltd. The interest of the Council in its joint ventures is brought to account by using the equity method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the Council's share of net assets of the joint venture. In addition, the Council's share of the profit or loss of the joint venture is included in the Council's operating result. Vaccine Solutions Pty Ltd is not equity accounted as QIMR has no claim over of joint venture. Further details of the Council's interest in jointly controlled operations are contained in note 24. (d)
Trust Transactions and Balances
The Council undertakes certain trustee transactions on behalf of CRC Vaccine Technology and QIMR employee research activities. As the Council acts only in a custodial role in respect of these transactions and balances, they are not recognised in the financial statements, but are disclosed in Note 25. (e)
Grants and other contributions
Grants, contributions, donations, bequests, gifts and fundraising that are non-reciprocal in nature are recognised as revenue in the year in which the Council obtains control over them. Where grants are received that are reciprocal in nature, revenue is recognised over the term of the funding arrangements. Contributed assets are recognised at their fair value. Contributions of services are recognised only when a fair value can be determined reliably and the services would be purchased if they had not been donated.
Page 80
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 (f)
User Charges and recoveries
User charges and fees from commercial services and recoveries of expenditure incurred by associated bodies which use QIMR laboratory consumables and services, controlled by the Council, are recognised as revenues when the revenue has been earned and can be measured reliably with a sufficient degree of certainty. This involves either invoicing for related goods/services and/or the recognition of accrued revenue. User charges and fees are controlled by the Council where they can be deployed for the achievement of departmental objectives. (g)
Interest, Dividends and Distributions
Revenue for interest is recognised and allocated over the reporting period by employment of the effective interest method. Revenue for dividends and distributions from managed funds classified as financial instruments held at fair value through profit or loss are recognised when the Council's right to receive payment is established. (h)
Imputation credits
As an endorsed income tax exempt charity, imputation credits attached to franked dividends received by the Council are refundable and may be claimed retrospectively after the end of the financial year. Imputation credits are brought to account when the right to receive the credits is established. (i)
Cash and cash equivalents
For the purposes of the Statement of Financial Position and the Statement of Cash Flows, cash assets include all cash and cheques receipted but not banked at 30 June as well as deposits at call with financial institutions. (j)
Receivables
Trade debtors are recognised at the amounts due at the time of sale or service delivery i.e. the agreed purchase/contract price. Settlement of these amounts is required within 30 days from invoice date. The collectability of receivables is assessed periodically with provision being made for impairment. All known bad debts were written-off as at 30 June. Other debtors generally arise from transactions outside the usual operating activities of the Council and are recognised at their assessed values. Terms are a maximum of one month, no interest is charged and no security is obtained. (k)
Inventories
Inventories are represented by consumable laboratory supplies valued at the lower of cost and net realisable value. Cost is assigned on a weighted average basis and includes expenditure incurred in acquiring the inventories and bringing them to their existing condition, except for training costs which are expensed as incurred. Net realisable value is determined by estimating the selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. No inventory assets have been classified as inventories held for distribution. (l)
Acquisitions of Assets
Actual cost is used for the initial recording of all non-current physical and intangible asset acquisitions. Cost is determined as the value given as consideration plus costs incidental to the acquisition, including all other costs incurred in getting the assets ready for use, including architects' fees and engineering design fees. However, any training costs are expensed as incurred. Where assets are received free of charge from another Queensland Government entity, the acquisition cost is recognised as the gross carrying amount in the books of the transferor immediately prior to the transfer together with any accumulated depreciation. Assets acquired at no cost or for nominal consideration, other than from an involuntary transfer from another Queensland Government entity, are recognised at their fair value at date of acquisition in accordance with AASB 116 Property, Plant and Equipment.
Page 81
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 (m) Property, Plant and Equipment Items of property, plant and equipment with a cost or other value equal to or in excess of the following thresholds are recognised for financial reporting purposes in the year of acquisition: Buildings
$10,000
Plant and Equipment
$5,000
Other (including heritage & cultural)
$5,000
Items with a lesser value are expensed in the year of acquisition. (n)
Revaluations of Non-Current Physical and Intangible Assets
Buildings and heritage and cultural assets are measured at fair value in accordance with AASB 116 Property, Plant and Equipment and Queensland Treasury’s Non-Current Asset Policies for the Queensland Public Sector . In respect of these asset classes, the cost of items acquired during the financial year has been judged by management of the Council to materially represent their fair value at the end of the reporting period. Where intangible assets have an active market, they are measured at fair value, otherwise they are measured at cost. Plant and equipment is measured at cost in accordance with Treasury's Non-Current Asset Policies . Non-current physical assets measured at fair value are independently re-valued by an external registered valuer at least once every five years with interim valuations, using appropriate indices, being otherwise performed on an annual basis where there has been a material variation in the index. Refer to note 15 for details. Any revaluation increment arising on the revaluation of an asset is credited to the asset revaluation surplus of the appropriate class, except to the extent it reverses a revaluation decrement for the class previously recognised as an expense. A decrease in the carrying amount on revaluation is charged as an expense, to the extent it exceeds the balance, if any, in the revaluation surplus relating to that asset class. On revaluation, accumulated depreciation is restated proportionately with the change in the carrying amount of the asset and any change in the estimate of remaining useful life. Materiality concepts under AASB 1031 Materiality are considered in determining whether the difference between the carrying amount and the fair value of an asset is material. Separately identified components of assets are measured on the same basis as the assets to which they relate. (o)
Intangibles
Intangible assets with a cost or other value equal to or greater than $100,000 are recognised in the balance sheet, items with a lesser value being expensed. Each intangible asset, less any anticipated residual value, is amortised over its estimated useful life to the council. The residual value is zero for all the council's intangible assets. It has been determined that there is not an active market for any of the Council's intangible assets. As such, the assets are recognised and carried at cost less accumulated amortisation and accumulated impairment losses. No intangible assets have been classified as held for sale or form part of a disposal group held for sale. Purchased Software The purchase cost of this software has been capitalised and is being amortised on a straight-line basis over the period of the expected benefit to the council, namely 10 years. Internally Generated Software Expenditure on research activities relating to internally-generated intangible assets is recognised as an expense in the period in which it is incurred. Costs associated with the development of computer software have been capitalised and are amortised on a straight line basis over the period of expected benefit to the council, namely 10 years.
Page 82
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 (p)
Amortisation and Depreciation of Intangibles and Property, Plant and Equipment
All intangible assets of the council have finite useful lives and are amortised on a straight line basis. Property, plant and equipment is depreciated on a straight-line basis so as to allocate the net cost or re-valued amount of each asset, less its estimated residual value, progressively over its estimated useful life to the council. Assets under construction (work-in-progress) are not depreciated until they reach service delivery capacity. Service delivery capacity relates to when construction is complete and the asset is first put to use or is installed ready for use in accordance with its intended application. These assets are then reclassified to the relevant classes within property, plant and equipment. Where assets have separately identifiable components that are subject to regular replacement, these components are assigned useful lives distinct from the asset to which they relate and are depreciated accordingly. Any expenditure that increases the originally assessed capacity or service potential of an asset is capitalised and the new depreciable amount is depreciated over the remaining useful life of the asset to the Council. The depreciable amount of improvements to or on leasehold land is allocated progressively over the estimated useful lives of the improvements or the unexpired period of the lease, whichever is the shorter. The unexpired period of a lease includes any option period where exercise of the option is probable. Common use items of the Institute's research library are expensed on acquisition. Heritage and cultural assets include research library monographs, Australiana and scarce items. The service potential of these assets is not expected to diminish with time or use and therefore, they are not depreciated. For each class of depreciable asset the following depreciation and amortisation rates are used: Class Buildings
Rate % 2
Plant and equipment: Motor Vehicles Scientific equipment Leasehold improvements Other equipment
20 5 - 33.3 4 5 - 33.3
Intangible Assets:
(q)
Software Purchased
10
Software Internally Generated
10
Impairment of Non-Current Assets
All non-current physical and intangible assets are assessed for indicators of impairment on an annual basis. If an indicator of possible impairment exists, the Council determines the asset's recoverable amount. Any amount by which the asset's carrying amount exceeds the recoverable amount is recorded as an impairment loss. The asset's recoverable amount is determined as the higher of the asset's fair value less costs to sell and depreciated replacement cost. An impairment loss is recognised immediately in the Statement of Comprehensive Income, unless the asset is carried at a re-valued amount. When the asset is measured at a re-valued amount, the impairment loss is offset against the asset revaluation surplus of the relevant class to the extent available. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised as income, unless the asset is carried at a re-valued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. Refer also note 1(n).
Page 83
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 (r)
Leasehold Improvements
The Queensland Institute of Medical Research occupies two buildings situated on Crown land reserved and set apart for hospital purposes and under the control of Queensland Health on behalf of the State of Queensland. A lease for the land and building known as the Bancroft Centre exists between the Institute and The State of Queensland (represented by the Department of Health), at a nominal rental, terminating on 27 June 2066. The Bancroft Centre was constructed by the Council using grants from the Federal and Queensland State Government. A lease for the land and building known as The Clive Berghoffer Cancer Research Centre exists between the Institute and The State of Queensland (represented by the Department of Health), at a nominal rental, terminating on 27 June 2066. The building was constructed by the Council using grants from the Federal and Queensland State Governments, and private donors. The costs of leasehold improvements relating to these properties will be amortised over the remaining period of the lease, or the estimated useful life to the Institute, whichever is shorter. The Council currently erected a new building. Costs are in work in progress. (s)
Leases
A distinction is made in the financial statements between finance leases that effectively transfer from the lessor to the lessee substantially all risks and benefits incidental to ownership, and operating leases, under which the lessor retains substantially all risks and benefits. Where a non-current physical asset is acquired by means of a finance lease, the asset is recognised at the lower of the fair value of the leased property and the present value of the minimum lease payments. The lease liability is recognised at the same amount. Lease payments are allocated between the principal component of the lease liability and the interest expense. Operating lease payments are representative of the pattern of benefits derived from the leased assets and are expensed in the periods in which they are incurred. Incentives received on entering into operating leases are recognised as liabilities. Lease payments are allocated between rental expense and reduction of the liability. (t)
Other Financial Assets
Other financial assets held at fair value through profit or loss represent investments in managed funds and shares in listed and unlisted companies. The investments are stated at current market value at the reporting date. Changes in the market value of these instruments, whether realised or unrealised, are recognised in the Statement of Comprehensive Income. These investments were originally classified as at fair value through profit or loss upon initial recognition and the Council manages these investments and makes purchases and sales decisions based on their fair value in accordance with the Council's documented investment strategy. (u)
Payables
Trade creditors are recognised upon receipt of the goods or services ordered and are measured at the nominal amount i.e. agreed purchase/contract price, gross of applicable trade and other discounts. Amounts owing are unsecured and are generally settled on 30 day terms. (v)
Financial Instruments
Recognition Financial assets and financial liabilities are recognised in the Statement of Financial Position when the Council becomes party to the contractual provisions of the financial instrument. Classification Financial instruments are classified and measured as follows: i) Cash and cash equivalents - held at fair value through profit or loss ii) Receivables - held at amortised cost iii) Other financial assets - held at fair value through profit or loss iv) Payables - held at amortised cost Page 84
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 The Council does not enter into transactions for hedging purposes. All other disclosures relating to the measurement and financial risk management of financial instruments held by the Council are included in Note 28. (w) Employee Benefits Employer superannuation contributions, annual leave and long service leave levies are regarded as employee benefits. Payroll tax and workers' compensation insurance are a consequence of employing employees, but are not counted in an employee's total remuneration package. They are not employee benefits and are recognised separately as employee related expenses. Wages, Salaries and Annual Leave and Sick Leave Wages, salaries and annual leave due but unpaid at reporting date are recognised in the Statement of Financial Position at the current salary rates. For unpaid entitlements expected to be paid within 12 months, the liabilities are recognised at their undiscounted values. Entitlements not expected to be paid within 12 months are classified as non-current liabilities and recognised at their present value, calculated using yields on Fixed Rate Commonwealth Government bonds of similar maturity, after projecting the remuneration rates expected to apply at the time of likely settlement. Prior history indicates that on average, sick leave taken each reporting period is less than the entitlement accrued. This is expected to continue in future periods. Accordingly, it is unlikely that existing accumulated entitlements will be used by employees and no liability for unused sick leave entitlements is recognised. As sick leave is non-vesting, an expense is recognised for this leave as it is taken. Long Service Leave Under the Queensland Government’s long service leave scheme, a levy is made on the statutory body to cover the cost of employees' long service leave. The levies are expensed in the period in which they are payable. Amounts paid to employees for long service leave are claimed from the scheme quarterly in arrears. No provision for long service leave is recognised in the Council's financial statements, the liability being held on a whole-of-government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting . Superannuation Employer superannuation contributions are paid to QSuper, the superannuation scheme for Queensland Government employees, at rates determined by the Treasurer on the advice of the State Actuary. Contributions are expensed in the period in which they are paid or payable. The council's obligation is limited to its contribution to QSuper. The QSuper scheme has defined benefit and defined contribution categories. The liability for defined benefits is held on a whole-of-government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting . Key executive management personnel and remuneration Key executive management personnel and remuneration disclosures are made in accordance with the section 5 Addendum (issued in May 2011) to the Financial Reporting Requirements for Queensland Government Agencies issued by Queensland Treasury. Refer to note 26 for the disclosures on key executive management personnel and remuneration.
Page 85
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 (x)
Provisions
Provisions are recorded when Council has a present obligation, either legal or constructive as a result of a past event. They are recognised at the amount expected at reporting date for which the obligation will be settled in a future period. Where the settlement of the obligation is expected after 12 or more months, the obligation is discounted to the present value using an appropriate discount rate. However, no present obligations have been identified by Council requiring the recognition of provision as at 30 June 2011. (y)
Insurance
The Council's non-current physical assets and other risks are insured through the Queensland Government Insurance Fund, premiums being paid on a risk assessment basis. In addition, the Council pays premiums to WorkCover Queensland in respect of its obligations for employee compensation. (z)
Services Received Free of Charge or for Nominal Value
Contributions of services are recognised only if the services would have been purchased if they had not been donated and their fair value can be measured reliably. Where this is the case, an equal amount is recognised as revenue and an expense. (aa) Taxation The Council is a State body as defined under the Income Tax Assessment Act 1936 and is exempt from Commonwealth taxation with the exception of Fringe Benefits Tax (FBT) and Goods and Services Tax (GST). FBT and GST are the only taxes accounted for by the Council. GST credits receivable from, and GST payable to the ATO, are recognised (refer to note 11). (ab) Issuance of Financial Statements The financial statements are authorised for issue by the Chairman of Council, Director and Secretary at the date of signing the Management Certificate. (ac) Judgements The preparation of financial statements necessarily requires the determination and use of certain critical accounting estimates, assumptions, and management judgements that have that potential to cause a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Such estimates, judgements and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in future periods as relevant. Estimates and assumptions that have a potential significant effect are outlined in the following financial statement notes: Valuation of Property, Plant and Equipment - notes 1(n) and 15 Contingencies - note 23 (ad) Rounding and Comparatives Amounts included in the financial statements are in Australian dollars and have been rounded to the nearest $1,000 or, where that amount is $500 or less, to zero, unless disclosure of the full amount is specifically required. Comparative information has been restated where necessary to be consistent with disclosures in the current reporting period. (ae) New and Revised Accounting Standards The Council did not voluntarily change any of its accounting policies during 2010-11. No amendments to the Australian accounting standards applicable for the first time for 2010-11 were relevant to the Council's financial statements. The Council is not permitted to early adopt a new or amended accounting standard ahead of the specified commencement date unless approval is obtained from the Treasury Department. Consequently, the Council has not applied any Australian accounting standards and interpretations that have been issued but are not yet effective. The Council applies standards and interpretations in accordance with their respective commencement dates. At the date of authorisation of the financial report, significant impacts of new or amended Australian accounting standards with future commencement dates are as set out below. Page 86
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 AASB 2010-4 Further Amendments to Australian Accounting Standards arising from the Annual Improvements Project [AASB 1, AASB 7, AASB 101 & AASB 134 and Interpretation 13] becomes effective from reporting periods beginning on or after 1 January 2011. The Council will then need to make changes to its disclosures about credit risk on financial instruments in note 28(c). No longer will the Council need to disclose amounts that best represent an entity’s maximum exposure to credit risk where the carrying amount of the instruments reflects this. If the Council holds collateral or other credit enhancements in respect of any financial instrument, it will need to disclose - by class of instrument - the financial extent to which those arrangements mitigate the credit risk. There will be no need to disclose the carrying amount of financial assets for which the terms have been renegotiated, which would otherwise be past due or impaired. Also, for those financial assets that are either past due but not impaired, or have been individually impaired, there will be no need to separately disclose details about any associated collateral or other credit enhancements held by the Council. AASB 9 Financial Instruments (December 2010) and AASB 2010-7 Amendments to Australian Accounting Standards arising from AASB 9 (December 2010) [AASB 1, 3, 4, 5, 7, 101, 102, 108, 112, 118, 120, 121, 127, 128, 131, 132, 136, 137, 139, 1023 & 1038 and Interpretations 2, 5, 10, 12, 19 & 127] become effective from reporting periods beginning on or after 1 January 2013. The main impacts of these standards on the Council are that they will change the requirements for the classification, measurement and disclosures associated with financial assets. Under the new requirements, financial assets will be more simply classified according to whether they are measured at either amortised cost or fair value. Pursuant to AASB 9, financial assets can only be measured at amortised cost if two conditions are met. One of these conditions is that the asset must be held within a business model whose objective is to hold assets in order to collect contractual cash flows. The other condition is that the contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. On initial application of AASB 9, the Council will need to re-assess the measurement of its financial assets against the new classification and measurement requirements, based on the facts and circumstances that exist at that date. Assuming no change in the types of transactions the Council enters into, it is not expected that any of the Council's financial assets will meet the criteria in AASB 9 to be measured at amortised cost. Therefore, as from the 2013-14 financial statements, all of the Council's financial assets will be required to be classified as "financial assets required to be measured at fair value through profit or loss" (instead of the measurement classifications presently used in notes 1(v) and 31). The same classification will be used for net gains/losses recognised in the Statement of Comprehensive Income in respect of those financial assets. In the case of the Council's receivables, the carrying amount is considered to be a reasonable approximation of fair value. AASB 1053 Application of Tiers of Australian Accounting Standards and AASB 2010-2 Amendments to Australian Accounting Standards arising from Reduced Disclosure Requirements [AASB 1, 2, 3, 5, 7, 8, 101, 102, 107, 108, 110, 111, 112, 116, 117, 119, 121, 123, 124, 127, 128, 131, 133, 134, 136, 137, 138, 140, 141, 1050 & 1052 and Interpretations 2, 4, 5, 15, 17, 127, 129, & 1052] apply to reporting periods beginning on or after 1 July 2013. AASB 1053 establishes a differential reporting framework for those entities that prepare general purpose financial statements, consisting of two tiers of reporting requirements – Australian Accounting Standards (commonly referred to as “tier 1”), and Australian Accounting Standards – Reduced Disclosure Requirements (commonly referred to as “tier 2”). Tier 1 requirements comprise the full range of AASB recognition, measurement, presentation and disclosure requirements that are currently applicable to reporting entities in Australia. The only difference between the tier 1 and tier 2 requirements is that tier 2 requires fewer disclosures than tier 1. AASB 2010-2 sets out the details of which disclosures in standards and interpretations are not required under tier 2 reporting. Pursuant to AASB 1053, public sector entities like the Council of the Queensland Institute of Medical Research may adopt tier 2 requirements for their general purpose financial statements. However, AASB 1053 acknowledges the power of a regulator to require application of the tier 1 requirements. In the case of the Council, the Treasury Department is the regulator. Treasury Department has advised that its policy decision is that statutory bodies captured within the whole-of-government financial statements require all to adopt tier 1 reporting requirements. In compliance with Treasury's policy which prohibits the early adoption of new or revised accounting standards unless Treasury approval is granted, the Council has not early adopted AASB 1053. All other Australian accounting standards and interpretations with future commencement dates are either not applicable to the council's activities, or have no material impact on the council.
Page 87
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 2011
2010
$'000
$'000
Grants and other contributions
2.
Grants Grants- Queensland Health* Grants- QIMR Trust- Research support Grants - Other Grants - RBWH Grants - Smart State Medical Research Centre* *
13,969
6,169
1,164
4,417
40,219
44,209
-
953
71,840
14,849
Grants - NHMRC Infrastructure Funding ^
4,765
5,011
Donations and fundraising
5,586
15
292
-
137,835
75,623
Bequests Total *
Included in revenue from grants for 2011 is a grant of $13.969 million from Queensland Health. The terms of the grant are that it must be used to fund the administrative operations and maintenance of the Institute throughout the reporting period. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, all of the grant had been spent. ** Included in revenue from grants for 2011 are milestone grant payments of $10 million from the Queensland Department of Employment, Economic Development and Innovation, $55.5 million from the Commonwealth Department of Education, Employment and Workplace Relations' Education Investment Fund, and $5.5 million from the Atlantic Philanthropies Group. The terms of these grants are that these moneys must be used to fund the construction and fit out of the QIMR Smart State Research Centre building on the Herston site. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, $66.550 million of the grant remained unspent. ^ Included in revenue from grants for 2011 is a grant of $4.765 million from the National Health and Medical Research Council. The terms of the grant are that it must be used to fund capital scientific equipment acquisitions and maintenance of the Institute. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, all of the grant had been spent. 3.
User charges
Commercial and contract research
1,912
1,966
Sundry tenants recoveries
1,869
2,551
Other Total 4.
687 5,204
2,115
1,185 4,288
Other revenue
Interest Interest-Smart State Medical Research Centre
3,242
Investment distributions
3,416
781
Reimbursements
1,028
4,488
Other Total
Page 88
605 4,386
QIMR Annual Report 2010–2011
149
34
9,950
10,776
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
5.
2011
2010
$'000
$'000
(1,053)
683
Gains
Net gain on market value of other financial asset Net gain on sale of property, plant and equipment Net gain on foreign exchange transactions
-
4
-
303
Net gain on transfer of QIMR Trust net assets to Council (note 27)
54,985
-
Total
53,932
990
32,051
32,162
3,744
3,740
632
512
3,040
3,104
241
272
6.
Employee expenses
Employee benefits Wages and salaries Employer superannuation contributions * Long service leave levy * Annual leave expense * Other employee benefits Employee related expenses Workers' compensation premium *
73
9
Fringe benefits tax expense
36
31
Other employee related expenses Total
75
90
39,892
39,920
* Refer to note 1(w) The number of employees including both full-time employees and part-time employees measured on a fulltime equivalent basis is: Number of Employees: 7.
448
453
Supplies and services
Consultants and contractors
3,221
7,655
Supplies and consumables
12,127
13,038
1,793
1,755
782
700
Travel Minor equipment and software purchases Rent
183
211
Total
18,106
23,359
Page 89
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
8.
2011
2010
$'000
$'000
Depreciation and amortisation
Depreciation and amortisation were incurred in respect of: Buildings
2,373
2,561
Plant and equipment
2,954
2,667
Software purchased
68
42
Software internally generated
17
2
5,412
5,272
Total
Heritage assets include research library monographs, Australiana and scarce items that were independently valued at $0.28 million. The service potential of these assets are not expected to diminish with time or use and therefore, they are not depreciated. 9.
Other expenses
Scientific collaboration distributions Audit fee*
3,714
3,285
182
107
Insurance
380
335
Legal expenses
112
103
Net loss on sale of property, plant and equipment
59
-
Net loss on foreign exchange transactions
33
-
Impairment of bad debts
16
-
-
49
4,496
3,879
Other Total
* Total external audit fees relating to the 2010-11 financial year are estimated to be $60,000 (2010: $52,000). There are no non audit services included in this amount. 10.
Cash and cash equivalents
Imprest accounts Cash at bank
1
7,140
2,615
Term deposits
105,312
78,032
Total
112,453
80,648
11.
Receivables
Trade Debtors
GST receivable GST payable
Long service leave reimbursements
4,220
3,634
4,220
3,634
1,226 (159)
586 (230)
1,067
356
91
210
NHMRC Infrastructure Funding
2,274
2,491
Other
2,836
1,655
10,488
8,346
Total
Page 90
1
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
12.
2011
2010
$'000
$'000
Inventories
Supplies and consumables - at cost
277
269
Total
277
269
During the 2011 reporting period, $1.065 million of inventories (2010: $1.219 million) were expensed. All inventories on hand at 30 June are expected to be realised before 12 months. 13.
Other financial assets
Other financial assets at fair value through profit or loss: Managed fund investments Shares - US listed entities Total
59,816
13,985
47
46
59,863
14,031
QIMR holds shares in Sequenom Inc. which were acquired as a result of the takeover of Gemini pic, in which the shares owned by QIMR were originally held. These shares are quoted on the NASDAQ exchange in the United States of America and are recorded at their market value at reporting date. 14.
Intangible assets
Software purchased: At cost Less: Accumulated amortisation
679
590
(110)
(42)
569
548
At cost
172
133
Less: Accumulated amortisation
(19)
Software internally generated: (2)
153
131
-
107
-
107
722
786
Software WIP At cost
Total
Page 91
Page 92
QIMR Annual Report 2010–2011
(17) 154
Amortisation
Carrying amount at 30 June 131
(2)
133
-
-
590 (42)
89 (68) 548
-
-
569
-
548
Software Purchased 2011 2010 $'000 $'000
-
-
(128)
21
107
107
-
(722)
636
193
Software WIP 2011 2010 $'000 $'000
Amortisation of intangibles is included in the line item Depreciation and Amortisation in the Statement of Comprehensive Income.
40
-
131
Software Internally Generated 2011 2010 $'000 $'000
Transfers between classes
Acquisitions
Carrying amount at 1 July
Intangibles Reconciliation
14. Intangible assets (cont'd)
Notes to and forming part of the financial statements 2010-11
The Council of The Queensland Institute of Medical Research
Total
722
(85)
1
21
786
2011 $'000
786
(44)
-
637
193
2010 $'000
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
the council of the Queensland institute of medical research The Council of The Queensland of Medicalstatements Research notes to and forming part Institute of the financial Notes to and forming part of the financial statements 2010-11
2010–11 2011
2010
$'000
$'000
At fair value
118,641
120,900
Less: Accumulated depreciation
(40,856)
(39,262)
77,785
81,638
15.
Property, plant and equipment
Buildings:
Heritage and cultural assets: At fair value
283
283
283
283
52,401
47,353
(28,441)
(25,837)
23,960
21,516
104,259
29,385
104,259
29,385
206,287
132,822
Plant and equipment: At cost Less: Accumulated depreciation Work in progress: At cost
Total
Buildings were last revalued as at 30 June 2008 by independent valuer Davis Langdon Australia Pty Ltd. Such valuations were based on calculation of the depreciable replacement cost as at 30 June 2008. The values for these asset classes have since been indexed annually to ensure the value materially reflect fair value as at each reporting date. An interim revaluation of buildings was performed as at 30 June 2011 by indexation using the implicit price deflator. The external registered valuer believed this was the most appropriate index given the number of laboratories contained within these buildings. A revaluation index of -1.9% was applied as at 30 June 2011 (2010: -5.6%).The building revaluation for 2010-11 resulted in a decrement of $1.480 million (2010:$5.290 million). Heritage and cultural assets consisting of research library monographs, Australiana and scarce items have been included at current replacement cost as assessed by an Approved Commonwealth Valuer (Books) Christine M. Tilley, MA QU, MA Adel, Dip ContEd UNE, GradDipLibSc QIT as at 5 September 2006. Management believe this valuation of periodicals to be applicable at 30 June 2011 as there is minimal market movement in the value of these rare documents.
Page 93
The Council of The Queensland Institute of Medical Research
Page 94 373 (2,667)
283
Heritage and Cultural 2011 $'000 283 283
(7,816) 2,526 (2,561) 81,640
Buildings 2011 $'000 81,640 (2,259) 779 (2,373) 77,787
Acquisitions
Disposals
QIMR Annual Report 2010–2011
Transfers between classes
Revaluation decrements
Accum Depn Revaluation adjustment
Depreciation/amortisation
Carrying amount at 30 June 2010
Acquisitions
Disposals
Transfers between classes
Depreciation/amortisation
Carrying amount at 30 June 2011
23,960
(2,954)
-
-
1,222
(777)
4,954
21,515
104,259
-
-
-
(1,222)
-
76,096
29,385
2011 $'000
Work In Progress
29,385
-
-
-
(373)
-
20,139
9,619
Work In Progress 2010 $'000
206,287
(5,327)
779
(2,259)
-
(777)
81,049
132,822
2011 $'000
Total
132,822
(5,228)
2,526
(7,816)
-
(35)
22,079
121,296
Total 2010 $'000
The Council has plant and equipment with an original cost of $15.939 million (2010: $14.854 million) and a written down value of zero still being used in the provision of services. The Institute intends to retire these assets over the following five years.
Accum Depn Revaluation adjustment
Revaluation decrements
Carrying amount at 1 July 2010
2011 $'000
Plant and Equipment
21,514
(35)
1,940
21,903
283
Carrying amount at 1 July 2009
89,491
Plant and Equipment 2010 $'000
Heritage and Cultural 2010 $'000
Buildings 2010 $'000
Property, plant and equipment reconciliation
15. Property, plant and equipment (cont'd)
Notes to and forming part of the financial statements 2010-11
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11
16.
2010 $'000
Payables
Trade creditors Others Total 17.
2011 $'000
10,792
7,358
12
23
10,804
7,381
Accrued employee benefits
Current Wages outstanding ^ Long service leave levy payable Annual leave entitlements payable
-
302
176
139
2,488
2,339
Other
440
433
Total
3,104
3,213
^ Wages outstanding in 2009-10 financial year relates to Enterprise Bargaining Agreement relating to accrued back pay. Non-Current Annual leave entitlements payable
870
763
Total
870
763
87,243
74,406
87,243
74,406
18.
Unearned revenue
Unearned revenue
As at 30 June 2011 ($'000) Grants Brought Forward 1 July 2010 Smart State Medical Research Centre
Grants Received to date
Grant Expenditure
Grant Carried Forward to next period
57,511
84,132
75,093
66,550
7,959
25,313
23,126
10,146
Queensland Health
-
13,969
13,969
-
QIMR Trust
-
1,160
1,160
-
National Health & Medical Research Council
Cancer Australia Cancer Council Qld National Institute of Health Other granting bodies Other Commercial Funding Bodies
1,222
819
749
1,292
415
1,447
1,616
246
647
2,310
2,879
78
6,089
13,894
11,895
8,088
563
830
550
843
74,406
143,874
131,037
87,243
Page 95
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 18.
Unearned Revenue (cont'd) 2011
As at 30 June 2010 ($'000) Grants Brought Forward 1 July 2009 Smart State Medical Research Centre National Health & Medical Research Council Queensland Health QIMR Trust Cancer Australia Cancer Council Qld National Institutes of Health
19,137
57,511
5,779
26,462
24,282
7,959
-
6,169
6,169
-
-
4,417
4,417
-
1,586
73
437
1,222
177
1,894
1,656
415
1,460
4,772
5,585
647
1,251 6,042
(335) 10,570
(17) 11,456
933 5,156
1,101
836
1,374
563
79,867
69,035
74,496
74,406
Asset revaluation surplus by class
Buildings
Heritage & cultural assets
Total
$'000
$'000
$'000
Balance 1 July 2009
45,714
Revaluation increments/decrements
(5,290)
Balance 30 June 2010
40,424
Balance 1 July 2010 Revaluation increments/decrements Balance 30 June 2011
Page 96
14,177
University of Queensland
19.
Grant Carried Forward to next period
62,471
Other Granting Bodies Other Commercial Funding Bodies
Grant Expenditure
Grants Received to date
QIMR Annual Report 2010–2011
183
45,897
-
(5,290)
183
40,607
Buildings
Heritage & cultural assets
Total
$'000
$'000
$'000
40,424 (1,480) 38,944
183
40,607
-
(1,480)
183
39,127
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 20.
Reconciliation of operating surplus to net cash from operating activities 2011 $'000
Operating surplus/(deficit) Depreciation and amortisation expense
2010 $'000
137,867
19,977
5,412
5,272
Loss on sale of property, plant and equipment
59
-
Gain on sale of property, plant and equipment
-
(4)
Net increase in other financial asset Transfer of gain and financial assets from QIMR Trust
(2,363)
(1,464)
(54,766)
-
(Increase)/decrease in trade receivables
(585)
1,188
(Increase)/decrease in GST input tax credits receivable
(640)
(178)
119
(170)
217
(3,700)
Change in assets and liabilities:
(Increase)/decrease in long service leave reimbursement receivables (Increase)/decrease in NHMRC Infrastructure Funding (Increase)/decrease in other receivables (Increase)/decrease in inventories (Increase)/decrease in prepayments Increase/(decrease) in accounts payable Increase/(decrease) in accrued employee benefits Increase/(decrease) in unearned revenue
(206)
(69)
(8)
21
353
206
(465)
(496)
(3) 12,837
325 (5,461)
Increase/(decrease) in GST payable
(71)
(223)
(Increase) / decrease in investments accounted for using equity method
189
130
97,946
15,354
Net cash from operating activities 21.
Non-cash financing and investing activities
Assets and liabilities received or donated/transferred by the council and recognised as revenues and expenses are included in balances contained in Notes 4 and 15 respectively. 22. Commitments for expenditure (a) Non-Cancellable Operating Lease Commitments under operating leases at reporting date are inclusive of anticipated GST and are payable as follows: Payable: Not later than one year
48
46
Later than one year and not later than five years
36
84
Later than five years Total
-
-
84
130
Page 97
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 22. Commitments for expenditure (cont'd) Operating lease have renewal options however, no leases have escalation clauses other than in the event of payment default. No lease arrangements create restrictions on other financing transactions. No other material expenditure items were committed by the Council as at the end of the reporting period. (b) Capital Expenditure Commitments Material classes of capital expenditure commitments inclusive of anticipated GST, contracted for at reporting date but not recognised in the accounts are payable as follows: 2011
2010
$'000
$'000
1,255
1,589
Later than one year and not later than five years
-
-
Later than five years
-
-
1,255
1,589
Payable: Not later than one year
Total
Other expenditure committed at the end of the period but not recognised in the accounts are as follows: Payable: Not later than one year Later than one year and not later than five years Later than five years Total
1,253
1,074
-
-
-
-
1,253
1,074
23. Contingencies Contingent assets Contributions to Queensland Community Foundation The abolished QIMR Trust established a fund with the Queensland Community Foundation (QCF) for the purpose of creating a specific fund to generate future income and donations. This fund was transferred to Council upon abolition of the Trust on the 1 February 2011. All contributions made to this named fund within QCF are held in trust and invested in perpetuity with net income distributed to the Council at the discretion of the Trustee in accordance with the Queensland Community Fund Declaration of Trust. The available balance of this fund was $ 0.358 million at 30 June 2011 (2010: $0.354 million) of which $10,000 was contributed by the former QIMR Trust. The Council expects that earnings from the 2010/11 financial year will be brought to account during the financial year ending 30 June 2012. Contingent liabilities There were no known contingent liabilities at 30 June 2011.
Page 98
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 24. Jointly controlled entities a) Q-Pharm Pty Ltd Q-Pharm Pty Limited is a Phase 1 Clinical Trial company. The company is a joint venture between Professors Hooper and Dickinson, QIMR and The University of Queensland. QIMR holds 24.5% of the shares of Q-Pharm Pty Limited [2009/10: 24.5%]. QIMR accounts for its 24.5% interest in Q-Pharm Pty Limited on an equity accounted basis. . A summary of the financial transactions and balances for Q-Pharm Pty Limited is as follows: Q-Pharm Pty Ltd
Income
2011
2010
$'000
$'000
5,129
5,538
(5,900)
(6,067)
Net Surplus/(Deficit)
(771)
(529)
Current Assets
1,994
2,380
369
359
(1,132)
(739)
Expenses
Non Current Assets Current Liabilities Non Current Liabilities Net Assets
1,231
2,000
Q-Pharm did not have any material contingent liabilities or commitments as at 30 June 2011. Council has not individually or jointly incurred any contingent liabilities in Q-Pharm. Council is not contingently liable for the liabilities of the other ventures of Q-Pharm. b) Vaccine Solutions Pty Ltd QIMR and CSL Limited are equal shareholders in Vaccine Solutions Pty Ltd, a company established in 1998 to provide Clinical Trial Sponsorship, intellectual property management and commercialisation services to the CRC for Vaccine Technology (CTC-VT). Upon the winding up of the CRC-VT the company manages a number of licensing arrangements for the benefit of the members of CRC-VT Trust II. Vaccine Solutions does not own any physical or intellectual property assets of its own and is required to return 97% of all commercial income received from licensing activities to the CRCVT Trust II for distribution to members of that trust. 25. Trust transactions and balances a)
Trust for the CRC for Vaccine Technology (CRCVT Trust I)
QIMR is the Trustee of the CRC for Vaccine Technology Trust [CRCVT Trust I], a trust managing shares in VacTx Pty Ltd on behalf of the participants of the CRC-VT. VacTx Pty Ltd is a company focused on the development of vaccines through intellectual property created by the CRC-VT. The CRC-VT wound up operations in June 2006. Income received from the sale of the shares is to be distributed to the members in the trust according to their participating share in the CRC-VT as of June 2006. The members of this trust are: The Queensland Institute of Medical Research, CSIRO, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University. b)
Trust for the CRC for Vaccine Technology (CRCVT Trust II)
QIMR is the Trustee of the CRC for Vaccine Technology (CRC-VT) Trust [CRCVT Trust II], a trust responsible for managing patent families and licensing arrangements on behalf of the participants in the CRC for Vaccine Technology since winding up in June 2006, Income received from licensing arrangements is distributed to the members in the trust according to their participating share in the CRC-VT as of June 2006. The members of the trust are: The Queensland Institute of Medical Research, CSIRO, CSL Limited, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University. As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in these notes for the information of users. Page 99
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 25. Trust transactions and balances (cont'd) Trust for the CRC for Vaccine Technology (CRCVT Trust II)
2011
2010
$'000
$'000
272
584
(275)
(576)
(3)
8
Trust Revenues and Expenses Income Expenses Net Surplus/(Deficit) Trust Assets and Liabilities Current Assets Cash
45
133
Receivables
572
411
Total Assets
617
544
4
14
Current Liabilities Payables
6
6
Beneficiaries entitlements payable
602
517
Total Liabilities
612
537
5
7
Provision for income tax
Total Trust Net Assets c)
Employee Research Services
The Institute undertakes a custodial role in respect of transactions and balances relating to employee research services and they are therefore not recognised in the financial statements. As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in these notes for the information of users. Employee Research Services Trust Revenues and Expenses Income Expenses Increase / (Decrease) in net employee research services
925
882
(931)
(475)
(6)
407
Trust Assets Current Assets Cash held in short term deposits
2,332
2,338
Total Trust Assets
2,332
2,338
26. Key executive management personnel and remuneration a)
Key Executive Management Personnel
The following details for key executive management personnel include those positions that had authority and responsibility for planning, directing and controlling the activities of the agency during 2010-11. Further information on these positions can be found in the body of the Annual Report under the section relating to Executive Management.
Page 100
QIMR Annual Report 2010–2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 26. Key executive management personnel and remuneration (cont'd)
Director
b)
Current Incumbent Contract classification and appointment authority Appointed by Governor in Council, s10 QIMR Act 1945
Responsibilities
Position
Director is responsible for efficient and effective administration of the Institute
Date appointed to position 4 January 2011
Remuneration
Remuneration policy for the agency’s key executive management personnel is set by Council as provided for under the Queensland Institute of Medical Research Act 1945 . The remuneration and other terms of employment for the key executive management personnel are specified in employment contracts. The contracts provide for the provision of other benefits including motor vehicles. Remuneration packages for key executive management personnel comprise the following components:i) Short term employee benefits which include: o Base - consisting of base salary, allowances and leave entitlements paid and provided for the entire year or for that part of the year during which the employee occupied the specified position. Amounts disclosed equal the amount expensed in the Statement of Comprehensive Income. o Non-monetary benefits – consisting of provision of vehicle together with fringe benefits tax applicable to the benefit. ii) Long term employee benefits include long service leave accrued. iii) Post employment benefits include superannuation contributions. iv) Redundancy payments are not provided for within individual contracts of employment. Contracts of employment provide only for notice periods or payment in lieu of notice on termination, regardless of the reason for termination. v) There are no performance bonuses payable to key executive management. Total fixed remuneration is calculated on a ‘total cost’ basis and includes the base and non-monetary benefits, long term employee benefits and post employment benefits: 1 July 2010 - 30 June 2011 Short Term Employee Benefits Position
Nonmonetary Benefits $'000
Base $'000 Director / Acting Directors
410
Long Term Employee Benefits
Post Employment benefits
Termination Benefits
Total Remuneration
$'000
$'000
$'000
$'000
27
8
25
-
470
1 July 2009 - 30 June 2010 Short Term Employee Benefits Position
Nonmonetary Benefits $'000
Base $'000 Director
293
25
Long Term Employee Benefits
Post Employment benefits
Termination Benefits
Total Remuneration
$'000
$'000
$'000
$'000
6
37
-
361
Page 101
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 27. Transfer of the assets and liabilities of the abolished QIMR Trust to the Council of the Queensland Institute of Medical Research The Queensland Institute of Medical Research Trust was abolished with effect on the 1 February 2011. On the Trust abolition day the net assets of the Trust immediately before the Trust abolition day became the assets and liabilities of the Council, as prescribed by the Water and Other Legislation Amendment Act 2010 . The 2010 balances have been reported below for comparative purposes only. The book values of the assets and liabilities transferred to the Council, as at 31 January 2011, were recorded in the abolished Trust as follows: 2011
2010
$'000
$'000
Cash and cash equivalents
651
1,067
Trade and other receivables
314
608
36
-
Current Assets
Other current assets Total Current Assets
1,001
1,675
54,115
50,029
Total Non Current Assets
54,115
50,029
Total Assets
55,116
51,704
131
246
Total Current Liabilities
131
246
Total Liabilities
131
246
54,985
51,458
10
112,453
80,648
Receivables
11
10,488
8,346
Other financial assets
13
59,863
14,031
182,804
103,025
Non Current Assets Other financial assets
Current Liabilities Payables
Net Assets 28. Financial Instruments (a)
Categorisation of Financial Instruments
The Council has the following categories of financial assets and financial liabilities: Category
Note
Financial Assets Cash and cash equivalents
Financial Liabilities Financial liabilities measured at amortised cost: Payables Total
Page 102
QIMR Annual Report 2010–2011
16
(10,804)
(7,381)
(10,804)
(7,381)
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 28. Financial Instruments (cont'd) (b) Financial Risk Management The Council's activities expose it to a variety of financial risks - interest rate risk, credit risk, liquidity risk and market risk. Financial risk management is implemented pursuant to Government and Council policy. These policies focus on the unpredictability of financial markets and seek to minimise potential adverse effects on the financial performance of the Council. All financial risk is managed by the Queensland Institute of Medical Research Corporate Services Division under policies approved by the Council. The Council provides written principles for overall risk management, as well as policies covering specific areas. The Council measures risk exposure using a variety of methods as follows Risk Exposure
Measurement method
Credit risk
Ageing analysis, earnings at risk
Liquidity risk
Sensitivity analysis
Market risk
interest rate sensitivity analysis
(c) Credit Risk Exposure Credit risk exposure refers to the situation where the Council may incur financial loss as a result of another party to a financial instrument failing to discharge their obligation. The maximum exposure to credit risk at balance date in relation to each class of recognised financial assets is the gross carrying amount of those assets inclusive of any provisions for impairment. The following table represents the Council's maximum exposure to credit risk based on contractual amounts net of any allowances: 2011
2010
Note
$'000
$'000
10
112,453
80,648
Financial Assets Cash and cash equivalents Receivables
11
10,488
8,346
Other financial assets
13
59,863
14,031
182,804
103,025
Total
No collateral is held as security and no credit enhancements relate to financial assets held by the Council. The Council manages credit risk through the use of a credit management strategy. This strategy aims to reduce the exposure to credit default by ensuring that the Council invests in secure assets and monitors all funds owed on a timely basis. Exposure to credit risk is monitored on an ongoing basis. No financial assets and financial liabilities have been offset and presented net in the Statement of Financial Position. The method for calculating any provision for impairment is based on past experience, current and expected changes in economic conditions and changes in client credit ratings. These economic and geographic changes form part of the council's documented risk analysis assessment in conjunction with historic experience and associated industry data. This analysis has identified that that none of the Trust's financial assets are impaired and subsequently provisions for impairment have not been raised. No financial assets have had their terms renegotiated so as to prevent them from being past due or impaired, and are stated at the carrying amounts as indicated. Ageing of past due but not impaired financial assets are disclosed in the following tables. No financial assets were assessed as being impaired as at 30 June 2011:
Page 103
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010–11 28. Financial Instruments (cont'd) 2011 Financial Assets Past Due But Not Impaired Overdue Less than 30 Days Note
30- 60 Days
61-90 Days
More than 90 Days
Total
$'000
$'000
$'000
$'000
$'000 Receivables
11
Total
9,448
657
7
376
10,488
9,448
657
7
376
10,488
2010 Financial Assets Past Due But Not Impaired Overdue Less than 30 Days Note
30- 60 Days
61-90 Days
More than 90 Days
Total
$'000
$'000
$'000
$'000
$'000 Receivables
11
Total
6,272
749
279
1,046
8,346
6,272
749
279
1,046
8,346
(d) Liquidity Risk Liquidity risk refers to the situation where the Council may encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Council is exposed to liquidity risk in respect of its payables. The Council manages liquidity risk through the use of a liquidity management strategy. This strategy aims to reduce the exposure to liquidity risk by ensuring the Council has sufficient funds available to meet employee and supplier obligations as they fall due. This is achieved by ensuring that minimum levels of cash are held within the various bank accounts so as to match the expected duration of the various employee and supplier liabilities. The following table sets out the liquidity risk of financial liabilities held by the Council. It represents the contractual maturity of financial liabilities, calculated based on undiscounted cash flows relating to the liabilities at reporting date. The undiscounted cash flows in these tables may differ from the amounts included in the Statement of Financial Position that are based on discounted cash flows. 2011 Payable in Note
Total >5 year
<1 year
1-5 years
$'000
$'000
(10,804)
-
-
(10,804)
(10,804)
-
-
(10,804)
$'000
$'000
Financial Liabilities Payables
16
Total
2010 Payable in Note
Total >5 year
<1 year
1-5 years
$'000
$'000
(7,381)
-
-
(7,381)
(7,381)
-
-
(7,381)
$'000
$'000
Financial Liabilities Payables
16
Total
Page 104
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010â&#x20AC;&#x201C;11 28. Financial Instruments (cont'd) (e)
Market Risk
The Council does not trade in foreign currency and is not materially exposed to movements in foreign currency exchange rates, although it does hold some residual funds in Hong Kong. The Council does not undertake any hedging in relation to interest risk and manages its risk as per the Council's liquidity risk management strategy articulated in the Council's policies. The Council is exposed to movements in interest rate risk through its investment in externally (f)
Interest Rate Sensitivity Analysis
The following interest rate sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on net income if interest rates would change by +/- 1% from the year-end rates applicable to the Council's financial assets and liabilities. With all other variables held constant, the Council would have a surplus and equity increase/(decrease) of $1,125million (2010: $806k). This is mainly attributable to the Council's exposure to interest rate movements in its holdings in cash and cash equivalents. 2011 Interest Rate Risk Financial Instruments
Carrying Amount
Cash & cash equivalents
112,453
$'000
-1%
+1%
Profit $'000
Potential Impact
Equity $'000
Profit $'000
Equity $'000
(1,125)
(1,125)
1,125
1,125
(1,125)
(1,125)
1,125
1,125
2010 Interest Rate Risk Financial Instruments
Carrying Amount $'000
Cash & cash equivalents
-1%
+1%
Profit $'000
80,648
Potential Impact
Equity $'000
Equity $'000
Profit $'000
(806)
(806)
806
806
(806)
(806)
806
806
Other Price Risk Sensitivity Analysis The following other price risk sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on profit or loss if unit/share price would change by +/-1% from the year-end price applicable to the Council's other financial asset investments. With all other variables held constant, the Council would have a surplus and equity increase/(decrease) of $599k (2010: $140k). This is mainly attributable to exposure to unit price movements in its investments managed funds and movements in market value of US listed shares. 2011 Other Price Rate Risk Financial Instruments
Carrying Amount $'000
Managed Funds & Listed Shares
-1%
+1%
Profit $'000
59,863
Potential Impact
Equity $'000
Profit $'000
Equity $'000
(599)
(599)
599
599
(599)
(599)
599
599
2010 Other Price Rate Risk Financial Instruments
Carrying Amount $'000
Managed Funds & Listed Shares Potential Impact
14,031
-1%
+1%
Profit $'000
Equity $'000
Profit $'000
Equity $'000
(140)
(140)
140
140
(140)
(140)
140
140
Page 105
the council of the Queensland institute of medical research
notes to and forming part of the financial statements 2010â&#x20AC;&#x201C;11 28. Financial Instruments (cont'd) (g) Fair Value The recognised fair values of financial assets and liabilities are classified according to the following fair value hierarchy that reflects the significance of the inputs used in making these measurements: Level 1 - fair values that reflect unadjusted quoted prices in active markets for identical assets/liabilities; Level 2 - fair values that are based on inputs that are directly or indirectly observable for the asset/liability (other than unadjusted quoted prices); and Level 3 - fair values that are derived from data not observable in a market. According to the above hierarchy, the fair values of each class of asset/liabilities recognised at fair value are as follows: 2011 Classification according to fair value hierarchy
Carrying Amount
Level 1
Level 2
Level 3
$'000
$'000
$'000
$'000
Managed fund investments
59,816
-
-
59,816
US listed entities
47
-
-
47
Total
59,863
-
-
59,863
Class Financial Assets
2010 Classification according to fair value hierarchy
Carrying Amount
Level 1
Level 2
Level 3
$'000
$'000
$'000
$'000
13,985
-
-
13,985
US listed entities
46
-
-
46
Total
14,031
-
-
14,031
Class Financial Assets Managed fund investments
The fair value of trade receivables and payables is assumed to approximate the value of the original transaction, less any provision for impairment. 29. Events Occurring After Balance Date There are no events occurring after balance date having a material impact on the figures reported in the above statements. 30. Changes in Accounting Estimates and Correction of Errors Financial Statement comparative figures have been restated to correct inaccurate revenue estimates in the financial years 2004-05 to 2009-10 related to estimates of funding receivable through the NHMRC Infrastructure Support (IRIIS). The cumulative effect of the error resulted in an overstatement of Receivables, and an overstatement of Accumulated Surplus at June 2010 of $1,209k. The error has been corrected by restating each affected financial statement line items for the prior year. Funding for the Smart State Medical Research Centre (SSMRC) is recognised as revenue in the financial statements in the period in which the Institute gains control of the funds. Since the commencement of the SSMRC project, revenue has been recognised in the financial statements as Capital Grants. Revenue recognised as Capital Grants includes amounts earned on investment of grant funds received. Financial Statement comparative figures have been restated to reflect the amount of interest earned on Capital Grant funds in the 2009-10 financial year. A reclassification of the revenue in the Statement of Comprehensive Income has resulted in a decrease to the line item Grants and other contributions and an increase to Other Revenue by $4,288k.
Page 106
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
the council of the Queensland institute of medical research
certificate of the council of the Queensland institute of medical research These general purpose financial statements have been prepared pursuant to section 62(1) of the Financial Accountability Act 2009 (the Act), relevant sections of the Financial and Performance Management Standard 2009 and other prescribed requirements. In accordance with section 62(1)(b) of the Act we certify that in our opinion: a)
the prescribed requirements for establishing and keeping the accounts have been complied with in all material respects; and
b)
the statements have been drawn up to present a true and fair view, in accordance with prescribed accounting standards, of the transactions of the Council of the Queensland Institute of Medical Research for the financial year ended 30 June 2011 and of the financial position of the Council at the end of that year.
Dated at Brisbane this 2nd day of September 2011
Professor John Hay AC Chairman of Council
Professor Frank Gannon Director & Chief Executive Officer
Donna Hancock Secretary
Page 107
the council of the Queensland institute of medical research
independent auditorâ&#x20AC;&#x2122;s report
Page 108
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Page 109
SuppoRtInG InFoRmAtIon
Page 110
QIMR Annual Report 2010–2011
aWarDS Recipient
Bestower of award
Date
Award
Reason
Kylie Alexander
ASMR
May-11
ASMR Premier's Award
1st place - oral presentation. Best research by postgraduate researcher
Prof Greg Anderson
International BioIron Society
May-11
President Elect of the Society
Voted by the membership to be the next President of IBIS Conference attendance
Dr Simon Apte
ASI
Aug-10
Travel award (international)
Dr Simon Apte
ASI
Jan-11
Appointment ASI Newsletter Editor
Assoc Prof Michael Breakspear
ASMR
Jun-11
Clinical Researcher Award
Enda Byrne
Australasian Society of Psychiatric Research
Young Investigator Travel Award
Conference attendance
Fernanda Cardoso
ASI
Aug-10
Travel award (international)
Conference attendance
Prof Denise Doolan
Australia - Europe Malaria Research Cooperation
Feb-10
Appointment
Scientific Advisory Board
Prof Denise Doolan
Australian Society for Parasitology
Aug-10
Appointment
President-Elect
Nov-10
1st prize poster competition, 7th Annual International Melanoma Congress
May-11
QIMR Postgraduate Travel Award 2011
Conference attendance Best paper in Public Health at GU
Blake Ferguson
Dr Katja Fischer
QIMR
Dr Darren Gray
GU
Dec-10
Publication of the Year
Prof Geoff Hill
NHMRC
Mar-11
Australia Fellowship
Prof Geoff Hill
OHMR
Jun-11
Senior Clinical Research Fellowship
Prof Geoff Hill
NHMRC
Mar-11
Practitioner Fellowship (level 2)
Assoc Prof Malcolm Jones
Australian Society for Parasitology
Aug-10
Fellow of the Australian Society for Parasitology
Contributions to Australian Parasitology
Dr Motoko Koyama
TSANZ
Jun-11
Young Investigator Award
Quality of research by young investigator
Dr Motoko Koyama
ASI
Dec-10
Travel award
Conference attendance
Dr Felicity Lose
PCFA
Aug-10
Travel award
Dr Felicity Lose
Contributing to Australian Scholarship and Science Foundation
Apr-11
Travel award
Dr Felicity Lose
CCQ
May-11
Travel award
Dr Kelli MacDonald
CCQ
Jan-11
Senior Research Fellowship
Dr Cameron McDonald
ALF
Jan-11
ALF Hospitality Industry Career Development Research Fellowship
Prof Don McManus
NHMRC
Dec-10
Senior Principal Research Fellowship
Prof Don McManus
Veterinarni Medicina
Jan-11
Invited Editorial Board Member
Prof Don McManus
American Society of Tropical Medicine and Hygiene
Nov-10
Honorary membership of the American Society of Tropical Medicine and Hygiene
In recognition of outstanding accomplishment by an individual not an American citizen who has made eminent contributions to some phase of tropical medicine and hygiene.
Dr Sarah Medland
Australian Institute of Policy and Science
Nov-10
Young Tall Poppy Science Award
Early career researcher award for scientific milestones and demonstrative ability to engage people in science
Dr Sarah Medland
Behavior Genetics Association
Jun-11
Fuller and Scott Award
Outstanding young investigator who has made substantial contributions to the field of Behavior Genetics
Dr Sarah Medland
Behavior Genetics Association
Jun-11
Fulker Award
Best paper published in the journal Behavior Genetics in 2010
NHMRC RF Scheme
Dr Sarah Medland
QIMR
Jun-11
QIMR Travel Award
Conference attendance
Dr Catherine Olsen
QIMR
Nov-10
QIMR Overseas Conference Support
1st International Conference on UV and Skin Cancer Prevention Best research at annual meeting
Renee Robb
TSANZ
Jun-11
Presidentâ&#x20AC;&#x2122;s prize
Dr David Reid
OHMR
Feb-11
Clinical Fellowship
Page 111
Recipient
Bestower of award
Date
Award
Reason
Haran Sivakumaran
MSD ScheringPlough Pty Ltd
Jun-11
Top Post-Doc Award (HIV)
Outstanding scientific presentation
Dr Patricia Valery
NHMRC
Dec-10
Excellence award
Highest ranked Career Development Award application
Prof Emma Whitelaw
ANZSCDB
Sep-10
President's Medal
Outstanding contribution to cell and developmental biology
Prof Emma Whitelaw
International Union of Biochemists and Molecular Biologists
Feb-11
IUBMB Jubilee Lecture and Medal
Contribution to the understanding of transcription and epigenetic inheritance
Dr Susan Woods
ASMR
Jun-11
2011 Queensland Senior Researcher Award
Dr Daniel Worthley
NHMRC
Jun-10
RG Menzies Fellowship
Most outstanding recipient of CJ Martin Postdoctoral Fellowship
Dr Neil Youngson
Lalor Foundation
Apr-11
Travel Award
Conference attendance
Legend ANZSCDB
Australia and New Zealand Society for Cell and Developmental Biology
ASI
Australasian Society of Immunology
ASMR
Australian Society of Medical Research
CCQ
Cancer Council Queensland
GU
Griffith University
NHMRC
National Health and Medical Research Council
OHMR
Office of Health and Medical Research
PCRFA
Prostate Cancer Research Foundation Australia
TSANZ
The Transplantation Society of Australia and New Zealand
inViteD LectureS
Page 112
Speaker
Title of lecture
Date
Audience or event
City, Country
Prof Greg Anderson
Iron absorption and its regulation in the perinatal period
Jul-10
Biometals 2010. Seventh International Biometals Symposium
Tucson, USA
Prof Greg Anderson
Iron metabolism.
Nov-10
Metabolism and Cancer Symposium. School of Biomedical Sciences, The University of Queensland
Brisbane, Australia
Prof Greg Anderson
Iron metabolism and testing
Mar-11
RCPA: Pathology Update 2011
Melbourne, Australia
Prof Greg Anderson
Essential but toxic: Controlling the flux of iron in the body
Apr-11
Third Australia-China Biomedical Research Conference
Melbourne, Australia
Prof Greg Anderson
Invited Session Chair - Iron signalling pathways
May-11
Bioiron 2011. World Congress on Iron Metabolism.
Vancouver, Canada
Kylie Alexander
Speaker
May-11
The ASMR Medical Research Week Student Conference
Brisbane, Australia
Dr Ann Apolloni
A New, Potent Transdominant Negative Tat Blocks HIV-1 Replication
Jun-11
Australian Centre for HIV and Hepatitis Research 7th Annual Workshop
Sunshine Coast, Australia
Dr Simon Apte
The role of PD-1 in malaria
Nov-10
Emory Vaccine Research Centre
Atlanta, USA
Dr Kathy Andrews
Transcriptional profiling the effects of hydroxamate-based HDAC inhibitors in P. falciparum
Aug-10
International Congress of Parasitology XII
Melbourne, Australia
Dr Kathy Andrews
Transcriptional profiling the effects of hydroxamate-based HDAC inhibitors in P. falciparum
Nov-10
Australian Health and Medical Research Congress
Melbourne, Australia
Dr Barrie Anthony
Schistosoma mansoni egg-induced downregulation of hepatic stellate cell activation and fibrogenesis
Oct-10
Australian Gastroenterology Week 2010 meetIng
Gold Coast, Australia
Dr Annika Antonsson
Viruses in breast cancer
May-11
National Breast Cancer Foundation
Sydney, Australia
Dr Vanessa Beesley
Current and planned cancer survivorship research at QIMR
Nov-10
Clinical Oncology Society of Australia Annual Scientific Meeting - Cancer Survivorship Workshop
Melbourne, Australia
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Vanessa Beesley
Pancreatic cancer patients’ supportive care needs and corresponding use of allied health services
Nov-10
Psycho-Oncology Co-operative Research Group (PoCoG) Professional Day
Melbourne, Australia
Gabriëlla Blokland
Genetic influences on white matter tract density within the working memory network
May-11
2011 Australian Society for Medical Research Postgraduate Student Conference
Brisbane, Australia
Prof Andrew Boyd
Recent advances in brain tumour research: Prospects for therapy
May-11
Cancer Council Queensland Brain Tumour Symposium
Brisbane, Australia
Dr Glen Boyle
Local cure of melanoma in mice and dogs by intratumoral injection of EBC46
Nov-10
Society for Melanoma Research 2010 Congress
Sydney, Australia
Assoc Prof Michael Breakspear
Predictive coding
Nov-10
Monash University neuroscience workshop
Melbourne, Australia
Assoc Prof Michael Breakspear
Brain modelling
Jan-11
University of Queensland Summer School
Brisbane, Australia
Assoc Prof Michael Breakspear
Neonatal burst suppresion
Jun-11
Brain Connectivity Workshop
Montreal, Canada
Assoc Prof Michael Breakspear
Multistable brain rhythms
Jun-11
Yale Seminar Series
New Haven, USA
Assoc Prof Michael Breakspear
Multistable brain rhythms
Jun-11
Human Brain Mapping
Quebec, Canada
Assoc Prof Michael Breakspear
Brain Modelling
Jun-11
Human Brain Mapping
Quebec, Canada
Assoc Prof Michael Breakspear
Scale-free brain dynamics
Nov-10
Computational neuroscience summer school
Brisbane, Australia
Assoc Prof Michael Breakspear
Brain connectivity: A primer
Dec-10
Australian Society for Psychiatric Research
Sydney, Australia
Assoc Prof Scott Burrows
Allelic polymorphism in the T cell receptor – assessing its overall importance
Jul-10
Structural Immunology Meeting, Monash University
Melbourne, Australia
Assoc Prof Scott Burrows
The sensitivity of peptide-MHC-TCR binding
Nov-10
Emory Vaccine Centre
Atlanta, USA
Assoc Prof Scott Burrows
T cell immune response to Epstein-Barr virus
Nov-10
Australian Society for Microbiology WA branch dinner
Perth, Australia
Assoc Prof Scott Burrows
The T cell immune response to EpsteinBarr virus
Nov-10
Institute for Immunology and Infectious Diseases, Murdoch University
Perth, Australia
Assoc Prof Scott Burrows
New insights into alloreactivity
Nov-10
Australian Society for Immunology (WA Branch) monthly meeting
Perth, Australia
Assoc Prof Scott Burrows
The T cell immune response to EpsteinBarr virus
May-11
Centenary Institute
Sydney, Australia
Dr Fernanda Cardoso
Development of a high throughput approach to identify the targets of cellular immunity on a proteome-wide scale
Aug-10
International Congress of Immunology
Kobe, Japan
Dr Fernanda Cardoso
Proteome-wide screening of complex pathogen to identify antigens targets by T cell mediated immune responses
Aug-10
International Congress of Parasitology
Melbourne, Australia
Prof Georgia ChenevixTrench
Genome wide association studies: are we there yet?
Jun-10
Children’s Medical Research Institute
Sydney, Australia
Prof Georgia ChenevixTrench
Genome wide association studies: are we there yet?
Nov-10
Human Genetics Society of Australasia Annual Scientific Conference
Melbourne, Australia
Prof Georgia ChenevixTrench
A guide for PhD students
Apr-11
Student Retreat, UQ Diamantina Institute
Brisbane Australia
Prof Georgia ChenevixTrench
Genome wide association studies: the role of biobanks
Dec-11
8th Annual Australasian Biospecimen Network Meeting
Brisbane Australia
Prof Georgia ChenevixTrench
Towards personalised therapy for ovarian cancer
Feb-11
The Charles Rodolphe Brupbacher Foundation
Zurich, Switzerland
Dr Qin Cheng
A large proportion of asymptomatic malaria infections with low parasite densities in Temotu province, Solomon Islands: challenges for malaria diagnostics in an elimination setting.
Nov-10
The 59th ASTMH annual meeting
Atlanta, USA
Dr Qin Cheng
Genotying P. vivax
May-11
APMEN vivax Working Group Genotyping Workshop
Kota Kinabalu, Malaysia
Dr Qin Cheng
Facts and challenges: knowledge gaps in malaria diagnosis for elimination
May-11
APMEN vivax Working Group Genotyping Workshop
Kota Kinabalu, Malaysia
Dr Suyinn Chong
Maternal ethanol consumption alters the epigenotype and the phenotype of offspring in a mouse model
May-10
Queensland Brain Institute Symposium: Epigenomics, Behaviour & Disease
Brisbane, Australia
Dr Suyinn Chong
Epigenetics and a mouse model of foetal alcohol syndrome
Oct-10
Annual inservice for Queensland geneticists and genetic counsellors, Royal Brisbane and Women’s Hospital
Brisbane, Australia
Page 113
invited lectures | continued
Page 114
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Suyinn Chong
The role of epigenetics in phenotypic variation and disease risk
Mar-11
Children's Medical Research Institute Seminar Series
Sydney, Australia
Dr Suyinn Chong
The role of epigenetics in gestational programming of progeny phenotype by maternal ethanol consumption
Sep-10
Endocrine Society of Australia & Society of Reproductive Biology Annual Scientific Meeting
Sydney, Australia
Dr Suyinn Chong
Maternal ethanol consumption alters the epigenotype and the phenotype of offspring in a mouse model
Oct-10
7th India-Australia Biotechnology Conference
Brisbane, Australia
Dr Jon Darbro
Assessment of Beauveria bassiana for control of Aedes aegypti: Effects on bloodfeeding behaviour, fecundity and virulence in semi-field conditions
Sep-10
Australian Mosqutio Control Association
Caloundra, Australia
Lucia Daxinger
Rif1, a novel modifier of epigenetic reprogramming in the mouse
Dec-10
Max-Planck Freiburg Epigenetics Meeting
Freiburg, Germany
Prof Denise Doolan
Mining genomic, proteomic and transcriptomic datasets for next generation malaria vaccine development
Aug-10
International Congress of Parasitology
Melbourne, Australia
Prof Denise Doolan
Molecular immunology in the genomics era: novel advances for vaccine development.
Dec-10
Australasian Society of Immunology Postgraduate Student Workshop
Perth, Australia
Prof Denise Doolan
Proteome-wide screening of P. falciparum CD4 and CD8 T cell epitopes
Dec-10
Australasian Society of Immunology Symposium
Perth, Australia
Prof Denise Doolan
Genomes to vaccines: a 21st century solution for complex pathogens
Oct-10
Pfizer Australia
Melbourne, Australia
Prof Denise Doolan
Malaria â&#x20AC;&#x201C; 21st century approaches to combating an ancient enemy
Apr-11
Papua New Guinea Biomedical and Social Sciences Society Symposium.
Papua New Guinea
Prof Denise Doolan
Molecular vaccinology
Nov-10
Emory Vaccine Research Centre
Atlanta, USA
Dr David Duffy
Estimating extremely small Monte-Carlo P-values cheaply
Apr-11
8th GeneMappers Conference
Hobart, Australia
Ken Dutton-Regester
A high throughput mutation screening panel for the identification of clinically relevant profiles in melanoma
Oct-10
TRX10- Translational Research Excellence 2010
Brisbane, Australia
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Jul-10
Biology of Parasitism Course
Woods Hole, USA
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Aug-10
The XIIth International Congress of Parasitology (ICOPA)
Melbourne, Australia
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Nov-10
Department of Biochemistry, Indian Institute of Chemical Biology
Kolkata, India
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Nov-10
Rajendra Memorial Research Institute of Medical Sciences
Patna, India
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Nov-10
Institute of Medical Sciences, Banaras Hindu University
Varabasi, India
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Dec-10
Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine
London, UK
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Dec-10
Use of animal models in malaria research (Wellcome Trust)
Cambridge, UK
Dr Christian Engwerda
Immune regulation during parasitic diseases.
Dec-10
Australian Society for Immunology
Perth, Australia
Dr Christan Engwerda
Immune regulation during parasitic diseases.
Apr-11
Local regulation of infection, inflammation and autoimmunity. SFB 841 Symposium. Bernhard Nocht Institute for Tropical Medicine
Hamburg, Germany
Dr Manuel Ferreira
Invited Faculty
Mar-11
2011 International Workshop on Statistical Methodology for Human Genomic Studies
Boulder, Colorado
Dr Manuel Ferreira
Mapping common and rare risk variants for asthma
Apr-11
8th GeneMappers Conference
Hobart, Australia
Dr Manuel Ferreira
Australian Asthma Genetics Consortium
Apr-11
2011 TSANZ ASM
Perth, Australia
Dr Katja Fischer
Scabies mite inactivated protease paralogs inhibit the human complement system
Aug-10
XIIth International Congress of Parasitology (ICOPA)
Melbourne, Australia
Dr Katja Fischer
Scabies mite complement inhibitors promote streptococcal skin infections, rheumatic fever and heart disease
Mar-11
Heart Foundation Conference 2011
Melbourne, Australia
Assoc Prof Maher Gandhi
'It started with a kiss: I never thought it would end like this'
Apr-11
World Immunology Day
Brisbane, Australia
Assoc Prof Maher Gandhi
ITP
Mar-11
Grand Rounds, Princess Alexandra Hospital
Brisbane, Australia
Assoc Prof Maher Gandhi
World Lymphoma Day
Sep-11
Leukaemia Foundation
Brisbane, Australia
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Assoc Prof Maher Gandhi
EBV-related post-transplantation lymphoproliferative disorders: a haematologists perspective
Jun-11
Transplantation Society of Australasian and New Zealand
Canberra, Australia
Assoc Prof Maher Gandhi
A new and highly aggressive lymphoma
Aug-11
World Congress of Virology and Immunology
Busan, South Korea
Assoc Prof Maher Gandhi
EBV+ DLBCL
Sep-11
International Association for Research on Epstein-Barr virus and Associated Diseases
Birmingham, UK
Assoc Prof Don Gardiner
High throughput screening for new anti gametocidal agents
Oct-10
Medicines for Malaria Venture ESCA Meeting
Geneva , Switzerland
Assoc Prof Gail Garvey
Understanding dementia in urban, rural and remote Aboriginal and Torres Strait Islander communities in Queensland
Aug-10
Statewide Dementia Clinical Network Forum
Brisbane, Australia
Assoc Prof Gail Garvey
Knowledge of dementia in an Indigenous population
Sept-10
Dementia Collaborative Research Centre Forum
Surfers Paradise Queensland
Dr Michelle Gatton
Quantifying the sensitivity of malaria transmission to temperature and seasonality: implications for malaria control programs
Aug-10
XIIth International Congress of Parasitology
Melbourne, Australia
Dr Michelle Gatton
Directions for infectious diseases modelling
Jan-11
Research and Policy for Infectious Disease Dynamics (RAPIDD) Annual Convocation
Washington, USA
Dr Michelle Gatton
Modelling mosquito adaptation to control
May-11
RAPIDD-sponsored workshop of international scientists
London, UK
Dr Michelle Gatton
Analysis of WHO Malaria RDT Product Testing (Round 3)
May-11
WHO Product Testing Steering Committee
London, UK
Dr Michelle Gatton
Disasters and Diseases
Jun-11
ASMR Science in the Pub
Brisbane, Australia
Imogen Gillions
Development and validation of a murine model for dendritic cell (DC)-based immunotherapy
Dec-10
ASI Tumour Immunology Workshop. ASI Annual Scientific Meeting
Perth, Australia
Priscilla Goh
The role of peritrophins in scabies mite innate immunity (poster presentation)
Aug-10
XIIth International Congress of Parasitology (ICOPA)
Melbourne, Australia
Dr Geoffrey Gobert
Schistosome cell and molecular biology
Nov-10
Department of Medicine, UNAM
Mexico City, Mexico
Dr Geoffrey Gobert
Schistosome comparative genomics
Nov-10
ASTMH Annual Meeting
Atlanta, USA
Prof Jeff Gorman
Regulation of Type I Interferon-Dependent and -Independent Antiviral Responses by Respiratory Syncytial Virus Non-Structural Protein 1
Sep-10
HUPO2010
Sydney, Australia
Prof Jeff Gorman
Global Proteomic Views of Interferon Responses in Respiratory Syncytial Virus Infected A549 Type II Alvelor Epithelial Cells
Feb-11
Australian Proteomics Society
Lorne, Australia
Prof Jeff Gorman
Global Proteomic Views of Interferon Responses in Respiratory Syncytial Virus Infected A549 Type II Alevelolar Epithelial Cells
Feb-11
Lorne Infection and Immunity Conference
Lorne, Australia
Dr Darren Gray
Schistosomiasis
Sep-10
MPH Students, School of Population Health, The University of Queensland
Brisbane, Australia
Prof Adèle Green
The role of sunscreen in melanoma prevention
Feb-11
Qld Mining Health Improvement and Awareness Committee
Brisbane, Australia
Prof Adèle Green
Current evidence on skin cancer prevention
Apr-11
British Society for Investigative Dermatology Annual Conference
Manchester
Prof Adèle Green
Childhood exposure to ultra-violet radiation and harmful skin effects: epidemiological evidence
May-11
International Joint Conference on Non-Ionizing Radiation and Children's Health
Ljubljana, Slovenia
Prof Adèle Green
Effectiveness of sunscreens in skin cancer prevention
May-11
22nd World Congress of Dermatology
Seoul, Korea
Prof Adèle Green
Melanomas in the Sunshine State- what's new?
Jun-11
Capacity Building Grant Public Health Leadership Forum
Melbourne, Australia
Dr Sarah Harten
Epigenetic control of reprogramming
May-11
Mater Medical Research Institute Stem Cell Symposium
Brisbane
Prof Nick Hayward
A multi-faceted approach to discover new familial melanoma genes
Sept-10
Queenstown Molecular Biology Meeting
Queenstown, New Zealand
Prof Nick Hayward
Update on the Aussie melanoma GWAS
May-11
International Melanoma Genetics Consortium meeting
Tel Aviv, Israel
Prof Nick Hayward
Approaches to discover new melanoma
Nov-10
Scott Kirkbride Melanoma Research Centre ‘Advances in melanoma’ satellite symposium
Perth, Australia
predisposition genes Prof Nick Hayward
An Australian genome-wide association study to identify melanoma predisposition genes
Nov-10
7th International Melanoma Research
Sydney, Australia
Prof Geoff Hill
Antigen presentation after transplantation: where and when?
Feb-11
American Society of Bone Marrow Transplantation
Hawaii, USA
Page 115
invited lectures | continued
Page 116
Speaker
Title of lecture
Date
Audience or event
City, Country
Prof Geoff Hill
IL-17 responses in transplantation
Sep-10
Society for Hematology and Stem Cells
Melbourne, Australia
Prof Geoff Hill
The great debate: doctors make poor scientists
Dec-10
Australasian Society of Immunology
Perth, Australia
Prof Geoff Hill
Antigen presentation in transplantation
Jun-11
Centenary Institute
Sydney, Australia
Prof Geoff Hill
Transplantation, from bench to bedside
May-11
Amgen Haematology and Oncology scientific meeting
Sydney, Australia
Dr Leon Hugo
Survival characteristics of a wild population of Aedes aegypti in central Vietnam as determined by transcriptional age grading
Sep-10
Australian Mosqutio Control Association
Caloundra, Australia
Dr Tim Hurst
Disasters and diseases ASMR
Jun -11
Australian Society of Medical Research lecture
Brisbane, Australia
Dr Tim Hurst
Tanks, buckets and drumsâ&#x20AC;Śoh my
Sep-10
Australian Mosqutio Control Association
Caloundra, Australia
Dr Masego Johnstone
Sars 1c, an active cysteine protease from Sarcoptes scabiei inhibits complement by degrading complement factors C3 and C5 (oral)
Aug-10
XII International Congress of Parasitology (ICOPA)
Melbourne, Australia
Assoc Prof Malcolm Jones
Correlative microscopy methods to investigate egg structure and development in schistosomes
Jul-10
Australian Conference of Microscopy and Microanalysis
Brisbane, Australia
Assoc Prof Malcolm Jones
Tissue-specific transcriptomics of the human helminth parasite Schistosoma mansoni
Aug-10
International Congress of Parasitology Associations
Melbourne, Australia
Assoc Prof Malcolm Jones
Advanced structural investigations of helminths
Mar-11
The International Congress of Liver Flukes, 96 Years of Opisthorchiasis: Past, Present and Future
Khon, Kaen Thailand
Assoc Prof Malcolm Jones
Functional genomics approaches for investigations into human schistosomiasis
Apr-11
Royal Golden Jubilee Postrgraduate Students Congress
Pattaya, Thailand
Prof Brian Kay
Update on Wolbachia and other mosquito research
Apr-11
MARC Inc.
Brisbane, Australia
Colm Keane
LMO2 and BCL6 in DLBCL
Jun-11
International Congress in Malignant Lymphoma
Lugano, Switzerland
Dr Douglas Kerlin
Modelling of P. vivax
Feb-11
Collaborator meeting
Darwin, Australia
Prof Kum Kum Khanna
New single-stranded DNA binding proteins involved in DNA damage repair
Nov-10
Indian Institute of Science
Bengalore, India
Prof Kum Kum Khanna
Cellular responses to DNA damage and their link with tumor suppression
Oct-10
Indo-Australia Biotechnology Conference
Brisbane, Australia
Prof Kum Kum Khanna
Defective DNA damage response and cancer susceptibility
Nov-10
International Conference of Radiation Biology: Nanotechnology, Imaging and Stem Cell Research in Radiation Oncology
Chennai, India
Prof Kum Kum Khanna
DNA damage repair and genome maintenance: discovery of new players
Jul-10
Murdoch Childrens Research Institute
Melbourne, Australia
Prof Kum Kum Khanna
Genome maintenance and role of singlestranded DNA binding proteins
Nov-10
Symposium entitled Current Trends in Radiation Biology and Radiation Countermeasures
Delhi, India
Prof Kum Kum Khanna
Novel players involved in cell division cycle regulation
Jan-11
Cancer Genomics and Development Biology School, Utretch University
Utretch, Netherlands
Prof Rajiv Khanna
Invited to chair (session on EBV immuneregulation) and participate as member of the International Scientific Committee
Sep-10
14th Biennial Conference of the International Association for Research on Epstein-Barr Virus and Associated Diseases
Birmingham, UK
Prof Rajiv Khanna
Using polyepitope vaccine technology for chronic viral infections.
Mar-11
World Vaccine Summit
New Delhi, India
Prof Rajiv Khanna
Clinical assessment of cytotoxic T cellbased adoptive immunotherapy for the treatment of late stage nasopharyngeal carcinoma
Apr-11
3rd Australia-China Biomedical Research Conference
Melbourne, Victoria
Prof Rajiv Khanna
EBV polyepitiope-based adoptive T cell therapy for nasopharngeal carcinoma.
Jun-11
5th International Symposium on Nasopharngeal Carcinoma
Penang, Malaysia
Prof Rajiv Khanna
Profiling of HCMV-specific T cell responses in patients with Glioblastoma Multiforme
May-11
13th International CMV/ BetaHerpesvirus Workshop.
Nuremberg, Germany
Dr Lutz Krause
Studying the Intestinal Microbiota by pyrosequencing of the 16S RNA Gene
Mar-11
Workshop: Application of Genomics and Bioinformatics to Clinical Samples, Australian Infectious Disease Research Centre
Brisbane, Australia
Dr Lutz Krause
Studying the human gut microbiota by high-throughput sequencing of the 16S ribosomal gene
Oct-10
7th Indo Australia Biotechnology Conference
Brisbane, Australia
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Lutz Krause
Human microbiota, diabetes and highthroughput sequencing of the 16S RNA gene
Mar-11
Brisbane Lung Research Group Seminar Series
Brisbane, Australia
Petra Lahmann
Adult weight change is associated with risk of aggressive prostate cancer: the MalmĂś Diet and Cancer Study, Sweden.
Oct-10
International Association for the Study of Obesity
Valencia, Spain
Min-Hsuan Lin
An HIV-1 Tat mutant interfers with Rev Trafficking
Jun-11
Australian Centre for HIV and Hepatitis Research 7th Annual Workshop
Sunshine Coast, Queensland
Dr Felicity Lose
Association of common variation in Kallikrein genes KLK5, KLK6, KLK12 and KLK13 with risk of prostate cancer and tumour aggressiveness
Aug-10
Prostate Cancer Foundation of Australia International Conference
Gold Coast, Australia
Guangjin Lu
The effect of endosymbiont Wolbachia on vector competence of Aedes aegypti
Sep-10
Australian Mosqutio Control Association
Caloundra, Australia
Kelly Loffler
Developmental roles of the tumour suppressor menin
Oct-10
Brisbane Cell and Developmental Biology Meeting
Brisbane, Australia
Prof Barbara Leggett
Serrated lesions: how they arise and what they mean in practice
Nov-10
Adelaide Gut Club
Adelaide, Australia
Prof Barbara Leggett
The serrated pathway in colonic tumorigenesis
May-11
Digestive Diseases Week
Chicago, USA
Dr Kelli MacDonald
Antigen presentation in graft-versus-host disease
Aug-11
ISEH International conference
Melbourne, Australia
Dr Kelli MacDonald
Stem cell mobilization with G-CSF promotes type-17 generation and scleroderma.
Mar-11
European Society of Bone Marrow Transplantation
Paris, France
Dr Kelli MacDonald
Evolving tolerance strategies II BMT and chimerism
June/July 2011
TSANZ Postgraduate course
Canberra, Australia
Prof Don McManus
Comparative genomics of schistosomes
Aug-10
ICOPA XII
Melbourne, Australia
Prof Don McManus
Large animal vaccines: Schistosoma japonicum zoonotic vaccines
Aug-10
ICOPA XII
Melbourne, Australia
Prof Don McManus
The interface of human and animal health: vaccine for Asian schistosomiasis
Oct-10
The Gairdner International Vaccine Symposium
Saskatoon, Canada
Prof Don McManus
Integrated control of schistosomiasis in Asia
Nov-10
Tenth Regional Network Meeting for Asian Schistosomiasis and Other Helminth Zoonoses
Wuxi, China
Prof Don McManus
Schistosome vaccines
Nov-10
Ningxia Medical University
Yinchuan, Ningxia, China
Prof Don McManus
Development of a Transmission Blocking Vaccine for Asian Schistosomiasis.
Dec-10
Gold Coast Health and Medical Research Conference 2010
Gold Coast, Australia
Prof Don McManus
Integrated Control of Schistosomiasis in China
Apr-11
British Society of Parasitology Spring Meeting
Nottingham, UK
Dr Kate Markey
Speaker
Aug-10
The Transplantation Society Congress
Vancouver, Canada
Dr Kate Markey
Speaker
Jun-11
The Transplantation Society of Australia and New Zealand
Canberra
Dr Kate Markey
GVHD induces immune suppression via a selective defect in MHC class II antigen processing
Aug-10
The World Transplant Congress
Vancouver, Canada
Prof Nick Martin
Longitudinal twin studies of anxiety and depression in adult and adolescent twins
Oct-10
CELSE 2010 5th Conference of Epidemiological Longitudinal Studies in Europe
Paphos, Cyprus
Prof Nick Martin
Translational medicine approaches to diseases of global impact - The genetic susceptibility to substance abuse
Nov-10
1st International Conference on Translational Medicine : the 13th Frank and Bobbie Fenner Conference
Canberra, Australia
Prof Nick Martin
VisiGen Consortium Meeting
Nov-10
VisiGen Consortium Meeting
Amsterdam, Holland
Prof Nick Martin
Connecting biobanks: the benefits for the researchers?
Nov-10
BBMRI-NL AMC Conference Connecting Biobanks
Amsterdam, Holland
Prof Nick Martin
Binocular rivalry and bipolar disorder (Poster)
Dec-10
Golden HelixÂŽ Symposium Genetic Analysis in Translational Medicine
Athens, Greece
Prof Nick Martin
Invited Faculty
Mar-11
2011 International Workshop on Statistical Methodology for Human Genomic Studies
Boulder, Colorado
Prof Nick Martin
Genome-wide association study of sleep disorders
Mar-11
Australasia Sleep Trials Network (ASTN) Biobanking
Sydney, Australia
Prof Nick Martin
Genetics of environmental exposure : a GWAS for sun-related skin damage
Apr-11
8th GeneMappers Conference
Hobart, Australia
Prof Nick Martin
The genetics of complex traits: the GWAS revolution and beoynd
Apr-11
JCSMR School Seminars 2011
Canberra, Australia
Prof Nick Martin
Personality, sex, and finger length: intersecting interests
Jun-11
41st Behaviour Genetics Association Meeting
Newport, USA
Prof Nick Martin
The Queensland Twin Imaging Project: Genetics of brain structure and function
Jun-11
Imaging and Cognition Genetics Meeting
Os, Norway
Page 117
invited lectures | continued
Page 118
Speaker
Title of lecture
Date
Audience or event
City, Country
Nico Martin
Educational attainment: a genome wide association study in over 10,000 Australians
Nov-10
The 60th American Society of Human Genetics 2011
Washington DC, USA
Nico Martin
Educational attainment : A meta-analysis of genome wide association studies
May-11
2011 Australian Society for Medical Research Postgraduate Student Conference
Brisbane, Australia
Dr Sarah Medland
Overcoming heterogeneity to identify genes influencing handedness: results from the International Handedness Consortium
Oct-10
18th World Congress on Psychiatric Genetics
Athens, Greece
Dr Sarah Medland
Invited to participate in forum
Feb-11
Explore a Social Science Genetic Association Consortium
Boston, USA
Dr Sarah Medland
Invited Faculty
Mar-11
2011 International Workshop on Statistical Methodology for Human Genomic Studies
Boulder, USA
Dr Sarah Medland
ENIGMA : Enhancing Neuro Imaging Genetics Through Meta-Analysis
Apr-11
8th GeneMappers Conference
Hobart, Australia
Dr Sarah Medland
Invited Teaching Position - Unravelling the genome in health and dusease
May-11
Croucher Advanced Study Institute Unravelling the genome in health and disease
Hong Kong
Dr Sarah Medland
ENIGMA : Enabling Neuroimaging Genetics Through Meta-Analysis : progress six months in.
Jun-11
41st Behaviour Genetics Association Meeting
Newport, USA
Dr Sarah Medland
Invited to instruct course
Jun-11
Summer School IOP Kings College
London, UK
Angela Mika
Scabies Mite Serpins inhibit all three pathways of the human complement system and enhance Group A streptococcal growth (oral)
Aug-10
XIIth International Congress of Parasitology (ICOPA)
Melbourne, Australia
Prof Grant Montgomery
Genome-wide association study identifies a locus at 7p15.2 associated with the development of moderate-severe endometriosis
Aug-11
Society for Reproductive Biology Conference
Sydney, Australia
Prof Grant Montgomery
Genetics of endometriosis
Oct-10
Fertility Society of Australia
Adelaide, Australia
Prof Grant Montgomery
Genetics of endometriosis
Mar-11
Society for Gynecological Investigation
Miami, USA
Miriam Mosing
Genetics of left-right asymmetry in the brain: a twin study focusing on the hippocampus
May-11
2011 Australian Society for Medical Research Postgraduate Student Conference
Brisbane, Australia
Miriam Mosing
Genetic influences on the relationship between personality and mortality
Oct-10
18th World Congress on Psychiatric Genetics
Athens, Greece
Miriam Mosing
Genetic influences on mortality and its relationship to personality : a 16 year prospective study of aged twins
May-11
2011 Australian Society for Medical Research Postgraduate Student Conference
Brisbane, Australia
Miriam Mosing
Genetic influences on mortality and its relationship to personality : a 16 year prospective study of aged twins
Jun-11
41st Behaviour Genetics Association Meeting
Newport, USA
Dr Christina Nagle
Time to diagnosis does not influence stage of disease or survival among women with symptomatic ovarian cancer.
Nov-10
Clinical Oncology Society of Australia Annual Scientific Meeting
Melbourne, Australia
Dr Christina Nagle
Alcohol and tobacco use predict survival in patients with esophageal squamous cell carcinoma.
Sep-10
Australasian Epidemiological Association, Annual Scientific Meeting
Sydney, Australia
Dr Christina Nagle
Dietary glycaemic load, glycaemic index, carbohydrates and risk of ovarian cancer
Sep-10
Australasian Epidemiological Association, Annual Scientific Meeting
Sydney, Australia
Sujeevi Nawaratna
Tissue-specific transcriptomics of the human helminth parasite, Schistosoma mansoni
Jul-10
Australian Conference of Microscopy and Microanalysis
Brisbane, Australia
Dr Jamie Nourse
EBV-microRNA
May-11
Diamantina Institute Lecture Series
Brisbane, Australia
Dr Dale Nyholt
The indirect estimation of risk using genomic data
Jun-10
PRIVATE Gen
Nuremberg, Germany
Dr Dale Nyholt
Examining the genetics of migraine and its symptoms
Oct-10
Colloquium organised by the William James Graduate School, VU
Amsterdam, The Netherlands
Tracy O'Mara
A genome-wide association study to identify genetic markers associated with endometrial cancer grade
May-11
ASMR Postgraduate Student Conference, Health and Medical Research Awards Finalist
Brisbane, Australia
Dr Colleen Olive
Understanding Toll-like receptor signaling in dendritic cells with a view to immune modulation
Sep-10
Bioengineering Department Seminar Series, Berkeley
California, USA
Dr Catherine Olsen
Towards melanoma risk prediction
Jul-10
Queensland Public Health Forum
Brisbane, Australia
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Assoc Prof Grant Ramm
Stellate cells and liver fibrosis
Aug-10
World Congress of the International Society for Hepatic Sinusoidal Research
Pasadena, USA
Assoc Prof Grant Ramm
Session Chair: Mechanisms of ironmediated tissue injury, ER stress
May-11
World Congress on Iron Metabolism
Vancouver, Canada
Dr Jodie Painter
Application of GWA data to address issues of genetic loading in complex human diseases
Jul-11
Genetics Society of Australasia annual meeting
Canberra, Australia
Dr Jodie Painter
Genome-wide linkage scan for familial dizygotic twinning
Sept-11
Endocrine Society of Australia and Society for Reproductive Biology Annual Scientific Meeting
Sydney, Australia
Dr Jodie Painter
Genetics of complex diseases: endometriosis
Nov-11
University of Connecticut Genetics Department
Storrs, USA
Dr Jodie Painter
Genome-wide association study identifies two candidate loci for endometriosis
Apr-11
Australasian Human Gene Mapping (Genemappers) Conference
Hobart, Australia
Dr Jodie Painter
Genetics of endometriosis
Mar-11
Queensland Endometriosis Support Association (QENDO) information night
Brisbane, Australia
David Pattinson
A novel DNA vaccine delivery strategy using bi-specific antibodies to target dendritic cells with bacterial minicells encapsulating plasmid DNA and recombinant protein
Aug-10
International Congress of Parasitology
Melbourne, Australia
Darren Pickering
Testing scabies mite complement Inhibitors under physiological conditions (poster presentation)
Aug-11
XIIth International Congress of Parasitology (ICOPA)
Melbourne, Australia
Dr Joseph Powell
Statistical programming
Dec-10
ICTE UQ – International postgraduate course at The University of Queensland
Brisbane, Australia
Prof Lawrie Powell
Iron overload - a global perspective
Feb-11
Asian Pacific Association for the Study of the Liver
Bangkok, Thailand
Andrew Redmond
Parenteral immunization with cholera toxin induces cellular immune responses
Aug-10
International Congress of Parasitology
Melbourne, Australia
Dr David Reid
Novel antimicrobials against Pseudomonas aeruginosa
Nov-10
Boden Research Conference: Metals in Biological Systems
Canberra, Australia
Dr David Reid
Is it asthma or COPD or both?
May-11
Australian Lung Foundation Education Day
Brisbane, Australia
Dr David Reid
Iron and Pseudomonas aeruginosa
Nov-10
Brisbane Lung Group
Brisbane, Australia
Dr David Reid
Neutrophil function in cystic fibrosis
Nov-11
Brisbane Lung Group
Brisbane, Australia
Dr David Reid
Transition to adult care in cystic fibrosis (CF)
Jul-10
Queensland Cystic Fibrosis Education Day
Brisbane, Australia
Miguel Renteria
Multivariate Genome-wide association study of height, occipito-frontal circumference and total brain volume
Apr-11
8th GeneMappers Conference
Hobart, Tasmania, Australia
Renee Robb
Speaker
Feb-11
European Bone Marrow Transplant Society
Paris, France
Renee Robb
Speaker
Jun/Jul-11
President’s Prize Session, TSANZ
Canberra, Australia
Dr Peter Ryan
Development of on-line decision support tools for surveillance and control of mosquitoes and vector-borne diseases in Queensland
Sep-10
Australian Mosquito Control Association
Caloundra, Australia
Dr Chris Schmidt
Characteristics of immunotherapeutic dendritic cells (Keynote)
Sep-11
Reliable Cancer Therapies Roundtable
Brussels, Belgium
Dr Chris Schmidt
MCM matured mo-DC with autologous tumour as antigen source
Sep-11
Reliable Cancer Therapies Roundtable
Brussels, Belgium
Dr Chris Schmidt
Characteristics of successful immune responses to melanoma
Oct-11
Perth Tumour Immunology Group Annual Scientific Meeting
Perth, Australia
Dr Chris Schmidt
How does cancer immunotherapy work?
Oct-11
National Centre for Asbestos Related Diseases Annual Scientific Meeting, Perth
Perth, Australia
Dr Chris Schmidt
Successful anti-tumour immune responses are broadly targeted
Dec-11
Australasian Society for Immunology Annual Meeting,
Perth, Australia
Dr Chris Schmidt
Burnet oration: Subverting paradigms
Dec-11
Tumour Immunology Workshop, Australasian Society for Immunology Annual Meeting
Perth, Australia
Dr Chris Schmidt
Dendritic cell immunotherapy of advanced metastatic melanoma – how does it really work?
Feb-11
University of Otago Wellington Cancer Symposium
Wellington, New Zealand
Maggy Sikulu
Age grading tools for Anopheles mosquitoes
Sep-10
Australian Mosquito Control Association
Sunshine Coast, Australia
Haran Sivakumaran
Arginine methylation increases the stability of Tat
Jun-11
Australian Centre for HIV and Hepatitits Research 7th Annual Workshop
Sunshine Coast, Australia
Page 119
invited lectures | continued
Page 120
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Tina Skinner-Adams
The Plasmodium falciparum neutral aminopeptidases: valid targets for novel anti-malarial drugs
Aug-10
International Congress of Parasitology
Melbourne. Australia
Dr Amanda Spurdle
Understanding unclassified variants in molecular diagnosis.
Nov-10
Human Variome Project and HGSA ASM joint meeting – understanding Human Variation
Melbourne, Australia
Dr Amanda Spurdle
Translational research capabilities of ANECS
Feb-10
Australian & New Zealand Gynaecological Oncology Group Annual Meeting
Noosa, Australia
Dr Amanda Spurdle
Mismatch repair gene unclassified variants – research in progress and suggestions for collaborative opportunities.
May-10
InSIGHT / Human Variome Project meeting
Paris, France
Dr Amanda Spurdle
Update on the moderate-risk study, assessing risk associated with the BRCA1 R1699Q variant
May-10
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Meeting
London, UK
Dr Amanda Spurdle
Pathology markers as predictors of BRCA1/2 mutation status; Results from segregation studies of the BRCA1 R1699Q variant; Activities of the ENIGMA Splicing Working Group.
Sep-10
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Meeting
Milan, Italy
Dr Amanda Spurdle
ENIGMA Splicing Working Group presentations: Clinical interpretation of splicing aberrations; ENIGMA variants to consider for splicing analysis
Jun-11
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Meeting
Stockholm, Sweden
Dr Brett Stringer
Targeting EphA3 in AML and other cancers
Oct-10
19th Annual RBWH Health Care Symposium
Brisbane, Australia
Assoc Prof Nathan Subramaniam
Non-HFE haemochromatosis
Nov-10
Boden Research Conference on Metals in Biological Systems: Structure, Catalysis and Metabolism
Canberra, Australia
Prof Andreas Suhrbier
Chikungunya virus disease: Pathogenesis, animal models and interventions.
Jun-11
Australasian Society for Microbiology
Hobart, Australia
Prof Andreas Suhrbier
Ingenol mebutate: a new topical treatment for actinic keratoses and non-melanoma skin cancer with a novel mechanism of action
May-11
Australasian Society for Dermatology Research
Perth, Australia
Prof Andreas Suhrbier
Chikungunya virus, mice, monkeys, macrophages and money
Aug-10
SMBS Seminar Series
Adelaide, Australia
Prof Andreas Suhrbier
The development of ingenol mebutate (PEP005) as a new chemotherapeutic agent
Oct-10
Peter MacCallum Cancer Centre
Melbourne, Australia
Prof Andreas Suhrbier
Chikungunya virus disease: models and interventions
Oct-10
7th Indo-Australia Biotechnology Conference
Brisbane, Australia
Prof Andreas Suhrbier
Viral arthritis and chikungunya virus disease
Sep-10
Griffith Medical Research College Retreat
Brisbane, Australia
Prof Andreas Suhrbier
Chikungunya virus arthritis in adult wildtype mice
Aug-10
Brisbane Immunology Group
Brisbane, Australia
Prof Andreas Suhrbier
Biological agents in war, terror and the everyday
Aug-10
Sydney Nursing School, University Sydney
Sydney, Australia
Prof Andreas Suhrbier
Chikungunya virus, mice, monkeys, macrophages and money
Aug-10
University of Adelaide School of Molecular and Biomedical Sciences Seminar series
Adelaide, Australia
Prof Andreas Suhrbier
Ingenol mebutate: a new topical treatment for actinic keratoses and non-melanoma skin cancer with a novel mechanism of action
Jun-11
LEO Pharma
Copenhagen, Denmark
Prof Andreas Suhrbier
Chikungunya virus; expression profile of a viral arthritis.
Nov-10
Joint QIMR, ACVD, Emory Vaccine Center Meeting
Atlanta, USA
Prof Andreas Suhrbier
The development of ingenol mebutate: a new topical skin cancer treatment with a novel mode of action
Nov-10
Leiden University Medical Center: Molecular tumor genetics seminar series
Leiden, The Netherlands
Dr Clara Tang
Invited Faculty - Tutorial on copy number analysis
Mar-11
2011 International Workshop on Statistical Methodology for Human Genomic Studies
Boulder, Colorado
Dr Clara Tang
A tool to test for functional enrichment of GWAS hits
Apr-11
8th GeneMappers Conference
Hobart, Australia
Bryony Thompson
Clinical evaluation of mismatch repair gene sequence variants using qualitative, analytical and molecular methods
Aug-10
kConFab familial aspects of cancer conference, 2010
Kingscliff, Australia
Assoc Prof Katharine Trenholme
Identification of lead gametocidal agents by high throughput screening
Oct-10
Medicines for Malaria Venture ESCA Meeting
Geneva , Switzerland
QIMR Annual Report 2010–2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Patricia Valery
Discussing strategies for successful community engagement
Nov-10
Tonkin’s Indigenous Health Care Delivery Conference
Brisbane, Australia
Dr Patricia Valery
The developmental origins of childhood obesity: a snapshot from the Torres Strait
Oct-10
Royal Brisbane and Women’s Hospital Health 19th Annual Health Care Symposium
Brisbane, Australia
Dr Patricia Valery
Adapting an existing Supportive Care Needs tool to be used with Indigenous cancer patients.
Mar-10
Cancer Care Coordination Conference, Clinical Oncological Society of Australia
Gold Coast, Australia
Dr Antiopi Varelias
Recipient HO-1 prevents GVHD.
May-11
American Association of Immunology
San Francisco, USA
Karin Verweij
Meta-analysis of genome-wide association studies on cannabis use initiation and quantity of use
Oct-10
18th World Congress on Psychiatric Genetics
Athens, Greece
Karin Verweij
Genetics of personality
Apr-11
8th GeneMappers Conference
Hobart, Tasmania, Australia
Karin Verweij
The genetic etiology of cannabis use
May-11
2011 Australian Society for Medical Research Postgraduate Student Conference
Brisbane, Australia
Karin Verweij
The genetic etiology of cannabis use
Jun-11
41st Behaviour Genetics Association Meeting
Newport, USA
Prof Peter Visscher
Genetics of complex traits
Jul-10
Western Australian Institute of Medical Research seminar
Perth, Australia
Prof Peter Visscher
Genetics of complex traits in human populations
Aug-10
World Congress of Genetics Applied to Livestock Production (plenary)
Leipzig, Germany
Prof Peter Visscher
Genetic analysis of complex traits
Aug-10
Max Planck Institute seminar
Leipzig, Germany
Prof Peter Visscher
Novel analyses of GWAS data
Aug-10
Illumina workshop
Brisbane, Australia
Prof Peter Visscher
Missing heritability
Sept-10
Peter MacCallum Institute seminar
Melbourne, Australia
Prof Peter Visscher
Genetic architecture of complex traits
Sept-10
Belgium Academy of Science thinktank workshop
Rome, Italy
Prof Peter Visscher
Genetic architecture of complex traits
Oct-10
Indo-Australia Biotechnology Conference
Brisbane, Australia
Prof Peter Visscher
Genetic architecture of complex traits
Nov-10
Institute of Psychiatry seminar
London, UK
Prof Peter Visscher
Genome partitioning of genetic variation
Feb-11
Erasmus University seminar
Rottterdam, The Netherlands
Prof Peter Visscher
Genome partitioning of genetic variation
Feb-11
University of Alabama seminar
Birmingham, USA
Prof Peter Visscher
Genome partitioning of genetic variation
Feb-11
Emory University seminar
Atlanta, USA
Prof Peter Visscher
Genome partitioning of genetic variation
Mar-11
Broad Institute seminar
Boston, USA
Prof Peter Visscher
Genome partitioning of genetic variation
Mar-11
Harvard Medical School seminar
Boston, USA
Prof Peter Visscher
New analyses of GWAS data
Mar-11
Genetics of ankylosing spondylitis conference presentation
Shanghai, China
Prof Peter Visscher
Genome partitioning of genetic variation
May-11
Biology of Genomes session chair and presentation
Cold Spring Harbor, USA
Dr Graeme Walker
Differential roles of the pRb and p53 pathways in naevo and melanoma genesis
Nov-10
7th Annual International Melanoma Congress
Sydney, Australia
Dr Graeme Walker
Transgenic mice as models for naevi and melanoma
May-11
International Skin Cancer Research Workshop
Brisbane, Australia
Dr Graeme Walker
Genetically modified mice as UVR-induced melanoma
Nov-10
Australian Health and Medical Research Conference
Melbourne, Australia
Logan Walker
The role of germ-line DNA copy number variation in familial breast cancer risk.
Aug-10
KConFab annual meeting: Familial Cancer and Research and Practice
Kingscliff, Australia
Logan Walker
The role of germ-line DNA copy number variation in familial breast cancer risk
Sep-10
Australasian Microarray and Associated Technologies Association (AMATA) Meeting
Hobart, Australia
Logan Walker
Germ-line DNA copy number variation and familial breast cancer development
May-11
New Zealand Society of Oncology
Auckland, New Zealand
Logan Walker
Copy number variants as modifiers of BRCA1 associated breast cancer risk and progression
Jun-11
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) Meeting
Stockholm, Sweden
Logan Walker
ENIGMA Splicing Working Group Project 1: Quality control and protocol comparison
Jun-11
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Meeting
Stockholm, Sweden
Dr Daniel Wallace
Investigating the role of Ataxia Telangiectasia Mutated (ATM) in iron homeostasis
Sept-10
Griffith Medical Research College Retreat
Brisbane, Australia
Dr Daniel Wallace
Blunted hepcidin response to inflammation in the absence of Hfe and Tfr2
Nov-10
Boden Research Conference on Metals in Biological Systems: Structure, Catalysis and Metabolism
Canberra, Australia
Dr Daniel Wallace
Blunted hepcidin response to inflammation in the absence of Hfe and Tfr2
Jun-11
London Iron Metabolism Group Meeting: Iron and immune responses
London, UK
Page 121
invited lectures | continued
Page 122
Speaker
Title of lecture
Date
Audience or event
City, Country
Dr Penny Webb
Ovarian Cancer Patterns of Care Study: management of women with invasive ovarian cancer in Australia in 2005
Feb-11
Australian and New Zealand Gynaecological Oncology Group
Gold Coast, Australia
Dr Penny Webb
Epidemiology in real life: case-control studies
Aug-10
Master of Public Health Program, The University of Queensland
Brisbane, Australia
Dr Penny Webb
Epidemiology in real life: dealing with error
Apr-11
Master of Public Health Program, The University of Queensland
Brisbane, Australia
Ting Wei
Cell factors and HIV-1 reverse transcripiton
Jun-11
Australian Centre for HIV and Hepatitits Research 7th Annual Workshop
Sunshine Coast, Qld
Phillip Whiley
Identification of clinically significant splicing aberrations for intronic BRCA1 and BRCA2 variants and the association of alternative splice isoform regulation with pathogenicity
Aug-10
kConFab Familial Aspects of Cancer Conference 2010
Kingscliff, Australia
Prof Emma Whitelaw
The genetics of epigenetics
Jul-10
Mater Medical Research Institute Annual Symposium
Brisbane, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Jul-10
School of Medical Sciences, UNSW
Sydney, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Jul-10
Children's Medical Research Institute, Westmead
Sydney, Australia
Prof Emma Whitelaw
Epigenetics in mammals
Jul-10
2nd Nutrigenomics Symposium
Adelaide, Australia
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
Aug-10
Telethon Institute for Child Health Research
Perth, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Sep-10
Asia Millipore Bioforum on Epigenetics and Stem cells
Singapore, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Sep-10
Asia Millipore Bioforum on Epigenetics and Stem cells
Beijing, China
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
Sep-10
Asia Millipore Bioforum on Epigenetics and Stem cells
Taipei, Taiwan
Prof Emma Whitelaw
Epigenetics in mammals
Sep-10
Cold Spring Harbour Asia Conference on Molecular Switches and Genome Function in Stem Cells and Development
Suzhou, China
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
Sep-10
ANZSCDB President's Medal and Lecture, OzBio2010
Melbourne, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Oct-10
7th Nestle International Nutrition Symposium
Lausanne, Switzerland
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
Dec-10
Howard Hughes Medical Institute, Symposium on the Epigenome
Bethesda, USA
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Feb-11
IUBMB Jubilee Lecture and Medal, Miami 2011 Winter Symposium
Miami, USA
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
Mar-11
Center for Developmental Biology Symposium Epigenetic Landscape in Development and Disease
Kobe, Japan
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
Apr-11
Plenary Lecture, Noncoding RNA, Epigenetic Memory and the Environment
London, UK
Prof Emma Whitelaw
Epigenetics in mammals
Mar-11
Keystone Environmental Epigenomics
North Carolina, USA
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
May-11
Workshop on Epigenetics, Garvan Institute
Sydney, Australia
Prof Emma Whitelaw
Transgenerational epigenetic inheritance
May-11
Fellows Lecture, Australian Academy of Science, Shine Dome
Canberra, Australia
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
May-11
Plenary Lecture, Advanced Studies Institute, Hong Kong University
Hong Kong
Prof Emma Whitelaw
Epigenetics and the determination of phenotype
May-11
Workshop Lecture, Advanced Studies Institute, Hong Kong University
Hong Kong
Prof David Whiteman
Obesity and cancer
May-11
Queen Elizabeth II Hospital Grand Rounds
Brisbane, Australia
Prof David Whiteman
Careers in medical research
May-11
Australian Society for Medical Research Student Conference
Brisbane, Australia
Prof David Whiteman
QSkin - sun and health study
May-11
1st International Conference on UV and Skin Cancer Prevention
Copenhagen, Denmark
Prof David Whiteman
The causes of melanoma
Jun-11
8th International Skin Cancer Conference
Gold Coast, Australia
Prof David Whiteman
The epidemiology and genetics of oesophageal cancer
Jun-11
15th Annual Gastroenterology Update, Gastroenterological Society of Queensland
Coolum, Australia
Prof David Whiteman
Oesophageal Cancer Research Progress
Nov-10
PROBE-NET annual meeting
Melbourne, Australia
Prof David Whiteman
Blue Sky Epidemiology
Feb-11
Queensland Epidemiology Group
Brisbane, Australia
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Speaker
Title of lecture
Date
Audience or event
City, Country
Prof David Whiteman
Skin cancer research in Queensland - an overview
Oct-10
Pan-Pacific Skin Cancer Consortium Meeting
Tucson, USA
Dr John Whitfield
Common variants of large effect : do they exist, do they matter?
Apr-11
8th GeneMappers Conference
Hobart, Australia
Dr Susan Woods
The pigment cell specific microRNA, miR211, as a novel tumour suppressor for melanoma
Nov-11
7th International Melanoma Research
Sydney, Australia
Dr Susan Woods
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
May-11
ASMR Awards presentation
Brisbane, Australia
Dr Naomi Wray
Recent advances in our understanding of the genetics of pscyhiatric disorders
Aug-10
Plenary,Youth Mental Health Symposium
Brisbane, Australia
Dr Naomi Wray
Genetics of psychiatric disorders:assimilating genome-wide association and genetic epidemiology studies
Sept-10
University of Queensland, Dept Psychiatry
Brisbane, Australia
Dr Naomi Wray
Prospects for genetic testing in psychiatry
Oct-10
Plenary, World Congress Psychiatric Genetics
Athens, Greece
Dr Naomi Wray
Whole-genome analysis of GWAS data for complex traits
Oct-10
Symposium, World Congress Psychiatric Genetics
Athens, Greece
Dr Naomi Wray
Insights into genetic architecture from genetic epidemiology and GWAS
Oct-10
Symposium, World Congress Psychiatric Genetics
Athens, Greece
Dr Naomi Wray
Use of GWAS for prediction of genetic risk to disease
Oct-10
Plenary, GWAS mega-analysis for complex diseases: Satellite workshop of the International Conference of Systems Biology
Edinburgh, Scotland
Dr Naomi Wray
Insights into genetic architecture from GWAS: Looking for the "missing heritability"
Dec-10
Bioinformatics Summer School
Melbourne, Australia
Dr Naomi Wray
Putting synthetic associations into perspective
Apr-11
Australian GeneMappers Meeting
Hobart, Australia
Dr Margie Wright
Neuroimaging genetics, finding genes for brain function and dysfunction
Sep-10
Queensland Brain Institute, The University of Queensland Seminar Series
Brisbane, Australia
Dr Margie Wright
Unravelling the genetic mechanisms influencing the human brain in health, illness, youth and old age
Dec-10
The Australasian Society for Psychiatric Research 2010 Conference: GlialNeuronal Networks in Neuropsychiatry
Sydney, Australia
Assoc Prof Joanne Young
Serrated neoplasia update
Jul-10
Norris Comprehensive Cancer Centre Seminar
Los Angeles, USA
Assoc Prof Joanne Young
Serrated polyposis risk factors
Nov-10
NZ Gastroenterology Society Meeting
Auckland, New Zealand
Assoc Prof Joanne Young
Epigenetics update
Oct-10
Australian Gastroenterology Week
Gold Coast, Australia
Assoc Prof Joanne Young
Molecular pathology of colorectal cancer
Oct-10
Australian Gastroenterology Week
Gold Coast, Australia
Assoc Prof Joanne Young
Origin of cancers in serrated polyposis
Oct-10
Consensus Meeting on Serrated Neoplasia
Cleveland, USA
Assoc Prof Joanne Young
The mucosa in serrated polyposis
Oct-10
Consensus Meeting on Serrated Neoplasia
Cleveland, USA
Page 123
graDuateD StuDentS Student
University
Supervisor
Thesis title
Ainslie CAMERON
QUT
David McMillan
Identification of the virulence gene, sicG, in Australian clinical isolates of Streptococcus dysgalactiae subspecies equisimilis
Carly PERRY
QUT
Geoffrey Gobert, Melissa Burke, Don McManus
Comparison of hepatic gene expression in mouse strains with contrasting pathology during infection with Schistosoma japonicum
Cornel MIRCIOV
Bond University
Greg Anderson
Characterisation of iron-related gene expression in the mouse lung
Ai Hwee KHO
University of Tunku Abdul Rahman, Malaysia
Leon Hugo
Combined effects of nutritional stress and Wolbachia infection on the vector competence of Aedes aegypti for dengue
Timothy REEKS
QUT
Keyur Dave, Jeff Gorman
Identification of cellular pathways perturbed by the human respiratory syncytial virus attachment protein
Yadveer GREWAL
QUT
Marcus Hastie, Jeff Gorman
Quantitative proteomics: using iTRAQ to examine changes involved in breast cancer mammosphere formation
BSC (HONS)
Annaliese WOODS
GU
Kathy Andrews
Antimalarial action of HDAC inhibitors
Priscilla GOH
UQ
Katja Fischer, Angela Mika
The role of peritrophins in scabies mite Immunity
Emma SEDLACEK
UQ
Amanda Spurdle, Phillip Whiley
Assessing the clinical relevance of rare sequence variants in BRCA1 and BRCA2 genes
Nurul OSMAN
UQ
Kelli MacDonald, Geoff Hill
Characterisation of molecular mediators of murine chronic graft-versus-host disease
Suzanne MOORE
UQ
Adèle Green, Gail Garvey
A comparative study of cancer incidence, diagnosis, treatment and survival between Indigenous and non-indigenous people in Queensland
Simin ARABSHAHI
UQ
Adèle Green, Jolieke van der Pols
Longitudinal change in anthropometric characteristics & diet quality in Australian adults
Jennifer MCCARRON
QUT
Andrew Boyd
The role of the Eph and ephrin proteins in prostate cancer
Hau Phuc TRAN
UQ
Brian Kay
Relationships between dengue vector abundance, household water storage practices and new water supply Infrastructure in Southern Vietnam
Amber GLANFIELD
UQ
Malcolm Jones
Iron biology of schistosomes: molecular characterisation and vaccine potential of iron homeostasis proteins
David HEWETT
UQ
Barbara Leggett
Communication between doctors and the quality of patient care: An intergroup perspective
Mikail RUBINOV
UNSW
Michael Breakspear
Brain networks
Meru SHEEL
QUT
Michael Batzloff
Immunogenicity and protective efficacy of an anti-Streptococcus pyogenes vaccine candidate in multiple animal species
Kate MARKEY
UQ
Kelli MacDonald, Geoff Hill
Antigen presentation and inflammation in allogeneic bone marrow transplantation
Andrew LALOO
UQ
David Harrich
Analysis of RNA binding and heat shock proteins in the regulation of HIV-1 reverse transcripiton
Lisa WHOP
ANU
Patricia Valery, Gail Garvey
Cadetship
Audra DE'WITT
UQ
Patricia Valery, Gail Garvey
Health behaviours in Indigenous and non-Indigenous people and their associations with asthma
Hosam ZOWAWI
GU
David McMillan
Development and evaluation of a rapid real-time PCR based diagnostic tool to detect pathogenic bacteria colonising catheters.
Elizabeth LEDDY
UQ
Nathan Subramaniam
The role on hemojuvelin and matriptase-2 in iron metabolism
PHD
MASTERS
Legend
Page 124
ANU
Australian National University
GU
Griffith University
QUT
Queensland University of Technology
UNSW
University of New South Wales
UQ
The University of Queensland
QIMR Annual Report 2010–2011
StuDent aWarDS Recipient
Bestower of award
Date
Award
Reason
Franziska Bieri
Queensland Tropical Health Alliance
Jun-11
Travel Award
Conference attendance
Franziska Bieri
ASMR
May-11
Postgraduate Student Conference
The People’s Choice prize for the best poster presentation: The Magic Glasses.
Franziska Bieri
QIMR
2011
QIMR PhD Award
Gabriëlla Blokland
QIMR
Jul-10
QIMR PhD Top-up Award
Scholarship Top-up
Gabriëlla Blokland
QIMR
2010
ANZ Trustees PhD scholarship in Medical Research
PhD scholarship
Gabriëlla Blokland
ANZ Trustees
Jan-11
Travel award
PhD scholarship
Gabriëlla Blokland
ATR
Mar-11
Travel award
Conference attendance Conference attendance
Gabriëlla Blokland
UQ School of Psychology
May-11
Honours scholarship
Catherine Bond
QIMR
2011
PhD Award
Zara Bruce
QIMR
Jan-11
Honours scholarship
Ainslee Cameron
QIMR
2011
Honours scholarship
Melody Cheong
QIMR
2011
Honours scholarship
Ken Dutton-Regester
QIMR
2010
QIMR PhD Award
Ken Dutton-Regester
Australian Academy for Technological Sciences and Engineering
2011
ATSE Young Science Ambassador Award
Ken Dutton-Regester
QIMR
2011
QIMR PhD Top-up Award
Ken Dutton-Regester
QIMR
2011
QIMR Postgraduate Student Travel Award
Ken Dutton-Regester
CCQ
2011
Cancer Council Queensland Travel Grant
Imogen Gillions
QIMR
Aug-10
Travel award
Catherine Gordon
QIMR
2011
QIMR PhD Award
Kimberley Jones
Boehringer Ingelheim Fonds
Dec-10
Travel award
Kimberely Jones
QIMR
2011
QIMR PhD Award
Yee Leow
ACVD
Feb-11
ACVD Edward Jenner PhD Scholarship
Yi Chieh Lim
QIMR
2010
QIMR PhD Award
Yi Lu
QIMR
2010
QIMR PhD Award
Rachael McGeorge
Australian Society for Parasitology
Jul-10
Travel award
Conference attendance
Travel to USA
Rachael McGeorge
QIMR
Jun-11
QIMR PhD Award
Kate Markey
ASI
Aug-10
Travel award
Conference attendance
Kate Markey
The Transplant Society
Aug-10
Astellas Pharma Educational Grant
A grant received for submission of one of the top 10 scored abstracts by a Young Investigator for The Transplantation Society annual meeting, to be held in Vancouver Canada
Kate Markey
TSANZ
Jun-11
Amgen Young Investigator Award
Awarded for the Best Presentation in the Field of Laboratory Research, TSANZ meeting
Kate Markey
School of Medicine
Jun-10
Selected to attend the 60th Meeting of Nobel Laureates in Lindau, Germany
After a competitive selection process, awarded a place as a “Young Researcher” delegate at this meeting. Part of the award includes full travel support to attend.
Quality of research by young investigator
Kate Markey
TSANZ
Jun-11
Young Investigator award
Kate Markey
NHMRC
Jan-11
Clinical Training Fellowship
Nico Martin
QIMR
Aug-10
Postgraduate Student Travel Award
Conference attendance
Nico Martin
ATR
Oct-10
Travel award
Conference attendance
Nico Martin
ANZ Trustees
Jan-11
ANZ Trustees PhD scholarship in Medical Research
PhD scholarship
Nico Martin
UQ School of Psychology
May-11
Travel award
Conference attendance
Cornel Mirciov
QIMR
2010
QIMR Honours Award
Marcela Montes de Oca
QIMR
2011
QIMR Honours Award
Brian Morrison
CCQ
Sep-10
Travel award
Conference attendance
Brian Morrison
QIMR
Sep-10
Travel award
Conference attendance
Miriam Mosing
World Congress on Psychiatric Genetics
Aug-10
Early Career Investigator Program Travel Award
Conference attendance
Page 125
Student awards | continued Recipient
Bestower of award
Date
Award
Reason
Miriam Mosing
ANZ Trustees
Jan-11
ANZ Trustees PhD scholarship in Medical Research
PhD scholarship
Miriam Mosing
ATR
Mar-11
Travel award
Conference attendance
Miriam Mosing
UQ School of Psychology
May-11
Travel award
Conference attendance
Miriam Mosing
Behavior Genetics Association
Jun-11
Travel award
Conference attendance
Sujeevi Nawaratna
QIMR
2010
QIMR PhD Award
Tracy O'Mara
ASMR
May-11
ASMR Postgraduate Student Conference, Health and Medical Research Awards Finalist
Thomas Partridge
QIMR
2011
Honours scholarship
David Pattinson
Australian Society for Parasitology
Aug-10
Travel award
David Pattinson
QIMR
2011
QIMR PhD Award
Chris Peatey
Australian Society for Parasitology
Sep-10
Travel award
Travel to Melbourne/Researcher exchange
Melinda Protani
QIMR
2011
QIMR PhD Award
Melanie Rampton
QIMR
2011
Honours scholarship
Andrew Redmond
Australian Society for Parasitology
Aug-10
Travel award
Conference attendance
Simone Reynolds
Australian Society for Parasitology & ARC/ NHMRC Network for Parasitology
Mar-11
ASP and ARC/NHMRC Network for Parasitology Travel Award 2011
Conference attendance
Simone Reynolds
Australian Society for Parasitology
Feb-11
Australian Society for Parasitology JD Smyth Postgraduate Travel Award 2010
International Summer School (Germany) and Researcher Exchange (Sweden) ($8000)
Simone Reynolds
QIMR
2010
QIMR Postgraduate Travel Award 2010
Conference attendance
Sophie Schussek
Australian Society for Parasitology
Aug-10
Travel award
Conference attendance
Maggy Sikulu
Aust Mosqutio Control Association
Sept-10
Best Student Presentation
Maggy Sikulu
QIMR
2011
QIMR PhD Award
Daniel Smith
Prince Charles Hospital Research Foundation
Feb-11
PhD scholarship
Dulangi Sumanadasa
Australian Society for Parasitology
Jul-11
ASP Travel Award
Aaron Thrift
QIMR
2011
QIMR PhD Award
Karin Verweij
QIMR
Jul-10
QIMR PhD Top-up Award
Karin Verweij
QIMR
Jul-10
Postgraduate Student Travel Award
Conference attendance
Karin Verweij
World Congress on Psychiatric Genetics
Aug-10
Early Career Investigator Program Travel Award
Conference attendance
Karin Verweij
ANZ Trustees
Jan-11
ANZ Trustees PhD scholarship in Medical Research
PhD scholarship
Karin Verweij
ATR
Apr-11
Travel award
Conference attendance
Karin Verweij
UQ School of Psychology
Apr-11
Travel award
Conference attendance
Karin Verweij
Behavior Genetics Association
Jun-11
Travel award
Conference attendance
Karin Verweij
UQ School of Psychology
Sep-10
2010 Psychology Student Research Excellence Award
Annaliese Woods
Australian Society for Parasitology
Jul-11
ASP Travel Award
Legend
Page 126
Conference attendance
ACVD
Australian Centre for Vaccine Development
ARC
Australian Research Council
ASI
Australasian Society of Immunology
ASMR
Australian Society of Medical Research
ATR
Australian Twin Registry
CCQ
Cancer Council Queensland
NHMRC
National Health and Medical Research Council
OHMR
Office of Health and Medical Research
PCRFA
Prostate Cancer Research Foundation Australia
TSANZ
The Transplantation Society of Australia and New Zealand
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
patentS patent families managed by Qimr Title
Inventor(s)
Application Number
Novel molecules
Toni Antalis; John Hooper
PCT/AU1998/000085
Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens
Michael Good; Mary Stevenson
PCT/AU2004/000870
Polytope vaccines
Andreas Suhrbier; Scott Thomson; Rajiv Khanna; Scott Burrows; Barbara Coupar; Denis Moss
PCT/AU1995/000461
Synthetic peptides and vaccines comprising the same
Juan Cooper; Wendy Relf; Michael Good; Allan Saul
PCT/AU1995/000681
Cytotoxic T-cell epitopes
Denis Moss; Scott Burrows; Rajiv Khanna; Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier
PCT/AU1995/000140
EBV CTL epitopes
Rajiv Khanna; Beverley Kerr; Ihor Misko; Denis Moss; Scott Burrows
PCT/AU1997/000328
CTL epitopes from EBV
Martina Sherritt; Scott Burrows; Rajiv Khanna
PCT/AU1998/000531
EBV peptide epitopes, polyepitopes and delivery system therefor
Rajiv Khanna; Jaikumar Duraiswamy
PCT/AU2003/001451
Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising same and diagnostic and prophylactic and therapeutics uses therefor
Rajiv Khanna; Rebecca Elkington; Susan Walker
PCT/AU2002/000829
Human cytomegalovirus immunotherapy
Rajiv Khanna
PCT/AU2005/001798
Peptide compounds
Istvan Toth; William Gibbons
PCT/GB1993/001558
Novel human ssDNA binding proteins and methods of cancer diagnosis
Kum Kum Khanna; Derek Richard; Malcolm White
PCT/AU2008/000181
Cancer drug targets and methods of diagnosis
Andrew Boyd; Bryan Day; Brett Stringer
PCT/AU2009/000672
Human cytomegalovirus immunotherapy
Rajiv Khanna
61/347,352
Qimr patent families managed outside Qimr Title
Inventor(s)
Application Number
Receptor ligand system and assay
Andrew Boyd
US 1998/104340
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
Andrew Boyd
PCT/AU2004/000142
A method of treatment
Andrew Boyd
PCT/AU1999/000931
Differentiation modulating agents and uses therefor
Johannes Prins
PCT/AU2005/000008
Melanoma-associated MHC Class 1 Associated oligopeptide and its use
Chris Schmidt
PCT/EP2006/008533
Method for screening for anticancer agents
Kum Kum Khanna
PCT/GB2008/003390
A novel growth factor and a genetic sequence encoding same
Nicholas Hayward
PCT/AU1996/000094
Page 127
patent families resulting from industry Sponsored contract research performed at Qimr Title
Inventor(s)
Application Number
Treatment of virally induced lesions
Andreas Suhrbier
PCT/AU2008/000596
Use of angeloyl-substituted ingenones in combination with other agents to treat cancer
Andreas Suhrbier; Peter Parsons
PCT/AU2006/001700
Treatment of solid tumours
Andreas Suhrbier
PCT/AU2005/001827
Chaperonin 10 modulators of toll-like receptors inducible cytokine and cytokine secretion
Andreas Suhrbier
PCT/AU2005/000041
Treatment of prostate cancer
Peter Parsons
PCT/AU2001/000966
Therapeutic agents I
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000679
Therapeutic agents II
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000680
Therapeutic agents III
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000678
patents families managed by Qimr as trustee for the crc-Vaccine technology Title
Inventor(s)
Application Number
T helper epitopes
David Jackson
PCT/AU2000/000070
Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitope
David Jackson
PCT/AU2003/001019
Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
David Jackson
PCT/AU2003/001018
Truncated LHRH formulations
David Jackson
PCT/AU2005/001383
Immunogenic molecules
David Jackson
PCT/AU2006/000162
trade marks managed by Qimr
Page 128
Mark
Status
Australian Trade Mark Number
Queensland Institute of Medical Research
Registered / Protected
1233303
QIMR
Registered / Protected
1233307
Hexagons device
Registered / Protected
1233317
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
grantS anD funDing (over $100,000) Total Funding
Source
Chief Investigators and Project Title
Term
Period
NHMRC
Antonsson, A – Squamous cell carcinomas of the head and neck: Exploring the role of human papillomavirus infection
2yrs
2011 – 2012
$212,015
ALF
McDonald, Cameron – Hospitality Industry Career Development Research Fellows
3yrs
2011 – 2013
$270,000
ARC
Chong, Suyinn – Epigenetic neurobehavioral changes in new mouse models of foetal alcohol spectrum disorders
4yrs
2011 – 2014
$701,842
ARC
Valery, Patricia – Developing an evidence base to improve the health Aboriginal and Torres Strait Islander people
4yrs
2011 – 2014
$568,352
ARC
Lopez, Alejandro et al – Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Administered by Griffith University)
4yrs
2010 – 2013
$530,000
ARC
Martin, Nick – From genotype to phenotype: Molecular photo fitting for criminal investigations (Administered by University of Canberra)
3yrs
2011 – 2013
$245,358
ARC
Kay, Graham and Hayward, Nick – Molecular characterization of the role of menin in embryonic development (Administered by The University of Queensland)
3yrs
2011 – 2013
$345,000
BUSHEL
Subramaniam, Nathan – Hereditary haemochromatosis: Characterisation of the HepcidiAxia.
4yrs
2010 – 2013
$288,400
CA/NBCF
MacGregor, Stuart – Identifying markers of risk and outcome in ovarian and breast cancer via efficient evaluation of DNA methylation
4yrs
2011 – 2014
$521,490
CANCERAU
Spurdle, Amanda – Development of a model to classify mismatch repair
3yrs
2011 – 2013
$600,000
CCQ
Boyd, Andrew – Suppression of high-grade glioma by Nfib over expression
2yrs
2011 – 2012
$146,500
CCQ
Hayward, Nick – Identification of novel methylated tumour suppressor genes in melanoma
2yrs
2011 – 2012
$199,472
CCQ
Hill, Geoff – Therapeutic targeting of adhesion and costimulatory pathways after transplantation
2yrs
2011 – 2012
$200,000
CCQ
Khanna, Kum Kum – Understanding the contribution of DNA repair genes in breast metastasis
2yrs
2011 – 2012
$199,472
CCQ
Khanna, Rajiv – Novel immunotherapy for herpes virus infection in stem cell transplant patients.
2yrs
2011 – 2012
$195,016
CCQ
MacDonald, Kelli – Requirements for class II antigen presentation to generate curative anti-leukaemic responses
5yrs
2011 – 2015
$594,970
CCQ
Walker, Graeme – Pilot study to assess the role of classical and oxidative UVR-induced DNA adducts in melanoma induction
2yrs
2011 – 2012
$200,000
CCQ
Young, Joanne – Excome capture, miRNA and next generation sequencing inprobands with hyperplastic polyposis
2 yrs
2011 – 2012
$200,000
CSIRO
Hurst, Tim – Urbanism, Climate Adaptation and Health Cluster (Flagship Cluster)
4yrs
2010 – 2013
$200,000
DEEDI
Boyle, Glen – Smart Futures Commercialisation Program
3yrs
2010 – 2012
$107,048
ECO
Boyle, Glen – Smart Futures Commercialisation Program
3yrs
2010 – 2012
$107,048
GARNETT
Antonsson, Annika – Exploring the role of human papillomavirus infection in mucosal squamous cell carcinomas of the head and neck.
3yrs
2011 – 2013
$150,016
HEARTF
McMillan, David – Grant in Aid Research Program
2yrs
2011 – 2012
$127,456
NHMRC
Hill, Geoff – NHMRC Australia Fellowship (Jan 2011-Dec 2015)
5yrs
2011 – 2015
$4,000,000
NHMRC
Parsons, Peter – Taking a cancer drug towards a clinical trial
3yrs
2011 – 2013
$254,584
NHMRC
Jones, Malcom – Roles of annexins in schistosome surface homeostasis and host parasite interaction
3yrs
2011 – 2013
$295,866
NHMRC
Beesley, Jonathan – The TERT locus as a susceptibility gene for ovarian and breast cancer: genetic and functional evaluation
3yrs
2011 – 2013
$382,524
NHMRC
Burrows, Scott – The impact of micropolymorphism within the T cell receptor genes and their target antigenic peptides
3yrs
2011 – 2013
$352,524
NHMRC
Chong, Suyinn – Epigenetic and neuribehavioural changes in a new mouse model of foetal alcohol spectrum disorder
3yrs
2011 – 2013
$701,732
NHMRC
Harrich, David – An RNA element negatively regulates HIV-1 reverse transcription and inhibits proviral intergration
3yrs
2011 – 2013
$561,453
NHMRC
Harrich, David – How does a host cell stimulatory factor stabilize the HIV-1 reverse transcription complex?
3yrs
2011 – 2013
$610,074
NHMRC
Khanna, Rajiv – Prophylactic vaccine to prevent cytomegalovirus disease.
3yrs
2011 – 2013
$421,299
NHMRC
MacDonald Kelli – The role of alloantigen presentation in transplantation
3yrs
2011 – 2013
$490,470
NHMRC
McRea, Allan – Inheritance of DNA methylation state in humans
3yrs
2011 – 2013
$579,766
NHMRC
Medland, Sarah – Genetic influences on the comorbidity between Attention Deficit Hyperactivity Disorder and substance use
2yrs
2011 – 2012
$238,978
Page 129
grants and funding | continued Chief Investigators and Project Title
Term
Period
NHMRC
Ramm, Grant – Role of tissue ferritin as a proinflammatory mediator of hepatic stellate cell activation in heptic iron overload
3yrs
2011 – 2013
$555,048
NHMRC
Spurdle, Amanda – Prediction, verification and clinical significance of splicing aberrations associated with BRAC1 and BRAC2 variants
3yrs
2011 – 2013
$553,390
NHMRC
Tellam, Judith – Enhanced expression of Epstein-Barr virus nuclear antigen, EBNA1, as a target for T cell based immunotherapy for prevention of viral-associated diseases
3yrs
2011 – 2013
$344,208
NHMRC
Valery, Patricia – A comparative study: Patterns of care, comorbidities and quality of life of Indigenous and non-Indigenous people with lung, head and neck, breast or gynaecological cancers
3yrs
2011 – 2013
$610,731
NHMRC
Wray, Naomi – Better methods for individual risk prediction of complex traits in human populations
3yrs
2011 – 2013
$578,416
NHMRC
Wright, Margaret – Genetics of brain structure and function
3yrs
2011 – 2013
$560,218
NHMRC
Yang, Yurong – Does environmental change drive the spatiotemporal transmission dynamics of Echinococcus spp. in Ningxia, China?
3yrs
2011 – 2013
$632,128
NHMRC
Duffy, David – Genetic epidemiology of complex disease
5yrs
2011 – 2015
$630,505
NHMRC
Khanna, Rajiv – Immunobiology of herpes virus infections
5yrs
2011 – 2015
$780,805
NHMRC
McManus, Don – Elimination of zoonotic schistosomiasis
5yrs
2011 – 2015
$855,805
NHMRC
Harten, Sarah – A piggy-back screen for genes involved involved in cancer
4yrs
2011 – 2014
$290,032
NHMRC
Markey, Kate – The immune system in graft-versus-host disease
4yrs
2011 – 2014
$145,016
NHMRC
Wei, Ting – A Novel RNA repressor element regulates HIV-1
4yrs
2011 – 2014
$290,032
NHMRC
Willis, Charlene – Haemolysines and haemoglobinases as anti-hookworm vaccines (Transferred from Griffith University)
2yrs
2011 – 2012
$122,875
NHMRC
Webb, Penny – CARE Kidney Study (Administered by The University of Queensland)
3yrs
2011 – 2013
$245,275
NHMRC
Hayward, Nick – Molecular determinants of risk, progression and treatment response in melanoma (Administered by University of Sydney)
5yrs
2011 – 2015
$1,608,665
NIH
Martin, Nick – Genetic and environmental pathways to drug use, abuse and dependence (Administered by Virginia Commonwealth University – USA)
4yrs
2010 – 2013
$389,251
OHMR
Hill, Geoff – Senior Clinical Research Fellowship
5yrs
2011 – 2015
$4,250,000
PCFA
Boyd, Andrew – Express and Function of Eph and ephrin proteins in prostate cancer
2yrs
2011 – 2012
$250,000
RBWH
Breakspear, Michael – Health Research Fellowship – Mental Health Research Division (Administered by RBWH)
5yrs
2011 – 2015
$375,000
ROTRF
Gandhi, Maher – Post transplant lymph proliferative disorders: A lab based study within LS CT
2yrs
2011 – 2012
$206,653
ROTRF
Khanna, Rajiv – MHC Class II all recognition by virus-specific CD*+ T cell
2yrs
2011 – 2012
$206,653
SMART
Wykes, Michelle – A novel treatment to generate long-term protection against malaria
4yrs
2010 – 2013
$300,000
Legend
Page 130
Total Funding
Source
ALF
Australian Liver Foundation
ARC
Australian Research Council
BUSHEL
Bushel Foundation
CA/NBCF
Cancer Australia/National Breast Cancer Foundation
CANCERAU
Cancer Australia
CCQ
Cancer Council Queensland
CSIRO
Commonwealth Scientific and Industrial Research Organisation
DEEDI
Dept of Employment, Economic Development and Innovation
ECO
Ecobiotics
GARNETT
Garnett Passe and Rodney Williams Memorial Foundation
HEARTF
Heart Foundation
NHMRC
National Health and Medical Research Council
NIH
National Institutes of Health
OHMR
Office of Health and Medical Research
PCFA
Prostate Cancer Foundation Australia
RBWH
Royal Brisbane and Women’s Hospital
ROTRF
Roche Organ Transplantation Research Foundation
SMART
Smart State Futures Fellowship
QIMR Annual Report 2010–2011
Qimr feLLoWS Sir Macfarlane Burnet
Dr Natth Bhamarapravati
Dr Michael O’Rourke
Prof Ralph Doherty
Dr Louis Miller
Mr Michael Barry
Prof Frank Fenner
Sir Eric Saint
Prof Kay Ellem
Dr Eric French
Dr Robert Shope
Dr Ian Taylor
Sir Abraham Fryberg
Sir Bruce Watson
Prof Lawrie Powell
Dr Douglas Lee
The Hon Mike Ahern
Mr Tom Veivers
Ms Margaret Macgregor
Dr Neville McCarthy
Mr Phillip Desbrow (Deceased)
Dr Aubrey Pye
Sir Gustav Nossal
Prof William O’Sullivan
Mr William Reeves
Dr E D O’Callaghan
Dr Diana Cavaye (Deceased)
Mr John Sprent
Prof Frank Schofield
Sr Regis Mary Dunne
Mr Harry Standfast
Sir Edward Stewart
Mr Clive Berghofer
Mr George Taylor
Prof Tao Yixun
Prof Bryan Campbell
Mr John Tonge
Dr Chamlong Harinasuta
Mr Sam Coco
Dr Carleton Gajdusek
Prof Chev Kidson
Dr Peter Wills
Dr David Henderson
Dr Peter Livingstone
Prof John Kerr
Prof Owen Powell
Dr Michael Alpers
Mr Paul Wright
Prof Julie Saroso
Mr Rod Wylie
Mr David Lyons
Prof Edwin Westaway
Prof Graham Mitchell
Mr Ian Goddard
Prof Vincent Zigas
Prof Mervyn Eadie
Ms Helen Luckoff
Sir Anthony Epstein
Prof Bryan Emmerson
Mr John Garnsey (Deceased)
Dr Douglas Gordon
Dr Ian Wilkey
Prof Graham Brown
Dr Elizabeth Marks
Prof Ted Brown
Prof Robert MacLennan
Dr Neville Davis
Prof Peter Doherty
Prof Peter Brooks
Dr Robert Porter
Prof Paul Korner
Dr Peter Roeser
Prof Brian Wilson
Dr Stephen Lynch
Page 131
oVerSeaS traVeL Travel by researchers and corporate staff is critical to facilitate collaborations and ensure the Institute keeps pace with new technologies and techniques. The following overseas travel was taken during the 2010–2011 financial year.
Agency Cost ($)
Contribution from other agencies or sources
Name of Officer & Position
Destination
Reason for Travel
Prof Frank Gannon (Director)
Europe
EMBO/EMBC Conference
Prof Frank Gannon (Director)
Europe
Invited Lecturer – Redfern Lecture at 50th Anniversary of the Dept of Biochemistry, Leicester; Speaker at meeting – “Starting from Transcription… Honneur a Pierre Chambon”, IGBMC; Meeting re. HIRF – Erlangen, Germany ; Attend the 36th FEBS Congress, Torino, Italy
Dr Cameron McDonald (Research Officer)
Canada
BioIron Conference
3,989
Dr Lutz Krause (Lab Head)
USA/Europe
Attend the Human Micro biome Research Conference; FASEB Conference and ISMB Conference
8,991
Prof Nick Hayward (Lab Head)
Israel/UK
International Melanoma Genetics Consortium (GenoMEL) Annual Conference – Israel : Meeting of BioGenoMEL Consortium (UK)
6,613
Ms Michelle Richards (Safety Officer)
Canada
Attend 2011 Annual International High Containment Bio-safety Workshop, International Centre for Infectious Diseases
3,523
Ms Grace Chojnowski (Scientific Technical Officer)
USA
Attend CYTO2011 and ISAC Council Meeting
4,300
Dr Antiopi Varelias (Research Officer)
USA
98th Annual Meeting of the American Association of Immunologists
2,043
Dr Ingrid Rowlands (Research Officer)
UK
Laboratory visit – National Perinatal Epidemiology Unit, Oxford
1,106
Mr Yi Chieh Lim (PhD Student)
USA
Gordon Research Conference
1,875
Dr Rachel Neale (Senior Research Fellow)
Copenhagen/ Denmark
1st International Conference on UV and Skin Cancer Prevention
3,972
$2,672
Dr Alex Combes (Research Officer)
Germany
Chromatin and Epigenetics Conference
3,505
$2,505
Dr Zhen Zhen Zhao (Senior Research Officer)
China
Attend and present at Cold Harbor Springs Asia Meeting
2,500
$1,500
Dr Olivier Becherel (Senior Research Officer)
USA
Keystone Symposia – Genomic Instability and DNA Repair
1,860
9,679
13,881
University of Leicester $4,288
Dr Deepak Darshan (Research Officer) Assoc Prof Nathan Subramaniam (Lab Head)
Page 132
QIMR Annual Report 2010–2011
European Commission grant $4,613
Scientific puBLicationS Abdel-Aal ABM, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I. Design of Three-Component Vaccines against Group A Streptococcal Infections: Importance of Spatial Arrangement of Vaccine Components. Journal of Medicinal Chemistry. 2010;53(22):8041-8046. Ainger SA, Wong SS, Roberts DW, Leonard JH, Sturm RA. Effect of MC1R variant allele status on MSH-ligand induction of dopachrome tautomerase in melanocytes co-cultured with keratinocytes. Experimental Dermatology. 2011;20(8):681-684. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene. 2010;29(46):6085-6098. Al-Ejeh F, Smart CE, Morrison BJ, ChenevixTrench G, Lopez JA, Lakhani SR, Brown MP, Khanna KK. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32(5):650-658. Alford JR, Hatemi PK, Hibbing JR, Martin NG, Eaves LJ. The Politics of Mate Choice. Journal of Politics. 2011;73(2):362–379. Allen HL, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, Willer CJ, Jackson AU, Vedantam S, Raychaudhuri S, Ferreira T, Wood AR, Weyant RJ, Segre AV, Speliotes EK, Wheeler E, Soranzo N, Park JH, Yang J, Gudbjartsson D, Heard-Costa NL, Randall JC, Qi L, Smith AV, Magi R, Pastinen T, Liang L, Heid IM, Luan J, Thorleifsson G, Winkler TW, Goddard ME, Lo KS, Palmer C, Workalemahu T, Aulchenko YS, Johansson A, Zillikens MC, Feitosa MF, Esko T, Johnson T, Ketkar S, Kraft P, Mangino M, Prokopenko I, Absher D, Albrecht E, Ernst F, Glazer NL, Hayward C, Hottenga JJ, Jacobs KB, Knowles JW, Kutalik Z, Monda KL, Polasek O, Preuss M, Rayner NW, Robertson NR, Steinthorsdottir V, Tyrer JP, Voight BF, Wiklund F, Xu JF, Zhao JH, Nyholt DR, Pellikka N, Perola M, Perry JRB, Surakka I, Tammesoo ML, Altmaier EL, Amin N, Aspelund T, Bhangale T, Boucher G, Chasman DI, Chen C, Coin L, Cooper MN, Dixon AL, Gibson Q, Grundberg E, Hao K, Junttila MJ, Kaplan LM, Kettunen J, Konig IR, Kwan T, Lawrence RW, Levinson DF, Lorentzon M, McKnight B, Morris AP, Muller M, Ngwa JS, Purcell S, Rafelt S, Salem RM, Salvi E, Sanna S, Shi JX, Sovio U, Thompson JR, Turchin MC, Vandenput L, Verlaan DJ, Vitart V, White CC, Ziegler A, Almgren P, Balmforth AJ, Campbell H, Citterio L, De Grandi A, Dominiczak A, Duan J, Elliott P, Elosua R, Eriksson JG, Freimer NB, Geus EJC, Glorioso N, Haiqing S, Hartikainen AL, Havulinna AS, Hicks AA, Hui JN, Igl W, Illig T, Jula A, Kajantie E, Kilpelaeinen TO, Koiranen M, Kolcic I, Koskinen S, Kovacs P, Laitinen J, Liu JJ, Lokki ML, Marusic A, Maschio A, Meitinger T, Mulas A, Pare G, Parker AN, Peden JF, Petersmann A, Pichler I, Pietilainen KH, Pouta A, Riddertrale M, Rotter JI, Sambrook JG, Sanders AR, Schmidt CO, Sinisalo J, Smit JH, Stringham HM, Walters GB, Widen E, Wild SH, Willemsen G, Zagato L, Zgaga L, Zitting P, Alavere H, Farrall M, McArdle WL, Nelis M, Peters MJ, Ripatti S, Meurs JBJ, Aben KK, Ardlie KG, Beckmann JS, Beilby JP, Bergman RN, Bergmann S, Collins FS, Cusi D, den Heijer M, Eiriksdottir G, Gejman PV, Hall AS, Hamsten A, Huikuri HV, Iribarren C, Kahonen M, Kaprio J, Kathiresan S, Kiemeney L, Kocher T, Launer LJ, Lehtimaki T, Melander O, Mosley TH, Musk AW, Nieminen MS, O’Donnell CJ, Ohlsson C,
Oostra B, Palmer LJ, Raitakari O, Ridker PM, Rioux JD, Rissanen A, Rivolta C, Schunkert H, Shuldiner AR, Siscovick DS, Stumvoll M, Tonjes A, Tuomilehto J, van Ommen GJ, Viikari J, Heath AC, Martin NG, Montgomery GW, Province MA, Kayser M, Arnold AM, Atwood LD, Boerwinkle E, Chanock SJ, Deloukas P, Gieger C, Gronberg H, Hall P, Hattersley AT, Hengstenberg C, Hoffman W, Lathrop GM, Salomaa V, Schreiber S, Uda M, Waterworth D, Wright AF, Assimes TL, Barroso I, Hofman A, Mohlke KL, Boomsma DI, Caulfield MJ, Cupples LA, Erdmann J, Fox CS, Gudnason V, Gyllensten U, Harris TB, Hayes RB, Jarvelin MR, Mooser V, Munroe PB, Ouwehand WH, Penninx BW, Pramstaller PP, Quertermous T, Rudan I, Samani NJ, Spector TD, Volzke H, Watkins H, Wilson JF, Groop LC, Haritunians T, Hu FB, Kaplan RC, Metspalu A, North KE, Schlessinger D, Wareham NJ, Hunter DJ, O’Connell JR, Strachan DP, Schadt HE, Thorsteinsdottir U, Peltonen L, Uitterlinden AG, Visscher PM, Chatterjee N, Loos RJF, Boehnke M, McCarthy MI, Ingelsson E, Lindgren CM, Abecasis GR, Stefansson K, Frayling TM, Hirschhorn JN. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832-838. Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, McLaren CE, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC. HFE Cys282Tyr Homozygotes With Serum Ferritin Concentrations Below 1000 mu g/L Are at Low Risk of Hemochromatosis. Hepatology. 2010;52(3):925-933. Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Beesley J, Webb PM; Australian Cancer Study (Ovarian Cancer), Pearce CL, Wu AH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjær SK, Høgdall E, Cramer DW, Terry KL, Garcia-Closas M, Yang H, Lissowska J, Anton-Culver H, Ziogas A, Schildkraut JM, Berchuck A, Pharoah PD; Ovarian Cancer Association Consortium. Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiology Biomarkers & Prevention. 2011;20(5):1028-31. Amankwah EK, Kelemen LE, Wang QG, Song HL, Chenevix-Trench G, Beesley J, Webb PM, Pearce CL, Wu ANH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjaer SK, Hogdall E, Cramer DW, Terry KL, Garcia-Closas M, Yang H, Lissowska J, AntonCulver H, Ziogas A, Schildkraut JM, Berchuck A, Pharoah PDP. Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 2011;20(5):1028-1031. Amankwah EK, Wang QG, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, Beesley J, Johnatty SE, Webb PM, Chenevix-Trench G, Dale LC, Lambrechts D, Amant F, Despierre E, Vergote
I, Gayther SA, Gentry-Maharaj A, Menon U, Chang-Claude J, Wang-Gohrke S, Anton-Culver H, Ziogas A, Dork T, Durst M, Antonenkova N, Bogdanova N, Brown R, Flanagan JM, Kaye SB, Paul J, Butzow R, Nevanlinna H, Campbell I, Eccles DM, Karlan BY, Gross J, Walsh C, Pharoah PDP, Song HL, Kjaer SK, Hogdall E, Hogdall C, Lundvall L, Nedergaard L, Kiemeney LALM, Massuger LFAG, van Altena AM, Vermeulen SHHM, Le ND, BrooksWilson A, Cook LS, Phelan CM, Cunningham JM, Vachon CM, Vierkant RA, Iversen ES, Berchuck A, Goode EL, Sellers TA, Kelemen LE. Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE. 2011;6(5). Amante FH, Engwerda CR, Good MF. Experimental asexual blood stage malaria immunity. Current Protocols in Immunology. 2011;Chapter19(Unit19.4). Amante FH, Haque A, Stanley AC, Rivera FD, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Pinzon-Charry A, Pearson MS, Duke MG, McManus DP, Loukas A, Hill GR, Engwerda CR. Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria. Journal of Immunology. 2010;185(6):36323642. Amstadter AB, Balachandar V, Bergen SE, Ceulemans S, Christensen JH, Cole J, Dagdan E, De Luca V, Ducci F, Tee SF, Hartz S, Keers R, Medland S, Melas PA, Muhleisen TW, Ozomaro U, Pidsley R, Scott AP, Sha L, Talati A, Teltsh O, Videtic A, Wang K, Wong CCY, DeLisi LE. Selected summaries from the XVII World Congress of Psychiatric Genetics, San Diego, California, USA, 4-8 November 2009 (vol 20, pg 229, 2010). Psychiatric Genetics. 2011;21(1):55-55. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RSN, Floyd JAB, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics. 2011;43(3):246-U94.
Page 133
Scientific publications | continued Anthony B, Allen JT, Li YSS, McManus DP. Hepatic stellate cells and parasite-induced liver fibrosis. Parasites & Vectors. 2010;3(1):60. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang XS, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall’Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL, Thomassen M, Gerdes AM, Sunde L, Cruger D, Jensen UB, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernstrom H, Lindblom A, Rantala J, StenmarkAskmalm M, Melin B, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Duran M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frenay M, Venat-Bouvet L, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TVO, Jnson L, Agnarsson BA, Kirchhoff T, offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, PreislerAdams S, Kast K, Schonbuchner I, Caldes T, de la Hoya M, Aittomaki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen XQ, Platte R, Chenevix-Trench G, Easton DF. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research. 2010;70(23):9742-9754. Antoniou AC, Wang XS, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P, Hogervorst FBL, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Garcia EBG, Devilee P, Vreeswijk MPG, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Gorski B, Cybulski C, Spurdle AB, Holland H, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M,
Page 134
QIMR Annual Report 2010–2011
Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TVO, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Silva IDS, Peto J, Lambrechts D, Paridaens R, Rudiger T, Forsti A, Winqvist R, Pylkaas K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PPD, offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptornegative breast cancer in the general population. Nature Genetics. 2010;42(10):885. Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pandeya N, Pawlita M, Waterboer T, Neale RE. Prevalence and stability of antibodies to 37 human papillomavirus types - A population-based longitudinal study. Virology. 2010;407(1):26-32. Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pawlita M, Waterboer T, Neale RE. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. Journal of General Virology. 2010;91(Part 7):1849-1853. Antonsson A, Nancarrow DJ, Brown IS, Green AC, Drew PA, Watson DI, Hayward NK, Whiteman DC. High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 2010;19(8):2080-2087. Antonsson A, Nancarrow DJ, Brown IS, Green AC, Drew PA, Watson DI, Hayward NK, Whiteman DC. High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma-Response. Cancer Epidemiology Biomarkers & Prevention. 2011;20(2):409-410. Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, Nyholt DR, Dimas AS, Freilinger T, Muller-Myhsok B, Artto V, Inouye M, Alakurtti K, Kaunisto MA, Hamalainen E, de Vries B, Stam AH, Weller CM, Heinze A, Heinze-Kuhn K, Goebel I, Borck G, Gobel H, Steinberg S, Wolf C, Bjornsson A, Gudmundsson G, Kirchmann M, Hauge A, Werge T, Schoenen J, Eriksson JG, Hagen K, Stovner L, Wichmann E, Meitinger T, Alexander M, Moebus S, Schreiber S, Aulchenko YS, Breteler MMB, Uitterlinden AG, Hofman A, van Duijn CM, Tikka-Kleemola P, Vepsalainen, Lucae S, Tozzi F, Muglia P, Barrett J, Kaprio J, Farkkila M, Peltonen L, Stefansson K, Zwart JA, Ferrari MD, Olesen J, Daly M, Wessman M, van den Maagdenberg AMJM, Dichgans M, Kubisch C, Dermitzakis ET, Frants RR, Palotie A. Genomewide association study of migraine implicates a common susceptibility variant on 8q22.1. Nature Genetics. 2010;42(10):869. Ao A, Morrison BJ, Wang H, López JA, Reynolds BA, Lu J. Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments. PLoS ONE. 2011;6(4):e18810. Apte SH, Groves P, Olver S, Baz A, Doolan DL, Kelso A, Kienzle N. IFN-gamma Inhibits IL-4Induced Type 2 Cytokine Expression by CD8 T Cells
In Vivo and Modulates the Anti-Tumor Response. Journal of Immunology. 2010;185(2):998-1004. Asojo OA, Loukas A, Inan M, Barent R, Huang JC, Plantz B, Swanson A, Gouthro M, Meagher MM, Hotez PJ. Crystallization and preliminary X-ray analysis of Na-ASP-1, a multi-domain pathogenesis-related-1 protein from the human hookworm parasite Necator americanus. Acta Crystallographica Section F-Structural Biology and Crystallization Communications. 2010;66:15491549. Aung HT, Harrison DK, Findlay I, Mattick JS, Martin NG, Carroll BJ. Stringent Programming of DNA Methylation in Humans. Twin Research and Human Genetics. 2010;13(5):405-411. Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF. Population-based survival estimates for childhood cancer in Australia during the period 1997-2006. British Journal of Cancer. 2010;103(11):1663-1670. Badrick AC, Jones CE. Reorganizing metals: the use of chelating compounds as potential therapies for metal-related neurodegenerative disease. Current Topics in Medicinal Chemistry. 2011;11(5):543-52. Balen J, McManus DP, Li YS, Zhao ZY, Yuan LP, Utzinger J, Williams GM, Li Y, Ren MY, Liu ZC, Zhou J, Raso G. Comparison of two approaches for measuring household wealth via an asset-based index in rural and peri-urban settings of Hunan province, China. Emerging Themes in Epidemiology. 2010;7(1):7. Barnett AG, Tong S, Clements ACA. What measure of temperature is the best predictor of mortality?. Environmental Research. 2010;110(6):604-611. Barnett AG, Tong SL, Clements ACA. Reply to commentary “Time series analysis on the health effects of temperature: Two areas for future research” by Gasparrini and Armstrong. Environmental Research. 2010;110(6):639-639. Bates TC, Lind PA, Luciano M, Montgomery GW, Martin NG, Wright MJ. Dyslexia and DYX1C1: deficits in reading and spelling associated with a missense mutation. Molecular Psychiatry. 2010;15(12):1190-1196. Bates TC, Luciano M, Medland SE, Montgomery GW, Wright MJ, Martin NG. Genetic Variance in a Component of the Language Acquisition Device: ROBO1 Polymorphisms Associated with Phonological Buffer Deficits. Behavior Genetics. 2011;41(1):50-57. Bates TC, Luciano M, Montgomery GW, Wright MJ, Martin NG. Genes for a component of the language acquisition mechanism: ROBO1 polymorphisms associated with phonological buffer deficits. Behavior Genetics. 2010;40(6):785-786. Batra J, Nagle CM, O’Mara T, Higgins M, Dong Y, Tan OL, Lose F, Skeie LM, Srinivasan S, Bolton KL, Song H, Ramus SJ, Gayther SA, Pharoah PDP, Kedda MA, Spurdle AB, Clements JA. A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer. 2011;11(Art. 119). Beadle G, Mengersen K, Moynihan S, Yates P. Perceptions of the ethical conduct of cancer trials by oncology nurses. European Journal of Cancer Care. 2011;1365-2354. Beam CR, Horn EE, Hunt SK, Emery RE, Turkheimer E, Martin N. Revisiting the effect of marital support on depressive symptoms in mothers and fathers: A genetically informed study. Journal of Family Psychology. 2011;23(3):336–344.
Beaumont KA, Wong SS, Ainger SA, Liu YY, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Leonard JH, Sturm RA. Melanocortin MC(1) receptor in human genetics and model systems. European Journal of Pharmacology. 2011;660(1):103-110. Bedi S, Nelson EC, Lynskey MT, Mc Cutcheon VV, Heath AC, Madden PA, Martin NG. Risk for Suicidal Thoughts and Behavior after Childhood Sexual Abuse in Women and Men. Suicide & Life-Threatening Behavior. 2011. [Published online ahead of print]. Beesley J, Johnatty SE, Chen XQ, Spurdle AB, Peterlongo P, Barile M, Pensotti V, Manoukian S, Radice P, Chenevix-Trench G. No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Research and Treatment. 2011;126(1):235-239. Beesley VL, Clavarino AM, Webb PM, Wyld DK, Francesconi AB, Horwood KR, Doecke JD, Loos CA, Green AC. Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer. 2010;18(8):943-949. Beesley VL, Price MA, Butow PN, Green AC, Olsen CM, Webb PM; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study Quality of Life Study Investigators. Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psychooncology. 2010. [Published online ahead of print]. Beesley VL, Price MA, Webb PM, Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study Quality of Life Study Investigators. Loss of lifestyle: health behaviour and weight changes after becoming a caregiver of a family member diagnosed with ovarian cancer. Supportive Care In Cancer. 2010. [Published online ahead of print]. Benyamin B, Montgomery GW, Martin NG, Whitfield JB. Transferrin saturation and mortality. Clin Chem. 2011;57(6):921-3. Berchuck A, Pharoah P, Ramus S, Gayther S, Palmieri R, Pearce C, Couch F, Antonio A, Goode E, Schildkraut J, Chenevix-Trench G, Sellers T, Risch H. Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing. Gynecologic Oncology. 2011;121(2):S2-S3. Bergen SE, Balhara YPS, Christoforou A, Cole J, Degenhardt F, Dempster E, Fatjo-Vilas M, Khedr Y, Lopez LM, Lysenko L, McGrath LM, Muhleisen TW, Neves FS, Nymberg C, Ozomaro U, Verweij KJH, Voineskos AN, Zai CC, O’Shea A, DeLisi LE. Summaries from the XVIII World Congress of Psychiatric Genetics, Athens, Greece, 3-7 October 2010. Psychiatric Genetics. 2011;21(3):136-172. Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O. Glutamate cysteine ligase (GCL) and self reported depression: An association study from the HUNT. Journal of Affective Disorders. 2011;131(1-3):207-213. Blokland G, McMahon K, Thompson P, Martin N, de Zubicaray G, Wright MJ. Heritability of FMRI response in young adult twins. Behavior Genetics. 2010;40(6):787-787. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS,
Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics. 2010;42(10):880-884.
susceptibility testing of cystic fibrosis and noncystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods. British Journal of Biomedical Science. 2011;68(1):1-4.
Bond CE, Umapathy A, Buttenshaw RL, Leggett BA, Whitehall VLJ. BRAF, MSI and CIN-molecular determinants of outcome of the serrated pathway of colorectal cancer. Journal of Gastroenterology and Hepatology. 2010;25:A12.
Breakspear M, Heitmann S, Daffertshofer A. Generative models of cortical oscillations: neurobiological implications of the Kuramoto model. Frontiers in Human Neuroscience. 2010;4:190.
Bond CE, Umapathy A, Ramsnes I, Greco SA, Zhao ZZ, Mallitt KA, Buttenshaw RL, Montgomery GW, Leggett BA, Whitehall VL. P53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. International Journal of Cancer. 2011. [Published online ahead of print]. Botelho NK, Schneiders FI, Lord SJ, Freeman AK, Tyagi S, Nancarrow DJ, Hayward NK, Whiteman DC, Lord RVN. Gene expression alterations in formalin-fixed, paraffin-embedded Barrett’s esophagus and esophageal adenocarcinoma tissues. Cancer Biology & Therapy. 2010;10(2):172-179. Bouzigon E, Forabosco P, Koppelman GH, Cookson WOCM, Dizier M-H, Duffy DL, Evans DM, Ferreira MAR, Kere J, Laitinen T, Malerba G, Meyers DA, Moffatt M, Martin NG, Ng MY, Pignatti PF, Wjst M, Kauffmann F, Demenais F, Lewis CM. Meta-analysis of 20 genome-wide linkage studies evidenced new regions linked to asthma and atopy. European Journal of Human Genetics. 2010;18(6):700-706. Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, Dutton-Regester K, Cook AL, Sturm RA, Hayward NK. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell & Melanoma Research. 2011;24(3):525-537. Boyle GM. Therapy for metastatic melanoma: an overview and update. Expert Reviews of Anticancer Therapy. 2011;11(5):725-37. Bradbury RS, Reid DW, Inglis TJ, Champion AC. Decreased virulence of cystic fibrosis Pseudomonas aeruginosa in Dictyostelium discoideum. Microbiology Immunology. 2011;55(4):224-30. Bradbury RS, Roddam LF, Merritt A, Reid DW, Champion AC. Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology. 2010;59(pt8):881-90.
Branstrom R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bergman W, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, Leachman SA, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y. Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online Study. Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2199-2210. Brant AM, Boomsma DI, Corley RP, DeFries JC, Haworth CMA, Hewitt JK, Martin NG, McGue M, Petrill SA, Plomin R, Wadsworth SJ, Wright MJ. Ability and heritability: investigating the continuous effect of IQ score on IQ etiology in multiple samples. Behavior Genetics. 2010;40(6):788-788. Braskie MN, Jahanshad N, Stein JL, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Ringman JM, Toga AW, Thompson PM. Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. Journal of Neuroscience. 2011;31(18):6764-6770
Breakspear M, Jirsa V, Deco G. Computational models of the brain: From structure to function. Neuroimage. 2010;52(3):727-730. Brennan PA, Hammen C, Sylvers P, Bor W, Najman J, Lind P, Montgomery G, Smith AK. Interactions between the COMT Val108/158Met polymorphism and maternal prenatal smoking predict aggressive behavior outcomes. Biological Psychology. 2011;87(1):99-105. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, English DR, Walsh MD, Clendenning M, McKeone DM, Walters RJ, Roberts A, Pearson SA, Pavluk E, Hopper JL, Gattas MR, Goldblatt J, George J, Suthers GK, Phillips KD, Woodall S, Arnold J, Tucker K, Muir A, Field M, Greening S, Gallinger S, Perrier R, Baron JA, Potter JD, Haile R, Frankel W, de la Chapelle A, Macrae F, Rosty C, Walker NI, Parry S, Young JP. Risk Factors for Colorectal Cancer in Patients with Multiple Serrated Polyps: A Cross-Sectional Case Series from Genetics Clinics. PLoS ONE. 2010;5(7). Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, Mills RA, Danoy P, Casson R, Viswanathan AC, Liu JZ, Landers J, Henders AK, Wood J, Souzeau E, Crawford A, Leo P, Wang JJ, Rochtchina E, Nyholt DR, Martin NG, Montgomery GW, Mitchell P, Brown MA, Mackey DA, Craig JE. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nature Genetics. 2011;43(6):574-U110. Burke ML, Mcmanus DP, Ramm GA, Duke M, Li Y, Jones MK, Gobert GN. Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis. Journal of Gastroenterology and Hepatology. 2010;25:A11-A11. Burrows SR, Moss DJ, Khanna R. Understanding human T-cell-mediated immunoregulation through herpesviruses. Immunology and Cell Biology. 2011;89(3):352-358.
Bradbury RS, Tristram SG, Roddam LF, Reid DW, Inglis TJ, Champion AC. Antimicrobial
Page 135
Scientific publications | continued Butterworth AS, Robertson AJ, Ho MF, Gatton ML, McCarthy JS, Trenholme KR. An improved method for undertaking limiting dilution assays for in vitro cloning of Plasmodium falciparum parasites. Malaria Journal. 2011;10.
Clements ACA, Kur LW, Gatpan G, Ngondi JM, Emerson PM, Lado M, Sabasio A, Kolaczinski JH. Targeting Trachoma Control through Risk Mapping: The Example of Southern Sudan. PLoS Neglected Tropical Diseases. 2010;4(8).
Catts V, Catts S, Jablensky A, Chandler D, Weickert CS, Lavin M. Genomic stability and DNA repair in lymphoblasts from patients with schizophrenia. Australian and New Zealand Journal of Psychiatry. 2010;44:A33-A33.
Clendenning M, Buchanan DD, Walsh MD, Nagler B, Rosty C, Thompson B, Spurdle AB, Hopper JL, Jenkins MA, Young JP. Mutation deep within an intron of MSH2 causes Lynch syndrome. Familial Cancer. 2011;10(2):297-301.
Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, Faria P, Pereira E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Khanna KK, Cummings M, Chenevix-Trench G, Lakhani SR. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research. 2010;12(4):R46.
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, Kolbe J, Landau LI, Maguire GP, McDonald MI, Reid DW, Thien FC, Torzillo PJ. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust. 2010;193(6):356-65.
Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malaria Journal. 2011;10:56.
Darshan D, Frazer DM, Anderson GJ. Molecular basis of iron-loading disorders. Expert Reviews in Molecular Medicine. 2010. [Published online ahead of print].
Chen NH, Chavchich M, Peters JM, Kyle DE, Gatton ML, Cheng Q. Deamplification of pfmdr1-Containing Amplicon on Chromosome 5 in Plasmodium falciparum Is Associated with Reduced Resistance to Artelinic Acid In Vitro. Antimicrobial Agents and Chemotherapy. 2010;54(8):3395-3401. Chiang MC, Barysheva M, Toga AW, Medland SE, Hansel NK, James MR, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM. BDNF gene effects on brain circuitry replicated in 455 twins. Neuroimage. 2011;55(2):448-454. Chiang MC, McMahon KL, de Zubicaray GI, Martin NG, Hickie I, Toga AW, Wright MJ, Thompson PM. Genetics of white matter development: A DTI study of 705 twins and their siblings aged 12 to 29. Neuroimage. 2011;54(3):2308-2317. Chuan J, Feng Z, Brindley PJ, McManus DP, Han Z, Jianxin P, Hu W. Our Wormy World: Genomics, Proteomics and Transcriptomics in East and Southeast Asia. Advances in Parasitology. 2010;73:327-371. Cichon S, Muehleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J, Steffens M, Meesters C, Herms S, Weingarten M, Priebe L, Haenisch B, Alexander M, Vollmer J, Breuer R, Schmal C, Tessmann P, Moebus S, Wichmann HE, Schreiber S, Muller-Myhsok B, Lucae S, Jamain S, Leboyer M, Bellivier F, Etain B, Henry C, Kahn JP, Heath S, Hamshere M, Oâ&#x20AC;&#x2122;Donovan MC, Owen MJ, Craddock N, Schwarz M, Vedder H, Kammerer-Ciernioch J, Reif A, Sasse J, Bauer M, Hautzinger M, Wright A, Mitchell PB, Schofield PR, Montgomery GW, Medland SE, Gordon SD, Martin NG, Gustafsson O, andreassen O, Djurovic S, Sigurdsson E, Steinberg S, Stefansson H, Stefansson K, Kapur-Pojskic L, Oruc L, Rivas F, Mayoral F, Chuchalin A, Babadjanova G, Tiganov AS, Pantelejeva G, Abramova LI, Grigoroiu-Serbanescu M, Diaconu CC, Czerski PM, Hauser J, Zimmer A, Lathrop M, Schulze TG, Wienker TF, Schumacher J, Maier W, Propping P, Rietschel M, Nothen MM. Genomewide Association Study Identifies Genetic Variation in Neurocan as a Susceptibility Factor for Bipolar Disorder. American Journal of Human Genetics. 2011;88(3):396-396. Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, Cloarec O, Richards SE, Wang Y, Dumas ME, Ross A, Rezzi S, Kochhar S, Van Bladeren P, Lindon JC, Holmes E, Nicholson JK. Colonization-induced host-gut microbial metabolic interaction. mBio. 2011;2(2):e00271-10.
Page 136
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
Combes AN, Whitelaw E. Epigenetic reprogramming: Enforcer or enabler of developmental fate?. Development Growth & Differentiation. 2010;52(6):483-491. Conrad M, Zubacova Z, Dunn LA, Upcroft J, Sullivan SA, Tachezy J, Carlton JM. Microsatellite polymorphism in the sexually transmitted human pathogen Trichomonas vaginalis indicates a genetically diverse parasite. Molecular and Biochemical Parasitology. 2011;175(1):30-38. Conway CC, Hammen C, Brennan PA, Lind PA, Najman JM. Interaction of Chronic Stress with Serotonin Transporter and Catechol-OMethyltransferase Polymorphisms In Predicting Youth Depression. Depression and Anxiety. 2010;27(8):737-745. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Pandeya N, Webb PM, Wu AH, Ward MH, Giffen C, Casson AG, Abnet CC, Murray LJ, Corley DA, Nyren O, Vaughan TL, Chow WH. Cigarette Smoking and Adenocarcinomas of the Esophagus and Esophagogastric Junction: A Pooled Analysis From the International BEACON Consortium. Journal of the National Cancer Institute. 2010;102(17):1344-1353. Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, Gueven N, DiRenzo J, Smith G, Hupp TR, Vojtesek B. Delta Np63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation. Molecular Cancer. 2010;9. Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, Lagergren J. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: A pooled analysis. European Journal of Cancer. 2010;46(11):20672076. Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, Lagergren J. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: A pooled analysis. European Journal of Cancer. 2010;46(11):20672076. Cuiv PO, de Carcer DA, Jones M, Klaassens ES, Worthley DL, Whitehall VLJ, Kang S, McSweeney CS, Leggett BA, Morrison M. The Effects from DNA Extraction Methods on the Evaluation of Microbial Diversity Associated with Human Colonic Tissue. Microbial Ecology. 2011;61(2):353-362. da Hora VP, Conceicao FR, Dellagostin OA, Doolan DL. Non-toxic derivatives of LT as potent adjuvants. Vaccine. 2011;29(8):1538-1544.
Darshan D, Frazer DM, Wilkins SJ, Anderson GJ. Severe iron deficiency blunts the response of the iron regulatory gene Hamp and proinflammatory cytokines to lipopolysaccharide. Haematologica-The Hematology Journal. 2010;95(10):1660-1667. Darshan D, Wilkins SJ, Frazer DM, Anderson GJ. Reduced expression of ferroportin-1 mediates hyporesponsiveness of suckling rats to stimuli that reduce iron absorption. Gastroenterology. 2011;141(1):300-9. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. Journal of General Virology. 2011;92:1021-1031. Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, Cooke S, Speare R, Macdonald GA, Anderson R, McCarthy JS, Loukas A, Croese J. Effect of Hookworm Infection on Wheat Challenge in Celiac Disease - A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE. 2011;6(3). Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV, Fong KM. MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma. PLoS ONE. 2010;5(9). Davidson SI, Liu Y, Danoy PA, Wu X, Thomas GP, Jiang L, Sun LY, Wang NS, Han J, Han HX, Visscher PM, Brown MA, Xu HJ. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Annals of the Rheumatic Diseases. 2011;70(2):289-292. Daxinger L, Whitelaw E. Transgenerational epigenetic inheritance: More questions than answers. Genome Research. 2010;20(12):1623-1628. de Carcer DA, Cuiv PO, Wang TT, Kang SH, Worthley D, Whitehall V, Gordon I, McSweeney C, Leggett B, Morrison M. Numerical ecology validates a biogeographical distribution and genderbased effect on mucosa-associated bacteria along the human colon. Isme Journal. 2011;5(5):801-809. Deleyrolle LP, Ericksson G, Morrison BJ, Lopez JA, Burrage K, Burrage P, Vescovi A, Rietze RL, Reynolds BA. Determination of somatic and cancer stem cell self-renewing symmetric division rate using sphere assays. PLoS ONE. 2011;6(1):e15844.
Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Bishop JAN, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, BianchiScarra G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Hoiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N. Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. Journal of the National Cancer Institute. 2010;102(20):1568-1583. Demirkan A, Amin N, Isaacs A, Jarvelin MR, Whitfield JB, Wichmann HE, Kyvik KO, Rudan I, Gieger C, Hicks AA, Johansson A, Hottenga JJ, Smith JJ, Wild SH, Pedersen NL, Willemsen G, Mangino M, Hayward C, Uitterlinden AG, Hofman A, Witteman J, Montgomery GW, Pietilainen KH, Rantanen T, Kaprio J, Doring A, Pramstaller PP, Gyllensten U, de Geus EJC, Penninx BW, Wilson JF, Rivadeneria F, Magnusson PKE, Boomsma DI, Spector T, Campbell H, Hoehne B, Martin NG, Oostra BA, McCarthy M, Peltonen-Palotie L, Aulchenko Y, Visscher PM, Ripatti S, Janssens ACJW, van Duijn CM. Genetic architecture of circulating lipid levels. European Journal of Human Genetics. 2011;19(7):813-819. Demirkan A, Penninx BWJH, Hek K, Wray NR, Amin N, Aulchenko YS, van Dyck R, de Geus EJC, Hofman A, Uitterlinden AG, Hottenga JJ, Nolen WA, Oostra BA, Sullivan PF, Willemsen G, Zitman FG, Tiemeier H, Janssens ACJW, Boomsma DI, van Duijn CM, Middeldorp CM. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Molecular Psychiatry. 2011;16(7):773-783. Demotte N, Wieers G, Van der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, Courtoy PJ, van der Bruggen P. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice. Cancer Research. 2010;70(19):7476-7488. Distel MA, Willemsen G, Ligthart L, Derom CA, Martin NG, Neale MC, Trull TJ, Boomsma DI. Genetic Covariance Structure of The Four Main Features of Borderline Personality Disorder. Journal of Personality Disorders. 2010;24(4):427–444. Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, Ocran J, Adu-Amankwah S, Geneshan H, Abot E, Legano J, Banania G, Sayo R, Brambilla D, Kumar S, Doolan DL, Rogers WO, Epstein J, Richie TL, Sedegah M. Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malaria Journal. 2011;10:168. Doecke J, Simms LA, Zhao ZZ, Huang N, Hanigan K, Croft A, Anzibdc, Hayward NK, Webb PM, Whiteman DC, Roberts RL, Andrews J, Bampton PA, Mahy G, Barclay ML, Florin TH, Lawrance IC, Gearry RB, Montgomery GW, Radford-Smith GL. Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn’s disease. Journal of Gastroenterology and Hepatology. 2010;25:A84. Doolan DL. Plasmodium immunomics. International Journal For Parasitology. 2011;41(1):43891. Douglas NC Douglas NC, Borgovan T, Carroll MJ, Siskind V, Wurm EMT, Smithers BM, Green AC, Soyer HP. Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populations. Australasian Journal of Dermatology. 2011;52:40825.
Douradinha B, Augustijn KD, Moore SG, Ramesar J, Mota MM, Waters AP, Janse CJ, Thompson J. Plasmodium Cysteine Repeat Modular Proteins 3 and 4 are essential for malaria parasite transmission from the mosquito to the host. Malaria Journal. 2011;10(71). Douradinha B, Doolan DL. Harnessing immune responses against Plasmodium for rational vaccine design. Trends in Parasitology. 2011;27(6):274-83. Drini M, Wong NC, Scott HS, Craig JM, Dobrovic A, Hewitt CA, Dow C, Young JP, Jenkins MA, Saffery R, Macrae FA. Investigating the Potential Role of Genetic and Epigenetic Variation of DNA Methyltransferase Genes in Hyperplastic Polyposis Syndrome. PLoS ONE. 2011;6(2). Duffy DL, Antill YC, Stewart CJ, Young JR, Spurdle AB. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families. Twin Research and Human Genetics. 2011;14(2):111-118. Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Hoiom V, Zhao ZZ, Sturm RA, Soranzo N, Hammond C, Kvaskoff M, Whiteman DC, Mangino M, Hansson J, Newton-Bishop JA, Bataille V, Hayward NK, Martin NG, Bishop DT, Spector TD, Montgomery GW. IRF4 Variants Have Age-Specific Effects on Nevus Count and Predispose to Melanoma. American Journal of Human Genetics. 2010;87(1):42522. Dunn LA, Burgess AG, Krauer KG, Eckmann L, Vanelle P, Crozet MD, Gillin FD, Upcroft P, Upcroft JA. A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro. International Journal of Antimicrobial Agents. 2010;36(1):37-42. Earl ST, Masci PP, de Jersey J, Lavin MF, Dixon J. Drug development from Australian elapid snake venoms and the Venomics pipeline of candidates for haemostasis: Textilinin-1 (Q8008), Haempatch™ (Q8009) and CoVase™ (V0801). Toxicon. 2010. [Published online ahead of print]. Earl STH, Robson J, Trabi M, de Jersey J, Masci PP, Lavin MF. Characterisation of a mannosebinding C-type lectin from Oxyuranus scutellatus snake venom. Biochimie. 2011;93(3):519-527. Elks CE, Perry JRB, Sulem P, Chasman DI, Franceschini N, He CY, Lunetta KL, Visser JA, Byrne EM, Cousminer DL, Gudbjartsson DF, Esko T, Feenstra B, Hottenga JJ, Koller DL, Kutalik Z, Lin P, Mangino M, Marongiu M, McArdle PF, Smith AV, Stolk L, Van Wingerden SH, Zhao JH, Albrecht E, Corre T, Ingelsson E, Hayward C, Magnusson PKE, Smith EN, Ulivi S, Warrington NM, Zgaga L, Alavere H, Amin N, Aspelund T, Bandinelli S, Barroso I, Berenson GS, Bergmann S, Blackburn H, Boerwinkle E, Buring JE, Busonero F, Campbell H, Chanock SJ, Chen W, Cornelis MC, Couper D, Coviello AD, d’Adamo P, de Faire U, de Geus EJC, Deloukas P, Doring A, Smith GD, Easton DF, Eiriksdottir G, Emilsson V, Eriksson J, Ferrucci L, Folsom AR, Foroud T, Garcia M, Gasparini P, Geller F, Gieger C, Gudnason V, Hall P, Hankinson SE, Ferreli L, Heath AC, Hernandez DG, Hofman A, Hu FB, Illig T, Jarvelin MR, Johnson AD, Karasik D, Khaw KT, Kiel DP, Kilpelainen TO, Kolcic I, Kraft P, Launer LJ, Laven JSE, Li SX, Liu JJ, Levy D, Martin NG, McArdle WL, Melbye M, Mooser V, Murray JC, Murray SS, Nalls MA, Navarro P, Nelis M, Ness AR, Northstone K, Oostra BA, Peacock M, Palmer LJ, Palotie A, Pare G, Parker AN, Pedersen NL, Peltonen L, Pennell CE, Pharoah P, Polasek O, Plump AS, Pouta A, Porcu E, Rafnar T, Rice JP, Ring SM, Rivadeneira F, Rudan I, Sala C, Salomaa V, Sanna S, Schlessinger D, Schork NJ, Scuteri
A, Segre AV, Shuldiner AR, Soranzo N, Sovio U, Srinivasan SR, Strachan DP, Tammesoo ML, Tikkanen E, Toniolo D, Tsui K, Tryggvadottir L, Tyrer J, Uda M, van Dam RM, van Meurs JBJ, Vollenweider P, Waeber G, Wareham NJ, Waterworth DM, Weedon MN, Wichmann HE, Willemsen G, Wilson JF, Wright AF, Young L, Zhai GJ, Zhuang WV, Bierut LJ, Boomsma DI, Boyd HA, Crisponi L, Demerath EW, van Duijn CM, Econs MJ, Harris TB, Hunter DJ, Loos RJF, Metspalu A, Montgomery GW, Ridker PM, Spector TD, Streeten EA, Stefansson K, Thorsteinsdottir U, Uitterlinden AG, Widen E, Murabito JM, Ong KK, Murray A. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nature Genetics. 2010;42(12):1077-U73. Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DDL, Harnett PR, Defazio A. Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS ONE. 2011;6(3). Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C, McGuffog L, Antoniou AC, StoppaLyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen XQ, Beesley J, Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A, van der Luijt RB, van Os TA, van Leeuwen FE, Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Cajal TRY, Konstantopoulou I, Benitez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomaki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK. Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 2010;19(11):2859-2868. Engwerda CR, Good MF. A novel pathway of haematopoiesis revealed after experimental malaria infection. Immunology and Cell Biology. 2010;88(7):692-694. Engwerda CR, Meeusen EN. Parasites and the immune system: a perspective from down under. Parasite Immunology. 2010;32(8):529-531. Eri RD, Adams RJ, Tran TV, Tong H, Das I, Roche DK, Oancea I, Png CW, Jeffery PL, Radford-Smith GL, Cook MC, Florin TH, McGuckin MA. An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity. Mucosal Immunology. 2011;4(3):354-64. Fahy SJ, Sun C, Zhu G, Healey PR, Spector TD, Martin NG, Mitchell P, Wong TY, Mackey DA, Hammond CJ, Andrew T. The Relationship between Retinal Arteriolar and Venular Calibers Is Genetically Mediated, and Each Is Associated with Risk of Cardiovascular Disease. Investigative Ophthalmology & Visual Science. 2011;52(2):975981. Fan J, Yin JJ, Ning B, Wu X, Hu Y, Ferrari M, Anderson GJ, Wei J, Zhao Y, Nie G. Direct evidence for catalase and peroxidase activities of ferritin-platinum nanoparticles. Biomaterials. 2011;32(6):1611-8.
Page 137
Scientific publications | continued Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes & Control. 2010;21(12):2303-2308.
Franić S, Middeldorp CM, Dolan CV, Ligthart L, Boomsma DI. Childhood and adolescent anxiety and depression: beyond heritability. Journal of the American Academy of Child & Adolescent Psychiatry. 2010;49(8):820-9.
Ferguson B, Muller HK, Handoko HY, Khosrotehrani K, Beermann F, Hacker E, Soyer HP, Bosenberg M, Walker GJ. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. Pigment Cell & Melanoma Research. 2010;23(6):771-780.
Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D’Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PCF, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D’Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nature Genetics. 2010;42(12):1118–1125.
Ferreira MA, McRae AF, Medland SE, Nyholt DR, Gordon SD, Wright MJ, Henders AK, Madden PA, Visscher PM, Wray NR, Heath AC, Montgomery GW, Duffy DL, Martin NG. Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. European Journal of Human Genetics. 2011;19(4):458-64. Ferriera I, Smyth D, Ruyssers N, Maizels RM, Loukas A, McSorley HJ. Hookworm Excretory/ Secretory products induce TH2 responses and suppress pathology in a mouse model of colitis. Immunology. 2010;131:57-58. Fletcher O, Johnson N, Silva ID, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MWR, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang XS, Fredericksen Z, Schurmann P, Waltes R, Bremer M, Dork T, Devilee P, van Asperen CJ, Tollenaar RAEM, Seynaeve C, Hall P, Czene K, Humphreys K, Liu JJ, Ahmed S, Dunning AM, Maranian M, Pharoah PDP, Chenevix-Trench G, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benitez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, Garcia-Closas M, Chanock S, Lissowska J, Brinton LA, ChangClaude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van’t Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2143-2151. Fogarty GB, Muddle R, Sprung CN, Chen W, Duffy D, Sturm RA, McKay MJ. Unexpectedly Severe Acute Radiotherapy Side Effects are Associated with Single Nucleotide Polymorphisms of the Melanocortin-1 Receptor. International Journal of Radiation Oncology Biology Physics. 2010;77(5):1486-1492. Foley DL, Morley KI, Madden PAF, Heath AC, Whitfield JB, Martin NG. Major Depression and the Metabolic Syndrome. Twin Research and Human Genetics. 2010;13(4):347-358. Fong AW, Lee GA, O’Rourke P, Thomas R. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab. Clinical and Experimental Ophthalmology. 2011;39(4):318-323. Francis SMS, Larsen JE, Pavey SJ, Duhig EE, Clarke BE, Bowman RV, Hayward NK, Fong KM, Yang IA. Genes and Gene Ontologies Common to Airflow Obstruction and Emphysema in the Lungs of Patients with COPD. PLoS ONE. 2011;6(3).
Page 138
QIMR Annual Report 2010–2011
Frazer DM, Darshan D, Anderson GJ. Intestinal iron absorption during suckling in mammals. Biometals. 2011;24(3):567-574. Frazer DM, Darshan D, Wilkins SJ, Anderson GJ. Intestinal iron absorption in the neonatal rat is refractory to systemic stimuli due to reduced ferroportin expression. Journal of Gastroenterology and Hepatology. 2010;25:A10. Freedman N, Murray LJ, Kamangar F, Abnet C, Cook MB, Nyren O, Ye W, Wu A, Bernstein L, Brown L, Ward M, Pandeya N, Green A, Casson A, Giffen C, Risch H, Gammon M, Chow WH, Vaughan T, Corley D, Whiteman DC. Alcohol intake and risk of esophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011;60:1029-1037. Freyer F, Roberts JA, Becker R, Robinson PA, Ritter P, Breakspear M. Biophysical Mechanisms of Multistability in Resting-State Cortical Rhythms. Journal of Neuroscience. 2011;31(17):6353-6361. Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandingham DL, Schnettler E, Vlak JM, Suhrbier A, Khromykh AA, Pijlman GP. Chikungunya Virus Nonstructural Protein 2 Inhibits Type I/II Interferon-Stimulated JAK-STAT Signaling. Journal of Virology. 2010;84(20):10877-10887. Gao Z, Wood-Baker R, Harle R, Muller K, Hauser J, Reid DW. “Bong lung” in cystic fibrosis: a case report. Journal of Medical Case Reports. 2010;4:371. Gardiner RA, Teng L, Buck M, Hancock J, Clarke R, Samaratunga H, Schirra HJ, Zenzmaier C, Berger P, Catto J, Yaxley J, Gianduzzo T, Coughlin G, Lavin MF. Multiple markers in prostate cancer detection from ejaculate. British Journal of Urology International. 2011;107:28-28. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A. Chikungunya Virus Arthritis in Adult Wild-Type Mice. Journal of Virology. 2010;84(16):8021-8032.
Garvey G, Cunningham J, Valery PC, Condon J, Roder D, Bailie R, Martin J, Olver I. Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priority-driven, Indigenous-led research program. Medical Journal of Australia. 2011;194(10):530-531. Garvey G, Simmonds D, Clements V, O’Rourke P, Sullivan K, Gorman D, Curnow V, Wise S, Beattie E. Making sense of dementia: understanding amongst Indigenous Australians. International Journal of Geriatric Psychiatry. 2011;26(6):649-656. Gatton ML, Cheng Q. Interrupting Malaria Transmission: Quantifying the Impact of Interventions in Regions of Low to Moderate Transmission. PLoS ONE. 2010;5(12). Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segre AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Hogervorst FBL, Rookus MA, Collee JM, Hoogerbrugge N, van Roozendaal KEP, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang XS, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Toland AE, Montagna M, D’andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen XQ, Holland H, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Hansen TVO, Nielsen FC, Greene MI, Mai PL, Osorio A, Duran M, andres R, Benitez J, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix-Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, offit K. Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics. 2010;6(10). Gaudet MM, Yang HP, Bosquet JG, Healey CS, Ahmed S, Dunning AM, Easton DF, Spurdle AB, Ferguson K, O’Mara T, Lambrechts D, Despierre E, Vergote I, Amant F, Lacey JV, Lissowska J, Peplonska B, Brinton LA, Chanock S, GarciaClosas M. No Association between FTO or HHEX and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers & Prevention. 2010;19(8):2106-2109. Gehrman PR, Byrne E, Gillespie N, Martin NG. Genetics of insomnia. Sleep Medicine Clinics. 2011;6(2):191-202. Gillespie NA, Kendler KS, Neale MC. Psychometric modeling of cannabis initiation and use and the symptoms of cannabis abuse, dependence and withdrawal in a sample of male and female twins. Drug Alcohol Depend. 2011. [Published online ahead of print]. Glanfield A, McManus DP, Smyth DJ, Lovas EM, Loukas A, Gobert GN, Jones MK. A Cytochrome b561 with Ferric Reductase Activity from the Parasitic Blood Fluke, Schistosoma japonicum. PLoS Neglected Tropical Diseases. 2010;4(11).
Gles P, Javorniczky J, Henderson S, McLennan A, Roy C, Lock J, Lynga C, Melbourne A, Gordon L. UVR Emissions from Solaria in Australia and Implications for the Regulation Process. Photochemistry and Photobiology. 2011;87(1):184-190. Gobert GN. Applications for profiling the schistosome transcriptome. Trends In Parasitology. 2010;26(9):434-439. Gobert GN. Better understanding of antischistosomal strategies through microarray analysis. Infectious Disorders - Drug Targets. 2010;10(4):251-7. Goel S, Valiyaveettil M, Achur RN, Goyal A, Mattei D, Salanti A, Trenholme KR, Gardiner DL, Gowda DC. Dual stage synthesis and crucial role of cytoadherence-linked asexual gene 9 in the surface expression of malaria parasite var proteins. PNAS. 2010;107(38):16643-16648. González LM, Ramiro R, García L, Parkhouse RM, McManus DP, Gárate T. Genetic variability of the 18 kDa/HP6 protective antigen in Taenia saginata and Taenia asiatica: implications for vaccine development. Molecular and Biochemical Parasitology. 2011;176(2):131-134. Good MF, Doolan DL. Malaria Vaccine Design: Immunological Considerations. Immunity. 2010;33(4):555-566. Good MF, Engwerda C. Defying malaria: Arming T cells to halt malaria. Nature Medicine. 2011;17(1):49-51. Goode EL Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut JM, Berchuck A, Larson MC, Fridley BL, Olson JE, Webb PM, Chen XQ, Beesley J, ChenevixTrench G, Sellers TA. Xenobiotic-Metabolizing Gene Polymorphisms and Ovarian Cancer Risk. Molecular Carcinogenesis. 2011;50(5):397-402. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, GarciaClosas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, ChangClaude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, GentryMaharaj A, Menon U, Wu AH, Stram DO, Pike MC; Wellcome Trust Case-Control Consortium, Beesley J, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics. 2010;42(10):874-879.
Gordon CA, Gray DJ, Gobert GN, McManus DP. DNA amplification approaches for the diagnosis of key parasitic helminth infections of humans. Molecular & Cellular Probes. 2011;25(4):143-52. Gordon LG, Beesley VL, Scuffham PA. Evidence on the economic value of psychosocial interventions to alleviate anxiety and depression among cancer survivors: A systematic review. Asia-Pacific Journal of Clinical Oncology. 2011;7(2):96-105. Gordon LG, Hirst NG, Young RP, Brown PM. Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?. Cost Effective Resource Allocation. 2010. [Published online ahead of print]. Gordon LG, Scuffham PA, Beesley VL, Green AC, DeFazio A, Wyld DK, Clavarino AM, Webb PM. Medical Costs and Outcomes for Australian Women With Ovarian Cancer A Patient-Level Analysis Over 2.5 Years. International Journal of Gynecological Cancer. 2010;20(5):757-765.
Green AC, Williams GM. Increased Melanoma After Regular Sunscreen Use? Reply. Journal of Clinical Oncology. 2011;29(18):E559. Green AC, Williams GM. Is Sunscreen Use for Melanoma Prevention Valid for All Sun Exposure Circumstances? Reply. Journal of Clinical Oncology. 2011;29(14):E427. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P, Marlton P, Griffiths LR. Integrative Genomic Profiling Reveals Conserved Genetic Mechanisms for Tumorigenesis in Common Entities of Non-Hodgkin’s Lymphoma. Genes Chromosomes & Cancer. 2011;50(5):313-326. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science. 2010;330(6003):517-521. Hacker E Hacker E, Boyce Z, Kimlin M, Hayward N, Whiteman D. The response of melanocytes to sunlight. Australasian Journal of Dermatology. 2011;52:19.
Goumidi L, Flamant F, Lendon C, Galimberti D, Pasquier F, Scarpini E, Hannequin D, Campion D, Amouyel P, Lambert JC, Meirhaeghe A. Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer’s disease. Neurobiology of Aging. 2011;32(4):624-630.
Haque A, Best SE, Amante FH, Ammerdorffer A, de Labastida F, Pereira T, Ramm GA, Engwerda CR. High Parasite Burdens Cause Liver Damage in Mice following Plasmodium berghei ANKA Infection Independently of CD8(+) T Cell-Mediated Immune Pathology. Infection and Immunity. 2011;79(5):1882-1888.
Gras S, Chen ZJ, Miles JJ, Liu YC, Bell MJ, Sullivan LC, Kjer-Nielsen L, Brennan RM, Burrows JM, Neller MA, Khanna R, Purcell AW, Brooks AG, McCluskey J, Rossjohn J, Burrows SR. Allelic polymorphism in the T cell receptor and its impact on immune responses. Journal of Experimental Medicine. 2010;207(7):1555-1567.
Haque A, Best SE, Amante FH, Mustafah S, Desbarrieres L, de Labastida F, Sparwasser T, Hill GR, Engwerda CR. CD4(+) Natural Regulatory T Cells Prevent Experimental Cerebral Malaria via CTLA-4 When Expanded In Vivo. PLoS Pathogens. 2010;6(12).
Gratten J, Wilson AJ, Mcrae AF, Beraldi D, Visscher PM, Pemberton JM, Slate J. No evidence for warming climate theory of coat colour change in Soay sheep: a comment on Maloney et al. Biology Letters. 2010;6(5):678-679. Gray DJ, McManus DP, Li YS, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infectious Diseases. 2010;10(10):733-736. Gray DJ, McManus DP, Li YS, Williams GM, Bergquist R, Ross AG. Untitled reply. Lancet Infectious Diseases. 2011;11(5):346-347. Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. British Medical Journal. 2011;342. Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, Haile R, Hopper J, Jenkins M, Young J, Buchanan D, Gallinger S, Adams M, Lewis S, Willis J, Elston R, Markowitz SD, Wiesner GL. Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22. Cancer Research. 2010;70(13):5409-5418. Greco SA, Chia J, Inglis KJ, Cozzi SJ, Ramsnes I, Buttenshaw RL, Spring KJ, Boyle GM, Worthley DL, Leggett BA, Whitehall VL. Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that exhibits age-related methylation. BMC Cancer. 2010;10. Green AC, Hughes MCB, McBride P, Fourtanier A. Factors Associated with Premature Skin Aging (Photoaging) before the Age of 55: A PopulationBased Study. Dermatology. 2011;222(1):74-80. Green AC, Williams GM, Logan V, Strutton GM. Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up. Journal of Clinical Oncology. 2011;29(3):257-263.
Haque A, Best SE, Ammerdorffer A, Desbarrieres L, de Oca MM, Amante FH, de Labastida Rivera F, Hertzog P, Boyle GM, Hill GR, Engwerda CR. Type I Interferons suppress CD4+ T cell-dependent parasite control during blood-stage Plasmodium infection. European Journal of Immunology. 2011. [Published online ahead of print]. Haque A, Best SE, Ammerdorffer A, Desbarrieres L, de Oca MM, Amante FH, de Labastida Rivera F, Hertzog P, Boyle GM, Hill GR, Engwerda CR. Type I interferons suppress CD4+ T cell-dependent parasite control during blood-stage plasmodium infection. European Journal of Immunology. 2011. [Published online ahead of print]. Haque A, Best SE, Unosson K, Amante FH, de Labastida F, Anstey NM, Karupiah G, Smyth MJ, Heath WR, Engwerda CR. Granzyme B Expression by CD8(+) T Cells Is Required for the Development of Experimental Cerebral Malaria. Journal of Immunology. 2011;186(11):6148-6156. Haque A, Engwerda CR. An Antioxidant Link between Sickle Cell Disease and Severe Malaria. Cell. 2011;145(3):335-336. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malaria Journal. 2010;9. Harris JL, Khanna KK. BRCA1 A-Complex fine tunes repair functions of BRCA1. Aging-Us. 2011;3(5):461-463. Hatemi PK, Hibbing JR, Medland SE, Keller MC, Alford JR, Smith KB, Martin NG, Eaves LJ. Not by Twins Alone: Using the Extended Twin Family Designed to Investigate the Genetic Basis of Political Beliefs. American Journal of Political Science. 2010;54(3):798-814.
Page 139
Scientific publications | continued Haworth CMA, Wright MJ, Luciano M, Martin NG, de Geus EJC, van Beijsterveldt CEM, Bartels M, Posthuma D, Boomsma DI, Davis OSP, Kovas Y, Corley RP, DeFries JC, Hewitt JK, Olson RK, Rhea SA, Wadsworth SJ, Iacono WG, McGue M, Thompson LA, Hart SA, Petrill SA, Lubinski D, Plomin R. The heritability of general cognitive ability increases linearly from childhood to young adulthood. Molecular Psychiatry. 2010;15(11):1112-1120. Heath AC, Whitfield JB, Martin NG, Pergadia ML, Goate AM, Lind PA, McEvoy BP, Schrage AJ, Grant JD, Chou YL, Zhu R, Henders AK, Medland SE, Gordon SD, Nelson EC, Agrawal A, Nyholt DR, Bucholz KK, Madden PA, Montgomery GW.. A Quantitative-Trait GenomeWide Association Study of Alcoholism Risk in the Community: Findings and Implications. Biological Psychiatry. 2011. [Published online ahead of print]. Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, Thorleifsson G, Zillikens MC, Speliotes EK, Magi R, Workalemahu T, White CC, Bouatia-Naji N, Harris TB, Berndt SI, Ingelsson E, Willer CJ, Weedon MN, Luan JA, Vedantam S, Esko T, Kilpelainen TO, Kutalik Z, Li SX, Monda KL, Dixon AL, Holmes CC, Kaplan LM, Liang LM, Min JL, Moffatt MF, Molony C, Nicholson G, Schadt EE, Zondervan KT, Feitosa MF, Ferreira T, Allen HL, Weyant RJ, Wheeler E, Wood AR, Estrada K, Goddard ME, Lettre G, Mangino M, Nyholt DR, Purcell S, Smith AV, Visscher PM, Yang JA, McCarroll SA, Nemesh J, Voight BF, Absher D, Amin N, Aspelund T, Coin L, Glazer NL, Hayward C, Heard-Costa NL, Hottenga JJ, Johansson A, Johnson T, Kaakinen M, Kapur K, Ketkar S, Knowles JW, Kraft P, Kraja AT, Lamina C, Leitzmann MF, McKnight B, Morris AP, Ong KK, Perry JRB, Peters MJ, Polasek O, Prokopenko I, Rayner NW, Ripatti S, Rivadeneira F, Robertson NR, Sanna S, Sovio U, Surakka I, Teumer A, van Wingerden S, Vitart V, Zhao JH, Cavalcanti-Proenca C, Chines PS, Fisher E, Kulzer JR, Lecoeur C, Narisu N, Sandholt C, Scott LJ, Silander K, Stark K, Tammesoo ML, Teslovich TM, Timpson NJ, Watanabe RM, Welch R, Chasman DI, Cooper MN, Jansson JO, Kettunen J, Lawrence RW, Pellikka N, Perola M, Vandenput L, Alavere H, Almgren P, Atwood LD, Bennett AJ, Biffar R, Bonnycastle LL, Bornstein SR, Buchanan TA, Campbell H, Day INM, Dei M, Dorr M, Elliott P, Erdos MR, Eriksson JG, Freimer NB, Fu M, Gaget S, Geus EJC, Gjesing AP, Grallert H, Grassler J, Groves CJ, Guiducci C, Hartikainen AL, Hassanali N, Havulinna AS, Herzig KH, Hicks AA, Hui JN, Igl W, Jousilahti P, Jula A, Kajantie E, Kinnunen L, Kolcic I, Koskinen S, Kovacs P, Kroemer HK, Krzelj V, Kuusisto J, Kvaloy K, Laitinen J, Lantieri O, Lathrop GM, Lokki ML, Luben RN, Ludwig B, McArdle WL, McCarthy A, Morken MA, Nelis M, Neville MJ, Pare G, Parker AN, Peden JF, Pichler I, Pietilainen KH, Platou CGP, Pouta A, Ridderstrale M, Samani NJ, Saramies J, Sinisalo J, Smit JH, Strawbridge RJ, Stringham HM, Swift AJ, Teder-Laving M, Thomson B, Usala G, van Meurs JBJ, van Ommen GJ, Vatin V, Volpato CB, Wallaschofski H, Walters GB, Widen E, Wild SH, Willemsen G, Witte DR, Zgaga L, Zitting P, Beilby JP, James AL, Kahonen M, Lehtimaki T, Nieminen MS, Ohlsson C, Palmer LJ, Raitakari O, Ridker PM, Stumvoll M, Tonjes A, Viikari J, Balkau B, BenShlomo Y, Bergman RN, Boeing H, Smith GD, Ebrahim S, Froguel P, Hansen T, Hengstenberg C, Hveem K, Isomaa B, Jorgensen T, Karpe F, Khaw KT, Laakso M, Lawlor DA, Marre M, Meitinger T, Metspalu A, Midthjell K, Pedersen O, Salomaa V, Schwarz PEH, Tuomi
Page 140
QIMR Annual Report 2010–2011
T, Tuomilehto J, Valle TT, Wareham NJ, Arnold AM, Beckmann JS, Bergmann S, Boerwinkle E, Boomsma DI, Caulfield MJ, Collins FS, Eiriksdottir G, Gudnason V, Gyllensten U, Hamsten A, Hattersley AT, Hofman A, Hu FB, Illig T, Iribarren C, Jarvelin MR, Kao WHL, Kaprio J, Launer LJ, Munroe PB, Oostra B, Penninx BW, Pramstaller PP, Psaty BM, Quertermous T, Rissanen A, Rudan I, Shuldiner AR, Soranzo N, Spector TD, Syvanen AC, Uda M, Uitterlinden A, Volzke H, Vollenweider P, Wilson JF, Witteman JC, Wright AF, Abecasis GR, Boehnke M, Borecki IB, Deloukas P, Frayling TM, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, North KE, O’Connell JR, Peltonen L, Schlessinger D, Strachan DP, Hirschhorn JN, Assimes TL, Wichmann HE, Thorsteinsdottir U, van Duijn CM, Stefansson K, Cupples LA, Loos RJF, Barroso I, McCarthy MI, Fox CS, Mohlke KL, Lindgren CM. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nature Genetics. 2010;42(11):949-U160. Helander A, Wielders JPM, Jeppsson JO, Weykamp C, Siebelder C, Anton RF, Schellenberg F, Whitfield JB. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. Performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material. Clinical Chemistry and Laboratory Medicine. 2010;48(11):1585-1592. Hill G. Cytokine Use In Transplantation. Experimental Hematology. 2010;38(9):S121-S122. Hill GR, Kuns RD, Raffelt NC, Don ALJ, Olver SD, Markey KA, Wilson YA, Tocker J, Alexander WS, Clouston AD, Roberts AW, MacDonald KPA. SOCS3 regulates graft-versus-host disease. Blood. 2010;116(2):287-296. Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, Markey KA, Wilson YA, Smyth MJ, Iwakura Y, Tocker J, Clouston AD, MacDonald KPA. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116(5):819-828. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C. A Cytoplasmic ATMTRAF6-cIAP1 Module Links Nuclear DNA Damage Signaling to Ubiquitin-Mediated NF-kappa B Activation. Molecular Cell. 2010;40(1):63-74. Hirst NG, Gordon LG, Whiteman DC, Watson DI, Barendregt JJ. Is endoscopic surveillance for non-dysplastic Barrett’s esophagus costeffective? Review of economic evaluations. Journal of Gastroenterology and Hepatology. 2011;26(2):247-254. Hochberg Z, Feil R, Constancia M, Fraga M, Junien C, Carel JC, Boileau P, Le Bouc Y, Deal CL, Lillycrop K, Scharfmann R, Sheppard A, Skinner M, Szyf M, Waterland RA, Waxman DJ, Whitelaw E, Ong K, Albertsson-Wikland K. Child Health, Developmental Plasticity, and Epigenetic Programming. Endocrine Reviews. 2011;32(2):159-224. Hofmann A, Osman A, Leow CY, Driguez P, McManus DP, Jones MK. Parasite annexins New molecules with potential for drug and vaccine development. Bioessays. 2010;32(11):967-976. Holt DC, McCarthy JS, Carapetis JR. Parasitic diseases of remote Indigenous communities in Australia. International Journal For Parasitology. 2010;40(10):1119-1126.
Holter S, Pollett A, Zogopoulos G, Kim H, Schwenter F, Asai K, Gallinger S, Clendenning M, Steinbach G, Jacobson A, Boycott KM. Hepatic Adenomas Caused by Somatic HNF1A Mutations in Children With Biallelic Mismatch Repair Gene Mutations. Gastroenterology. 2011;140(2):735-736. Hong YS, Kang SK, Han MJ, Gobert GN, Jones MK. High quality RNA isolation from Aedes aegypti midguts using laser microdissection microscopy. Parasites & Vectors. 2011;4. Hopkins H, Oyibo W, Luchavez J, Mationg ML, Asiimwe C, Albertini A, Gonzalez IJ, Gatton ML, Bell D. Blood transfer devices for malaria rapid diagnostic tests: evaluation of accuracy, safety and ease of use. Malaria Journal. 2011;10. Horn DI, Lord AR, Osoba A, Metzger CD, Kaufmann J, Schiltz K, Steiner J, Bogerts B, Walter M, Breakspear M. Cingulate MR Spectroscopy is Related to Abnormal Graph Metrics in the Salience Network of Depressive Patients. Biological Psychiatry. 2011;69(9):165S-166S. Hou XY, Ellis MK, McManus DP, Wang YY, Li SD, Williams GM, Li YS. Diagnostic value of noninvasive bio-markers for stage-specific diagnosis of hepatic fibrosis in patients with advanced schistosomiasis japonica. International Journal For Parasitology. 2011;41(3-4):325-332. Hu W, Clements A, Williams G, Tong S. Spatial analysis of notified dengue fever infections. Epidemiology and Infection. 2011;139(3):391-399. Hu WB, Clements A, Williams G, Tone SL. Socioecological Changes and Dengue Fever Transmission in Queensland, Australia: A Spatial Bayesian Approach. Epidemiology. 2011;22(1):S138-S138. Hughes AM, Lucas RM, Ponsonby AL, Chapman C, Coulthard A, Dear K, Dwyer T, Kilpatrick TJ, McMichael AJ, Pender MP, Taylor BV, Valery P, van der Mei IAF, Williams D. The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatric Allergy and Immunology. 2011;22(3):327-333. Hugo LE, Kay BH, O’Neill SL, Ryan PA. Investigation of Environmental Influences on a Transcriptional Assay for the Prediction of Age of Aedes aegypti (Diptera: Culicidae) Mosquitoes. Journal of Medical Entomology. 2010;47(6):1044-1052. Hutley LJ, Newell FS, Kim YH, Luo X, Widberg CH, Shurety W, Prins JB, Whitehead JP. A putative role for endogenous FGF-2 in FGF-1 mediated differentiation of human preadipocytes. Molecular Cell Endocrinology. 2011;339(12):165-71. Hysi PG, Young TL, Mackey DA, andrew T, Fernandez-Medarde A, Solouki AM, Hewitt AW, Macgregor S, Vingerling JR, Li YJ, Ikram MK, Fai LY, Sham PC, Manyes L, Porteros A, Lopes MC, Carbonaro F, Fahy SJ, Martin NG, van Duijn CM, Spector TD, Rahi JS, Santos E, Klaver CCW, Hammond CJ. A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25. Nature Genetics. 2010;42(10):902. Ibiebele TI, Hughes MC, Pandeya N, Zhao Z, Montgomery G, Hayward N, Green AC, Whiteman DC, Webb PM. High Intake of Folate from Food Sources Is Associated with Reduced Risk of Esophageal Cancer in an Australian Population. Journal of Nutrition. 2011;141(2):274-283.
Ibiebele TI, Taylor AR, Whiteman DC, van der Pols JC. Eating habits and risk of esophageal cancers: a population-based case-control study. Cancer Causes & Control. 2010;21(9):1475-1484. Ider BE, Clements A, Adams J, Whitby M, Muugolog T. Organisation of hospital infection control in Mongolia. Journal of Hospital Infection. 2010;75(3):209-213. Ider BE, Clements A, Adams J, Whitby M, Muugolog T. Prevalence of hospital-acquired infections and antibiotic use in two tertiary Mongolian hospitals. Journal of Hospital Infection. 2010;75(3):214-219. Ikram MK, Xueling S, Jensen RA, Cotch MF, Hewitt AW, Ikram MA, Wang JJ, Klein R, Klein BEK, Breteler MMB, Cheung N, Liew G, Mitchell P, Uitterlinden AG, Rivadeneira F, Hofman A, de Jong PTVM, van Duijn CM, Kao L, Cheng CY, Smith AV, Glazer NL, Lumley T, McKnight B, Psaty BM, Jonasson F, Eiriksdottir G, Aspelund T, Harris TB, Launer LJ, Taylor KD, Li XH, Iyengar SK, Xi QS, Sivakumaran TA, Mackey DA, MacGregor S, Martin NG, Young TL, Bis JC, Wiggins KL, Heckbert SR, Hammond CJ, andrew T, Fahy S, Attia J, Holliday EG, Scott RJ, Islam FMA, Rotter JI, McAuley AK, Boerwinkle E, Tai ES, Gudnason V, Siscovick DS, Vingerling JR, Wong TY. Four Novel Loci (19q13, 6q24, 12q24, and 5q14) Influence the Microcirculation In Vivo. PLoS Genetics. 2010;6(10). Ishii T, Notohara K, Umapathy A, Mallitt KA, Chikuba H, Moritani Y, Tanaka N, Rosty C, Matsubara N, Jass J, Leggett B, Whitehall V. Tubular Adenomas With Minor Villous Changes Show Molecular Features Characteristic of Tubulovillous Adenomas. American Journal of Surgical Pathology. 2011;35(2):212-220. Jabbar A, Crawford S, Mlocicki D, Swiderski ZP, Conn DB, Jones MK, Beveridge I, Lightowlers MW. Ultrastructural reconstruction of Taenia ovis oncospheres from serial sections. International Journal For Parasitology. 2010;40(12):1419-1431. Jaenicke S, ander C, Bekel T, Bisdorf R, Droge M, Gartemann KH, Junemann S, Kaiser O, Krause L, Tille F, Zakrzewski M, Puhler A, Schluter A, Goesmann A. Comparative and Joint Analysis of Two Metagenomic Datasets from a Biogas Fermenter Obtained by 454-Pyrosequencing. PLoS ONE. 2011;6(1). Jahanshad N, Lee AD, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Toga AW, Thompson PM. Genetic influences on brain asymmetry: A DTI study of 374 twins and siblings. Neuroimage. 2010;52(2):455-469. Janda M, Neale RE, Youl P, Whiteman DC, Gordon L, Baade PD. Impact of a Video-Based Intervention to Improve the Prevalence of Skin Self-examination in Men 50 Years or Older: The Randomized Skin Awareness Trial. Archives of Dermatology. 2011;147(7):799-806. Jirsa VK, Sporns O, Breakspear M, Deco G, McIntosh AR. Towards the virtual brain: network modeling of the intact and the damaged brain. Archives Italiennes de Biologie. 2011;148(3):189-205. Johnatty SE, Beesley J, Chen XQ, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM, Rossing MA, Doherty JA, Goodman MT, Lurie G, Thompson PJ, Wilkens LR, Ness RB, Moysich KB, Chang-Claude J, Wang-Gohrke S, Cramer DW, Terry KL, Hankinson SE, Tworoger SS, Garcia-Closas M, Yang H, Lissowska J, Chanock SJ, Pharoah PD, Song HL, Whitemore AS, Pearce CL, Stram DO, Wu AH, Pike MC, Gayther SA, Ramus SJ, Menon U, GentryMaharaj A, Anton-Culver H, Ziogas A, Hogdall E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut
JM, Iversen ES, Moorman PG, Phelan CM, Sellers TA, Cunningham JM, Vierkant RA, Rider DN, Goode EL, Haviv I, Chenevix-Trench G. Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility “Hot-Spot’’. PLoS Genetics. 2010;6(7). Johnson J, Healey S, Khanna KK, kConFab, Chenevix-Trench G. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. Breast Cancer Research and Treatment. 2011;129(1):255-63. Jones K, Nourse JP, Morrison L, NguyenVan D, Moss DJ, Burrows SR, Gandhi MK. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood. 2010;116(13):2245-2252. Jones MK, Keiser J, McManus DP. Trematodes. Manual of Clinical Microbiology 10th edition. 2011;Chapter 144(2230-2242):ASM Press, Washington. Jordan SJ, Coory MD, Webb PM. Re: Predictive Value of Symptoms for Early Detection of Ovarian Cancer. Journal of the National Cancer Institute. 2010;102(20):1599-1601. Jordan SJ, Francis JE, Nelson AE, Zorbas HM, Luxford KA, Webb PM. Pathways to the diagnosis of epithelial ovarian cancer in Australia. Medical Journal of Australia. 2010;193(6):326-330. Joshi AA, Lepore N, Joshi SH, Lee AD, Barysheva M, Stein JL, McMahon KL, Johnson K, de Zubicaray GI, Martin NG, Wright MJ, Toga AW, Thompson PM. The contribution of genes to cortical thickness and volume. Neuroreport. 2011;22(3):101-105. Jurado S, Smyth I, van Denderen B, Tenis N, Hammet A, Hewitt K, Ng JL, McNees CJ, Kozlov SV, Oka H, Kobayashi M, Conlan LA, Cole TJ, Yamamoto K, Taniguchi Y, Takeda S, Lavin MF, Heierhorst J. Dual Functions of ASCIZ in the DNA Base Damage Response and Pulmonary Organogenesis. PLoS Genetics. 2010;6(10). Kaminen-Ahola N, Ahola A, Flatscher-Bader T, Wilkins SJ, Anderson GJ, Whitelaw E, Chong SY. Postnatal Growth Restriction and Gene Expression Changes in a Mouse Model of Fetal Alcohol Syndrome. Birth Defects Research Part A-Clinical and Molecular Teratology. 2010;88(10):818-826. Kane-Maguire NL, Cozzi SJ, Boyle GM, Steadman R, Thomas DW, Ogbourne SM, Moseley R. Modulation of fibroblast phenotype and extracellular matrix composition by 3-ingeyl angelate induces improved dermal cosmesis. Wound Repair and Regeneration. 2010;18(6):A85-A85. Karagas MR, Waterboer T, Li ZZ, Nelson HH, Michael KM, Bavinck JNB, Perry AE, Spencer SK, Daling J, Green AC, Pawlita M. Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. British Medical Journal. 2010;341. Kaufman B, Laitman Y, Ziv E, Hamann U, Torres D, Lahad EL, Beeri R, Renbaum P, Jakubowska A, Lubinski J, Huzarski T, Toloczko-Grabarek A, Jaworska K, Durda K, Sprudle AB, ChenevixTrench G, Simard J, Easton DF, Antonis A, Szabo C, Friedman E. The CYP17A1-34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 2011;126(2):521-527. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Kobel M, Anton-Culver H, Beesley J, Berchuck A, Brar S, Carney ME,
Chang-Claude J, Chenevix-Trench G, Cramer DW, Cunningham JM, DiCioccio RA, Doherty JA, Easton DF, Fredericksen ZS, Fridley BL, Gates MA, Gayther SA, Gentry-Maharaj A, Hogdall E, Kjaer SK, Lurie G, Menon U, Moorman PG, Moysich K, Ness RB, Palmieri RT, Pearce CL, Pharoah PDP, Ramus SJ, Song HL, Stram DO, Tworoger SS, Van Den Berg D, Vierkant RA, Wang-Gohrke S, Whittemore AS, Wilkens LR, Wu AH, Schildkraut JM, Sellers TA, Goode EL. Genetic Variation in TYMS in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention. 2010;19(7):1822-1830. Kendall BJ, Macdonald GA, Hayward NK, Prins JB, O’Brien S, Whiteman DC. Daytime sleepiness, gastro-oesophageal reflux and Barrett’s oesophagus: a case-control study. Journal of Gastroenterology and Hepatology. 2010;25:A41-A41. Kendall BJ, Macdonald GA, Hayward NK, Prins JB, O’Brien S, Whiteman DC. Metabolic syndrome and the risk of Barrett’s oesophagus. Journal of Gastroenterology and Hepatology. 2010;25:A78. Khanna R, Burrows SR. Human immunology: a case for the ascent of non-furry immunology. Immunology and Cell Biology. 2011;89(3):330-331. Kim TS, Kawaguchi M, Suzuki M, Jung CG, Asai K, Shibamoto Y, Lavin MF, Khanna KK, Miura Y. The ZFHX3 (ATBF1) transcription factor induces PDGFRB, which activates ATM in the cytoplasm to protect cerebellar neurons from oxidative stress. Disease Models & Mechanisms. 2010;3(1112):752-762. Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: developments over the past 10 years. Expert Reviews of Vaccines. 2011;10(6):853-873. Knox TB, Nguyen YT, Vu NS, Kay BH, Ryan PA. Quantitative Relationships Between Immature and Emergent Adult Aedes aegypti (Diptera: Culicidae) Populations in Water Storage Container Habitats. Journal of Medical Entomology. 2010;47(5):748-758. Kochan NA, Breakspear M, Slavin MJ, Valenzuela M, McCraw S, Brodaty H, Sachdev PS. Functional alterations in brain activation and deactivation in mild cognitive impairment in response to a graded working memory challenge. Dementia and Geriatric Cognitive Disorders. 2011;30(6):553–568. Kochan NA, Breakspear M, Valenzuela M, Slavin MJ, Brodaty H, Wen W, Trollor JN, Turner A, Crawford JD, Sachdev PS. Cortical Responses to a Graded Working Memory Challenge Predict Functional Decline in Mild Cognitive Impairment. Biological Psychiatry. 2011;70(2):123-130. Kohonen-Corish MRJ, Macrae F, Genuardi M, Aretz S, Bapat B, Bernstein IT, Burn J, Cotton RGH, den Dunnen JT, Frebourg T, Greenblatt MS, Hofstra R, Holinski-Feder E, Lappalainen I, Lindblom A, Maglott D, Moller P, Morreau H, Moslein G, Sijmons R, Spurdle AB, Tavtigian S, Tops CMJ, Weber TK, de Wind N, Woods MO. Deciphering the Colon Cancer GenesReport of the InSiGHT-Human Variome Project Workshop, UNESCO, Paris 2010. Human Mutation. 2011;32(4):491-494. Kondalsamy-Chennakesavan S, Gordon LG, Sanday K, Bouman C, De Jong S, Nicklin J, Land R, Obermair A. Hospital costs associated with adverse events in gynecological oncology. Gynecologic Oncology. 2011;121(1):70-75.
Page 141
Scientific publications | continued Kote-Jarai Z, Al Olama AA, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PDP, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O’Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Human Genetics. 2011;129(6):687-694. Kovac S, Anderson GJ, Alexander WS, Shulkes A, Baldwin GS. Gastrin-Deficient Mice Have Disturbed Hematopoiesis in Response to Iron Deficiency. Endocrinology. 2011;152(8):3062-3073. Kovac S, Anderson GJ, Baldwin GS. Gastrins, iron homeostasis and colorectal cancer. Biochimica Et Biophysica Acta-Molecular Cell Research. 2011;1813(5):889-895. Koyama M, Kuns R, Olver S, Wilson Y, Don A, Raffelt N, Varelias A, Robb RJ, Markey K, Hill G, MacDonald K. The presentation of an exogenous minor HA by host but not donor APC initiates GvHD; however, dendritic cells are redundant. Bone Marrow Transplantation. 2011;46:S241. Kozlov SV, Graham ME, Jakob B, Tobias F, Kijas AW, Tanuji M, Chen PL, Robinson PJ, Taucher-Scholz G, Suzuki K, So SR, Chen DV, Lavin MF. Autophosphorylation and ATM Activation ADDITIONAL SITES ADD TO THE COMPLEXITY. Journal of Biological Chemistry. 2011;286(11):9107-9119. Krishnaprasad K, andrews J, Grafton R, Lawrance I, Florin T, Leong R, Mahy G, Cooke S, Croft A, Prosser R, Leach P, Edwards S, Chitti L, Cock C, Bampton P, Gearry R, Doecke J, Radford-Smith G. Inter-observer agreement for Crohn’s disease sub-phenotypes using the Montreal classification: how good are we? A multi-centre Australasian study. Journal of Gastroenterology and Hepatology. 2010;25:A98. Kuwahata M, Wijesinghe R, Ho MF, Pelecanos A, Bobogare A, Landry L, Bugora H, Vallely A, McCarthy J. Population screening for glucose-6phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. Malaria Journal. 2010;9. Lang JM, Shennan M, Njauw JCN, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, Puig S, Gruis NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, Hogg D, Tsao H. A Flexible Multiplex Bead-Based Assay for Detecting Germline CDKN2A and CDK4 Variants in Melanoma-Prone Kindreds. Journal of Investigative Dermatology. 2011;131(2):480-486. Langdon AJ, Boonstra TW, Breakspear M. Multifrequency phase locking in human somatosensory cortex. Progress In Biophysics & Molecular Biology. 2011;105(1-2):58-66. Lavin MF, Clarke RA, Teng L, Fang Z, Samaratunga H, Gardiner RA. Relationship between the TMPRSS2-ERG gene fusion and prostate cancer metastases. BJU International. 2011;107:15. Lawrance IC, Radford-Smith GL, Bampton PA, andrews JM, Tan PK, Croft A, Gearry RB, Florin THJ. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience. Journal of Gastroenterology and Hepatology. 2010;25(11):1732-1738.
Page 142
QIMR Annual Report 2010–2011
Le AT, Miller PW, Slutske WS, Martin NG. Are Attitudes Towards Economic Risk Heritable? Analyses Using the Australian Twin Study of Gambling. Twin Research and Human Genetics. 2010;13(4):330-339. Lee SH, Nyholt DR, Macgregor S, Henders AK, Zondervan KT, Montgomery GW, Visscher PM. A Simple and Fast Two-Locus Quality Control Test to Detect False Positives Due to Batch Effects in Genome-Wide Association Studies. Genetic Epidemiology. 2010;34(8):854-862. Lee SH, van der Werf JHJ, Lee SH, Park EW, Oh SJ, Gibson JP, Thompson JM. Genetic polymorphisms of the bovine Fatty acid binding protein 4 gene are significantly associated with marbling and carcass weight in Hanwoo (Korean Cattle). Animal Genetics. 2010;41(4):442-444.
Resistance to Type I Interferon. Journal of Virology. 2011;85(11):5651-5663. Ligthart L, Nyholt DR, Penninx BWJH, Boomsma DI. Shared genetic factors influencing migraine and anxious depression. Behavior Genetics. 2010;40(6):803-803. Ligthart L, Nyholt DR, Penninx BWJH, Boomsma DI. The Shared Genetics of Migraine and Anxious Depression. Headache. 2010;50(10):1549-1560. Ligthart L, Penninx BWJH, Nyholt DR, Distel MA, de Geus EJC, Willemsen G, Smit JH, Boomsma DI. Migraine symptomatology and major depressive disorder. Cephalalgia. 2010;30(9):10731081.
Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating Missing Heritability for Disease from Genome-wide Association Studies. American Journal of Human Genetics. 2011;88(3):294-305.
Lin D, Tian F, Wu H, Gao Y, Wu J, Zhang D, Ji M, McManus DP, Driguez HP, Wu G. Multiple vaccinations with UV-attenuated cercariae in pig enhance protective immunity against Schistosoma japonicum infection as compared to single vaccination. Parasites & Vectors. 2011;4(103).
Levinson DF, Duan JB, Oh S, Wang K, Sanders AR, Shi JX, Zhang N, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman R, Dudbridge F, Pe’er I, Hakonarson H, Bergen SE, Fanous AH, Holmans PA, Gejman PV. Copy Number Variants in Schizophrenia: Confirmation of Five Previous Findings and New Evidence for 3q29 Microdeletions and VIPR2 Duplications. American Journal of Psychiatry. 2011;168(3):302-316.
Lindor NM, Rabe KG, Petersen GM, Chen H, Bapat B, Hopper J, Young J, Jenkins M, Potter J, Newcomb P, Templeton A, LeMarchand L, Grove J, Burgio MR, Haile R, Green J, Woods MO, Seminara D, Limburg PJ, Thibodeau SN. Parent of origin effects on age at colorectal cancer diagnosis. International Journal of Cancer. 2010;127(2):361-366.
Lewindon PJ, Ramm GA. Cystic fibrosis cirrhosis, portal hypertension and liver biopsy. Hepatology. 2011;53(3):1065-1066. Lewindon PJ, Ramm GA. Reply: The Utility of Noninvasive Imaging in Cystic Fibrosis Liver Disease. Hepatology. 2011;53(5):1780-1781. Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, Frawley K, Bell SC, Smith JL, Ramm GA. Importance of liver fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology. 2011;53(1):193-201. Li Y, Ross AG, Hou X, Lou Z, McManus DP. Oriental schistosomiasis with neurological complications. Annals of Clinical Microbiology and Antimicrobials. 2011;10(5):. Li YS, Chen DL, Ross AG, Burke ML, Yu XL, Li RS, Zhou J, McManus DP. Severe hepatosplenic schistosomiasis: clinicopathologic study of 102 cases undergoing splenectomy. Human Pathology. 2011;42(1):111-119. Liberton DK, Claes P, Mcevoy B, Beleza S, Barsh G, Tang H, Absher D, Shriver MD. Using automated high density quasi-landmarks to test for associations between normal facial feature variation, genetic ancestry and candidate gene variation in Cape Verdeans. American Journal of Physical Anthropology. 2011;144:198-198. Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, Griffin M, Milne R, McCarron J, Yeadon T, Wilks A, Cubitt A, Wyld DK, Vasey PA. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer. 2010;103(5):597-606. Lidbury BA, Rulli NE, Musso CM, Cossetto SB, Zaid A, Suhrbier A, Rothenfluh HS, Rolph MS, Mahalingam S. Identification and Characterization of a Ross River Virus Variant That Grows Persistently in Macrophages, Shows Altered Disease Kinetics in a Mouse Model, and Exhibits
Liu A, Menon S, Colson NJ, Quinlan S, Cox H, Peterson M, Tiang T, Haupt LM, Lea RA, Griffiths LR. Analysis of the MTHFR C677T variant with migraine phenotypes. BMC Research Notes. 2010;28(3):213. Liu JZ, Mcrae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, Hayward NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S. A Versatile Gene-Based Test for Genome-wide Association Studies. American Journal of Human Genetics. 2010;87(1):139-145. Liu Y, Blackwood DH, Caesar S, de Geus EJC, Farmer A, Ferreira MAR, Ferrier IN, Fraser C, Gordon-Smith K, Green EK, Grozeva D, Gurling HM, Hamshere ML, Heutink P, Holmans PA, Hoogendijk WJ, Hottenga JJ, Jones L, Jones IR, Kirov G, Lin D, McGuffin P, Moskvina V, Nolen WA, Perlis RH, Posthuma D, Scolnick EM, Smit AB, Smit JH, Smoller JW, St Clair D, van Dyck R, Verhage M, Willemsen G, Young AH, Zandbelt T, Boomsma DI, Craddock N, O’Donovan MC, Owen MJ, Penninx BWJH, Purcell S, Sklar P, Sullivan PF. Meta-analysis of genomewide association data of bipolar disorder and major depressive disorder. Molecular Psychiatry. 2011;16(1):40635. Locke S, Osborne M, O’Rourke P. Persistent fatigue in young athletes: measuring the clinical course and identifying variables affecting clinical recovery. Scandinavian Journal of Medicine & Science In Sports. 2011;21(1):90-97. Loehlin JC, Martin NG. The general factor of personality: Questions and elaborations. Journal of Research in Personality. 2011;45(1):44-49. Lose F, Nagle CM, O’Mara T, Batra J, Bolton KL, Song HL, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PDP, Kedda MA, Spurdle AB. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncology. 2010;119(3):479-483.
Lucas RM, Ponsonby AL, Burrows J, Chapman C, Coulthard A, Dear K, Dwyer T, Kilpatrick TJ, McMichael AJ, Taylor BV, Valery P, van der Mei I, Williams D, Pender MP. Epstein Barr viral infection and onset of central nervous system demyelination. Multiple Sclerosis. 2010;16(8):1007-1007. Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV, Kilpatrick TJ, Dwyer T, Coulthard A, Chapman C, van der Mei I, Williams D, McMichael AJ. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76(6):540-548. Luciano M, Hansell NK, Lahti J, Davies G, Medland SE, Raikkonen K, Tenesa A, Widen E, McGhee KA, Palotie A, Liewald D, Porteous DJ, Starr JM, Montgomery GW, Martin NG, Eriksson JG, Wright MJ, Deary IJ. Whole genome association scan for genetic polymorphisms influencing information processing speed. Biological Psychology. 2011;86(3):193-202. Luciano M, Montgomery GW, Martin NG, Wright MJ, Bates TC. SNP Sets and Reading Ability: Testing Confirmation of a 10-SNP Set in a Population Sample. Twin Research and Human Genetics. 2011;14(3):228-232. Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K, Setiawan VW, Rebbeck TR, Prescott J, Orlow I, O’Mara T, Olson SH, Narod SA, Matsuno RK, Lissowska J, Liang XL, Levine DA, Le Marchand L, Kolonel LN, Henderson BE, Garcia-Closas M, Doherty JA, De Vivo I, Chen C, Brinton LA, Akbari MR, Goodman MT. The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in NonHispanic White Women. PLoS ONE. 2011;6(2). Lurie G, Wilkens LR, Thompson PJ, Shvetsov YB, Matsuno RK, Carney ME, Palmieri RT, Wu AH, Pike MC, Pearce CL, Menon U, GentryMaharaj A, Gayther SA, Ramus SJ, Whittemore AS, McGuire V, Sieh W, Pharoah PDP, Song HL, Gronwald J, Jakubowska A, Cybulski C, Lubinski J, Schildkraut JM, Berchuck A, Kjaer SK, Hogdall E, Fasching PA, Beckmann MW, Ekici AB, Hein A, Chenevix-Trench G, Webb PM, Beesley J, Goodman MT. Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE. 2011;6(6). MacDonald K. Antigen Presentation in GraftVersus-Host Disease. Experimental Hematology. 2010;38(9):S123. MacDonald KPA, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Branstetter D, Smith J, Paxton RJ, Cerretti DP, Bonham L, Hill GR, Hume DA. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010;116(19):3955-3963. Macgregor S, Hewitt AW, Hysi PG, Ruddle JB, Medland SE, Henders AK, Gordon SD, andrew T, McEvoy B, Sanfilippo PG, Carbonaro F, Tah V, Li YJ, Bennett SL, Craig JE, Montgomery GW, Tran-Viet KN, Brown NL, Spector TD, Martin NG, Young TL, Hammond CJ, Mackey DA. Genomewide association identifies ATOH7 as a major gene determining human optic disc size. Human Molecular Genetics. 2010;19(13):2716-2724. Mackey DA, Sherwin JC, Kearns LS, Ma Y, Kelly J, Chu BS, Macmillan R, Barbour JM, Wilkinson CH, Matovinovic E, Cox HC, Bellis C, Lea RA, Quinlan S, Griffiths LR, Hewitt AW. The Norfolk Island Eye Study (NIES): rationale, methodology and distribution of ocular biometry (biometry of
the bounty). Twin Research and Human Genetics. 2011;14(1):42-52. Magalhaes RJS, Clements ACA, Patil AP, Gething PW, Brooker S. The Applications of Model-Based Geostatistics in Helminth Epidemiology and Control. Advances In Parasitology, Vol 74. 2011;74:267-296. Maher C, O’Rourke P. Trocar-Guided Mesh Compared With Conventional Vaginal Repair in Recurrent Prolapse: A Randomized Controlled Trial. Obstetrics and Gynecology. 2011;117(6):1435-1436. Maher CF, Feiner B, DeCuyper EM, Nichlos CJ, Hickey KV, O’Rourke P. Laparoscopic sacral colpopexy versus total vaginal mesh for vaginal vault prolapse: a randomized trial. American Journal of Obstetrics and Gynecology. 2011;204(4). Major L, Schroder WA, Gardner J, Fish RJ, Suhrbier A. Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2. Experimental Cell Research. 2011;317(3):338-347. Mallitt KA, O’Rourke P, Bavinck JNB, Abeni D, de Koning MNC, Feltkamp MCW, Green AC, Quint WGV, Michael KM, Pawlita M, Pfister H, Weissenborn S, Waterboer T, Neale RE. An analysis of clustering of betapapillomavirus antibodies. Journal of General Virology. 2010;91:2062-2067. Manh BH, Clements ACA, Thieu NQ, Hung NM, Hung LX, Hay SI, Hien TT, Wertheim HFL, Snow RW, Horby P. Social and environmental determinants of malaria in space and time in Viet Nam. International Journal For Parasitology. 2011;41(1):109-116. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Anstey NM, andrews KT, Price RN. Ex Vivo Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparum and P-vivax. Antimicrobial Agents and Chemotherapy. 2011;55(3):961-966. Martin NW, Benyamin B, Hansell NK, Montgomery GW, Martin NG, Wright MJ, Bates TC. Cognitive Function in Adolescence: Testing for Interactions Between Breast-Feeding and FADS2 Polymorphisms. Journal of The American Academy of Child and Adolescent Psychiatry. 2011;50(1):55-62. Martin NW, Medland SE, Verweij KJH, Lee SH, Nyholt DR, Madden PA, Heath AC, Montgomery GW, Wright MJ, Martin NG. Educational Attainment: A Genome Wide Association Study in 9538 Australians. PLoS ONE. 2011;6(6). Martrat G, Maxwell CA, Tominaga E, Portade-la-Riva M, Bonifaci N, Gómez-Baldó L, Bogliolo M, Lázaro C, Blanco I, Brunet J, Aguilar H, Fernández-Rodríguez J, Seal S, Renwick A, Rahman N, Kühl J, Neveling K, Schindler D, Ramírez MJ, Castellà M, Hernández G; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Ong KR, Cook J, Douglas F, Hodgson S, Brewer C, Morrison PJ, Porteous M, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Pasini B, Ottini L, Putignano AL, Savarese A, Bernard L, Radice P, Healey S, Spurdle A, Chen X, Beesley J; kConFab, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Asperen CJ, Bodmer D, Ausems MG, van Os TA, Blok MJ, Meijers-Heijboer HE, Hogervorst FB; HEBON, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR; SWE-BRCA, Harbst K, Borg A, Rantala J, Barbany-Bustinza G, Ehrencrona H, Stenmark-Askmalm M, Kaufman B, Laitman Y, Milgrom R, Friedman E, Domchek
SM, Nathanson KL, Rebbeck TR, Johannsson OT, Couch FJ, Wang X, Fredericksen Z, Cuadras D, Moreno V, Pientka FK, Depping R, Caldés T, Osorio A, Benítez J, Bueren J, Heikkinen T, Nevanlinna H, Hamann U, Torres D, Caligo MA, Godwin AK, Imyanitov EN, Janavicius R; GEMO Study Collaborators, Sinilnikova OM, StoppaLyonnet D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Ferrer SF, Collonge-Rame MA, Mortemousque I, McGuffog L, Chenevix-Trench G, Pereira-Smith OM, Antoniou AC, Cerón J, Tominaga K, Surrallés J, Pujana MA. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research. ;13(2):R40. Maslovskaya LA, Savchenko AI, Gordon VA, Reddell PW, Pierce CJ, Parsons PG, Williams CM. Isolation and Confirmation of the Proposed Cleistanthol Biogentic Link from Croton insularis. Organic Letters. 2011;13(5):1032-1035. Mason SA, Cozzi SJ, Pierce CJ, Pavey SJ, Parsons PG, Boyle GM. The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Investigational New Drugs. 2010;28(5):575-586. Massicotte R, Whitelaw E, Angers B. DNA methylation A source of random variation in natural populations. Epigenetics. 2011;6(4):422-428. Maugeri N, Powell J, ‘t Hoen PA, de Geus EJ, Willemsen G, Kattenberg M, Henders AK, Wallace L, Penninx B, Hottenga JJ, Medland SE, Saviouk V, Martin NG, Visscher PM, van Ommen GJ, Frazer IH, Boomsma DI, Montgomery GW, Ferreira MA. LPAR1 and ITGA4 regulate peripheral blood monocyte counts. Human Mutation. 2011. [Published online ahead of print]. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG. Subtypespecific mutation of PPP2R1A in endometrial and ovarian carcinomas. Journal of Pathology. 2011;223(5):567-573. McDonald CJ, Ostini L, Wallace DF, John AN, Watters DJ, Subramaniam VN. Iron loading and oxidative stress in the Atm(-/-) mouse liver. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2011;300(4):G554-G560. McDonald CJ, Wallace DF, Ostini L, Bell SJ, Demediuk B, Subramaniam VN. G80S-linked ferroportin disease: Classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective. Journal of Hepatology. 2011;54(3):538-544. McEvoy BP, Lind JM, Wang ET, Moyzis RK, Visscher PM, Pellekaan SMV, Wilton AN. Whole-Genome Genetic Diversity in a Sample of Australians with Deep Aboriginal Ancestry. American Journal of Human Genetics. 2010;87(2):297-305. McEvoy BP, Powell JE, Goddard ME, Visscher PM. Human population dispersal “Out of Africa’’ estimated from linkage disequilibrium and allele frequencies of SNPs. Genome Research. 2011;21(6):821-829. McEvoy BP, Zhao ZZ, Macgregor S, Bellis C, Lea RA, Cox H, Montgomery GW, Griffiths LR, Visscher PM. European and Polynesian admixture in the Norfolk Island population. Heredity. 2010;105(2):229-234. McLachlan S, Lee SM, Steele TM, Hawthorne PL, Zapala MA, Eskin E, Schork NJ, Anderson GJ, Vulpe CD. In silico QTL mapping of basal liver iron levels in inbred mouse strains. Physiological Genomics. 2011;43(3):136-147.
Page 143
Scientific publications | continued McManus DP, Yang YR. Helminthic diseases: Echinococcosis. Public Health and Infectious Disease. 2010;(340-345):Elsevier, San Diego, USA. McManus DP. Echinococcosis with Particular Reference to Southeast Asia. Advances in Parasitology. 2010;72:267-303. McManus DP. Liver worms. Textbook of Clinical Gastroeneterology and Hepatology 2nd Edition. 2011;Wiley Blackwell Publishing, Wiley & Sons, Oxford, UK. McManus DP. Schistosomiasis work in China and developing a transmission blocking vaccine for use in water buffaloes. Proceedings of the 3rd AVA/ NZVA Pan Pacific Veterinary Conference, Brisbane. 2010;PF45b.5. McManus DP. Vaccines for schistosomiasis. McGraw Hill Yearbook of Science and Technology 2010, McGraw Hill, New York. 2010;(400-403). McMillan DJ, Bessen DE, Pinho M, Ford C, Hall GS, Melo-Cristino J, Ramirez M. Population Genetics of Streptococcus dysgalactiae Subspecies equisimilis Reveals Widely Dispersed Clones and Extensive Recombination. PLoS ONE. 2010;5(7). McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD4(+)CD25(+) regulatory T cells control CD8(+) T-cell effector differentiation by modulating IL-2 homeostasis. PNAS. 2011;108(18):7529-7534. Medland SE, Verweij KJH. Examining the effects of common environment and non-additive effects on family based association results. Behavior Genetics. 2010;40(6):804-804. Meier MH, Slutske WS, Heath AC, Martin NG. Sex differences in the genetic and environmental influences on childhood conduct disorder and adult antisocial behavior. Journal of Abnormal Psychology. 2011;120(2):377-388. Menon S, Cox HC, Kuwahata M, Quinlan S, MacMillan JC, Haupt LM, Lea RA, Griffiths LR. Association of a Notch 3 gene polymorphism with migraine susceptibility. Cephalalgia. 2011;31(3):264-270. Mesnard L Mesnard L, Prignon A, Halabi M, Hodgson S, Handoko H, Walker G, Hollier B, Rondeau E, Aractingi S, Khosrotehrani K. In vivo melanoma phenotype switch from invasive to proliferative in the absence of the extracellular matrix protein vitronectin. Journal of Investigative Dermatology. 2011;131:S126-S126. Micallef LS, Loughrey BT, Healy PC, Parsons PG, Williams ML. Mono- and 1,1 ‘-Disubstituted Organoruthenium Cyclopentadiene Complexes: Synthesis, Structural Characterization, and Antitumoral Evaluation. Organometallics. 2011;30(6):1395-1403. Micallef LS, Loughrey BT, Healy PC, Parsons PG, Williams ML. Synthesis, Spectroscopic Characterization, and Cytotoxic Evaluation of Pentasubstituted Ruthenocenyl Esters. Organometallics. 2010;29(23):6237-6244. Middeldorp CM, Slof-Op ‘t Landt MCT, Medland SE, van Beijsterveldt CEM, Bartels M, Willemsen G, Hottenga JJ, de Geus EJC, Suchiman HED, Dolan CV, Neale MC, Slagboom PE, Boomsma DI. Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes?. Genes Brain and Behavior. 2010;9(7):808-816. Miles JJ, Bulek AM, Cole DK, Gostick E, Schauenburg AJA, Dolton G, Venturi V,
Page 144
QIMR Annual Report 2010–2011
Davenport MP, Tan MP, Burrows SR, Wooldridge L, Price DA, Rizkallah PJ, Sewell AK. Genetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus Infection. PLoS Pathogens. 2010;6(11). Miles JJ, Douek DC, Price DA. Bias in the alpha beta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunology and Cell Biology. 2011;89(3):375-387. Miles JJ, Thammanichanond D, Moneer S, Nivarthi UK, Kjer-Nielsen L, Tracy SL, Aitken CK, Brennan RM, Zeng WG, Marquart L, Jackson D, Burrows SR, Bowden DS, Torresi J, Hellard M, Rossjohn J, McCluskey J, Bharadwaj M. Antigen-Driven Patterns of TCR Bias Are Shared across Diverse Outcomes of Human Hepatitis C Virus Infection. Journal of Immunology. 2011;186(2):901-912. Miles KM, Miles JJ, Madura F, Sewell AK, Cole DK. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Molecular Immunology. 2011;48(4):728-732. Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benítez J, Arias Pérez JI, Zamora MP, Malats N, Dos Santos Silva I, Gibson LJ, Fletcher O, Johnson N, Anton-Culver H, Ziogas A, Figueroa J, Brinton L, Sherman ME, Lissowska J, Hopper JL, Dite GS, Apicella C, Southey MC, Sigurdson AJ, Linet MS, Schonfeld SJ, Freedman DM, Mannermaa A, Kosma VM, Kataja V, Auvinen P, Andrulis IL, Glendon G, Knight JA, Weerasooriya N, Cox A, Reed MW, Cross SS, Dunning AM, Ahmed S, Shah M, Brauch H, Ko YD, Brüning T; GENICA Network, Lambrechts D, Reumers J, Smeets A, WangGohrke S, Hall P, Czene K, Liu J, Irwanto AK, Chenevix-Trench G, Holland H; kConFab; AOCS, Giles GG, Baglietto L, Severi G, Bojensen SE, Nordestgaard BG, Flyger H, John EM, West DW, Whittemore AS, Vachon C, Olson JE, Fredericksen Z, Kosel M, Hein R, Vrieling A, Flesch-Janys D, Heinz J, Beckmann MW, Heusinger K, Ekici AB, Haeberle L, Humphreys MK, Morrison J, Easton DF, Pharoah PD, García-Closas M, Goode EL, Chang-Claude J. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research. 2010;12(6):R110. Mine S. Cicek, Noralane M. Lindor, Steven Gallinger, Bharati Bapat, John L. Hopper, Mark A. Jenkins, Joanne Young, Daniel Buchanan, Michael D. Walsh, Loic Le Marchand, Terrilea Burnett, Polly A. Newcomb, William M. Grady, Robert W. Haile, Graham Casey, Sarah J. Plummer, Lisa A. Krumroy, John A. Baron, and Stephen N. Thibodeau. Quality Assessment and Correlation of MSI and IHC Markers among Population- and Clinic-Based Colorectal Tumors. Journal of Molecular Diagnostics. 2011;13(3):271-81. Mirza H, Teo JDW, Upcroft J, Tan KSW. A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent Variations in Drug Susceptibilities. Antimicrobial Agents and Chemotherapy. 2011;55(2):637-648. Mitchell D, Olive C. Regulation of Toll-like receptor-induced chemokine production in murine
dendritic cells by mitogen-activated protein kinases. Molecular Immunology. 2010;47(11-12):2065-2073. Mitchell D, Yong M, Raju J, Willemsen N, Black M, Trent A, Tirrell M, Olive C. Toll-like receptormediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines. Human Vaccines. 2011;7:85-93. Mitchell D, Yong M, Schroder W, Black M, Tirrell M, Olive C. Dual Stimulation of MyD88-Dependent Toll-Like Receptors Induces Synergistically Enhanced Production of Inflammatory Cytokines in Murine Bone Marrow-Derived Dendritic Cells. Journal of Infectious Diseases. 2010;202(2):318-329. Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S, Ramos-Jimenez P, Gotuzzo E, Kar K, Sanchez A, Garba A, Carabin H, Bassili A, Chaignat CL, Meslin FX, Abushama HM, Willingham AL, Kioy D. Zoonoses and marginalised infectious diseases of poverty: where do we stand?. Parasites & Vectors. 2011;4(106). Montgomery GW. Genetics of Endometriosis. Australian & New Zealand Journal of Obstetrics & Gynaecology. 2010;50:29-29. Montgomery GW. Genome-wide association studies and genetic architecture of common human diseases. BMC Proceedings. 2011;5(Suppl 4):S16. Moore SP, O’Rourke PK, Mallitt KA, Garvey G, Green AC, Coory MD, Valery PC. Cancer incidence and mortality in Indigenous Australians in Queensland, 1997-2006. Medical Journal of Australia. 2010;193(10):590. Morrison BL, Reynolds BA, Schmidt CW, López JA. Stem Cells and Breast Cancer. Stem cell, Regenerative Medicine and Cancer. 2011:Chapter 22. Morrow BJ, Keddie DJ, Gueven N, Lavin MF, Bottle SE. A novel profluorescent nitroxide as a sensitive probe for the cellular redox environment. Free Radical Biology and Medicine. 2010;49(1):67-76. Mosing MA, Pedersen NL, Martin NG, Wright MJ. Sex Differences in the Genetic Architecture of Optimism and Health and Their Interrelation: A Study of Australian and Swedish Twins. Twin Research and Human Genetics. 2010;13(4):322-329. Mosing MA, Verweij KJH, Medland SE, Painter J, Gordon SD, Heath AC, Madden PA, Montgomery GW, Martin NG. A Genome-Wide Association Study of Self-Rated Health. Twin Research and Human Genetics. 2010;13(4):398-403. Mosing MA, Wright MJ, Pedersen NL, Martin NG. Genetic influences on optimism and its relationship to health. Behavior Genetics. 2010;40(6):806-806. Moskvina V, Smith M, Ivanov D, Blackwood D, Stclair D, Hultman C, Toncheva D, Gill M, Corvin A, O’Dushlaine C, Morris DW, Wray NR, Sullivan P, Pato C, Pato MT, Sklar P, Purcell S, Holmans P, O’Donovan MC, Owen MJ, Kirov G. Genetic Differences between Five European Populations. Human Hereditary. 2010;70(2):141-149. Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, Kemp DJ, McCarthy JS, Fischer K. A Tractable Experimental Model for Study of Human and Animal Scabies. PLoS Neglected Tropical Diseases. 2010;4(7).
Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, Kemp DJ, McCarthy JS, Fischer K. A Tractable Experimental Model for Study of Human and Animal Scabies. PLoS Neglected Tropical Diseases. 2010;4(7). Mudge AM, O’Rourke P, Denaro CP. Timing and Risk Factors for Functional Changes Associated With Medical Hospitalization in Older Patients. Journals of Gerontology Series A-Biological Sciences and Medical Sciences. 2010;65(8):863-869. Mujaj SA, Spanevello MM, Gandhi MK, Nourse JP. Molecular mechanisms influencing NK cell development: implications for NK cell malignancies. American Journal of Blood Research. ;1(1):34-45. Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, de Fazio A, Fereday S, Bowtell DD, Green AC, Webb PM. Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2011;29(16):2253-2258. Nagle CM, Kolahdooz F, Ibiebele TI, Olsen CM, Lahmann PH, Green AC, Webb PM. Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer. Annals of Oncology. 2011;22(6):1332-1338. Nagle CM, Kolahdooz F, Ibiebele TI, Olsen CM, Lahmann PH, Green AC, Webb PM. Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer. Annals of Oncology. 2011;22(6):1332-1338. Nagle CM, Olsen CM, Bain CJ, Whiteman DC, Green AC, Webb PM. Tea consumption and risk of ovarian cancer. Cancer Causes & Control. 2010;21(9):1485-1491. Nawaratna SSK, McManus DP, Moertel L, Gobert GN, Jones MK. Gene Atlasing of Digestive and Reproductive Tissues in Schistosoma mansoni. PLoS Neglected Tropical Diseases. 2011;5(4). Neale BM, Medland S, Ripke S, Anney RJL, Asherson P, Buitelaar J, Franke B, Gill M, Kent L, Holmans P, Middleton F, Thapar A, Lesch KP, Faraone SV, Daly M, Nguyen TT, Schafer H, Steinhausen HC, Reif A, Renner TJ, Romanos M, Romanos J, Warnke A, Walitza S, Freitag C, Meyer J, Palmason H, Rothenberger A, Hawi Z, Sergeant J, Roeyers H, Mick E, Biederman J. Case-Control Genome-Wide Association Study of Attention-Deficit/Hyperactivity Disorder. Journal of The American Academy of Child and Adolescent Psychiatry. 2010;49(9):906-920. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP, Faraone SV, Nguyen TT, Schafer H, Holmans P, Daly M, Steinhausen HC, Freitag C, Reif A, Renner TJ, Romanos M, Romanos J, Walitza S, Warnke A, Meyer J, Palmason H, Buitelaar J, Vasquez AA, Lambregts-Rommelse N, Gill M, Anney RJL, Langely K, O’Donovan M, Williams N, Owen M, Thapar A, Kent L, Sergeant J, Roeyers H, Mick E, Biederman J, Doyle A, Smalley S, Loo S, Hakonarson H, Elia J, Todorov A, Miranda A, Mulas F, Ebstein RP, Rothenberger A, Banaschewski T, Oades RD, Sonuga-Barke E, McGough J, Nisenbaum L, Middleton F, Hu XL, Nelson S. Meta-Analysis of GenomeWide Association Studies of Attention-Deficit/ Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49(9):884-897. Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM, Kjaer SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman
PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertility and Sterility. 2011;95(1):40-45. Ngo TT, Mitchell PB, Martin NG, Miller SM. Psychiatric and genetic studies of binocular rivalry: an endophenotype for bipolar disorder?. Acta Neuropsychiatrica. 2011;23(1):37-42. Nguyen LAP, Clements ACA, Jeffery JAL, Nguyen YT,Vu SN, Vaughan G, Shinkfield R, Kutcher SC, Gatton ML, KAY BH, Ryan PA. Abundance and prevalence of Aedes aegypti immatures and relationships with household water storage in rural areas in southern Viet Nam. International Health. 2011;3(2):115-125. Norgate M, Southon A, Greenough M, Cater M, Farlow A, Batterham P, Bush AI, Subramaniam VN, Burke R, Camakaris J. Syntaxin 5 Is Required for Copper Homeostasis in Drosophila and Mammals. PLoS ONE. 2010;5(12). Notaridou M, Quaye L, Dafou D, Jones C, Song HL, Hogdall E, Kjaer SK, Christensen L, Hogdall C, Blaakaer J, McGuire V, Wu AH, Van den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Medrek K, Lubinski J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, Wang-Gohrke S, Doherty JA, Rossing MA, Beckmann MW, Thiel FC, Ekici AB, Chen XQ, Beesley J, Gronwald J, Fasching PA, ChangClaude J, Goodman MT, Chenevix-Trench G, Berchuck A, Pearce CL, Whittemore AS, Menon U, Pharoah PDP, Gayther SA, Ramus SJ. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer. 2011;128(9):2063-2074. Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy. American Journal of Transplantation. 2011;11(5):888-895. Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R, Jenkins MA. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. International Journal of Cancer. 2010;127(11):2678-2684. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. International Journal of Cancer. 2010;127(10):2430-45. Olsen CM, Pandeya N, Green AC, Webb PM, Whiteman DC. Population Attributable Fractions of Adenocarcinoma of the Esophagus and Gastroesophageal Junction. American Journal of Epidemiology. 2011. [Published online ahead of print]. Olsen CM, Zens MS, Green AC, Stukel TA, Holman CDJ, Mack T, Elwood JM, Holly EA, Sacerdote C, Gallagher R, Swerdlow AJ, Armstrong BK, Rosso S, Kirkpatrick C, Zanetti R, Bishop JN, Bataille V, Chang YM, Mackie R, Osterlind A, Berwick M, Karagas MR, Whiteman DC. Biologic markers of sun exposure and melanoma risk in women: pooled casecontrol analysis. International Journal of Cancer. 2011;129(3):713-723. Olsen CM, Zens MS, Green AC, Stukel TA, Holman CDJ, Mack T, Elwood JM, Holly EA, Sacerdote C, Gallagher R, Swerdlow AJ, Armstrong BK, Rosso S, Kirkpatrick C, Zanetti R, Bishop JN, Bataille V, Chang YM, Mackie
R, Osterlind A, Berwick M, Karagas MR, Whiteman DC. Biologic markers of sun exposure and melanoma risk in women: pooled casecontrol analysis. International Journal of Cancer. 2011;129(3):713-723. O’Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu JJ, Czene K, Rebbeck TR, Ahmed S, Dunning AM, Gregory CS, Shah M, Webb PM, Spurdle AB. Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis. 2011;32(3):331-335. Osorio A, Milne RL, Alonso R, Pita G, Peterlongo P, Teule A, Nathanson KL, Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van Dooren MF, Jager A, Ausems MGEM, Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz Q, Van Roozendaal CE, Ligtenberg MJ, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Adlard J, Eccles D, Ong KR, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna H, Aittomaki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo MA, Loman N, Jernstrom H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, Stenmark-Askmalm M, Feliubadalo L, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Fortuzzi S, Johannsson OT, Chenevix-Trench G, Chen XC, Beesley J, Spurdle AB, Sinilnikova OM, Healey S, McGuffog L, Antoniou AC, Brunet J, Radice P, Benitez J. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer. 2011;104(8):1356-1361. Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin JH, Lee SH, Lambert A, Zhao ZZ, Roseman F, Guo Q, Gordon SD, Wallace L, Henders AK, Visscher PM, Kraft P, Martin NG, Morris AP, Treloar SA, Kennedy SH, Missmer SA, Montgomery GW, Zondervan KT. Genomewide association study identifies a locus at 7p15.2 associated with endometriosis. Nature Genetics. 2011;43(1):51-U69. Painter JN, Nyholt DR, Morris A, Zhao ZZ, Henders AK, Lambert A, Wallace L, Martin NG, Kennedy SH, Treloar SA, Zondervan KT, Montgomery GW. High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Fertility and Sterility. 2011;95(7):2236-2240. Pandian JD, Dalton K, Scott J, Read SJ, Henderson RD. Cardiovascular autonomic dysfunction in acute stroke. International Journal of Stroke. 2011;6(2):176-178. Parker G, Fletcher K, Barrett M, Breakspear M, Rees AM. Evaluating the first 1000 patients referred to a specialist depression clinic: A case for tertiary referral facilities. Journal of Affective Disorders. 2011;131(1-3):52-58. Parker G, Fletcher K, Barrett M, Synnott H, Breakspear M, Rees AM, Blanch B. The Impact of Detecting Bipolar Disorder in Previously Diagnosed Unipolar Patients at a Specialist Depression Clinic. Journal of Nervous and Mental Disease. 2011;199(6):419-422. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, Baron JA, Giles GG, Leggett BA, Winship I, Lipton L, Young GP, Young JP, Lodge CJ, Southey MC, Newcomb PA, Le Marchand L, Haile RW, Lindor NM, Gallinger S, Hopper JL, Jenkins MA. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60(7):950-957.
Page 145
Scientific publications | continued Pasay C, Mounsey K, Stevenson G, Davis R, Arlian L, Morgan M, Vyszenski-Moher D, andrews K, McCarthy J. Acaricidal activity of eugenol based compounds against scabies mites. PLoS ONE. 2010;5(8):e12079. Patel J, Landers K, Mortimer RH, Richard K. Regulation of Hypoxia Inducible Factors (HIF) in Hypoxia and Normoxia During Placental Development. Placenta. 2010;31(11):951-957. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P. Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival. Journal of Clinical Oncology. 2011;29(12):1539-1546. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G; AOCS/ACS Study Group, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics. 2011;20(11):2263-72. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PDP, Song H, Kjaer SK, Hogdall E, Hodgall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G, AOCS/ACS Study Group, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. on behalf of the Ovarian Cancer Association Consortium. Genetic Variation in Insulin-like Growth Factor 2 is Associated with Ovarian Cancer Risk. Human Molecular Genetics. 2011;20(11):2263-2272. Pelecanos AM, Ryan PA, Gatton ML. Outbreak detection algorithms for seasonal disease data: a case study using ross river virus disease. BMC Medical Informatics and Decision Making. 2010;10. Pelecanos AM, Ryan PA, Gatton ML. SpatialTemporal Epidemiological Analyses of Two Sympatric, Co-Endemic Alphaviral Diseases in Queensland, Australia. Vector-Borne and Zoonotic Diseases. 2011;11(4):375-382. Peng JB, Gobert GN, Hong Y, Jiang WB, Han HX, McManus DP, Wang XZ, Liu JM, Fu ZQ, Shi YJ, Lin JJ. Apoptosis Governs the Elimination of Schistosoma japonicum from the Non-Permissive Host Microtus fortis. PLoS ONE. 2011;6(6). Pereira TN, Lewindon PJ, Shepherd RW, Walsh MJ, Tirnitz-Parker JE, Olynyk JK, Yeoh G, Ramm GA. The Role of Monocyte Chemotaxis Protein-1 and The Ductular Reaction In Initiating Fibrogenesis in Pediatric Cholestatic Liver Disease. Hepatology. 2010;52(4):1266A-1267A. Pergadia ML, Agrawal A, Heath AC, Martin NG, Bucholz KK, Madden PAF. Nicotine Withdrawal Symptoms in Adolescent and Adult Twins. Twin Research and Human Genetics. 2010;13(4):359-369.
Page 146
QIMR Annual Report 2010–2011
Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, Broms U, Korhonen T, Penninx BW, Grant JD, Nelson EC, Henders AK, Schrage AJ, Chou YL, Keskitalo-Vuokko K, Zhu Q, Gordon SD, Vink JM, de Geus EJ, Macgregor S, Liu JZ, Willemsen G, et al. A 3p263p25 Genetic Linkage Finding for DSM-IV Major Depression in Heavy Smoking Families. American Journal of Psychiatry. 2011. [Published online ahead of print]. Perry CR, Burke ML, Stenzel DJ, McManus DP, Ramm GA, Gobert GN. Differential expression of chemokine and matrix re-modelling genes is associated with contrasting schistosomeinduced hepatopathology in murine models. PLoS Neglected Tropical Diseases. 2011;5(6):e1178. Pharoah PDP, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, ChangClaude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dork T, Durst M, Eccles DM, Ekici AB, Easton D, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TVO, Harnett P, Rookus M, Heikkinen T, Hein R, Hogdall C, Hogdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, LaPolla JP, Lazaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song HL, Stram DO, Sutphen R, Lindblom A, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA. The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research. 2011;17(11):3742-3750. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010;52(5):1671-779. Pinzon-Charry A, McPhun V, Kienzle V, Hirunpetcharat C, Engwerda C, McCarthy J, Good MF. Low doses of killed parasite in CpG elicit vigorous CD4(+) T cell responses against blood-stage malaria in mice. Journal of Clinical Investigation. 2010;120(8):2967-2978. Piper M, Barry G, Hawkins J, Mason S, Lindwall C, Little E, Sarkar A, Smith AG, Moldrich RX, Boyle GM, Tole S, Gronostajski RM, Bailey TL, Richards LJ. NFIA Controls Telencephalic Progenitor Cell Differentiation through Repression of the Notch Effector Hes1. Journal of Neuroscience. 2010;30(27):9127-9139. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Nutlin-3a Is a Potential Therapeutic for
Ewing Sarcoma. Clinical Cancer Research. 2011;17(3):494-504. Plasmeijer EI, Neale RE, O’Rourke P, Mallitt KA, de Koning MNC, Quint W, Buettner PG, Pawlita M, Waterboer T, Green AC, Feltkamp MCW. Lack of association between the presence and persistence of betapapillomavirus DNA in eyebrow hairs and betapapillomavirus L1 antibodies in serum. Journal of General Virology. 2010;91:2073-2079. Ponsonby AL, Lucas RM, van der Mei I, Dear K, Taylor BV, McMichael AJ, Valery P, Dwyer T, Chapman C, Pender MP, Coulthard A, Williams D, Kilpatrick TJ. Investigation of the role of pregnancy and exposure to biological children in the onset of central nervous system demyelination. Multiple Sclerosis. 2010;16(8):1007-1008. Powell JE, Visscher PM, Goddard ME. Reconciling the analysis of IBD and IBS in complex trait studies. Nature Reviews Genetics. 2010;11(11):800-805. Powell JE, Zietsch BP. Predicting sensation seeking from dopamine genes: use and misuse of genetic prediction. Psychological Science. 2011;22(3):413-5. Pretorius CJ, Dimeski G, O’Rourke PK, Marquart L, Tyack SA, Wilgen U, Ungerer JPJ. Outliers as a Cause of False Cardiac Troponin Results: Investigating the Robustness of 4 Contemporary Assays. Clinical Chemistry. 2011;57(5):710-718. Price MA, Butow PN, Costa DSJ, King MT, Aldridge LLJ, Fardell JE, DeFazio A, Webb PM. Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of Australia. 2010;193(5):S52-S57. Ramm GA, Ruddell RG. Iron Homeostasis, Hepatocellular Injury, and Fibrogenesis in Hemochromatosis: The Role of Inflammation in a Noninflammatory Liver Disease. Seminars in Liver Disease. 2010;30(3):271-287. Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, Baumann KC, Welburn P, Redlich GL, Parsons PG. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. British Journal of Dermatology. 2011;164(3):633-636. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PDP, Sinilnikova OM, Beesley J, Chen XQ, McGuffog L, Healey S, Couch FJ, Wang XS, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Askmalm MS, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gronwald J, Gorski B, Cybulski C, Debniak T, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MGEM, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HEJ, Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues
C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert-Ferrer S, Miron A, Buys SS, Hopper JL, Daly MB, John EM, Terry MB, Goldgar D, Hansen TVO, Jonson L, Ejlertsen B, Agnarsson BA, offit K, Kirchhoff T, Vijai J, DutraClarke AVC, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lazaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Simard J, Soucy P, Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute. 2011;103(2). Randall LM, Engwerda CR. TNF family members and malaria: Old observations, new insights and future directions. Experimental Parasitology. 2010;126(3):326-331. Randall LM, Kenangalem E, Lampah DA, Tjitra E, Mwaikambo ED, Handojo T, Piera KA, Zhao ZZ, Rivera FD, Zhou YH, McSweeney KM, Le LE, Amante FH, Haque A, Stanley AC, Woodberry T, Salwati E, Granger DL, Hobbs MR, Price RN, Weinberg JB, Montgomery GW, Anstey NM, Engwerda CR. A study of the TNF/ LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults. Malaria Journal. 2010;9. Randall LM, Kenangalem E, Lampah DA, Tjitra E, Mwaikambo ED, Handojo T, Piera KA, Zhao ZZ, Rivera FD, Zhou YH, McSweeney KM, Le L, Amante FH, Haque A, Stanley AC, Woodberry T, Salwati E, Granger DL, Hobbs MR, Price RN, Weinberg JB, Montgomery GW, Anstey NM, Engwerda CR. Age-Related Susceptibility to Severe Malaria Associated with Galectin-2 in Highland Papuans. Journal of Infectious Diseases. 2010;202(1):117-124. Rattanasena P, Anraku I, Gardner J, Le TT, Wang XJ, Khromykh AA, Suhrbier A. Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis. Immunol Cell Biol. 2011;89(3):426-36. Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 2011;32(5):741-747. Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B. Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. British Journal of Cancer. 2011;104(12):1906-1912. Redmond AM, Doolan DL. The Australasian contribution to malaria vaccine development. Parasite Immunology. 2010;32(8):607-622. Reed DR, Zhu G, Breslin PAS, Duke FF, Henders AK, Campbell MJ, Montgomery GW, Medland SE, Martin NG, Wright MJ. The perception of quinine taste intensity is associated with common genetic variants in a bitter receptor cluster on chromosome 12. Human Molecular Genetics. 2010;19(21):4278-4285. Reid H, Haque U, Clements ACA, Tatem AJ, Vallely A, Ahmed SM, Islam A, Haque R. Mapping Malaria Risk in Bangladesh Using
Bayesian Geostatistical Models. American Journal of Tropical Medicine and Hygiene. 2010;83(4):861-867. Richard DJ, Cubeddu L, Urquhart AJ, Bain A, Bolderson E, Menon D, White MF, Khanna KK. hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity. Nucleic Acids Research. 2011;39(9):3643-3651. Richard DJ, Savage K, Bolderson E, Cubeddu L, So S, Ghita M, Chen DJ, White MF, Richard K, Prise KM, Schettino G, Khanna KK. hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. Nucleic Acids Research. 2011;39(5):1692-1702. Richards R, St Pierre L, Trabi M, Johnson LA, de Jersey J, Masci PP, Lavin MF. Cloning and characterisation of novel cystatins from elapid snake venom glands. Biochimie. 2011;93(4):659-668. Richmond-Sinclair NM, Pandeya N, Williams GM, Neale RE, van der Pols JC, Green AC. Clinical signs of photodamage are associated with basal cell carcinoma multiplicity and site: a 16-year longitudinal study. International Journal of Cancer. 2010;127(11):2622-2629. Rizzi TS, Arias-Vasquez A, Rommelse N, Kuntsi J, Anney R, Asherson P, Buitelaar J, Banaschewski T, Ebstein R, Ruano D, Van der Sluis S, Markunas CA, Garrett ME, AshleyKoch AE, Kollins SH, Anastopoulos AD, Hansell NK, Wright MJ, Montgomery GW, Martin NG, Harris SE, Davies G, Tenesa A, Porteous DJ, Starr JM, Deary IJ, St Pourcain B, Smith GD, Timpson NJ, Evans DM, Gill M, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Faraone SV, Franke B, Posthuma D. The ATXN1 and TRIM31 Genes Are Related to Intelligence in an ADHD Background: Evidence From a Large Collaborative Study Totaling 4,963 Subjects. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. 2011;156B(2):145-157. Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, Raffelt NC, De Weerd NA, Lineburg KE, Varelias A, Markey KA, Koyama M, Clouston AD, Hertzog PJ, Macdonald KP, Hill GR. Type I interferons control GVHD and GVL responses after transplantation. Blood. 2011. Robb RJ, Kuns R, Wilson Y, Olver S, Don A, Raffelt N, Lineburg KE, Varelias A, Markey K, Koyama M, Hill G, MacDonald K. Identification of a novel CD8+FoxP3+population following allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2011;46:S48. Roberts A, Nancarrow D, Clendenning M, Buchanan DD, Jenkins MA, Duggan D, Taverna D, McKeone D, Walters R, Walsh MD, Young BW, Jass JR, Rosty C, Gattas M, Pelzer E, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Parry S, Woodall S, Arnold J, Tucker K, Muir A, Drini M, Macrae F, Newcomb P, Potter JD, Pavluk E, Lindblom A, Young JP. Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Familial Cancer. 2011;10(2):245-254. Roberts TL Roberts TL, Dunn JA, Sweet MJ, Hume DA, Stacey KJ. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes. Molecular Immunology. 2011;48(8):1027-1034.
exposure of DNA to toll-like receptor-9. Immunology and Cell Biology. 2011;89(4):517-525. Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, Nissen MD, Trenholme K, Mc Carthy JS, Sloots TP. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malaria Journal. 2011;10. Roque JB, Oâ&#x20AC;&#x2122;Leary CA, Kyaw-Tanner M, Latter M, Mason K, Shipstone M, Vogelnest L, Duffy D. High allergen-specific serum immunoglobulin E levels in nonatopic West Highland white terriers. Veterinary Dermatology. 2011;22(3):257-266. Rosty C, Parry S, Young JP. Serrated polyposis:an enigmatic model of colorectal cancer predisposition. Pathology Research International. 2011;2011:157073. Royce-Tolland ME, Andersen AA, Koyfman HR, Talbot DJ, Wutz A, Tonks ID, Kay GF, Panning B. The A-repeat links ASF/SF2-dependent Xist RNA processing with random choice during X inactivation. Nature Structural & Molecular Biology. 2010;17(8):948-U55. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal Adenocarcinoma Incidence in Individuals With Gastroesophageal Reflux: Synthesis and Estimates From Population Studies. American Journal of Gastroenterology. 2011;106(2):254-260. Rubinov M, Bassett DS. Emerging Evidence of Connectomic Abnormalities in Schizophrenia. Journal of Neuroscience. 2011;31(17):6263-6265. Rubinov M, Sporns O, Thivierge JP, Breakspear M. Neurobiologically realistic determinants of selforganized criticality in networks of spiking neurons. PLoS Computational Biology. 2011;7(6):e1002038. Rubinov M, Sporns O. Complex network measures of brain connectivity: Uses and interpretations. Neuroimage. 2010;52(3):1059-1069. Rubinov M, Sporns O. Weight-conserving characterization of complex functional brain networks. Neuroimage. 2011;56(4):2068-2079. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen XN, Cichon S, Giegling I, Han SZ, Han YH, Keskitalo-Vuokko K, Kong XY, Landi MT, Ma JZ, Short SE, Stephens SH, Stevens VL, Sun LW, Wang YF, Wenzlaff AS, Aggen SH, Breslau N, Broderick P, Chatterjee N, Chen JC, Heath AC, Heliovaara M, Hoft NR, Hunter DJ, Jensen MK, Martin NG, Montgomery GW, Niu TH, Payne TJ, Peltonen L, Pergadia ML, Rice JP, Sherva R, Spitz MR, Sun JZ, Wang JC, Weiss RB, Wheeler W, Witt SH, Yang BZ, Caporaso NE, Ehringer MA, Eisen T, Gapstur SM, Gelernter J, Houlston R, Kaprio J, Kendler KS, Kraft P, Leppert MF, Li MD, Madden PAF, Nothen MM, Pillai S, Rietschel M, Rujescu D, Schwartz A, Amos CI, Bierut LJ. Multiple Independent Loci at Chromosome 15q25.1 Affect Smoking Quantity: a Meta-Analysis and Comparison with Lung Cancer and COPD. PLoS Genetics. 2010;6(8). Schettino G, Ghita M, Richard DJ, Prise KM. Spatiotemporal investigations of DNA damage repair using microbeams. Radiation Protection Dosimetry. 2011;143(2-4):340-343.
Roberts TL, Turner ML, Dunn JA, Lenert P, Ross IL, Sweet MJ, Stacey KJ. B cells do not take up bacterial DNA: an essential role for antigen in
Page 147
Scientific publications | continued Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, Padidela R, Ceron-Gutierrez L, Doffinger R, Prevosto C, Luan J, Montano S, Lu J, Castanet M, Clemons N, Groeneveld M, Castets P, Karbaschi M, Aitken S, Dixon A, Williams J, Campi I, Blount M, Burton H, Muntoni F, O’Donovan D, Dean A, Warren A, Brierley C, Baguley D, Guicheney P, Fitzgerald R, Coles A, Gaston H, Todd P, Holmgren A, Khanna KK, Cooke M, Semple R, Halsall D, Wareham N, Schwabe J, Grasso L, Beck-Peccoz P, Ogunko A, Dattani M, Gurnell M, Chatterjee K. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. Journal of Clinical Investigation. 2010;120(12):4220-4235. Schroder WA Schroder WA, Major L, Suhrbier A. The Role of SerpinB2 in Immunity. Critical Reviews In Immunology. 2011;31(1):15-30. Schroder WA, Gardner J, Le TT, Duke M, Burke ML, Jones MK, McManus DP, Suhrbier A. SerpinB2 deficiency modulates Th1/Th2 responses after schistosome infection. Parasite Immunology. 2010;32(11-12):764-768. Schulte L, Glanfield A, Nawaratna S, Gobert GN, McManus DP, Jones MK. Molecular analysis of zinc transporters in Schistosoma japonicum. Experimental Parasitology. 2011;127(4):768-776. Schultze-Kraft M, Becker R, Breakspeare M, Ritter P. Exploiting the potential of three dimensional spatial wavelet analysis to explore nesting of temporal oscillations and spatial variance in simultaneous EEG-fMRI data. Progress In Biophysics & Molecular Biology. 2011;105(12):67-79. Schumann G, Coin LJ, Lourdusamy A, Charoen P, Berger KH, Stacey D, Desrivieres S, Aliev FA, Khan AA, Amin N, Aulchenko YS, Bakalkin G, Bakker SJ, Balkau B, Beulens JW, Bilbao A, de Boer RA, Beury D, Bots ML, Breetvelt EJ, Cauchi S, Cavalcanti-Proenca C, Chambers JC, Clarke TK, Dahmen N, de Geus EJ, Dick D, Ducci F, Easton A, Edenberg HJ, Esk T, Fernandez-Medarde A, Foroud T, Freimer NB, Girault JA, Grobbee DE, Guarrera S, Gudbjartsson DF, Hartikainen AL, Heath AC, Hesselbrock V, Hofman A, Hottenga JJ, Isohanni MK, Kaprio J, Khaw KT, Kuehnel B, Laitinen J, Lobbens S, Luan JA, Mangino M, Maroteaux M, Matullo G, McCarthy MI, Mueller C, Navis G, Numans ME, Nunez A, Nyholt DR, OnlandMoret CN, Oostra BA, O’Reilly PF, Palkovits M, Penninx BW, Polidoro S, Pouta A, Prokopenko I, Ricceri F, Santos E, Smit JH, Soranzo N, Song K, Sovio U, Stumvoll M, Surakk I, Thorgeirsson TE, Thorsteinsdottir U, Troakes C, Tyrfingsson T, Tonjes A, Uiterwaal CS, Uitterlinden AG, van der Harst P, van der Schouw YT, Staehlin O, Vogelzangs N, Vollenweider P, Waeber G, Wareham NJ, Waterworth DM, Whitfield JB, Wichmann EH, Willemsen G, Witteman JC, Yuan X, Zhai GJ, Zhao JH, Zhang WH, Martin NG, Metspalu A, Doering A, Scott J, Spector TD, Loos RJ, Boomsma DI, Mooser V, Peltonen L, Stefansson K, van Duijn CM, Vineis P, Sommer WH, Kooner JS, Spanagel R, Heberlein UA, Jarvelin MR, Elliott P. Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. Proceedings of The National Academy of Sciences of The United States of America. 2011;108(17):7119-7124. Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, Lejano J, Abot E, Banania G,
Page 148
QIMR Annual Report 2010–2011
Belmonte M, Sayo R, Farooq F, Doolan DL, Regis D, Tamminga C, Chuang I, Bruder JT, King CR, Ockenhouse CF, Faber B, Remarque E, Hollingdale MR, Richie TL, Sette A. Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malaria Journal. 2010;9. Serewko-Auret MM, Mould AW, Loffler KA, Duncan R, Kay GF, Hayward NK. Alterations in Gene Expression in MEN1-Associated Insulinoma Development. Pancreas. 2010;39(8):1140-1146. Simmonds DM, West L, Porter J, Davies M, Holland C, Preston-Thomas A, O’Rourke PK, Tangey A. The role of support person for Ngaanyatjarra women during pregnancy and birth. Women Birth. 2011. [Published online ahead of print]. Simms LA, Doecke J, Huang N, Zhao ZZ, Kristine FU, Roberts RL, Barclay ML, Montgomery GW, Lawrance IC, Gearry RB, Radford-Smith GL. Genotype markers predict time to first resection in Crohn’s disease patients. Journal of Gastroenterology and Hepatology. 2010;25:A82-A83. Simms LA, Doecke JD, Roberts RL, Fowler EV, Zhao ZZ, McGuckin MA, Huang N, Hayward NK, Webb PM, Whiteman DC, Cavanaugh JA, McCallum R, Florin THJ, Barclay ML, Gearry RB, Merriman TR, Montgomery GW, Radford-Smith GL. KCNN4 Gene Variant Is Associated With Ileal Crohn’s Disease in the Australian and New Zealand Population. American Journal of Gastroenterology. 2010;105(10):2209-2217. Simpson PT, Vargas AC, Al-Ejeh F, Khanna KK, Chenevix-Trench G, Lakhani SR. Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. Human Pathology. 2011;42(2):153-165. Singh AL, D’Onofrio BM, Slutske WS, Turkheimer E, Emery RE, Harden KP, Heath AC, Madden PAF, Statham DJ, Martin NG. Parental depression and offspring psychopathology: a Children of Twins study. Psychological Medicine. 2011;41(7):1385-1395. Siskind V, Hughes MCB, Palmer JM, Symmons JM, Aitken JF, Martin NG, Hayward NK, Whiteman DC. Nevi, Family History, and Fair Skin Increase the Risk of Second Primary Melanoma. Journal of Investigative Dermatology. 2011;131(2):461-467. Slutske WS, Bascom EN, Meier MH, Medland SE, Martin NG. Sensation Seeking in Females from Opposite- Versus Same-Sex Twin Pairs: Hormone Transfer or Sibling Imitation?. Behavior Genetics. 2011;41(4):533-542. Slutske WS, Piasecki TM, Blaszczynski A, Martin NG. Pathological gambling recovery in the absence of abstinence. Addiction. 2010;105(12):2169-2175. Slutske WS, Piasecki TM, Ellingson JM, Martin NG. The Family History Method in Disordered Gambling Research: A Comparison of Reports Obtained from Discordant Twin Pairs. Twin Research and Human Genetics. 2010;13(4):340346. Smit DJA, Luciano M, Bartels M, van Beijsterveldt CEM, Wright MJ, Hansell NK, Brunner HG, Estourgie-van Burk GF, de Geus EJC, Martin NG, Boomsma DI. Heritability of Head Size in Dutch and Australian Twin Families
at Ages 0-50 Years. Twin Research and Human Genetics. 2010;13(4):370-380. Smith C, Khanna R. Herpesvirus vaccines Challenges and future prospects. Human Vaccines. 2010;6(12):1062-1067. Smith C, Martinez M, Peet J, Khanna R. Differential Outcome of IL-2/Anti-IL-2 Complex Therapy on Effector and Memory CD8(+) T Cells following Vaccination with an Adenoviral Vector Encoding EBV Epitopes. Journal of Immunology. 2011;186(10):5784-5790. Smith NL, Huffman JE, Strachan DP, Huang J, Dehghan A, Trompet S, Lopez LM, Shin SY, Baumert J, Vitart V, Bis JC, Wild SH, Rumley A, Yang Q, Uitterlinden AG, Stott DJ, Davies G, Carter AM, Thorand B, Polasek O, McKnight B, Campbell H, Rudnicka AR, Chen MH, Buckley BM, Harris SE, Peters A, Pulanic D, Lumley T, de Craen AJM, Liewald DC, Gieger C, Campbell S, Ford I, Gow AJ, Luciano M, Porteous DJ, Guo XQ, Sattar N, Tenesa A, Cushman M, Slagboom PE, Visscher PM, Spector TD, Illig T, Rudan I, Bovill EG, Wright AF, McArdle WL, Tofler G, Hofman A, Westendorp RGJ, Starr JM, Grant PJ, Karakas M, Hastie ND, Psaty BM, Wilson JF, Lowe GDO, O’Donnell CJ, Witteman JCM, Jukema JW, Deary IJ, Soranzo N, Koenig W, Hayward C. Genetic Predictors of Fibrin D-Dimer Levels in Healthy Adults. Circulation. 2011;123(17):1864. Smithers BM, Fahey PP, Corish T, Gotley DC, Falk GL, Smith GS, Kiroff GK, Clouston AD, Watson DI, Whiteman DC. Symptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australia. Medical Journal of Australia. 2010;193(10):572-577. Smout MJ, Kotze AC, McCarthy JS, Loukas A. A Novel High Throughput Assay for Anthelmintic Drug Screening and Resistance Diagnosis by Real-Time Monitoring of Parasite Motility. PLoS Neglected Tropical Diseases. 2010;4(11):. Soltani A, Reid DW, Sohal SS, Wood-Baker R, Weston S, Muller HK, Walters EH. Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respiratory Research. 2010;11:105. Sommerlad S, Mcrae AF, McDonald B, Johnstone I, Cuttell L, Seddon JM, O’Leary CA. Congenital Sensorineural Deafness in Australian Stumpy-Tail Cattle Dogs Is an Autosomal Recessive Trait That Maps to CFA10. PLoS ONE. 2010;5(10). Spatola CAM, Scaini S, Pesenti-Gritti P, Medland SE, Moruzzi S, Ogliari A, Tambs K, Battaglia M. Gene-Environment Interactions in Panic Disorder and CO(2) Sensitivity: Effects of Events Occurring Early in Life. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. 2011;156B(1):79-88. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan J, Magi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segre AV, Estrada K, Liang LM, Nemesh J, Park JH, Gustafsson S, Kilpelanen TO, Yang JA, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ,
Johansson A, Johnson T, Ketkar S, Lamina C, Li SX, Moffatt MF, Myers RH, Narisu N, Perry JRB, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi JX, Thiering E, Alavere H, Alibrandi MTS, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AIF, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, Busonero F, Campbell H, Cappuccio FP, Cavalcanti-Proenca C, Chen YDI, Chen CM, Chines PS, Clarke R, Coin L, Connell J, Day INM, den Heijer M, Duan JB, Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, Erdos MR, Eriksson JG, Facheris MF, Felix SB, Fischer-Posovszky P, Folsom AR, Friedrich N, Freimer NB, Fu M, Gaget S, Gejman PV, Geus EJC, Gieger C, Gjesing AP, Goel A, Goyette P, Grallert H, Grassler J, Greenawalt DM, Groves CJ, Gudnason V, Guiducci C, Hartikainen AL, Hassanali N, Hall AS, Havulinna AS, Hayward C, Heath AC, Hengstenberg C, Hicks AA, Hinney A, Hofman A, Homuth G, Hui J, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, John U, Jorgensen T, Jousilahti P, Jula A, Kaakinen M, Kajantie E, Kaplan LM, Kathiresan S, Kettunen J, Kinnunen L, Knowles JW, Kolcic I, Konig IR, Koskinen S, Kovacs P, Kuusisto J, Kraft P, Kvaloy K, Laitinen J, Lantieri O, Lanzani C, Launer LJ, Lecoeur C, Lehtimaki T, Lettre G, Liu JJ, Lokki ML, Lorentzon M, Luben RN, Ludwig B, Manunta P, Marek D, Marre M, Martin NG, McArdle WL, McCarthy A, McKnight B, Meitinger T, Melander O, Meyre D, Midthjell K, Montgomery GW, Morken MA, Morris AP, Mulic R, Ngwa JS, Nelis M, Neville MJ, Nyholt DR, O’Donnell CJ, O’Rahilly S, Ong KK, Oostra B, Pare G, Parker AN, Perola M, Pichler I, Pietilainen KH, Platou CGP, Polasek O, Pouta A, Rafelt S, Raitakari O, Rayner NW, Ridderstrale M, Rief W, Ruokonen A, Robertson NR, Rzehak P, Salomaa V, Sanders AR, Sandhu MS, Sanna S, Saramies J, Savolainen MJ, Scherag S, Schipf S, Schreiber S, Schunkert H, Silander K, Sinisalo J, Siscovick DS, Smit JH, Soranzo N, Sovio U, Stephens J, Surakka I, Swift AJ, Tammesoo ML, Tardif JC, TederLaving M, Teslovich TM, Thompson JR, Thomson B, Tonjes A, Tuomi T, van Meurs JBJ, van Ommen GJ, Vatin V, Viikari J, VisvikisSiest S, Vitart V, Vogel CIG, Voight BF, Waite LL, Wallaschofski H, Walters GB, Widen E, Wiegand S, Wild SH, Willemsen G, Witte DR, Witteman JC, Xu JF, Zhang QY, Zgaga L, Ziegler A, Zitting P, Beilby JP, Farooqi IS, Hebebrand J, Huikuri HV, James AL, Kahonen M, Levinson DF, Macciardi F, Nieminen MS, Ohlsson C, Palmer LJ, Ridker PM, Stumvoll M, Beckmann JS, Boeing H, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Gronberg H, Gyllensten U, Hall P, Hansen T, Harris TB, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe F, Khaw KT, Kiemeney LA, Krude H, Laakso M, Lawlor DA, Metspalu A, Munroe PB, Ouwehand WH, Pedersen O, Penninx BW, Peters A, Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PEH, Shuldiner AR, Spector TD, Tuomilehto J, Uda M, Uitterlinden A, Valle TT, Wabitsch M, Waeber G, Wareham NJ, Watkins H, Wilson JF, Wright AF, Zillikens MC, Chatterjee N, McCarroll SA, Purcell S, Schadt EE, Visscher PM, Assimes TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, Mohlke KL, O’Connell JR, Peltonen L, Schlessinger D, Strachan DP, van Duijn CM, Wichmann HE, Frayling TM, Thorsteinsdottir U, Abecasis GR,
Barroso I, Boehnke M, Stefansson K, North KE, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos RJF. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics. 2010;42(11):937-U53. Sprangers MAG, Bartels M, Veenhoven R, Baas F, Martin NG, Mosing M, Movsas B, Ropka ME, Shinozaki G, Swaab D. Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states. Quality of Life Research. 2010;19(10):1429-1437. Spurdle AB, Fahey P, Chen XQ, McGuffog L, Easton D, Peock S, Cook M, Simard J, Rebbeck TR, Antoniou AC, Chenevix-Trench G. Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 2010;122(1):281-285. Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen XQ, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MGEM, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HEJ, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang XS, Thomassen M, Domchek S, Nathanson K, Caligo MA, Jernstrom H, Liljegren A, Ehrencrona H, For PK, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR. Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 2011;20(5):1032-1038. Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O’Mara T, Walker LC, Montgomery SB, Dermitzakis ET, Fahey P, Montgomery GW, Webb PM, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Coenegrachts L, Vergote I, Amant F, Salvesen HB, Trovik J, Njolstad TS, Helland H, Scott RJ, Ashton K, Proietto T, Otton G, Tomlinson I, Gorman M, Howarth K, Hodgson S, Garcia-Closas M, Wentzensen N, Yang HN, Chanock S, Hall P, Czene K, Liu JJ, Li JM, Shu XO, Zheng W, Long JR, Xiang YB, Shah M, Morrison J, Michailidou K, Pharoah PD, Dunning AM, Easton DF. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics. 2011;43(5):451.
Endophenotypes: The Australian Twins Eye Study. American Journal of Ophthalmology. 2010;150(6):909-916. Sun C, Yang H, Yuan Y, Tian X, Wang L, Guo Y, Xu L, Lei J, Gao N, Anderson GJ, Liang XJ, Chen C, Zhao Y, Nie G. Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging. Journal of the American Chemistry Society. 2011;133(22):8617-24. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L’Etoile N, Goga A. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCNamplified neuroblastoma. Nature Medicine. 2010;16(10):1134-U113. Tang W, Cushman M, Schwienbacher C, Lopez LM, Ben Shlomo Y, Basu S, Gogele M, Davies G, Lowe G, Pankow JS, Tenesa A, Volpato C, Rumley A, Gow A, Minelli C, Yarnell JWG, Porteous D, Starr JM, Boerwinkle E, Visscher PM, Pramstaller PP, Deary IJ, Hicks AA, Folsom AR. Genome Wide Association Study Identifies Multiple Genetic Loci for Activated Partial Thromboplastin Time and Prothrombin Time. Blood. 2010;116(21):1715-1716. Tarutta E, Chua WH, Young T, Goldschmidt E, Saw SM, Rose KA, Smith E 3rd, Mutti DO, Ashby R, Stone RA, Wildsoet C, Howland HC, Fischer AJ, Stell WK, Reichenbach A, Frost M, Gentle A, Zhu X, Summers-Rada J, Barathi V, Jiang L, McFadden S, et al. Myopia: Why Study the Mechanisms of Myopia? Novel Approaches to Risk Factors Signalling Eye Growth- How Could Basic Biology Be Translated into Clinical Insights? Where Are Genetic and Proteomic Approaches Leading? How Does Visual Function Contribute to an. Optometry & Vision Science. 2011. [Published online ahead of print]. Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun YP, Lowler KP, Malter C, Nishimoto N, Hill GR, Reddy P. Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clinical Cancer Research. 2011;17(1):77-88. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell & Melanoma Research. 2010;23(6):781-794.
Sriram KB, Larsen JE, Francis SMS, Wright CM, Mattar K, Windsor M, Clarke BE, Duhig EE, Hayward NK, Bowman RV, Yang IA, Fong KM. Array-Comparative Genomic Hybridization Identifies Novel Copy Number Alterations in Recurrent Squamous Cell Lung Cancer. Journal of Thoracic Oncology. 2011;6(3):S34-S34. Straub CP, Lau WH, Preston FM, Headlam MJ, Gorman JJ, Collins PL, Spann KM. Mutation of the elongin C binding domain of human respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of NS1 and attenuation of the virus. Virology Journal. 2011;8. Sun C, Ponsonby AL, Brown SA, Kearns LS, MacKinnon JR, Barbour JM, Ruddle JB, Hewitt AW, Wright MJ, Martin NG, Dwyer T, Mackey DA. Associations of Birth Weight With Ocular Biometry, Refraction, and Glaucomatous
Page 149
Scientific publications | continued Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee J-Y, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan Ja, Lamina C, Ziegler A, Zhang W, Zee RYL, Wright AF, Witteman JCM, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJG, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BWJH, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O/’Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PKE, Lucas G, Luben R, Loos RJF, Lokki M-L, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw K-T, Kaprio J, Kaplan LM, Johansson A, Jarvelin M-R, Cecile J. W. Janssens A, Ingelsson E, Igl W, Kees Hovingh G, Hottenga J-J, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJC, de Faire U, Crawford G, Collins FS, Chen Y-dI, Caulfield MJ, Campbell H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor Jr HA, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJP, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-13. Teuscher F, Gatton ML, Chen NH, Peters J, Kyle DE, Cheng Q. Artemisinin-Induced Dormancy in Plasmodium falciparum: Duration, Recovery Rates, and Implications in Treatment Failure. Journal of Infectious Diseases. 2010;202(9):1362-1368. Tey SK, Goodrum F, Khanna R. CD8(+) T-cell recognition of human cytomegalovirus latencyassociated determinant pUL138. Journal of General Virology. 2010;91:2040-2048. Thompson PM, Martin NG, Wright MJ. Imaging genomics. Current Opinion In Neurology. 2010;23(4):368-373. Thomsen SF, Duffy DL, Kyvik KO, Backer V. Genetic influence on the age at onset of asthma: A twin study. Journal of Allergy and Clinical Immunology. 2010;126(3):626-630.
Page 150
QIMR Annual Report 2010–2011
Thomsen SF, Duffy DL, Kyvik KO, Skytthe A, Backer V. Relationship between type 1 diabetes and atopic diseases in a twin population. Allergy. 2011;66(5):645-647. Thomsen SF, Duffy DL, Kyvik KO, Skytthe A, Backer V. Risk of asthma in adult twins with type 2 diabetes and increased body mass index. Allergy. 2011;66(4):562-568. Thomson IG, Smithers BM, Gotley DC, Martin I, Thomas JM, O’Rourke P, Barbour AP. Thoracoscopic-Assisted Esophagectomy for Esophageal Cancer Analysis of Patterns and Prognostic Factors for Recurrence. Annals of Surgery. 2010;252(2):281-291. Thorleifsson G, Walters GB, Hewitt AW, Masson G, Helgason A, Dewan A, Sigurdsson A, Jonasdottir A, Gudjonsson SA, Magnusson KP, Stefansson H, Lam DSC, Tam POS, Gudmundsdottir GJ, Southgate L, Burdon KP, Gottfredsdottir MS, Aldred MA, Mitchell P, St Clair D, Collier DA, Tang N, Sveinsson O, Macgregor S, Martin NG, Cree AJ, Gibson J, MacLeod A, Jacob A, Ennis S, Young TL, Chan JCN, Karwatowski WSS, Hammond CJ, Thordarson K, Zhang M, Wadelius C, Lotery AJ, Trembath RC, Pang CP, Hoh J, Craig JE, Kong A, Mackey DA, Jonasson F, Thorsteinsdottir U, Stefansson K. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nature Genetics. 2010;42(10):906. Thorne RF, Ralston KJ, de Bock CE, Mhaidat NM, Zhang XD, Boyd AW, Burns GF. Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum. Biochimica Et Biophysica Acta-Molecular Cell Research. 2010;1803(11):1298-1307. Thrift AP, Pandeya N, Smith KJ, Green AC, Hayward NK, Webb PM, Whiteman DC. Helicobacter pylori infection and the risks of Barrett’s oesophagus: A population-based casecontrol study. International Journal of Cancer. 2011. [Published online ahead of print]. Thrift AP, Pandeya N, Smith KJ, Mallitt KA, Green AC, Webb PM, Whiteman DC. Lifetime Alcohol Consumption and Risk of Barrett’s Esophagus. American Journal of Gastroenterology. 2011;106(7):1220-30. Ting MJ, Day BW, Spanevello MD, Boyd AW. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Experimental Hematology. 2010;38(11):1087-1098. Toh SQ, Glanfield A, Gobert GN, Jones MK. Heme and blood-feeding parasites: friends or foes?. Parasites & Vectors. 2010;3. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, Palles C, Broderick P, Jaeger EE, Farrington S, Lewis A, Prendergast JG, Pittman AM, Theodoratou E, Olver B, Walker M, Penegar S, Barclay E, Whiffin N, Martin L, Ballereau S, Lloyd A, Gorman M, Lubbe S, The COGENT Consortium, The CORGI Collaborators, The EPICOLON Consortium, Howie B, Marchini J, Ruiz-Ponte C, Fernandez-Rozadilla C, Castells A, Carracedo A, Castellvi-Bel S, Duggan D, Conti D, Cazier JB, Campbell H, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Gallinger S, Newcomb P, Hopper J, Jenkins MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah P, Casey G, Houlston RS, Dunlop MG:. Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of
the Missing Heritability of Colorectal Cancer. PLoS Genetics. 2011;7(6):e1002105. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, Palles C, Broderick P, Jaeger EE, Farrington S, Lewis A, Prendergast JG, Pittman AM, Theodoratou E, Olver B, Walker M, Penegar S, Barclay E, Whiffin N, Martin L, Ballereau S, Lloyd A, Gorman M, Lubbe S; The COGENT Consortium; The CORGI Collaborators; The EPICOLON Consortium, Howie B, Marchini J, Ruiz-Ponte C, Fernandez-Rozadilla C, Castells A, Carracedo A, Castellvi-Bel S, Duggan D, Conti D, Cazier JB, Campbell H, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Gallinger S, Newcomb P, Hopper J, Jenkins MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah P, Casey G, Houlston RS, Dunlop MG. Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer. PLoS Genetics. 2011;7(6):e1002105. Tonks ID, Mould AW, Schroder WA, Hacker E, Bosenberg M, Hayward NK, Walker GJ, Kay GF. Melanocyte homeostasis in vivo tolerates Rb1 loss in a developmentally independent fashion. Pigment Cell & Melanoma Research. 2010;23(4):564-570. Turner M, Jackson H, Harle R, Bohmer R, Reid DW. Atypical presentation of acute pancreatitis in a man with pancreatic insufficiency and cystic fibrosis: a case report. Journal of Medical Case Reports. 2010;4:275. Tyagi S, Stark MS, Hayward NK, Whiteman DC, Nancarrow DJ. webFOG: A web tool to map genomic features onto genes. Biochemical and Biophysical Research Communications. 2010;401(3):447-450. Upcroft JA, Krauer KG, Upcroft P. Chromosome sequence maps of the Giardia lamblia assemblage A isolate WB. Trends in Parasitology. 2010;26(10):484-491. Urquhart AJ, Gatei M, Richard DJ, Khanna KK. ATM mediated phosphorylation of CHD4 contributes to genome maintenance. Genome Integrity. 2011;2(1):1. van der Pols JC, Hughes MCB, Ibiebele TI, Marks GC, Green AC. Food intake and risk of basal cell carcinoma in an 11-year prospective study of Australian adults. European Journal of Clinical Nutrition. 2011;65(1):39-46. van der Pols JC, Xu C, Boyle GM, Hughes MC, Carr SJ, Parsons PG, Green AC. Serum omega-3 and omega-6 fatty acids and cutaneous p53 expression in an Australian population. Cancer Epidemiology, Biomarkers & Prevention. 2011;20(3):530-6. van Uitregt VO, Hurst TP, Wilson RS. Reduced size and starvation resistance in adult mosquitoes, Aedes notoscriptus, exposed to predation cues as larvae. Journal of Animal Ecology. 2011. [Published online ahead of print]. Vanoaica L, Darshan D, Richman L, Schümann K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metabolism. 2010;12(3):273-82. Vari V, Gandhi MK. Broad spectrum immunosuppression by classless monocytes in Non-Hodgkin Lymphoma. Immunotherapy. 2011;3(6):723-726. Verhulst B, Hatemi PK, Martin NG. The nature of the relationship between personality traits
and political attitudes. Personality and Individual Differences. 2010;49(4):306-316. Verweij KJ, Zietsch BP, Liu JZ, Medland SE, Lynskey MT, Madden PA, Agrawal A, Montgomary GW, Heath AC, Martin NG. No association of candidate genes with cannabis use in a large sample of Australian twin families. Addiction Biology. 2011. [Published online ahead of print]. Verweij KJH, Zietsch BP, Lynskey MT, Nelson EC, Heath AC, Martin NG. Examining the relationship between sexual orientation and depression: overlapping genetic and early environmental influences. Behavior Genetics. 2010;40(6):816-816. Verweij KJH, Zietsch BP, Medland SE, Gordon SD, Benyamin B, Nyholt DR, McEvoy BP, Sullivan PF, Heath AC, Madden PAF, Henders AK, Montgomery GW, Martin NG, Wray NR. A genome-wide association study of Cloninger’s temperament scales: Implications for the evolutionary genetics of personality. Biological Psychology. 2010;85(2):306-317. Vink JM, Boomsma DI, Medland SE, de Moor MHM, Stubbe JH, Cornes BK, Martin NG, Skytthea A, Kyvik KO, Rose RJ, Kujala UM, Kaprio J, Harris JR, Pedersen NL, Cherkas L, Spector TD, de Geus EJC. Variance Components Models for Physical Activity With Age as Modifier: A Comparative Twin Study in Seven Countries. Twin Research and Human Genetics. 2011;14(1):25-34. Vinkhuyzen AA, Dumenil T, Ryan L, Gordon SD, Henders AK, Madden PA, Heath AC, Montgomery GW, Martin NG, Wray NR. Identification of tag haplotypes for 5HTTLPR for different genome-wide SNP platforms. Molecular Psychiatry. 2011. [Published online ahead of print]. Visscher PM, Goddard ME. Cattle gain stature. Nature Genetics. 2011;43(5):397-398. Visscher PM, McEvoy B, Yang J. From Galton to GWAS: quantitative genetics of human height. Genetics Research. 2010;92(5-6):371-9. Visscher PM, Posthuma D. Statistical Power to Detect Genetic Loci Affecting Environmental Sensitivity. Behavior Genetics. 2010;40(5):728-733. Visscher PM, Yang JA, Goddard ME. A Commentary on ‘Common SNPs Explain a Large Proportion of the Heritability for Human Height’ by Yang et al. (2010). Twin Research and Human Genetics. 2010;13(6):517-524. Vu LH, Whiteman DC, van der Pols JC, Kimlin MG, Neale RE. Serum Vitamin D Levels in office Workers in a Subtropical Climate. Photochemistry and Photobiology. 2011;87(3):714-720. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FBL, Couch F, Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment. 2010;123(3):661-677. Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, da Silva L, Vargas AC, Reid L, Simpson PT, Lakhani SR, Chenevix-Trench G. Gene expression profiling of formalin-fixed, paraffinembedded familial breast tumours using the whole genome-DASL assay. Journal of Pathology. 2010;221(4):452-461. Wade TD, Zhu G, Martin NG. Body mass index and breast size in women: same or different genes?. Twin Research and Human Genetics. 2010;13(5):450-454.
Wade TD, Zhu G, Martin NG. Undue influence of weight and shape: is it distinct from body dissatisfaction and concern about weight and shape?. Psychological Medicine. 2011;41(4):819-828.
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 2010;19(14):2886-2897.
Waldron M, Heath AC, Lynskey, MT, Bucholz KK, Madden, PAF, Martin NG. Alcoholic Marriage: Later Start, Sooner End. Alcoholism: Clinical and Experimental Research. 2011;35(4):632–642.
Warrilow D, Warren K, Harrich D. Strand Transfer and Elongation of HIV-1 Reverse Transcription Is Facilitated by Cell Factors In Vitro. PLoS ONE. 2010;5(10).
Walker GJ, Soyer HP, Handoko HY, Ferguson B, Kunisada T, Khosrotehrani K, Box NF, Muller HK. Superficial Spreading-Like Melanoma in Arf(/-):: Tyr-Nras(Q61K)::K14-Kitl Mice: Keratinocyte Kit Ligand Expression Sufficient to “Translocate” Melanomas from Dermis to Epidermis. Journal of Investigative Dermatology. 2011;131(6):1384-1387.
Webb A, Lind PA, Kalmijn J, Feiler HS, Smith TL, Schuckit MA, Wilhelmsen K. The Investigation into CYP2E1 in Relation to the Level of Response to Alcohol Through a Combination of Linkage and Association Analysis. Alcoholism-Clinical and Experimental Research. 2011;35(1):43374.
Walker LC, Fredericksen ZS, Wang X, Tarrell R, Pankratz VS, Lindor NM, Beesley J, Healey S, Chen X, kConFab, Stoppa-Lyonnet D, Tirapo C, Giraud S, Mazoyer S, Muller D, Fricker JP, Delnatte C, GEMO Study Collaborators, Schmutzler RK, Wappenschmidt B, Engel. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research. 2010;12(6):R102. Walker RG, Landmann JK, Hewett DG, Worthley DL, Buttenshaw RL, Knight N, Webb PM, Whiteman DC, Whitehall VL, Leggett BA. Hyperplastic Polyposis Syndrome Is Associated With Cigarette Smoking, Which May Be a Modifiable Risk Factor. American Journal of Gastroenterology. 2010;105(7):1642-1647. Wallace DF, McDonald C, Subramaniam VN. Transferrin receptor 1: a ferritin receptor as well?. Gastroenterology. 2010;139(3):1052-3. Wallace DF, McDonald CJ, Ostini L, Subramaniam VN. Blunted hepcidin response to inflammation in the absence of Hfe and transferrin receptor 2. Blood. 2011;117(10):2960-2966. Wallingford S, Alston RD, Green AC, Birch JM. Comparison of trends in the incidence of cutaneous malignant melanoma. Pediatric Blood & Cancer. 2010;55(5):933-933. Wallingford SC, Alston RD, Birch JM, Green AC. Increases in invasive melanoma in England, 1979-2006, by anatomic site. British Journal of Dermatology. 2011. [Published online ahead of print]. Wallingford SC, Alston RD, Birch JM, Green AC. Temporal trends in the incidence of invasive cutaneous melanoma by anatomic site in UK, 1979-2006. British Journal of Dermatology. 2011;164(4):938-938. Wallingford SC, Olsen CM, Plasmeijer E, Green AC. Skin Cancer Arising in Scars: A Systematic Review. Dermatologic Surgery. 2011. [Published online ahead of print]. Wang D Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, Dong JY. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine. 2011;29(15):2803-2809. Wang XS, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, Cook M, Oliver C, Frost D, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Houdayer C, Hogervorst FBL, Hooning MJ, Ligtenberg MJ, Spurdle A, Chenevix-Trench G, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Domchek SM, Nathanson KL, Rebbeck TR, Singer CF, Gschwantler-Kaulich D, Dressler C, Fink A, Szabo CI, Zikan M, Foretova L, Claes K, Thomas G, Hoover RN, Hunter DJ, Chanock SJ, Easton DF, Antoniou AC, Couch FJ.
Webb PM, Ibiebele TI, Hughes MC, Beesley J, van der Pols JC, Chen X, Nagle CM, Bain CJ, Chenevix-Trench G. Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. European Journal of Clinical Nutrition. 2011. [Published online ahead of print]. Webbink D, Martin N, Visscher P. Does teenage childbearing reduce investment in human capital?. Journal of Population Economics. 2011;24(2):701-30. Wen Y, Reid DW, Zhang D, Ward C, Wood-Baker R, Walters EH. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2010;5:327-34. Wheatley NC, andrews KT, Tran TL, Lucke AJ, Reid RC, Fairlie DP. Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorganic & Medicinal Chemistry Letters. 2010;20(23):7080-7084. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB. Splicing and Multifactorial Analysis of Intronic BRCA1 and BRCA2 Sequence Variants Identifies Clinically Significant Splicing Aberrations up to 12 Nucleotides from the Intron/Exon Boundary. Human Mutation. 2011;32(6):678-687. Whitelaw NC, Chong S, Morgan DK, Nestor C, Bruxner TJ, Ashe A, Lambley E, Meehan R, Whitelaw E. Reduced levels of two modifiers of epigenetic gene silencing, Dnmt3a and Trim28, cause increased phenotypic noise. Genome Biology. 2010;11(11):R111. Whitelaw NC, Chong S, Whitelaw E. Tuning In to Noise: Epigenetics and Intangible Variation. Developmental Cell. 2010;19(5):649-650. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, Montgomery GW, Green AC, Hayward NK, Webb PM. Association of Helicobacter pylori Infection With Reduced Risk for Esophageal Cancer Is Independent of Environmental and Genetic Modifiers. Gastroenterology. 2010;139(1):73-83. Whiteman DC, Pavan WJ, Bastian BC. The Melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Research. 2011. [Published online ahead of print]. Whiteman DC. ‘Blue Sky’ epidemiology: definition, examples and a plea for understanding. Australian and New Zealand Journal of Public Health. 2011;35(1):4-U6. Whitfield JB. Molecular biology and genetics in clinical chemistry and laboratory medicine. Clinical Chemistry and Laboratory Medicine. 2010;48(4):431–434.
Page 151
Scientific publications | continued Whitfield JB. The Australian Experience with CDT. Alcoholism-Clinical and Experimental Research. 2010;34(8):58A-58A. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin- 1-receptor and risk of cutaneous melanoma: A meta-analysis and estimates of population burden. International Journal of Cancer. 2010. [Published online ahead of print]. Wilson R, Diseberg A, Zivkovic S, Gordon L, Tatarczuch L, Mackie E, Gorman J, Bateman J. Proteomic Profiling Of Cartilage Extracellular Matrix Maturation. Osteoarthritis and Cartilage. 2010;18:S225-S225. Win AK, Dowty JG, Antill YC, English DR, Baron JA, Young JP, Giles GG, Southey MC, Winship I, Lipton L, Parry S, Thibodeau SN, Haile RW, Gallinger S, Le Marchand L, Lindor NM, Newcomb PA, Hopper JL, Jenkins MA. Body Mass Index in Early Adulthood and Endometrial Cancer Risk for Mismatch Repair Gene Mutation Carriers. Obstetrics and Gynecology. 2011;117(4):899-905. Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, Macrae FA, Lipton L, Parry S, Young GP, Buchanan DD, Martinez ME, Jacobs ET, Ahnen DJ, Haile RW, Casey G, Baron JA, Lindor NM, Thibodeau SN, Newcomb PA, Potter JD, Le Marchand L, Gallinger S, Hopper JL, Jenkins MA. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. British Journal of Cancer. 2011;105(1):162-169. Winzer BM, Whiteman DC, Reeves MM, Paratz JD. Physical activity and cancer prevention: a systematic review of clinical trials. Cancer Causes & Control. 2011;22(6):811-826. Wood MJ, Powell LW, Ramm GA, Clouston AD. The role of the ductular reaction in the progression of hepatic fibrosis in haemochromatosis. Journal of Gastroenterology and Hepatology. 2010;25:A110-A111. Wood MJ, Vigh S, Dixon JL, Ramm GA, Powell LW. Diabetes is associated with fibrosis progression in haemochromatosis. Journal of Gastroenterology and Hepatology. 2010;25:A110. Woods SL, Bishop JM. A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter. Transgenic Research. 2011;20(2):421-428. Worthley DL, Hewett DG, Spring KJ, Whitehall VLJ, Leggett BA. Re: Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. Journal of the National Cancer Institute. 2010;102(13):990-990. Worthley DL, Whitehall VLJ, Le Leu RK, Irahara N, Buttenshaw RL, Mallitt KA, Greco SA, Ramsnes I, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA Methylation in the Rectal Mucosa Is Associated with Crypt Proliferation and Fecal Short-Chain Fatty Acids. Digestive Diseases and Sciences. 2011;56(2):387-396. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, Ripke S, Macintyre DJ, McGhee KA, Maclean AW, Smit JH, Hottenga JJ, Willemsen G, Middeldorp CM, de Geus EJ, Lewis CM, McGuffin P, Hickie IB, van den Oord EJ, Liu JZ, Macgregor S, McEvoy. Genome-wide association study of major depressive disorder: new results, meta-analysis,
Page 152
QIMR Annual Report 2010–2011
and lessons learned. Molecular Psychiatry. 2010. [Published online ahead of print]. Wray NR, Purcell SM, Visscher PM. Synthetic Associations Created by Rare Variants Do Not Explain Most GWAS Results. PLoS Biology. 2011;9(1). Wright CM, Francis SMS, Sriram KB, Quinn KR, Stark MS, Hayward NK, Yang IA, Bowman RV, Fong KM. Mapping the Lung Cancer Methylome. Journal of Thoracic Oncology. 2011;6(3):S10-S10. Wright CM, Larsen JE, Hayward NK, Martins MU, Tan ME, Davidson MR, Savarimuthu SM, McLachlan RE, Passmore LH, Windsor MN, Clarke BE, Duhig EE, Yang IA, Bowman RV, Fong KM. ADAM28: A Potential Oncogene Involved in Asbestos-Related Lung Adenocarcinomas. Genes Chromosomes & Cancer. 2010;49(8):688-698. Wright JM, Dunn LA, Kazimierczuk Z, Burgess AG, Krauer KG, Upcroft P, Upcroft JA. Susceptibility in vitro of clinically metronidazoleresistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2’-deoxyadenosine. Parasitology Research. 2010;107(4):847-853. Wykes MN, Kay JG, Manderson A, Liu XQ, Brown DL, Richard DJ, Wipasa J, Jiang SH, Jones MK, Janse CJ, Waters AP, Pierce SK, Miller LH, Stow JL, Good MF. Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. PNAS. 2011;108(27):11205-10. Wynne A, Kanwar RK, Khanna R, Kanwar JR. Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System. Current Neuropharmacology. 2010;8(3):268-275. Xu HL, Balakrishnan K, Malaterre J, Beasley M, Yan YQ, Essers J, Appeldoorn E, Thomaszewski JM, Vazquez M, Verschoor S, Lavin MF, Bertonchello I, Ramsay RG, Mckay MJ. Rad21Cohesin Haploinsufficiency Impedes DNA Repair and Enhances Gastrointestinal Radiosensitivity in Mice. PLoS ONE. 2010;5(8). Xu M, andrews KT, Birrell GW, Tran TL, Camp D, Davis RA, Quinn RJ. Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine sponge of the genus Pseudoceratina. Bioorganic & Medicinal Chemistry Letters. 2011;21(2):846-848. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM, de andrade M, Feenstra B, Feingold E, Hayes MG, Hill WG, Landi MT, Alonso A, Lettre G, Lin P, Ling H, Lowe W, Mathias RA, Melbye M, Pugh E, Cornelis MC, Weir BS, Goddard ME, Visscher PM. Genome partitioning of genetic variation for complex traits using common SNPs. Nature Genetics. 2011;43(6):519-U44. Yang J, Weedon MN, Purcell S, Lettre G, Estrada K, Willer CJ, Smith AV, Ingelsson E, O’Connell JR, Mangino M, Magi R, Madden PA, Heath AC, Nyholt DR, Martin NG, Montgomery GW, Frayling TM, Hirschhorn JN, McCarthy MI, Goddard ME, Visscher PM. Genomic inflation factors under polygenic inheritance. European Journal of Human Genetics. 2011;19(7):807-812. Yang JA, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA, Heath AC, Martin NG, Montgomery GW, Goddard ME, Visscher PM. Common SNPs explain a large proportion of the heritability for human height. Nature Genetics. 2010;42(7):565-569.
Yang JA, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex Trait Analysis. American Journal of Human Genetics. 2011;88(1):76-82. Yang JA, Visscher PM, Wray NR. Sporadic cases are the norm for complex disease. European Journal of Human Genetics. 2010;18(9):1039-1043. Yang SH, Brindley PJ, Zeng QR, Li YS, Zhou J, Liu Y, Liu BY, Cai LT, Zeng TB, Wei Q, Lan LM, McManus DP. Transduction of Schistosoma japonicum schistosomules with vesicular stomatitis virus glycoprotein pseudotyped murine leukemia retrovirus and expression of reporter human telomerase reverse transcriptase in the transgenic schistosomes. Molecular and Biochemical Parasitology. 2010;174(2):109-116. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van ‘t Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Pérez JI, Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, AntonCulver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Górski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, TilanusLinthorst MM, Collée M, Wang-Gohrke S, Pylkäs K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Ørsted DD, KaurKnudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Journal of the National Cancer Institute. 2011;103(3):250-63. Yang YR, Williams GM, Craig PS, McManus DP. Impact of Increased Economic Burden Due to Human Echinococcosis in an Underdeveloped Rural Community of the People’s Republic of China. PLoS Neglected Tropical Diseases. 2010;4(9).
Yenamandra SP, Hellman U, Kempkes B, Darekar SD, Petermann S, Sculley T, Klein G, Kashuba E. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cellular and Molecular Life Sciences. 2010;67(24):4249-4256.
Zamudio NM Zamudio NM, Scott HS, Wolski K, Lo CY, Law C, Leong D, Kinkel SA, Chong SY, Jolley D, Smyth GK, de Kretser D, Whitelaw E, Oâ&#x20AC;&#x2122;Bryan MK. DNMT3L Is a Regulator of X Chromosome Compaction and Post-Meiotic Gene Transcription. PLoS ONE. 2011;6(3).
Yin S, Boyle GM, Carroll AR, Kotiw M, Dearnaley J, Quinn RJ, Davis RA. Caelestines A-D, Brominated Quinolinecarboxylic Acids from the Australian Ascidian Aplidium caelestis. Journal of Natural Products. 2010;73(9):1586-1589.
Zhang L, Sriprakash KS, McMillan D, Gowardman JR, Patel B, Rickard CM. Microbiological pattern of arterial catheters in the intensive care unit. BMC Microbiology. 2010;10.
You H, Gobert GN, Jones MK, Zhang WB, McManus DP. Signalling pathways and the hostparasite relationship: Putative targets for control interventions against schistosomiasis Signalling pathways and future anti-schistosome therapies. Bioessays. 2011;33(3):203-214. Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. British Journal of Dermatology. 2011;165(1):35-43. Young JP, Parry S. Hyperplastic polyposis syndrome and risk of colorectal cancer. Nature Reviews Gastroenterology & Hepatology. 2010;7(11):594-595. Youngson N, Oey H, Whitelaw E. Paternal Effects in Mice Caused by Dicer Or Dnmt1 Haploinsufficiency are Associated with Changes in Spermatozoal Mirna Expression Profile. Journal of Andrology. 2011;94-95. Youngson NA, Chong S, Whitelaw E. Gene silencing is an ancient means of producing multiple phenotypes from the same genotype. Bioessays. 2011;33(2):95-99. Youngson NA, Vickaryous N, van der Horst A, Epp T, Harten S, Fleming JS, Khanna KK, de Kretser DM, Whitelaw E. A missense mutation in the transcription factor Foxo3a causes teratomas and oocyte abnormalities in mice. Mammalian Genome. 2011;22(40636):235-248. Youngson NA, Whitelaw E. The effects of acquired paternal obesity on the next generation. Asian Journal of Andrology. 2011;13(2):195-196.
Zhang WB, Li J, Duke M, Jones MK, Kuang L, Zhang JF, Blair D, Li YS, McManus DP. Inconsistent Protective Efficacy and Marked Polymorphism Limits the Value of Schistosoma japonicum Tetraspanin-2 as a Vaccine Target. PLoS Neglected Tropical Diseases. 2011;5(5). Zhang WB, Li J, Jones MK, Zhang ZZ, Zhao L, Blair D, McManus DP. The Echinococcus granulosus Antigen B Gene Family Comprises at Least 10 Unique Genes in Five Subclasses Which Are Differentially Expressed. PLoS Neglected Tropical Diseases. 2010;4(8).
Zhu R, Gray DJ, Thrift AP, Williams GM, Zhang Y, Qiu DC, Zheng F, Li YS, Guo JG, Zhu HQ, Wu WP, Li RS, McManus DP. A 5-year longitudinal study of schistosomiasis transmission in Shian village, the Anning River Valley, Sichuan Province, the Peoplesâ&#x20AC;&#x2122; Republic of China. Parasites & Vectors. 2011;4. Zietsch BP, Miller GF, Bailey JM, Martin NG. Female Orgasm Rates are Largely Independent of Other Traits: Implications for Female Orgasmic Disorder and Evolutionary Theories of Orgasm. Journal of Sexual Medicine. 2011. [Published online ahead of print]. Zietsch BP, Verweij KJ, Bailey JM, Wright MJ, Martin NG. Sexual orientation and psychiatric vulnerability: a twin study of neuroticism and psychoticism. Archives of Sexual Behaviour. 2011;40(1):133-42. Zietsch BP, Verweij KJH, Bailey JM, Wright MJ, Martin NG. Psychiatric vulnerability in nonheterosexuals. Behavior Genetics. 2010;40(6):821-821.
Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DDL, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30(25):2810-2822.
Zietsch BP, Verweij KJH, Heath AC, Martin NG. Variation in Human Mate Choice: Simultaneously Investigating Heritability, Parental Influence, Sexual Imprinting, and Assortative Mating. American Naturalist. 2011;177(5):605-616.
Zhao ZZ, Croft L, Nyholt DR, Chapman B, Treloar SA, Hull ML, Montgomery GW. Evaluation of polymorphisms in predicted target sites for micro RNAs differentially expressed in endometriosis. Molecular Human Reproduction. 2011;17(2):92-103.
Zondervan KT, Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lee H, Visscher PM, Kraft P, Martin NG, Morris AP, Treloar SA, Kennedy SH, Missmer SA, Montgomery GW. GenomeWide Association Study of Endometriosis Shows Differential Etiology by Stage and Identifies a Locus at 7p15.2 Associated with the Development of Moderate-Severe Disease. Reproductive Sciences. 2011;18(3):197A.
Zheng WJ, Yang JA, Zhu J. QTLNetworkR: an interactive R package for QTL visualization. Journal of Zhejiang University-Science B. 2010;11(7):512-515. Zhong J, Khanna R. Delineating the role of CD4(+) T cells in the activation of human cytomegalovirusspecific immune responses following immunization with Ad-gBCMVpoly vaccine implications for vaccination of immunocompromised individuals. Journal of General Virology. 2010;91:2994-3001.
Zondervan KT, Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lee SH, Visscher PM, Kraft P, Martin NG, Morris AP, Treloar SA, Kennedy SH, Missmer SA, Montgomery GW. Genomewide Association Study of Endometriosis Shows Differential Etiology by Stage and Identifies a Locus at 7p15.2 Associated with the Development of Moderate-severe Disease. Genetic Epidemiology. 2010;34(8):976-977.
Page 153
compLiance cHeckLiSt FA ACT Financial Accountability Act 2009 FPMS Financial and Performance Management Standard 2009 ARRs Annual Report Requirements for Queensland Government Agencies Summary of requirement Accessibility
Annual report reference
Table of contents Glossary/Acronyms
ARRs – section 8.1
Page 1 Page 156
Public availability
ARRs – section 8.2
Inside front cover
Interpreter service statement
Queensland Government Language Services Policy
Inside front cover
Copyright notice
Copyright Act 1968
Inside front cover
Letter of compliance
A letter of compliance from the accountable officer or statutory body to the relevant Minister(s)
ARRs – section 9
Page 2
Introductory information
Agency role and main functions
ARRs – section 10.3
Page 16
Operating environment
ARRs – section 10.3
Page 17
External scrutiny
ARRs – section 10.3
Page 26
Machinery of government changes
ARRs – section 10.3
Page 17
Review of proposed forward operations
ARRs – section 10.3
Page 18
Government objectives for the community
ARRs – section 11.2
Page 17
Agency objectives and performance indicators
ARRs – section 11.5
Page 18
Agency outputs and output performance measures
ARRs – section 11.6
Page 18
Summary of financial performance
ARRs – section 12.1
Page 73
Disclosure of budget v actual results
ARRs – section 12.2
N/A
Chief Finance Officer (CFO) statement
ARRs – section 12.3
N/A
Organisational structure
ARRs – section 13.1
Page 20
Executive management
ARRs – section 13.2
Page 27
Related entities
ARRs – section 13.3
Page 40
Non-financial performance
Financial performance
Governance – management and structure
Page 154
Basis for requirement
Schedule of statutory authorities or instrumentalities
ARRs – section 13.4
N/A
Boards and committees
ARRs – section 13.5
Page 25
Public Sector Ethics Act 1994 - implementation statement giving details of the action taken during the reporting period
Public Sector Ethics Act 1994 (section 23 and Schedule)
Page 19
Whistleblowers Protection Act 1994 - public interest disclosures received
Whistleblowers Protection Act 1994 (sections 30 – 31 and Schedule)
Page 26
QIMR Annual Report 2010–2011
Summary of requirement Governance – risk management and accountability Governance – human resources
Governance – operations
Other prescribed requirements
Optional information that may be reported
Financial statements
Basis for requirement
Annual report reference
Risk management
ARRs – section 14.1
Page 25
Audit committee
ARRs – section 14.2
Page 26
Internal Audit
ARRs – section 14.3
Page 26
Workforce planning, attraction and retention
ARRs – section 15.1
Page 19
Early retirement, redundancy and retrenchment
Directive No.17/09 Early Retirement, Redundancy and Retrenchment
Initiatives for women
ARRs – section 15.1 and 15.3
Consultancies
ARRs – section 16.1
Page 73
Overseas travel
ARRs – section 16.2
Page 132
Information systems and recordkeeping
Public Records Act 2002
Page 26
Waste management
Environmental Protection (Waste Management) Policy 2000, Environmental Protection Act 1994
N/A
Indigenous matters (Queensland Government Reconciliation Action Plan 2009–2012)
Queensland Government Reconciliation Action Plan 2009–2012
N/A
Shared services
ARRs – section 17.1
N/A
Carbon emissions
Premier’s Statement
N/A
Corrections to previous annual reports
ARRs – section 18.2
N/A
Right to Information
Right to Information Act 2009
N/A
Information Privacy
Information Privacy Act 2009
N/A
Native title
N/A
N/A
Annual general purpose financial statements
Financial Reporting Requirements for Queensland Government Agencies
Page 74
Certification of financial statements
FA Act – section 62 FPMS – sections 42, 43 and 50
Page 107
Independent Auditors Report
FA Act – section 62 FPMS – section 50
Page 108
Remuneration disclosures
Financial Reporting Requirements for Queensland Government Agencies
Page 101
N/A N/A
Page 155
ACRonymS QIMR | Queensland Institute of Medical Research
AC | Companion of the Order of Australia
DC | Dendritic cell
ACVD | Australian Centre for Vaccine Development
DEEDI | Department of Employment, Economic Development and Innovation (Qld)
QSA | Queensland Studies Authority
ACRF | Australian Cancer Research Foundation
DNA | Deoxyribonucleic acid
QUT | Queensland University of Technology
EBV | Epstein-Barr virus
RBWH | Royal Brisbane and Womenâ&#x20AC;&#x2122;s Hospital
AIBN | Australian Institute for Bioengineering and Nanotechnology
EVC | Emory Vaccine Center
ALF | Australian Liver Foundation
FTE | Full time equivalent
ANU | Australian National University
GMP | Good manufacturing practice
ARC | Australian Research Council
GWA | Genome-wide association
ASI | Australasian Society of Immunology
HDL | High density lipoprotein
ASMR | Australian Society for Medical Research
HIV | Human immunodeficiency virus
RNA | Ribonucleic acid ROTRF | Roche Organ Transplantation Research Foundation SSMRC | Smart State Medical Research Centre TLR | Toll-like receptor UCLA | University of California, Los Angeles HR | Human resources UNSW | University of New South Wales
ATM | Ataxia-telangiectasia mutated ATR | Australian Twin Registry
IARC | International Agency for Research on Cancer
BRCA1 | Breast cancer type 1 susceptibility gene
IUBMB | The International Union of Biochemistry and Molecular Biology
CCQ | Cancer Council Queensland
LDL | Low density lipoprotein
CEO | Chief Executive Officer
MAG | Management Advisory Group
CF | Cystic fibrosis
MIC-1 | Macrophage inhibitory cytokine 1
CMV | Cytomegalovirus
NHMRC | National Health and Medical Research Council
UQ | The University of Queensland VU | Vrije Universiteit, Amsterdam WHO | World Health Organization
Colon CFR | Colon cancer family registry NIH | National Institutes of Health COPD | Chronic obstructive pulmonary disease
OHMR | Office of Health and Medical Research
CRC | Cooperative Research Centre PCFA | Prostate Cancer Foundation Australia CSIRO | Commonwealth Scientific and Industrial Research Organisation
Page 156
QIMR Annual Report 2010â&#x20AC;&#x201C;2011
300 Herston Road Herston QLD 4006 Australia
T +61 7 3362 0222 1800 993 000
Locked Bag 2000 RBH QLD 4029 Australia
F +61 7 3362 0102 E enquiries@qimr.edu.au
Better health through medical research | www.qimr.edu.au